TW201408638A - 隱花色素調節劑之含咔唑磺醯胺類 - Google Patents
隱花色素調節劑之含咔唑磺醯胺類 Download PDFInfo
- Publication number
- TW201408638A TW201408638A TW102116699A TW102116699A TW201408638A TW 201408638 A TW201408638 A TW 201408638A TW 102116699 A TW102116699 A TW 102116699A TW 102116699 A TW102116699 A TW 102116699A TW 201408638 A TW201408638 A TW 201408638A
- Authority
- TW
- Taiwan
- Prior art keywords
- aryl
- heterocyclic group
- membered heterocyclic
- membered
- alkyl
- Prior art date
Links
- 108010037139 Cryptochromes Proteins 0.000 title claims description 85
- KCYOZNARADAZIZ-CWBQGUJCSA-N 2-[(2e,4e,6e,8e,10e,12e,14e)-15-(4,4,7a-trimethyl-2,5,6,7-tetrahydro-1-benzofuran-2-yl)-6,11-dimethylhexadeca-2,4,6,8,10,12,14-heptaen-2-yl]-4,4,7a-trimethyl-2,5,6,7-tetrahydro-1-benzofuran-6-ol Chemical compound O1C2(C)CC(O)CC(C)(C)C2=CC1C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)C1C=C2C(C)(C)CCCC2(C)O1 KCYOZNARADAZIZ-CWBQGUJCSA-N 0.000 title claims description 52
- KCYOZNARADAZIZ-PPBBKLJYSA-N Cryptochrome Natural products O[C@@H]1CC(C)(C)C=2[C@@](C)(O[C@H](/C(=C\C=C\C(=C/C=C/C=C(\C=C\C=C(\C)/[C@H]3O[C@@]4(C)C(C(C)(C)CCC4)=C3)/C)\C)/C)C=2)C1 KCYOZNARADAZIZ-PPBBKLJYSA-N 0.000 title claims description 52
- KCYOZNARADAZIZ-XZOHMNSDSA-N beta-cryptochrome Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C1OC2(C)CC(O)CC(C)(C)C2=C1)C=CC=C(/C)C3OC4(C)CCCC(C)(C)C4=C3 KCYOZNARADAZIZ-XZOHMNSDSA-N 0.000 title claims description 52
- 229940124530 sulfonamide Drugs 0.000 title abstract description 18
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 title abstract description 10
- 150000003456 sulfonamides Chemical class 0.000 title abstract description 10
- 150000001875 compounds Chemical class 0.000 claims abstract description 180
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 126
- 201000010099 disease Diseases 0.000 claims abstract description 125
- 230000001404 mediated effect Effects 0.000 claims abstract description 93
- 150000003839 salts Chemical class 0.000 claims abstract description 39
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 27
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 18
- 208000008589 Obesity Diseases 0.000 claims abstract description 17
- 235000020824 obesity Nutrition 0.000 claims abstract description 17
- 208000010412 Glaucoma Diseases 0.000 claims abstract description 11
- 208000001145 Metabolic Syndrome Diseases 0.000 claims abstract description 11
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims abstract description 11
- 208000014311 Cushing syndrome Diseases 0.000 claims abstract description 9
- 201000009395 primary hyperaldosteronism Diseases 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims description 181
- 125000000623 heterocyclic group Chemical group 0.000 claims description 141
- -1 azido, hydroxy Chemical group 0.000 claims description 128
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 126
- 239000000203 mixture Substances 0.000 claims description 103
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 68
- 101150078024 CRY2 gene Proteins 0.000 claims description 66
- 101150102464 Cry1 gene Proteins 0.000 claims description 64
- 238000011282 treatment Methods 0.000 claims description 59
- 239000003814 drug Substances 0.000 claims description 48
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 45
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 39
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 37
- 230000000694 effects Effects 0.000 claims description 32
- 229940124597 therapeutic agent Drugs 0.000 claims description 32
- 125000005843 halogen group Chemical group 0.000 claims description 24
- 238000009739 binding Methods 0.000 claims description 23
- 125000002619 bicyclic group Chemical group 0.000 claims description 22
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 21
- 230000027455 binding Effects 0.000 claims description 21
- 125000002950 monocyclic group Chemical group 0.000 claims description 21
- 239000000049 pigment Substances 0.000 claims description 21
- 102000003676 Glucocorticoid Receptors Human genes 0.000 claims description 20
- 108090000079 Glucocorticoid Receptors Proteins 0.000 claims description 20
- 101150074181 PER2 gene Proteins 0.000 claims description 16
- 229910052757 nitrogen Inorganic materials 0.000 claims description 15
- 101150008094 per1 gene Proteins 0.000 claims description 15
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 125000003118 aryl group Chemical group 0.000 claims description 14
- 229910052799 carbon Inorganic materials 0.000 claims description 13
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 12
- 206010036790 Productive cough Diseases 0.000 claims description 12
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 12
- 210000003802 sputum Anatomy 0.000 claims description 12
- 208000024794 sputum Diseases 0.000 claims description 12
- 210000001519 tissue Anatomy 0.000 claims description 12
- 238000012544 monitoring process Methods 0.000 claims description 11
- 238000004422 calculation algorithm Methods 0.000 claims description 10
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 10
- 208000031773 Insulin resistance syndrome Diseases 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 208000024827 Alzheimer disease Diseases 0.000 claims description 8
- 206010013654 Drug abuse Diseases 0.000 claims description 8
- 208000001132 Osteoporosis Diseases 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 210000004369 blood Anatomy 0.000 claims description 8
- 239000008280 blood Substances 0.000 claims description 8
- 230000007423 decrease Effects 0.000 claims description 8
- 208000004296 neuralgia Diseases 0.000 claims description 8
- 208000021722 neuropathic pain Diseases 0.000 claims description 8
- 208000011117 substance-related disease Diseases 0.000 claims description 8
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- 239000003085 diluting agent Substances 0.000 claims description 7
- 230000002401 inhibitory effect Effects 0.000 claims description 7
- 208000002780 macular degeneration Diseases 0.000 claims description 7
- 208000024714 major depressive disease Diseases 0.000 claims description 7
- 210000002966 serum Anatomy 0.000 claims description 7
- 125000001424 substituent group Chemical group 0.000 claims description 7
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 7
- 239000002671 adjuvant Substances 0.000 claims description 6
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 6
- 238000004393 prognosis Methods 0.000 claims description 6
- 208000021642 Muscular disease Diseases 0.000 claims description 5
- 201000009623 Myopathy Diseases 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 230000004807 localization Effects 0.000 claims description 5
- 230000004048 modification Effects 0.000 claims description 5
- 238000012986 modification Methods 0.000 claims description 5
- 238000011477 surgical intervention Methods 0.000 claims description 5
- 239000003451 thiazide diuretic agent Substances 0.000 claims description 5
- KBUAONWROSSDRE-CQSZACIVSA-N (2s)-1-carbazol-9-yl-3-(1,1-dioxo-1,2-thiazolidin-2-yl)propan-2-ol Chemical compound C([C@@H](O)CN1C2=CC=CC=C2C2=CC=CC=C21)N1CCCS1(=O)=O KBUAONWROSSDRE-CQSZACIVSA-N 0.000 claims description 4
- KBUAONWROSSDRE-UHFFFAOYSA-N 1-carbazol-9-yl-3-(1,1-dioxo-1,2-thiazolidin-2-yl)propan-2-ol Chemical compound C12=CC=CC=C2C2=CC=CC=C2N1CC(O)CN1CCCS1(=O)=O KBUAONWROSSDRE-UHFFFAOYSA-N 0.000 claims description 4
- SJBUXTRTPSOWNK-UHFFFAOYSA-N 1-carbazol-9-yl-3-(1,1-dioxo-3h-1,2-benzothiazol-2-yl)propan-2-ol Chemical compound C12=CC=CC=C2C2=CC=CC=C2N1CC(O)CN1S(=O)(=O)C2=CC=CC=C2C1 SJBUXTRTPSOWNK-UHFFFAOYSA-N 0.000 claims description 4
- 108010088547 ARNTL Transcription Factors Proteins 0.000 claims description 4
- 102000008867 ARNTL Transcription Factors Human genes 0.000 claims description 4
- 230000009471 action Effects 0.000 claims description 4
- 238000001574 biopsy Methods 0.000 claims description 4
- 230000008859 change Effects 0.000 claims description 4
- 210000003722 extracellular fluid Anatomy 0.000 claims description 4
- 239000012530 fluid Substances 0.000 claims description 4
- WSHSYFLVJQWDJH-UHFFFAOYSA-N n-(3-carbazol-9-yl-2-hydroxypropyl)-n-(1-methylcyclopentyl)methanesulfonamide Chemical compound C12=CC=CC=C2C2=CC=CC=C2N1CC(O)CN(S(C)(=O)=O)C1(C)CCCC1 WSHSYFLVJQWDJH-UHFFFAOYSA-N 0.000 claims description 4
- 210000002381 plasma Anatomy 0.000 claims description 4
- 206010003445 Ascites Diseases 0.000 claims description 3
- 125000003342 alkenyl group Chemical group 0.000 claims description 3
- 210000001185 bone marrow Anatomy 0.000 claims description 3
- 210000002751 lymph Anatomy 0.000 claims description 3
- 210000003097 mucus Anatomy 0.000 claims description 3
- 210000003296 saliva Anatomy 0.000 claims description 3
- 210000000582 semen Anatomy 0.000 claims description 3
- 210000004243 sweat Anatomy 0.000 claims description 3
- 210000002700 urine Anatomy 0.000 claims description 3
- RVQVMQYSHGPVLW-UHFFFAOYSA-N 1-carbazol-9-yl-3-(5-fluoro-1,1-dioxo-1,2-thiazolidin-2-yl)propan-2-ol Chemical compound C12=CC=CC=C2C2=CC=CC=C2N1CC(O)CN1CCC(F)S1(=O)=O RVQVMQYSHGPVLW-UHFFFAOYSA-N 0.000 claims description 2
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- DNGMYXZLJGHHOM-UHFFFAOYSA-N thiazinane 1,1-dioxide Chemical compound O=S1(=O)CCCCN1 DNGMYXZLJGHHOM-UHFFFAOYSA-N 0.000 claims description 2
- 150000004677 hydrates Chemical class 0.000 abstract description 3
- 208000035475 disorder Diseases 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 158
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 100
- 108090000623 proteins and genes Proteins 0.000 description 77
- 235000019439 ethyl acetate Nutrition 0.000 description 66
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 63
- 239000000523 sample Substances 0.000 description 63
- 239000000243 solution Substances 0.000 description 60
- 238000006243 chemical reaction Methods 0.000 description 56
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 46
- 230000008569 process Effects 0.000 description 45
- 235000018102 proteins Nutrition 0.000 description 45
- 102000004169 proteins and genes Human genes 0.000 description 45
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 45
- 238000005481 NMR spectroscopy Methods 0.000 description 44
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 42
- 229920006395 saturated elastomer Polymers 0.000 description 35
- 150000007523 nucleic acids Chemical class 0.000 description 32
- 239000002904 solvent Substances 0.000 description 32
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 28
- 210000004027 cell Anatomy 0.000 description 27
- 238000001514 detection method Methods 0.000 description 27
- 102000039446 nucleic acids Human genes 0.000 description 27
- 108020004707 nucleic acids Proteins 0.000 description 27
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 24
- 239000003112 inhibitor Substances 0.000 description 21
- 239000000047 product Substances 0.000 description 21
- 239000011780 sodium chloride Substances 0.000 description 21
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
- 238000005259 measurement Methods 0.000 description 20
- 102000004877 Insulin Human genes 0.000 description 19
- 108090001061 Insulin Proteins 0.000 description 19
- 230000000875 corresponding effect Effects 0.000 description 19
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 18
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 17
- 108090000765 processed proteins & peptides Proteins 0.000 description 17
- 239000007787 solid Substances 0.000 description 17
- 239000000725 suspension Substances 0.000 description 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 16
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 16
- 238000004458 analytical method Methods 0.000 description 16
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 15
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 15
- 238000004128 high performance liquid chromatography Methods 0.000 description 15
- 239000012044 organic layer Substances 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 14
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 14
- 230000014509 gene expression Effects 0.000 description 14
- 238000004949 mass spectrometry Methods 0.000 description 14
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 14
- 238000003556 assay Methods 0.000 description 13
- 229940125396 insulin Drugs 0.000 description 13
- 229940002612 prodrug Drugs 0.000 description 13
- 239000000651 prodrug Substances 0.000 description 13
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000003153 chemical reaction reagent Substances 0.000 description 12
- 230000003247 decreasing effect Effects 0.000 description 12
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 12
- 230000001225 therapeutic effect Effects 0.000 description 12
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 11
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Natural products CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 11
- 238000009472 formulation Methods 0.000 description 11
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 11
- 238000010898 silica gel chromatography Methods 0.000 description 11
- 239000000758 substrate Substances 0.000 description 11
- 238000003786 synthesis reaction Methods 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- 239000004480 active ingredient Substances 0.000 description 10
- 239000003463 adsorbent Substances 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
- 206010022489 Insulin Resistance Diseases 0.000 description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 description 9
- 125000004429 atom Chemical group 0.000 description 9
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 9
- 238000004587 chromatography analysis Methods 0.000 description 9
- 239000012043 crude product Substances 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 238000000132 electrospray ionisation Methods 0.000 description 9
- 238000000605 extraction Methods 0.000 description 9
- 239000008103 glucose Substances 0.000 description 9
- 238000003018 immunoassay Methods 0.000 description 9
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 9
- 235000015277 pork Nutrition 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 229910052938 sodium sulfate Inorganic materials 0.000 description 9
- 235000011152 sodium sulphate Nutrition 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 8
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 8
- 229910000024 caesium carbonate Inorganic materials 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 8
- 235000019341 magnesium sulphate Nutrition 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 239000011159 matrix material Substances 0.000 description 8
- 239000002207 metabolite Substances 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 7
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical class OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 7
- 108700008625 Reporter Genes Proteins 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 239000008199 coating composition Substances 0.000 description 7
- 238000003745 diagnosis Methods 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- 230000026731 phosphorylation Effects 0.000 description 7
- 238000006366 phosphorylation reaction Methods 0.000 description 7
- 230000004481 post-translational protein modification Effects 0.000 description 7
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 7
- 235000017557 sodium bicarbonate Nutrition 0.000 description 7
- 238000013518 transcription Methods 0.000 description 7
- 230000035897 transcription Effects 0.000 description 7
- RFFLAFLAYFXFSW-UHFFFAOYSA-N 1,2-dichlorobenzene Chemical compound ClC1=CC=CC=C1Cl RFFLAFLAYFXFSW-UHFFFAOYSA-N 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- LEMUFSYUPGXXCM-JNEQYSBXSA-N caninsulin Chemical compound [Zn].C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3N=CN=C3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1C=NC=N1 LEMUFSYUPGXXCM-JNEQYSBXSA-N 0.000 description 6
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- 229940083542 sodium Drugs 0.000 description 6
- 235000015424 sodium Nutrition 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 239000012312 sodium hydride Substances 0.000 description 6
- 229910000104 sodium hydride Inorganic materials 0.000 description 6
- 239000012453 solvate Substances 0.000 description 6
- 238000001228 spectrum Methods 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- XDLNRRRJZOJTRW-UHFFFAOYSA-N thiohypochlorous acid Chemical compound ClS XDLNRRRJZOJTRW-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 108091026890 Coding region Proteins 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 5
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 5
- 239000012491 analyte Substances 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 238000002648 combination therapy Methods 0.000 description 5
- 229940111134 coxibs Drugs 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 125000004122 cyclic group Chemical group 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 239000003862 glucocorticoid Substances 0.000 description 5
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 5
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 238000002493 microarray Methods 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 229940044551 receptor antagonist Drugs 0.000 description 5
- 239000002464 receptor antagonist Substances 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 229960003010 sodium sulfate Drugs 0.000 description 5
- 238000004611 spectroscopical analysis Methods 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- DIIIISSCIXVANO-UHFFFAOYSA-N 1,2-Dimethylhydrazine Chemical compound CNNC DIIIISSCIXVANO-UHFFFAOYSA-N 0.000 description 4
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 4
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- JBMKAUGHUNFTOL-UHFFFAOYSA-N Aldoclor Chemical class C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O JBMKAUGHUNFTOL-UHFFFAOYSA-N 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 4
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 102000013266 Human Regular Insulin Human genes 0.000 description 4
- 108010090613 Human Regular Insulin Proteins 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 239000007832 Na2SO4 Substances 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 4
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 4
- YAJCHEVQCOHZDC-QMMNLEPNSA-N actrapid Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3N=CNC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@H](C)CC)[C@H](C)CC)[C@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C(N)=O)C1=CNC=N1 YAJCHEVQCOHZDC-QMMNLEPNSA-N 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 229940121363 anti-inflammatory agent Drugs 0.000 description 4
- 239000002260 anti-inflammatory agent Substances 0.000 description 4
- 239000003472 antidiabetic agent Substances 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 4
- 238000013528 artificial neural network Methods 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000012472 biological sample Substances 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 239000007859 condensation product Substances 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 238000003795 desorption Methods 0.000 description 4
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 239000005090 green fluorescent protein Substances 0.000 description 4
- 229940103471 humulin Drugs 0.000 description 4
- 150000002430 hydrocarbons Chemical group 0.000 description 4
- 201000001421 hyperglycemia Diseases 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 238000001616 ion spectroscopy Methods 0.000 description 4
- 239000007791 liquid phase Substances 0.000 description 4
- 239000012280 lithium aluminium hydride Substances 0.000 description 4
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 229960003512 nicotinic acid Drugs 0.000 description 4
- 235000001968 nicotinic acid Nutrition 0.000 description 4
- 239000011664 nicotinic acid Substances 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 229960002702 piroxicam Drugs 0.000 description 4
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 238000000513 principal component analysis Methods 0.000 description 4
- 238000012628 principal component regression Methods 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 4
- 238000003127 radioimmunoassay Methods 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000033764 rhythmic process Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 4
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- VZXTWGWHSMCWGA-UHFFFAOYSA-N 1,3,5-triazine-2,4-diamine Chemical compound NC1=NC=NC(N)=N1 VZXTWGWHSMCWGA-UHFFFAOYSA-N 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 101800000733 Angiotensin-2 Proteins 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 3
- 229940127291 Calcium channel antagonist Drugs 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 3
- 108010016626 Dipeptides Proteins 0.000 description 3
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 108010092277 Leptin Proteins 0.000 description 3
- 102000016267 Leptin Human genes 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 3
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 3
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 3
- 101150039326 PCK1 gene Proteins 0.000 description 3
- 108090000445 Parathyroid hormone Proteins 0.000 description 3
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 3
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 description 3
- 108010071390 Serum Albumin Proteins 0.000 description 3
- 102000007562 Serum Albumin Human genes 0.000 description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 229940093740 amino acid and derivative Drugs 0.000 description 3
- 239000000730 antalgic agent Substances 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 239000007900 aqueous suspension Substances 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 238000000668 atmospheric pressure chemical ionisation mass spectrometry Methods 0.000 description 3
- 238000001854 atmospheric pressure photoionisation mass spectrometry Methods 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 235000015278 beef Nutrition 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 229960001058 bupropion Drugs 0.000 description 3
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 3
- 239000000480 calcium channel blocker Substances 0.000 description 3
- 229910001424 calcium ion Inorganic materials 0.000 description 3
- 235000013877 carbamide Nutrition 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000007621 cluster analysis Methods 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000002852 cysteine proteinase inhibitor Substances 0.000 description 3
- 238000007405 data analysis Methods 0.000 description 3
- 238000003066 decision tree Methods 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 238000000572 ellipsometry Methods 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 229960002390 flurbiprofen Drugs 0.000 description 3
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 3
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 3
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 3
- 230000009229 glucose formation Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 150000002431 hydrogen Chemical group 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 229940126904 hypoglycaemic agent Drugs 0.000 description 3
- 229960001680 ibuprofen Drugs 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- 238000001114 immunoprecipitation Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 229960000905 indomethacin Drugs 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 239000004816 latex Substances 0.000 description 3
- 229920000126 latex Polymers 0.000 description 3
- 229940039781 leptin Drugs 0.000 description 3
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000007937 lozenge Substances 0.000 description 3
- 230000005291 magnetic effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 229960002704 metipranolol Drugs 0.000 description 3
- BQIPXWYNLPYNHW-UHFFFAOYSA-N metipranolol Chemical compound CC(C)NCC(O)COC1=CC(C)=C(OC(C)=O)C(C)=C1C BQIPXWYNLPYNHW-UHFFFAOYSA-N 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- 229960001785 mirtazapine Drugs 0.000 description 3
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 description 3
- 229960004270 nabumetone Drugs 0.000 description 3
- 229960002009 naproxen Drugs 0.000 description 3
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 3
- 150000002924 oxiranes Chemical class 0.000 description 3
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 3
- 229960005141 piperazine Drugs 0.000 description 3
- 210000002706 plastid Anatomy 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 108010029667 pramlintide Proteins 0.000 description 3
- NRKVKVQDUCJPIZ-MKAGXXMWSA-N pramlintide acetate Chemical compound C([C@@H](C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 NRKVKVQDUCJPIZ-MKAGXXMWSA-N 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000002461 renin inhibitor Substances 0.000 description 3
- 229940086526 renin-inhibitors Drugs 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 230000011218 segmentation Effects 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 230000003595 spectral effect Effects 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 229940126585 therapeutic drug Drugs 0.000 description 3
- 150000003573 thiols Chemical class 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 229960004441 tyrosine Drugs 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 229960004295 valine Drugs 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- FLCRKCCKSJQLQA-UHFFFAOYSA-N (1-methylsulfonylpiperidin-2-yl)methanol Chemical compound CS(=O)(=O)N1CCCCC1CO FLCRKCCKSJQLQA-UHFFFAOYSA-N 0.000 description 2
- BSMNRYCSBFHEMQ-KCJUWKMLSA-N (1r,5s)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane Chemical compound C1=C(Cl)C(Cl)=CC=C1[C@]1(CNC2)[C@@H]2C1 BSMNRYCSBFHEMQ-KCJUWKMLSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- XMAYWYJOQHXEEK-ZEQKJWHPSA-N (2S,4R)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@H]1O[C@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-ZEQKJWHPSA-N 0.000 description 2
- CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- FEHSEZUGDOTYAE-UHFFFAOYSA-N (4-fluorophenyl) trifluoromethanesulfonate Chemical compound FC1=CC=C(OS(=O)(=O)C(F)(F)F)C=C1 FEHSEZUGDOTYAE-UHFFFAOYSA-N 0.000 description 2
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 2
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 2
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- DVXDJQKEEKXJBW-UHFFFAOYSA-N 1-chloro-4-fluoro-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC(F)=CC=C1Cl DVXDJQKEEKXJBW-UHFFFAOYSA-N 0.000 description 2
- SJHRILRATRAHJL-UHFFFAOYSA-N 1-methylsulfonylpiperidine-2-carbaldehyde Chemical compound CS(=O)(=O)N1CCCCC1C=O SJHRILRATRAHJL-UHFFFAOYSA-N 0.000 description 2
- NKWYBAIDBGUFRD-UHFFFAOYSA-N 1-methylsulfonylpyrrolidine-2-carbaldehyde Chemical compound CS(=O)(=O)N1CCCC1C=O NKWYBAIDBGUFRD-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- LSKONYYRONEBKA-UHFFFAOYSA-N 2-Dodecanone Chemical compound CCCCCCCCCCC(C)=O LSKONYYRONEBKA-UHFFFAOYSA-N 0.000 description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 2
- PPLLIWYVCSXZHW-UHFFFAOYSA-N 2-chloro-3-fluoro-n-phenylaniline Chemical compound FC1=CC=CC(NC=2C=CC=CC=2)=C1Cl PPLLIWYVCSXZHW-UHFFFAOYSA-N 0.000 description 2
- JFTHZXWWFJYKCE-UHFFFAOYSA-N 2-chloro-4-fluoro-n-(4-fluorophenyl)aniline Chemical compound C1=CC(F)=CC=C1NC1=CC=C(F)C=C1Cl JFTHZXWWFJYKCE-UHFFFAOYSA-N 0.000 description 2
- PJXVLJVJDCLXQO-UHFFFAOYSA-N 2-ethenyl-1-methylsulfonylpiperidine Chemical compound CS(=O)(=O)N1CCCCC1C=C PJXVLJVJDCLXQO-UHFFFAOYSA-N 0.000 description 2
- VMEVTYCKTNNHIV-UHFFFAOYSA-N 2-fluoro-n-phenylaniline Chemical compound FC1=CC=CC=C1NC1=CC=CC=C1 VMEVTYCKTNNHIV-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- BCSVCWVQNOXFGL-UHFFFAOYSA-N 3,4-dihydro-4-oxo-3-((5-trifluoromethyl-2-benzothiazolyl)methyl)-1-phthalazine acetic acid Chemical compound O=C1C2=CC=CC=C2C(CC(=O)O)=NN1CC1=NC2=CC(C(F)(F)F)=CC=C2S1 BCSVCWVQNOXFGL-UHFFFAOYSA-N 0.000 description 2
- WIBSYPXJJKRRRB-UHFFFAOYSA-N 3,6-difluoro-9h-carbazole Chemical compound C1=C(F)C=C2C3=CC(F)=CC=C3NC2=C1 WIBSYPXJJKRRRB-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- XPCTZQVDEJYUGT-UHFFFAOYSA-N 3-hydroxy-2-methyl-4-pyrone Chemical compound CC=1OC=CC(=O)C=1O XPCTZQVDEJYUGT-UHFFFAOYSA-N 0.000 description 2
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 2
- IICCLYANAQEHCI-UHFFFAOYSA-N 4,5,6,7-tetrachloro-3',6'-dihydroxy-2',4',5',7'-tetraiodospiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound O1C(=O)C(C(=C(Cl)C(Cl)=C2Cl)Cl)=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 IICCLYANAQEHCI-UHFFFAOYSA-N 0.000 description 2
- BYZUXVJUDULKSD-UHFFFAOYSA-N 4-fluoro-1-(4-fluorophenyl)-2-nitrobenzene Chemical group [O-][N+](=O)C1=CC(F)=CC=C1C1=CC=C(F)C=C1 BYZUXVJUDULKSD-UHFFFAOYSA-N 0.000 description 2
- JKWHEAGMVRSASJ-UHFFFAOYSA-N 4-fluoro-2-nitro-1-phenylbenzene Chemical group [O-][N+](=O)C1=CC(F)=CC=C1C1=CC=CC=C1 JKWHEAGMVRSASJ-UHFFFAOYSA-N 0.000 description 2
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 2
- VAJIZAPXBKMPRO-UHFFFAOYSA-N 9-(oxiran-2-ylmethyl)carbazole Chemical compound C12=CC=CC=C2C2=CC=CC=C2N1CC1CO1 VAJIZAPXBKMPRO-UHFFFAOYSA-N 0.000 description 2
- 239000005541 ACE inhibitor Substances 0.000 description 2
- 101150032765 ARNTL gene Proteins 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- 102400000345 Angiotensin-2 Human genes 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical group CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- 229940123208 Biguanide Drugs 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229940123158 Cannabinoid CB1 receptor antagonist Drugs 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 2
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 2
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 2
- 229920002911 Colestipol Polymers 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 2
- 208000002249 Diabetes Complications Diseases 0.000 description 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 208000032928 Dyslipidaemia Diseases 0.000 description 2
- 108010008165 Etanercept Proteins 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 2
- 238000004252 FT/ICR mass spectrometry Methods 0.000 description 2
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 2
- DGMPVYSXXIOGJY-UHFFFAOYSA-N Fusaric acid Chemical compound CCCCC1=CC=C(C(O)=O)N=C1 DGMPVYSXXIOGJY-UHFFFAOYSA-N 0.000 description 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 2
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 2
- 208000002705 Glucose Intolerance Diseases 0.000 description 2
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 2
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 2
- 108010065920 Insulin Lispro Proteins 0.000 description 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 2
- 108091027974 Mature messenger RNA Proteins 0.000 description 2
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 2
- 238000004497 NIR spectroscopy Methods 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- MITFXPHMIHQXPI-UHFFFAOYSA-N Oraflex Chemical compound N=1C2=CC(C(C(O)=O)C)=CC=C2OC=1C1=CC=C(Cl)C=C1 MITFXPHMIHQXPI-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 102000003982 Parathyroid hormone Human genes 0.000 description 2
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 108010005991 Pork Regular Insulin Proteins 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 108090000783 Renin Proteins 0.000 description 2
- 102100028255 Renin Human genes 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000002847 Surgical Wound Diseases 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 108010049264 Teriparatide Proteins 0.000 description 2
- DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229960002632 acarbose Drugs 0.000 description 2
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 2
- 229960001466 acetohexamide Drugs 0.000 description 2
- VGZSUPCWNCWDAN-UHFFFAOYSA-N acetohexamide Chemical compound C1=CC(C(=O)C)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 VGZSUPCWNCWDAN-UHFFFAOYSA-N 0.000 description 2
- 229960004308 acetylcysteine Drugs 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- 230000001919 adrenal effect Effects 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 239000000048 adrenergic agonist Substances 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 125000003158 alcohol group Chemical group 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- 229960004538 alprazolam Drugs 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229940025084 amphetamine Drugs 0.000 description 2
- 229950006323 angiotensin ii Drugs 0.000 description 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
- 239000003524 antilipemic agent Substances 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 125000001769 aryl amino group Chemical group 0.000 description 2
- 125000005110 aryl thio group Chemical group 0.000 description 2
- YCOXTKKNXUZSKD-UHFFFAOYSA-N as-o-xylenol Natural products CC1=CC=C(O)C=C1C YCOXTKKNXUZSKD-UHFFFAOYSA-N 0.000 description 2
- 238000000065 atmospheric pressure chemical ionisation Methods 0.000 description 2
- 238000004630 atomic force microscopy Methods 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- UUQMNUMQCIQDMZ-UHFFFAOYSA-N betahistine Chemical compound CNCCC1=CC=CC=N1 UUQMNUMQCIQDMZ-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 150000001649 bromium compounds Chemical class 0.000 description 2
- 229960004436 budesonide Drugs 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 2
- 229960001736 buprenorphine Drugs 0.000 description 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 2
- 229960005069 calcium Drugs 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000003555 cannabinoid 1 receptor antagonist Substances 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 229960001222 carteolol Drugs 0.000 description 2
- LWAFSWPYPHEXKX-UHFFFAOYSA-N carteolol Chemical compound N1C(=O)CCC2=C1C=CC=C2OCC(O)CNC(C)(C)C LWAFSWPYPHEXKX-UHFFFAOYSA-N 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 229960000590 celecoxib Drugs 0.000 description 2
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002301 cellulose acetate Polymers 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 239000000544 cholinesterase inhibitor Substances 0.000 description 2
- 238000002487 chromatin immunoprecipitation Methods 0.000 description 2
- YKCWQPZFAFZLBI-UHFFFAOYSA-N cibacron blue Chemical compound C1=2C(=O)C3=CC=CC=C3C(=O)C=2C(N)=C(S(O)(=O)=O)C=C1NC(C=C1S(O)(=O)=O)=CC=C1NC(N=1)=NC(Cl)=NC=1NC1=CC=CC=C1S(O)(=O)=O YKCWQPZFAFZLBI-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Natural products OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 2
- 238000013145 classification model Methods 0.000 description 2
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 2
- 229960002896 clonidine Drugs 0.000 description 2
- GMRWGQCZJGVHKL-UHFFFAOYSA-N colestipol Chemical compound ClCC1CO1.NCCNCCNCCNCCN GMRWGQCZJGVHKL-UHFFFAOYSA-N 0.000 description 2
- 229960002604 colestipol Drugs 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000013058 crude material Substances 0.000 description 2
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 229960001251 denosumab Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- SSQJFGMEZBFMNV-PMACEKPBSA-N dexanabinol Chemical compound C1C(CO)=CC[C@@H]2C(C)(C)OC3=CC(C(C)(C)CCCCCC)=CC(O)=C3[C@H]21 SSQJFGMEZBFMNV-PMACEKPBSA-N 0.000 description 2
- 208000033679 diabetic kidney disease Diseases 0.000 description 2
- 238000012774 diagnostic algorithm Methods 0.000 description 2
- BPXYEYJNCXITEY-UHFFFAOYSA-N diazonio(trifluoromethoxy)azanide Chemical compound FC(F)(F)ON=[N+]=[N-] BPXYEYJNCXITEY-UHFFFAOYSA-N 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 2
- 229960000616 diflunisal Drugs 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 2
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 229960002866 duloxetine Drugs 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000002848 electrochemical method Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000002337 electrophoretic mobility shift assay Methods 0.000 description 2
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- GKIPXFAANLTWBM-UHFFFAOYSA-N epibromohydrin Chemical compound BrCC1CO1 GKIPXFAANLTWBM-UHFFFAOYSA-N 0.000 description 2
- 229960004341 escitalopram Drugs 0.000 description 2
- WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 description 2
- 229940031098 ethanolamine Drugs 0.000 description 2
- WYBRECQQABVCJS-UHFFFAOYSA-N ethyl 1-methylsulfonylpiperidine-2-carboxylate Chemical compound CCOC(=O)C1CCCCN1S(C)(=O)=O WYBRECQQABVCJS-UHFFFAOYSA-N 0.000 description 2
- 229960005293 etodolac Drugs 0.000 description 2
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 2
- 229960004945 etoricoxib Drugs 0.000 description 2
- MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 229960002714 fluticasone Drugs 0.000 description 2
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 2
- 238000001640 fractional crystallisation Methods 0.000 description 2
- DDRPCXLAQZKBJP-UHFFFAOYSA-N furfurylamine Chemical compound NCC1=CC=CO1 DDRPCXLAQZKBJP-UHFFFAOYSA-N 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 229960003627 gemfibrozil Drugs 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229960004580 glibenclamide Drugs 0.000 description 2
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 2
- 229960002442 glucosamine Drugs 0.000 description 2
- 230000002641 glycemic effect Effects 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 229960002449 glycine Drugs 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 229940115747 halobetasol Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- WNRQPCUGRUFHED-DETKDSODSA-N humalog Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 WNRQPCUGRUFHED-DETKDSODSA-N 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 2
- 201000008980 hyperinsulinism Diseases 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- SNHMUERNLJLMHN-UHFFFAOYSA-N iodobenzene Chemical compound IC1=CC=CC=C1 SNHMUERNLJLMHN-UHFFFAOYSA-N 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 2
- 229960003827 isosorbide mononitrate Drugs 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- 125000000468 ketone group Chemical group 0.000 description 2
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 2
- 229960000991 ketoprofen Drugs 0.000 description 2
- 229960001632 labetalol Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- GXESHMAMLJKROZ-IAPPQJPRSA-N lasofoxifene Chemical compound C1([C@@H]2[C@@H](C3=CC=C(C=C3CC2)O)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 GXESHMAMLJKROZ-IAPPQJPRSA-N 0.000 description 2
- 229960002367 lasofoxifene Drugs 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 229960000831 levobunolol Drugs 0.000 description 2
- IXHBTMCLRNMKHZ-LBPRGKRZSA-N levobunolol Chemical compound O=C1CCCC2=C1C=CC=C2OC[C@@H](O)CNC(C)(C)C IXHBTMCLRNMKHZ-LBPRGKRZSA-N 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 238000007477 logistic regression Methods 0.000 description 2
- 229960004844 lovastatin Drugs 0.000 description 2
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 2
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 2
- 229960004090 maprotiline Drugs 0.000 description 2
- QSLMDECMDJKHMQ-GSXCWMCISA-N maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 description 2
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 2
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 2
- 229960004640 memantine Drugs 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 2
- 229960001797 methadone Drugs 0.000 description 2
- IRLDTDIFEQDIND-UHFFFAOYSA-N methyl 1-methylsulfonylpyrrolidine-2-carboxylate Chemical compound COC(=O)C1CCCN1S(C)(=O)=O IRLDTDIFEQDIND-UHFFFAOYSA-N 0.000 description 2
- CDMLLMOLWUKNEK-AOHDELFNSA-M methylprednisolone suleptanate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCCCCCC(=O)N(C)CCS([O-])(=O)=O)CC[C@H]21 CDMLLMOLWUKNEK-AOHDELFNSA-M 0.000 description 2
- 229950010796 methylprednisolone suleptanate Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 description 2
- 229960004644 moclobemide Drugs 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- RAHOHKTXDOPJHI-UHFFFAOYSA-N n-(2-bromoethyl)-4-chlorobenzenesulfonamide Chemical compound ClC1=CC=C(S(=O)(=O)NCCBr)C=C1 RAHOHKTXDOPJHI-UHFFFAOYSA-N 0.000 description 2
- IOXWRKGTSWFDAU-UHFFFAOYSA-N n-[2-(hydroxymethyl)phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC=C1CO IOXWRKGTSWFDAU-UHFFFAOYSA-N 0.000 description 2
- DVFPSRARRBNMBH-UHFFFAOYSA-N n-butyl-3-(2,4-dichlorophenyl)-n-ethyl-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-amine Chemical compound CC1=NN2C(N(CC)CCCC)=CC(C)=NC2=C1C1=CC=C(Cl)C=C1Cl DVFPSRARRBNMBH-UHFFFAOYSA-N 0.000 description 2
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 2
- 229960003086 naltrexone Drugs 0.000 description 2
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 2
- 229960001597 nifedipine Drugs 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 231100000344 non-irritating Toxicity 0.000 description 2
- 229940121367 non-opioid analgesics Drugs 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- 229940103453 novolin Drugs 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 239000000014 opioid analgesic Substances 0.000 description 2
- 229940005483 opioid analgesics Drugs 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229960001319 parathyroid hormone Drugs 0.000 description 2
- 239000000199 parathyroid hormone Substances 0.000 description 2
- 229960002296 paroxetine Drugs 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 238000003909 pattern recognition Methods 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 description 2
- 229960005301 pentazocine Drugs 0.000 description 2
- 229960001476 pentoxifylline Drugs 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 150000004032 porphyrins Chemical class 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 235000019814 powdered cellulose Nutrition 0.000 description 2
- 229920003124 powdered cellulose Polymers 0.000 description 2
- 229960003611 pramlintide Drugs 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 235000008160 pyridoxine Nutrition 0.000 description 2
- 239000011677 pyridoxine Substances 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000005493 quinolyl group Chemical group 0.000 description 2
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 239000013074 reference sample Substances 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000012340 reverse transcriptase PCR Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000001020 rhythmical effect Effects 0.000 description 2
- JZCPYUJPEARBJL-UHFFFAOYSA-N rimonabant Chemical compound CC=1C(C(=O)NN2CCCCC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 JZCPYUJPEARBJL-UHFFFAOYSA-N 0.000 description 2
- 229960003015 rimonabant Drugs 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- 229940089617 risedronate Drugs 0.000 description 2
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 2
- 229960000371 rofecoxib Drugs 0.000 description 2
- 229940081623 rose bengal Drugs 0.000 description 2
- 229930187593 rose bengal Natural products 0.000 description 2
- STRXNPAVPKGJQR-UHFFFAOYSA-N rose bengal A Natural products O1C(=O)C(C(=CC=C2Cl)Cl)=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 STRXNPAVPKGJQR-UHFFFAOYSA-N 0.000 description 2
- 229960004586 rosiglitazone Drugs 0.000 description 2
- 229960001860 salicylate Drugs 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 2
- WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 229960001153 serine Drugs 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 229940009188 silver Drugs 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 235000010265 sodium sulphite Nutrition 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- 239000002195 soluble material Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000003871 sulfonates Chemical class 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229960000894 sulindac Drugs 0.000 description 2
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 2
- 238000012706 support-vector machine Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 229940037128 systemic glucocorticoids Drugs 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- 229960003676 tenidap Drugs 0.000 description 2
- LXIKEPCNDFVJKC-QXMHVHEDSA-N tenidap Chemical compound C12=CC(Cl)=CC=C2N(C(=O)N)C(=O)\C1=C(/O)C1=CC=CS1 LXIKEPCNDFVJKC-QXMHVHEDSA-N 0.000 description 2
- OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 description 2
- VCVWXKKWDOJNIT-ZOMKSWQUSA-N tesofensine Chemical compound C1([C@H]2C[C@@H]3CC[C@@H](N3C)[C@@H]2COCC)=CC=C(Cl)C(Cl)=C1 VCVWXKKWDOJNIT-ZOMKSWQUSA-N 0.000 description 2
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- 238000011285 therapeutic regimen Methods 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 229960004605 timolol Drugs 0.000 description 2
- 229960002277 tolazamide Drugs 0.000 description 2
- OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- OFOUJHGWJJEVMF-SZJYFORJSA-N trichodimerol Chemical compound C\C=C\C=C\C(\O)=C(/[C@@H]12)C(=O)[C@@]3(C)[C@H]4\C(=C(\O)/C=C/C=C/C)C(=O)[C@]2(C)[C@@]2(O)O[C@]1(C)[C@]3(O)O[C@]24C OFOUJHGWJJEVMF-SZJYFORJSA-N 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- VFJYIHQDILEQNR-UHFFFAOYSA-M trimethylsulfanium;iodide Chemical compound [I-].C[S+](C)C VFJYIHQDILEQNR-UHFFFAOYSA-M 0.000 description 2
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 2
- 229960001641 troglitazone Drugs 0.000 description 2
- LEHFPXVYPMWYQD-XHIJKXOTSA-N ulobetasol Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H](C)[C@@](C(=O)CCl)(O)[C@@]2(C)C[C@@H]1O LEHFPXVYPMWYQD-XHIJKXOTSA-N 0.000 description 2
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 2
- 239000002691 unilamellar liposome Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229940011671 vitamin b6 Drugs 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 2
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 description 2
- 229960000607 ziprasidone Drugs 0.000 description 2
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 2
- 229950005346 zopolrestat Drugs 0.000 description 2
- BRLQWZUYTZBJKN-GSVOUGTGSA-N (+)-Epichlorohydrin Chemical compound ClC[C@@H]1CO1 BRLQWZUYTZBJKN-GSVOUGTGSA-N 0.000 description 1
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- GDFVYUDIAQQDTA-OLZOCXBDSA-N (+)-cpca Chemical compound COC(=O)[C@H]1CN(C)CC[C@@H]1C1=CC=C(Cl)C=C1 GDFVYUDIAQQDTA-OLZOCXBDSA-N 0.000 description 1
- YQYVFVRQLZMJKJ-JBBXEZCESA-N (+)-cyclazocine Chemical compound C([C@@]1(C)C2=CC(O)=CC=C2C[C@@H]2[C@@H]1C)CN2CC1CC1 YQYVFVRQLZMJKJ-JBBXEZCESA-N 0.000 description 1
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 description 1
- CEMAWMOMDPGJMB-UHFFFAOYSA-N (+-)-Oxprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1OCC=C CEMAWMOMDPGJMB-UHFFFAOYSA-N 0.000 description 1
- BRLQWZUYTZBJKN-VKHMYHEASA-N (-)-Epichlorohydrin Chemical compound ClC[C@H]1CO1 BRLQWZUYTZBJKN-VKHMYHEASA-N 0.000 description 1
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- XYBYLDAUSPCICO-UHFFFAOYSA-N (1-methylsulfonylpyrrolidin-2-yl)methanol Chemical compound CS(=O)(=O)N1CCCC1CO XYBYLDAUSPCICO-UHFFFAOYSA-N 0.000 description 1
- IGLYMJRIWWIQQE-QUOODJBBSA-N (1S,2R)-2-phenylcyclopropan-1-amine (1R,2S)-2-phenylcyclopropan-1-amine Chemical compound N[C@H]1C[C@@H]1C1=CC=CC=C1.N[C@@H]1C[C@H]1C1=CC=CC=C1 IGLYMJRIWWIQQE-QUOODJBBSA-N 0.000 description 1
- RJNRORZRFGUAKL-ADMBVFOFSA-N (1r)-1-[(3ar,5r,6s,6ar)-6-[3-(dimethylamino)propoxy]-2,2-dimethyl-3a,5,6,6a-tetrahydrofuro[2,3-d][1,3]dioxol-5-yl]ethane-1,2-diol;hydrochloride Chemical compound Cl.O1C(C)(C)O[C@@H]2[C@@H](OCCCN(C)C)[C@@H]([C@H](O)CO)O[C@@H]21 RJNRORZRFGUAKL-ADMBVFOFSA-N 0.000 description 1
- NXWGWUVGUSFQJC-GFCCVEGCSA-N (2r)-1-[(2-methyl-1h-indol-4-yl)oxy]-3-(propan-2-ylamino)propan-2-ol Chemical compound CC(C)NC[C@@H](O)COC1=CC=CC2=C1C=C(C)N2 NXWGWUVGUSFQJC-GFCCVEGCSA-N 0.000 description 1
- YWPHCCPCQOJSGZ-LLVKDONJSA-N (2r)-2-[(2-ethoxyphenoxy)methyl]morpholine Chemical compound CCOC1=CC=CC=C1OC[C@@H]1OCCNC1 YWPHCCPCQOJSGZ-LLVKDONJSA-N 0.000 description 1
- RJMIEHBSYVWVIN-LLVKDONJSA-N (2r)-2-[4-(3-oxo-1h-isoindol-2-yl)phenyl]propanoic acid Chemical compound C1=CC([C@H](C(O)=O)C)=CC=C1N1C(=O)C2=CC=CC=C2C1 RJMIEHBSYVWVIN-LLVKDONJSA-N 0.000 description 1
- VYPKEODFNOEZGS-VIFPVBQESA-N (2r)-2-acetamido-3-(2-hydroxybenzoyl)sulfanylpropanoic acid Chemical compound CC(=O)N[C@H](C(O)=O)CSC(=O)C1=CC=CC=C1O VYPKEODFNOEZGS-VIFPVBQESA-N 0.000 description 1
- POCOFJTXQYWTDN-LREBCSMRSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;n-(1-methylpyrrolidin-2-ylidene)-n'-phenylpyrrolidine-1-carboximidamide Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.CN1CCCC1=NC(N1CCCC1)=NC1=CC=CC=C1 POCOFJTXQYWTDN-LREBCSMRSA-N 0.000 description 1
- FOZFSEMFCIPOSZ-SPCKQMHLSA-N (2r,3r,4r,5s)-2-(hydroxymethyl)-1-[[(2r,3s,4s,5r,6s)-3,4,5-trihydroxy-6-methoxyoxan-2-yl]methyl]piperidine-3,4,5-triol;trihydrate Chemical compound O.O.O.O[C@H]1[C@H](O)[C@@H](O)[C@@H](OC)O[C@@H]1CN1[C@H](CO)[C@@H](O)[C@H](O)[C@@H](O)C1.O[C@H]1[C@H](O)[C@@H](O)[C@@H](OC)O[C@@H]1CN1[C@H](CO)[C@@H](O)[C@H](O)[C@@H](O)C1 FOZFSEMFCIPOSZ-SPCKQMHLSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
- MDKGKXOCJGEUJW-VIFPVBQESA-N (2s)-2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-VIFPVBQESA-N 0.000 description 1
- AUDFHJLSHQWFQQ-SFHVURJKSA-N (2s)-2-[[2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetyl]amino]-3-hydroxypropanoic acid Chemical compound CC1=C(CC(=O)N[C@@H](CO)C(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 AUDFHJLSHQWFQQ-SFHVURJKSA-N 0.000 description 1
- SBBYBXSFWOLDDG-JLTOFOAXSA-N (2s)-n-[(1r)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-n-methylpiperazine-1-carboxamide Chemical compound C1([C@H]2CNCCN2C(=O)N(C)[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)=CC=C(F)C=C1C SBBYBXSFWOLDDG-JLTOFOAXSA-N 0.000 description 1
- ZIWFCOIGUNPHPM-HKUYNNGSSA-N (2s,3s)-n-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenylpiperidin-3-amine Chemical compound COC1=CC=C(OC(F)(F)F)C=C1CN[C@@H]1[C@H](C=2C=CC=CC=2)NCCC1 ZIWFCOIGUNPHPM-HKUYNNGSSA-N 0.000 description 1
- LHYMPSWMHXUWSK-STZFKDTASA-N (2z)-4-(3,4-dichlorophenyl)-2-[[2-(4-methylpiperazin-1-yl)phenyl]methylidene]thiomorpholin-3-one Chemical compound C1CN(C)CCN1C1=CC=CC=C1\C=C/1C(=O)N(C=2C=C(Cl)C(Cl)=CC=2)CCS\1 LHYMPSWMHXUWSK-STZFKDTASA-N 0.000 description 1
- XYRIRLDHOQSNLW-UHFFFAOYSA-N (3-oxo-1h-2-benzofuran-1-yl) 2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetate Chemical compound CC1=C(CC(=O)OC2C3=CC=CC=C3C(=O)O2)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 XYRIRLDHOQSNLW-UHFFFAOYSA-N 0.000 description 1
- SHCYQUDTKWHARF-UHFFFAOYSA-N (3-oxo-1h-2-benzofuran-1-yl) 2-acetyloxybenzoate Chemical compound CC(=O)OC1=CC=CC=C1C(=O)OC1C2=CC=CC=C2C(=O)O1 SHCYQUDTKWHARF-UHFFFAOYSA-N 0.000 description 1
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 1
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 1
- BVNJBATUHVXZKP-QXMHVHEDSA-N (3z)-6-chloro-5-fluoro-3-[hydroxy(thiophen-2-yl)methylidene]-2-oxoindole-1-carboxamide Chemical compound C12=CC(F)=C(Cl)C=C2N(C(=O)N)C(=O)\C1=C(/O)C1=CC=CS1 BVNJBATUHVXZKP-QXMHVHEDSA-N 0.000 description 1
- ZDHHGGFQZRPUSN-UHFFFAOYSA-N (4-chlorophenyl)-[3-(2h-tetrazol-5-ylmethyl)indol-1-yl]methanone Chemical compound C1=CC(Cl)=CC=C1C(=O)N1C2=CC=CC=C2C(CC2=NNN=N2)=C1 ZDHHGGFQZRPUSN-UHFFFAOYSA-N 0.000 description 1
- PPQZABOURJVKNI-UHFFFAOYSA-N (4-fluorophenyl)-[4-(4-fluorophenyl)-4-hydroxy-1-methylpiperidin-3-yl]methanone Chemical compound C1N(C)CCC(O)(C=2C=CC(F)=CC=2)C1C(=O)C1=CC=C(F)C=C1 PPQZABOURJVKNI-UHFFFAOYSA-N 0.000 description 1
- OSCCDBFHNMXNME-YUPRTTJUSA-N (4S)-4-hydroxy-L-isoleucine zwitterion Chemical compound C[C@H](O)[C@H](C)[C@H](N)C(O)=O OSCCDBFHNMXNME-YUPRTTJUSA-N 0.000 description 1
- AXJQVVLKUYCICH-OAQYLSRUSA-N (4s)-5-(4-chlorophenyl)-n-(4-chlorophenyl)sulfonyl-n'-methyl-4-phenyl-3,4-dihydropyrazole-2-carboximidamide Chemical compound C=1C=C(Cl)C=CC=1C([C@H](C1)C=2C=CC=CC=2)=NN1C(=NC)NS(=O)(=O)C1=CC=C(Cl)C=C1 AXJQVVLKUYCICH-OAQYLSRUSA-N 0.000 description 1
- QGKMIGUHVLGJBR-UHFFFAOYSA-M (4z)-1-(3-methylbutyl)-4-[[1-(3-methylbutyl)quinolin-1-ium-4-yl]methylidene]quinoline;iodide Chemical compound [I-].C12=CC=CC=C2N(CCC(C)C)C=CC1=CC1=CC=[N+](CCC(C)C)C2=CC=CC=C12 QGKMIGUHVLGJBR-UHFFFAOYSA-M 0.000 description 1
- JFTOCKFCHJCDDX-UVTDQMKNSA-N (4z)-4-benzylidene-5,6,7,8-tetrahydroisoquinoline-1,3-dione Chemical compound C1CCCC2=C1C(=O)NC(=O)\C2=C/C1=CC=CC=C1 JFTOCKFCHJCDDX-UVTDQMKNSA-N 0.000 description 1
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 1
- VDNZZIYSCXESNI-ILSZZQPISA-N (6s,8s,9s,10r,11s,13s,14s,17s)-17-acetyl-11-hydroxy-6,10,13-trimethyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@H](C(C)=O)CC[C@H]21 VDNZZIYSCXESNI-ILSZZQPISA-N 0.000 description 1
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 1
- DFELGYQKEOCHOA-BZAFBGKRSA-N (8s,11r,13s,14s,17s)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=C1 DFELGYQKEOCHOA-BZAFBGKRSA-N 0.000 description 1
- RWIUTHWKQHRQNP-ZDVGBALWSA-N (9e,12e)-n-(1-phenylethyl)octadeca-9,12-dienamide Chemical compound CCCCC\C=C\C\C=C\CCCCCCCC(=O)NC(C)C1=CC=CC=C1 RWIUTHWKQHRQNP-ZDVGBALWSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- SYTBZMRGLBWNTM-SNVBAGLBSA-N (R)-flurbiprofen Chemical compound FC1=CC([C@H](C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-SNVBAGLBSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UWTATZPHSA-M (R)-lactate Chemical compound C[C@@H](O)C([O-])=O JVTAAEKCZFNVCJ-UWTATZPHSA-M 0.000 description 1
- YCFJXOFFQLPCHD-UHFFFAOYSA-N (S)-Spinacine Chemical compound C1NC(C(=O)O)CC2=C1NC=N2 YCFJXOFFQLPCHD-UHFFFAOYSA-N 0.000 description 1
- MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 description 1
- OPPLDIXFHYTSSR-GLECISQGSA-N (ne)-n-(1-methylpyrrolidin-2-ylidene)-n'-phenylmorpholine-4-carboximidamide Chemical compound CN1CCC\C1=N/C(N1CCOCC1)=NC1=CC=CC=C1 OPPLDIXFHYTSSR-GLECISQGSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- RHUYHJGZWVXEHW-UHFFFAOYSA-N 1,1-Dimethyhydrazine Chemical compound CN(C)N RHUYHJGZWVXEHW-UHFFFAOYSA-N 0.000 description 1
- DBNWBEGCONIRGQ-UHFFFAOYSA-N 1,1-diphenylpropan-2-one Chemical compound C=1C=CC=CC=1C(C(=O)C)C1=CC=CC=C1 DBNWBEGCONIRGQ-UHFFFAOYSA-N 0.000 description 1
- PUNXVEAWLAVABA-UHFFFAOYSA-N 1,2,3,4-tetrahydroanthracene;1,2,5,6-tetrahydroanthracene Chemical compound C1=CC=C2C=C(CCCC3)C3=CC2=C1.C1=CCCC2=C1C=C1CCC=CC1=C2 PUNXVEAWLAVABA-UHFFFAOYSA-N 0.000 description 1
- 125000005943 1,2,3,6-tetrahydropyridyl group Chemical group 0.000 description 1
- FHGWEHGZBUBQKL-UHFFFAOYSA-N 1,2-benzothiazepine Chemical compound S1N=CC=CC2=CC=CC=C12 FHGWEHGZBUBQKL-UHFFFAOYSA-N 0.000 description 1
- BGJSXRVXTHVRSN-UHFFFAOYSA-N 1,3,5-trioxane Chemical compound C1OCOCO1 BGJSXRVXTHVRSN-UHFFFAOYSA-N 0.000 description 1
- OJWMDOIYUCEXNF-UHFFFAOYSA-N 1,3-dihydro-2,1-benzothiazole 2,2-dioxide Chemical compound C1=CC=C2NS(=O)(=O)CC2=C1 OJWMDOIYUCEXNF-UHFFFAOYSA-N 0.000 description 1
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 1
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- ZHXUEUKVDMWSKV-UHFFFAOYSA-N 1-(3,5-ditert-butyl-4-hydroxyphenyl)hex-5-yn-1-one Chemical compound CC(C)(C)C1=CC(C(=O)CCCC#C)=CC(C(C)(C)C)=C1O ZHXUEUKVDMWSKV-UHFFFAOYSA-N 0.000 description 1
- SUQZXLUIKZXADU-UHFFFAOYSA-N 1-(4-chlorophenyl)sulfonyl-3-[4-(dimethylamino)phenyl]urea Chemical compound C1=CC(N(C)C)=CC=C1NC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 SUQZXLUIKZXADU-UHFFFAOYSA-N 0.000 description 1
- RCFWWYVWLFLGRO-UHFFFAOYSA-N 1-(butylamino)-3-(2,5-dichlorophenoxy)propan-2-ol Chemical compound CCCCNCC(O)COC1=CC(Cl)=CC=C1Cl RCFWWYVWLFLGRO-UHFFFAOYSA-N 0.000 description 1
- MOHYOXXOKFQHDC-UHFFFAOYSA-N 1-(chloromethyl)-4-methoxybenzene Chemical compound COC1=CC=C(CCl)C=C1 MOHYOXXOKFQHDC-UHFFFAOYSA-N 0.000 description 1
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 1
- VFIDUCMKNJIJTO-UHFFFAOYSA-N 1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)-2-butanol Chemical compound CC(C)NC(C)C(O)COC1=CC=C(C)C2=C1CCC2 VFIDUCMKNJIJTO-UHFFFAOYSA-N 0.000 description 1
- QXKZYKFVUJEGTM-UHFFFAOYSA-N 1-[4-(2-cyclopropyloxyethyl)phenoxy]-3-(dimethylamino)propan-2-ol Chemical compound C1=CC(OCC(O)CN(C)C)=CC=C1CCOC1CC1 QXKZYKFVUJEGTM-UHFFFAOYSA-N 0.000 description 1
- YZUPZGFPHUVJKC-UHFFFAOYSA-N 1-bromo-2-methoxyethane Chemical compound COCCBr YZUPZGFPHUVJKC-UHFFFAOYSA-N 0.000 description 1
- HLVFKOKELQSXIQ-UHFFFAOYSA-N 1-bromo-2-methylpropane Chemical compound CC(C)CBr HLVFKOKELQSXIQ-UHFFFAOYSA-N 0.000 description 1
- AITNMTXHTIIIBB-UHFFFAOYSA-N 1-bromo-4-fluorobenzene Chemical compound FC1=CC=C(Br)C=C1 AITNMTXHTIIIBB-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- PWDXMUGOYSJNDS-UHFFFAOYSA-N 1-carbazol-9-yl-3-(furan-2-ylmethylamino)propan-2-ol Chemical compound C12=CC=CC=C2C2=CC=CC=C2N1CC(O)CNCC1=CC=CO1 PWDXMUGOYSJNDS-UHFFFAOYSA-N 0.000 description 1
- XTOBSLUVJNOXGB-UHFFFAOYSA-N 1-cyclooctyl-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NC1CCCCCCC1 XTOBSLUVJNOXGB-UHFFFAOYSA-N 0.000 description 1
- YETULFFXNIHQLK-UHFFFAOYSA-N 1-ethynyl-4-(2-fluorophenyl)benzene Chemical compound FC1=CC=CC=C1C1=CC=C(C#C)C=C1 YETULFFXNIHQLK-UHFFFAOYSA-N 0.000 description 1
- HPJCIBVGJBEJPU-UHFFFAOYSA-N 1-fluoro-9h-carbazole Chemical compound N1C2=CC=CC=C2C2=C1C(F)=CC=C2 HPJCIBVGJBEJPU-UHFFFAOYSA-N 0.000 description 1
- ITUWITWZEKHMRV-UHFFFAOYSA-N 1-heptadecoxyhexadecan-1-ol Chemical compound C(CCCCCCCCCCCCCCCC)OC(O)CCCCCCCCCCCCCCC ITUWITWZEKHMRV-UHFFFAOYSA-N 0.000 description 1
- SJJCQDRGABAVBB-UHFFFAOYSA-N 1-hydroxy-2-naphthoic acid Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CC=C21 SJJCQDRGABAVBB-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- TWIRUSBHSPLVST-UHFFFAOYSA-N 1-methylsulfonyl-2-(oxiran-2-yl)piperidine Chemical compound CS(=O)(=O)N1CCCCC1C1OC1 TWIRUSBHSPLVST-UHFFFAOYSA-N 0.000 description 1
- BYOUKSKDPCDNMO-UHFFFAOYSA-N 1-methylsulfonyl-2-(oxiran-2-yl)pyrrolidine Chemical compound CS(=O)(=O)N1CCCC1C1OC1 BYOUKSKDPCDNMO-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- RQEUFEKYXDPUSK-UHFFFAOYSA-N 1-phenylethylamine Chemical compound CC(N)C1=CC=CC=C1 RQEUFEKYXDPUSK-UHFFFAOYSA-N 0.000 description 1
- ULIDRMKBVYYVIQ-UHFFFAOYSA-N 1-phenyltetrazol-5-amine Chemical compound NC1=NN=NN1C1=CC=CC=C1 ULIDRMKBVYYVIQ-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 102000004277 11-beta-hydroxysteroid dehydrogenases Human genes 0.000 description 1
- 108090000874 11-beta-hydroxysteroid dehydrogenases Proteins 0.000 description 1
- WHBHBVVOGNECLV-OBQKJFGGSA-N 11-deoxycortisol Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 WHBHBVVOGNECLV-OBQKJFGGSA-N 0.000 description 1
- ABEXEQSGABRUHS-UHFFFAOYSA-N 16-methylheptadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C ABEXEQSGABRUHS-UHFFFAOYSA-N 0.000 description 1
- IHWDSEPNZDYMNF-UHFFFAOYSA-N 1H-indol-2-amine Chemical compound C1=CC=C2NC(N)=CC2=C1 IHWDSEPNZDYMNF-UHFFFAOYSA-N 0.000 description 1
- OFGDSGVGRWPQJQ-UHFFFAOYSA-N 1h-imidazol-1-ium;acetate Chemical class CC(O)=O.C1=CNC=N1 OFGDSGVGRWPQJQ-UHFFFAOYSA-N 0.000 description 1
- XYHKNCXZYYTLRG-UHFFFAOYSA-N 1h-imidazole-2-carbaldehyde Chemical compound O=CC1=NC=CN1 XYHKNCXZYYTLRG-UHFFFAOYSA-N 0.000 description 1
- IANXAXNUNBAWBA-UHFFFAOYSA-N 2,2,3-trimethylundecane Chemical compound CCCCCCCCC(C)C(C)(C)C IANXAXNUNBAWBA-UHFFFAOYSA-N 0.000 description 1
- SRETXDDCKMOQNE-UHFFFAOYSA-N 2,3-bis(4-methoxyphenyl)-1h-indole Chemical compound C1=CC(OC)=CC=C1C1=C(C=2C=CC(OC)=CC=2)C2=CC=CC=C2N1 SRETXDDCKMOQNE-UHFFFAOYSA-N 0.000 description 1
- GVYVHZKTSVDMNT-UHFFFAOYSA-N 2,3-dihydro-1,2-benzothiazole 1,1-dioxide Chemical compound C1=CC=C2S(=O)(=O)NCC2=C1 GVYVHZKTSVDMNT-UHFFFAOYSA-N 0.000 description 1
- SNLMPYICHHTGGG-UHFFFAOYSA-N 2,7-difluoro-9h-carbazole Chemical compound FC1=CC=C2C3=CC=C(F)C=C3NC2=C1 SNLMPYICHHTGGG-UHFFFAOYSA-N 0.000 description 1
- IZGMROSLQHXRDZ-UHFFFAOYSA-N 2-(1-propyl-4,9-dihydro-3h-pyrano[3,4-b]indol-1-yl)acetic acid Chemical compound N1C2=CC=CC=C2C2=C1C(CCC)(CC(O)=O)OCC2 IZGMROSLQHXRDZ-UHFFFAOYSA-N 0.000 description 1
- KLIVRBFRQSOGQI-UHFFFAOYSA-N 2-(11-oxo-6h-benzo[c][1]benzothiepin-3-yl)acetic acid Chemical compound S1CC2=CC=CC=C2C(=O)C2=CC=C(CC(=O)O)C=C12 KLIVRBFRQSOGQI-UHFFFAOYSA-N 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- NOHRDTUNBMLAFR-UHFFFAOYSA-N 2-(3-amino-2-hydroxy-4,4-dimethylpentoxy)pyridine-3-carbonitrile Chemical compound CC(C)(C)C(N)C(O)COC1=NC=CC=C1C#N NOHRDTUNBMLAFR-UHFFFAOYSA-N 0.000 description 1
- ODZUWQAFWMLWCF-UHFFFAOYSA-N 2-(3-phenyl-1-benzofuran-7-yl)propanoic acid Chemical compound C=1OC=2C(C(C(O)=O)C)=CC=CC=2C=1C1=CC=CC=C1 ODZUWQAFWMLWCF-UHFFFAOYSA-N 0.000 description 1
- YGTUPRIZNBMOFV-UHFFFAOYSA-N 2-(4-hydroxybenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)C1=CC=C(O)C=C1 YGTUPRIZNBMOFV-UHFFFAOYSA-N 0.000 description 1
- KLOXEYMSPNBMHD-UHFFFAOYSA-N 2-(4-nitrophenyl)-1,3-benzoxazole Chemical compound C1=CC([N+](=O)[O-])=CC=C1C1=NC2=CC=CC=C2O1 KLOXEYMSPNBMHD-UHFFFAOYSA-N 0.000 description 1
- LRXFKKPEBXIPMW-UHFFFAOYSA-N 2-(9h-fluoren-2-yl)propanoic acid Chemical compound C1=CC=C2C3=CC=C(C(C(O)=O)C)C=C3CC2=C1 LRXFKKPEBXIPMW-UHFFFAOYSA-N 0.000 description 1
- DCXHLPGLBYHNMU-UHFFFAOYSA-N 2-[1-(4-azidobenzoyl)-5-methoxy-2-methylindol-3-yl]acetic acid Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(N=[N+]=[N-])C=C1 DCXHLPGLBYHNMU-UHFFFAOYSA-N 0.000 description 1
- IDCAZKFFVIMCCS-UHFFFAOYSA-N 2-[3-(4-chlorophenyl)-4-imino-2-oxoimidazolidin-1-yl]acetonitrile Chemical compound C1=CC(Cl)=CC=C1N1C(=O)N(CC#N)CC1=N IDCAZKFFVIMCCS-UHFFFAOYSA-N 0.000 description 1
- ANMLJLFWUCQGKZ-UHFFFAOYSA-N 2-[3-(trifluoromethyl)anilino]-3-pyridinecarboxylic acid (3-oxo-1H-isobenzofuran-1-yl) ester Chemical compound FC(F)(F)C1=CC=CC(NC=2C(=CC=CN=2)C(=O)OC2C3=CC=CC=C3C(=O)O2)=C1 ANMLJLFWUCQGKZ-UHFFFAOYSA-N 0.000 description 1
- XILVEPYQJIOVNB-UHFFFAOYSA-N 2-[3-(trifluoromethyl)anilino]benzoic acid 2-(2-hydroxyethoxy)ethyl ester Chemical compound OCCOCCOC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 XILVEPYQJIOVNB-UHFFFAOYSA-N 0.000 description 1
- NLGUJWNOGYWZBI-UHFFFAOYSA-N 2-[3-chloro-4-(thiophene-2-carbonyl)phenyl]propanoic acid Chemical compound ClC1=CC(C(C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 NLGUJWNOGYWZBI-UHFFFAOYSA-N 0.000 description 1
- JIEKMACRVQTPRC-UHFFFAOYSA-N 2-[4-(4-chlorophenyl)-2-phenyl-5-thiazolyl]acetic acid Chemical compound OC(=O)CC=1SC(C=2C=CC=CC=2)=NC=1C1=CC=C(Cl)C=C1 JIEKMACRVQTPRC-UHFFFAOYSA-N 0.000 description 1
- QKKLKGVIECOSRM-CODXZCKSSA-N 2-[4-[3-(2-chlorophenothiazin-10-yl)propyl]piperazin-1-yl]ethanol;4-[2-[(8s,9s,10r,11s,13s,14s,17r)-11,17-dihydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-17-yl]-2-oxoethoxy]-4-oxobutanoic acid Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21.O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COC(=O)CCC(O)=O)[C@@H]4[C@@H]3CCC2=C1 QKKLKGVIECOSRM-CODXZCKSSA-N 0.000 description 1
- LNXXSBRGLBOASF-UHFFFAOYSA-N 2-[[2-(4-chlorophenyl)-4-methyl-1,3-oxazol-5-yl]methoxy]-2-methylpropanoic acid Chemical compound O1C(COC(C)(C)C(O)=O)=C(C)N=C1C1=CC=C(Cl)C=C1 LNXXSBRGLBOASF-UHFFFAOYSA-N 0.000 description 1
- IOJUJUOXKXMJNF-UHFFFAOYSA-N 2-acetyloxybenzoic acid [3-(nitrooxymethyl)phenyl] ester Chemical compound CC(=O)OC1=CC=CC=C1C(=O)OC1=CC=CC(CO[N+]([O-])=O)=C1 IOJUJUOXKXMJNF-UHFFFAOYSA-N 0.000 description 1
- UMUPQWIGCOZEOY-JOCHJYFZSA-N 2-amino-2-methyl-n-[(2r)-1-(1-methylsulfonylspiro[2h-indole-3,4'-piperidine]-1'-yl)-1-oxo-3-phenylmethoxypropan-2-yl]propanamide Chemical compound C([C@@H](NC(=O)C(C)(N)C)C(=O)N1CCC2(C3=CC=CC=C3N(C2)S(C)(=O)=O)CC1)OCC1=CC=CC=C1 UMUPQWIGCOZEOY-JOCHJYFZSA-N 0.000 description 1
- WJAXXWSZNSFVNG-UHFFFAOYSA-N 2-bromoethanamine;hydron;bromide Chemical compound [Br-].[NH3+]CCBr WJAXXWSZNSFVNG-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- KGKMETLQCMSQNT-UHFFFAOYSA-N 2-butyl-1-(diaminomethylidene)-3-ethylguanidine;hydrochloride Chemical compound Cl.CCCCN=C(NCC)N=C(N)N KGKMETLQCMSQNT-UHFFFAOYSA-N 0.000 description 1
- GXEUNRBWEAIPCN-UHFFFAOYSA-N 2-chloro-2-(3-chloro-4-cyclohexylphenyl)acetic acid Chemical compound ClC1=CC(C(Cl)C(=O)O)=CC=C1C1CCCCC1 GXEUNRBWEAIPCN-UHFFFAOYSA-N 0.000 description 1
- FJKIADFDXOCBRV-UHFFFAOYSA-N 2-chloro-3-fluoroaniline Chemical compound NC1=CC=CC(F)=C1Cl FJKIADFDXOCBRV-UHFFFAOYSA-N 0.000 description 1
- XRAKCYJTJGTSMM-UHFFFAOYSA-N 2-chloro-4-fluoroaniline Chemical compound NC1=CC=C(F)C=C1Cl XRAKCYJTJGTSMM-UHFFFAOYSA-N 0.000 description 1
- FNRMMDCDHWCQTH-UHFFFAOYSA-N 2-chloropyridine;3-chloropyridine;4-chloropyridine Chemical compound ClC1=CC=NC=C1.ClC1=CC=CN=C1.ClC1=CC=CC=N1 FNRMMDCDHWCQTH-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- RQGSXFCTBTUNRR-UHFFFAOYSA-N 2-fluoro-9h-carbazole Chemical compound C1=CC=C2C3=CC=C(F)C=C3NC2=C1 RQGSXFCTBTUNRR-UHFFFAOYSA-N 0.000 description 1
- FTZQXOJYPFINKJ-UHFFFAOYSA-N 2-fluoroaniline Chemical compound NC1=CC=CC=C1F FTZQXOJYPFINKJ-UHFFFAOYSA-N 0.000 description 1
- SMNDYUVBFMFKNZ-UHFFFAOYSA-N 2-furoic acid Chemical compound OC(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-N 0.000 description 1
- ASUDFOJKTJLAIK-UHFFFAOYSA-N 2-methoxyethanamine Chemical compound COCCN ASUDFOJKTJLAIK-UHFFFAOYSA-N 0.000 description 1
- 125000006020 2-methyl-1-propenyl group Chemical group 0.000 description 1
- ILPUOPPYSQEBNJ-UHFFFAOYSA-N 2-methyl-2-phenoxypropanoic acid Chemical class OC(=O)C(C)(C)OC1=CC=CC=C1 ILPUOPPYSQEBNJ-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- AKLMUGFDGONMAA-UHFFFAOYSA-N 268545-87-5 Chemical compound C=12C3=NC(C)=CC=1N(C(CCC)CCC)CCN2N=C3C1=CC=C(Cl)C=C1Cl AKLMUGFDGONMAA-UHFFFAOYSA-N 0.000 description 1
- 125000001698 2H-pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000001627 3 membered heterocyclic group Chemical group 0.000 description 1
- NMKSAYKQLCHXDK-UHFFFAOYSA-N 3,3-diphenyl-N-(1-phenylethyl)-1-propanamine Chemical compound C=1C=CC=CC=1C(C)NCCC(C=1C=CC=CC=1)C1=CC=CC=C1 NMKSAYKQLCHXDK-UHFFFAOYSA-N 0.000 description 1
- PYSICVOJSJMFKP-UHFFFAOYSA-N 3,5-dibromo-2-chloropyridine Chemical compound ClC1=NC=C(Br)C=C1Br PYSICVOJSJMFKP-UHFFFAOYSA-N 0.000 description 1
- BMOVDIHDGSRAIP-UHFFFAOYSA-N 3,6-difluoro-9-(oxiran-2-ylmethyl)carbazole Chemical compound C12=CC=C(F)C=C2C2=CC(F)=CC=C2N1CC1CO1 BMOVDIHDGSRAIP-UHFFFAOYSA-N 0.000 description 1
- ALKYHXVLJMQRLQ-UHFFFAOYSA-N 3-Hydroxy-2-naphthoate Chemical compound C1=CC=C2C=C(O)C(C(=O)O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-N 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-M 3-Methylbutanoic acid Natural products CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 1
- XWPBINGFFFZAOZ-UMSFTDKQSA-N 3-[1-[3-[(3r)-1-benzoyl-3-(3,4-dichlorophenyl)piperidin-3-yl]propyl]-4-phenylpiperidin-4-yl]-1,1-dimethylurea Chemical compound C([C@](C1)(CCCN2CCC(CC2)(NC(=O)N(C)C)C=2C=CC=CC=2)C=2C=C(Cl)C(Cl)=CC=2)CCN1C(=O)C1=CC=CC=C1 XWPBINGFFFZAOZ-UMSFTDKQSA-N 0.000 description 1
- PLZMRGRLCWCLFW-UHFFFAOYSA-N 3-[5-(3-bromophenyl)tetrazol-2-yl]-1-piperidin-1-ylpropan-1-one Chemical compound BrC1=CC=CC(C2=NN(CCC(=O)N3CCCCC3)N=N2)=C1 PLZMRGRLCWCLFW-UHFFFAOYSA-N 0.000 description 1
- YLJRTDTWWRXOFG-UHFFFAOYSA-N 3-[5-(4-chlorophenyl)furan-2-yl]-3-hydroxypropanoic acid Chemical compound O1C(C(CC(O)=O)O)=CC=C1C1=CC=C(Cl)C=C1 YLJRTDTWWRXOFG-UHFFFAOYSA-N 0.000 description 1
- HGWUUOXXAIISDB-UHFFFAOYSA-N 3-azabicyclo[3.1.0]hexane Chemical compound C1NCC2CC21 HGWUUOXXAIISDB-UHFFFAOYSA-N 0.000 description 1
- GBJSOMRKIQYYQB-UHFFFAOYSA-N 3-decylphthalic acid Chemical compound CCCCCCCCCCC1=CC=CC(C(O)=O)=C1C(O)=O GBJSOMRKIQYYQB-UHFFFAOYSA-N 0.000 description 1
- ZYJSTSMEUKNCEV-UHFFFAOYSA-N 3-diazo-1-diazonioprop-1-en-2-olate Chemical compound [N-]=[N+]=CC(=O)C=[N+]=[N-] ZYJSTSMEUKNCEV-UHFFFAOYSA-N 0.000 description 1
- IEUMYICVZHBVAV-UHFFFAOYSA-N 3-fluoro-9h-carbazole Chemical compound C1=CC=C2C3=CC(F)=CC=C3NC2=C1 IEUMYICVZHBVAV-UHFFFAOYSA-N 0.000 description 1
- YUORBURTMIUPMW-UHFFFAOYSA-N 3-methyl-5-[2-(4-phenyl-3,6-dihydro-2h-pyridin-1-yl)ethyl]-1,3-oxazolidin-2-one Chemical compound O1C(=O)N(C)CC1CCN1CC=C(C=2C=CC=CC=2)CC1 YUORBURTMIUPMW-UHFFFAOYSA-N 0.000 description 1
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- PIAMNHTVFPWVHG-UHFFFAOYSA-N 4-(4-chlorophenyl)-5-methyl-1h-imidazole;hydrochloride Chemical compound Cl.N1C=NC(C=2C=CC(Cl)=CC=2)=C1C PIAMNHTVFPWVHG-UHFFFAOYSA-N 0.000 description 1
- INDZCVYWKNWKIQ-UHFFFAOYSA-N 4-(fluoren-9-ylidenemethyl)benzenecarboximidamide;hydrochloride Chemical compound Cl.C1=CC(C(=N)N)=CC=C1C=C1C2=CC=CC=C2C2=CC=CC=C21 INDZCVYWKNWKIQ-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical class COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 description 1
- LQVMQEYROPXMQH-UHFFFAOYSA-N 4-dibenzofuran-2-yl-4-oxobutanoic acid Chemical compound C1=CC=C2C3=CC(C(=O)CCC(=O)O)=CC=C3OC2=C1 LQVMQEYROPXMQH-UHFFFAOYSA-N 0.000 description 1
- XJTRMPVQSUJFRA-UHFFFAOYSA-N 4-fluoro-9h-carbazole Chemical compound N1C2=CC=CC=C2C2=C1C=CC=C2F XJTRMPVQSUJFRA-UHFFFAOYSA-N 0.000 description 1
- RHMPLDJJXGPMEX-UHFFFAOYSA-N 4-fluorophenol Chemical compound OC1=CC=C(F)C=C1 RHMPLDJJXGPMEX-UHFFFAOYSA-N 0.000 description 1
- LBUNNMJLXWQQBY-UHFFFAOYSA-N 4-fluorophenylboronic acid Chemical compound OB(O)C1=CC=C(F)C=C1 LBUNNMJLXWQQBY-UHFFFAOYSA-N 0.000 description 1
- SYCHUQUJURZQMO-UHFFFAOYSA-N 4-hydroxy-2-methyl-1,1-dioxo-n-(1,3-thiazol-2-yl)-1$l^{6},2-benzothiazine-3-carboxamide Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=CS1 SYCHUQUJURZQMO-UHFFFAOYSA-N 0.000 description 1
- SJZRECIVHVDYJC-UHFFFAOYSA-M 4-hydroxybutyrate Chemical compound OCCCC([O-])=O SJZRECIVHVDYJC-UHFFFAOYSA-M 0.000 description 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
- 125000001826 4H-pyranyl group Chemical group O1C(=CCC=C1)* 0.000 description 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 description 1
- CXSJGNHRBWJXEA-UHFFFAOYSA-N 5,12-dihydrophthalazino[3,2-b]phthalazine-7,14-dione Chemical compound C1C2=CC=CC=C2C(=O)N2N1C(=O)C1=CC=CC=C1C2 CXSJGNHRBWJXEA-UHFFFAOYSA-N 0.000 description 1
- HEOZYYOUKGGSBJ-UHFFFAOYSA-N 5-(4-methoxybenzoyl)-2,3-dihydro-1h-pyrrolizine-1-carboxylic acid Chemical compound C1=CC(OC)=CC=C1C(=O)C1=CC=C2N1CCC2C(O)=O HEOZYYOUKGGSBJ-UHFFFAOYSA-N 0.000 description 1
- QPGGEKPRGVJKQB-UHFFFAOYSA-N 5-[2-(dimethylamino)ethyl]-11-methyl-6-benzo[b][1,4]benzodiazepinone Chemical compound O=C1N(CCN(C)C)C2=CC=CC=C2N(C)C2=CC=CC=C21 QPGGEKPRGVJKQB-UHFFFAOYSA-N 0.000 description 1
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 1
- YWLXLRUDGLRYDR-ZHPRIASZSA-N 5beta,20-epoxy-1,7beta,10beta,13alpha-tetrahydroxy-9-oxotax-11-ene-2alpha,4alpha-diyl 4-acetate 2-benzoate Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](O)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 YWLXLRUDGLRYDR-ZHPRIASZSA-N 0.000 description 1
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
- OAIZNWQBWDHNIH-UHFFFAOYSA-N 6-chloro-4-phenyl-1-(2,2,2-trifluoroethyl)quinazolin-2-one Chemical compound N=1C(=O)N(CC(F)(F)F)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 OAIZNWQBWDHNIH-UHFFFAOYSA-N 0.000 description 1
- KTIQCDLYPPAYBF-UHFFFAOYSA-N 7-[3-(tert-butylamino)-2-hydroxypropoxy]-3h-2-benzofuran-1-one;hydrochloride Chemical compound Cl.CC(C)(C)NCC(O)COC1=CC=CC2=C1C(=O)OC2 KTIQCDLYPPAYBF-UHFFFAOYSA-N 0.000 description 1
- XWXVKXXKKLBDDJ-UHFFFAOYSA-N 7-chloro-3,3a-dihydro-2h-[1,2]oxazolo[3,2-b][1,3]benzoxazin-9-one Chemical compound O1C2CCON2C(=O)C2=CC(Cl)=CC=C21 XWXVKXXKKLBDDJ-UHFFFAOYSA-N 0.000 description 1
- HCKFPALGXKOOBK-NRYMJLQJSA-N 7332-27-6 Chemical compound C1([C@]2(O[C@]3([C@@]4(C)C[C@H](O)[C@]5(F)[C@@]6(C)C=CC(=O)C=C6CC[C@H]5[C@@H]4C[C@H]3O2)C(=O)CO)C)=CC=CC=C1 HCKFPALGXKOOBK-NRYMJLQJSA-N 0.000 description 1
- HFDKKNHCYWNNNQ-YOGANYHLSA-N 75976-10-2 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)N)C(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 HFDKKNHCYWNNNQ-YOGANYHLSA-N 0.000 description 1
- LDIOUQIXNSSOGU-UHFFFAOYSA-N 8-(3-pentylamino)-2-methyl-3-(2-chloro-4-methoxyphenyl)-6,7-dihydro-5h-cyclopenta[d]pyrazolo[1,5-a]pyrimidine Chemical compound CC1=NN2C(NC(CC)CC)=C3CCCC3=NC2=C1C1=CC=C(OC)C=C1Cl LDIOUQIXNSSOGU-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- VAJIZAPXBKMPRO-LLVKDONJSA-N 9-[[(2r)-oxiran-2-yl]methyl]carbazole Chemical compound C12=CC=CC=C2C2=CC=CC=C2N1C[C@@H]1CO1 VAJIZAPXBKMPRO-LLVKDONJSA-N 0.000 description 1
- VAJIZAPXBKMPRO-NSHDSACASA-N 9-[[(2s)-oxiran-2-yl]methyl]carbazole Chemical compound C12=CC=CC=C2C2=CC=CC=C2N1C[C@H]1CO1 VAJIZAPXBKMPRO-NSHDSACASA-N 0.000 description 1
- ZOCUOMKMBMEYQV-GSLJADNHSA-N 9alpha-Fluoro-11beta,17alpha,21-trihydroxypregna-1,4-diene-3,20-dione 21-acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ZOCUOMKMBMEYQV-GSLJADNHSA-N 0.000 description 1
- HMAKCHLSXJDBPZ-UHFFFAOYSA-N 9h-carbazole-1-sulfonamide Chemical class C12=CC=CC=C2NC2=C1C=CC=C2S(=O)(=O)N HMAKCHLSXJDBPZ-UHFFFAOYSA-N 0.000 description 1
- 241000208140 Acer Species 0.000 description 1
- OQLZINXFSUDMHM-UHFFFAOYSA-N Acetamidine Chemical compound CC(N)=N OQLZINXFSUDMHM-UHFFFAOYSA-N 0.000 description 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical class CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 108010076365 Adiponectin Proteins 0.000 description 1
- 102000011690 Adiponectin Human genes 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 description 1
- RDJQCOBTKKAQAH-FPOVZHCZSA-N Amibegron Chemical compound C1([C@@H](O)CN[C@H]2CCC3=CC=C(C=C3C2)OCC(=O)OCC)=CC=CC(Cl)=C1 RDJQCOBTKKAQAH-FPOVZHCZSA-N 0.000 description 1
- 102000005862 Angiotensin II Human genes 0.000 description 1
- 229940123413 Angiotensin II antagonist Drugs 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 230000007134 Aβ oligomerisation Effects 0.000 description 1
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 1
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 1
- HNNIWKQLJSNAEQ-UHFFFAOYSA-N Benzydamine hydrochloride Chemical compound Cl.C12=CC=CC=C2C(OCCCN(C)C)=NN1CC1=CC=CC=C1 HNNIWKQLJSNAEQ-UHFFFAOYSA-N 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 108010004032 Bromelains Proteins 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- VCBYBANKNKTWLQ-UHFFFAOYSA-N C(C)(C)C(C(COC1=CC=C(C=C1)CCOCC1CC1)O)N Chemical compound C(C)(C)C(C(COC1=CC=C(C=C1)CCOCC1CC1)O)N VCBYBANKNKTWLQ-UHFFFAOYSA-N 0.000 description 1
- ADFDCMITPGBMAO-UHFFFAOYSA-N C(CCCCCCCCC)NC=1C(N=NC1)=O Chemical compound C(CCCCCCCCC)NC=1C(N=NC1)=O ADFDCMITPGBMAO-UHFFFAOYSA-N 0.000 description 1
- BRZJKSLFPJQQIM-UHFFFAOYSA-N C(CCCCCCCCC)NCC(CNCCCCCCCCCC)=O Chemical compound C(CCCCCCCCC)NCC(CNCCCCCCCCCC)=O BRZJKSLFPJQQIM-UHFFFAOYSA-N 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- IRDQNLLVRXMERV-UHFFFAOYSA-N CCCC[Na] Chemical compound CCCC[Na] IRDQNLLVRXMERV-UHFFFAOYSA-N 0.000 description 1
- 101150038243 CLOCK gene Proteins 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 101001120790 Caenorhabditis elegans UDP-N-acetylglucosamine-peptide N-acetylglucosaminyltransferase Proteins 0.000 description 1
- 208000004434 Calcinosis Diseases 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 229940123613 Calcium receptor antagonist Drugs 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- JOATXPAWOHTVSZ-UHFFFAOYSA-N Celiprolol Chemical compound CCN(CC)C(=O)NC1=CC=C(OCC(O)CNC(C)(C)C)C(C(C)=O)=C1 JOATXPAWOHTVSZ-UHFFFAOYSA-N 0.000 description 1
- 229920001268 Cholestyramine Polymers 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- KATBVKFXGKGUFE-UHFFFAOYSA-N Cintazone Chemical compound C12=CC=CC=C2N2C(=O)C(CCCCC)C(=O)N2C=C1C1=CC=CC=C1 KATBVKFXGKGUFE-UHFFFAOYSA-N 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- YXKFATPOEMHNMJ-KJEYTGHBSA-N Cormethasone acetate Chemical compound C1C(F)(F)C2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COC(C)=O)(O)[C@@]1(C)C[C@@H]2O YXKFATPOEMHNMJ-KJEYTGHBSA-N 0.000 description 1
- 108010056643 Corticotropin-Releasing Hormone Receptors Proteins 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 102000013717 Cyclin-Dependent Kinase 5 Human genes 0.000 description 1
- 108010025454 Cyclin-Dependent Kinase 5 Proteins 0.000 description 1
- 102000015833 Cystatin Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- JVHXJTBJCFBINQ-ADAARDCZSA-N Dapagliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=C1Cl JVHXJTBJCFBINQ-ADAARDCZSA-N 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000001380 Diabetic Ketoacidosis Diseases 0.000 description 1
- 208000032781 Diabetic cardiomyopathy Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 1
- WYQPLTPSGFELIB-JTQPXKBDSA-N Difluprednate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2CC[C@@](C(=O)COC(C)=O)(OC(=O)CCC)[C@@]2(C)C[C@@H]1O WYQPLTPSGFELIB-JTQPXKBDSA-N 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 108010065372 Dynorphins Proteins 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- RHAXSHUQNIEUEY-UHFFFAOYSA-N Epirizole Chemical compound COC1=CC(C)=NN1C1=NC(C)=CC(OC)=N1 RHAXSHUQNIEUEY-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 239000005897 Etoxazole Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 240000006927 Foeniculum vulgare Species 0.000 description 1
- 235000004204 Foeniculum vulgare Nutrition 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 101150023900 G6PC1 gene Proteins 0.000 description 1
- 208000025499 G6PD deficiency Diseases 0.000 description 1
- 208000027472 Galactosemias Diseases 0.000 description 1
- XQLWNAFCTODIRK-UHFFFAOYSA-N Gallopamil Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC(OC)=C(OC)C(OC)=C1 XQLWNAFCTODIRK-UHFFFAOYSA-N 0.000 description 1
- 102400000921 Gastrin Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 102000030595 Glucokinase Human genes 0.000 description 1
- 108010021582 Glucokinase Proteins 0.000 description 1
- 102000003638 Glucose-6-Phosphatase Human genes 0.000 description 1
- 108010086800 Glucose-6-Phosphatase Proteins 0.000 description 1
- 206010018444 Glucose-6-phosphate dehydrogenase deficiency Diseases 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- MUQNGPZZQDCDFT-JNQJZLCISA-N Halcinonide Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CCl)[C@@]1(C)C[C@@H]2O MUQNGPZZQDCDFT-JNQJZLCISA-N 0.000 description 1
- YCISZOVUHXIOFY-HKXOFBAYSA-N Halopredone acetate Chemical compound C1([C@H](F)C2)=CC(=O)C(Br)=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2CC[C@](OC(C)=O)(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O YCISZOVUHXIOFY-HKXOFBAYSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101001125071 Homo sapiens Neuromedin-K receptor Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102000005561 Human Isophane Insulin Human genes 0.000 description 1
- 108010084048 Human Isophane Insulin Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 244000141009 Hypericum perforatum Species 0.000 description 1
- 235000017309 Hypericum perforatum Nutrition 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 229940126557 INCB13739 Drugs 0.000 description 1
- ACEWLPOYLGNNHV-UHFFFAOYSA-N Ibuprofen piconol Chemical compound C1=CC(CC(C)C)=CC=C1C(C)C(=O)OCC1=CC=CC=N1 ACEWLPOYLGNNHV-UHFFFAOYSA-N 0.000 description 1
- 206010061217 Infestation Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 1
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 1
- 102000010781 Interleukin-6 Receptors Human genes 0.000 description 1
- 108010038501 Interleukin-6 Receptors Proteins 0.000 description 1
- 241000764238 Isis Species 0.000 description 1
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 1
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 1
- 102000005237 Isophane Insulin Human genes 0.000 description 1
- 108010081368 Isophane Insulin Proteins 0.000 description 1
- KLDXJTOLSGUMSJ-JGWLITMVSA-N Isosorbide Chemical compound O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 KLDXJTOLSGUMSJ-JGWLITMVSA-N 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- NHTGHBARYWONDQ-JTQLQIEISA-N L-α-methyl-Tyrosine Chemical compound OC(=O)[C@](N)(C)CC1=CC=C(O)C=C1 NHTGHBARYWONDQ-JTQLQIEISA-N 0.000 description 1
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 229940127470 Lipase Inhibitors Drugs 0.000 description 1
- 108010007859 Lisinopril Proteins 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- HYMLWHLQFGRFIY-UHFFFAOYSA-N Maltol Natural products CC1OC=CC(=O)C1=O HYMLWHLQFGRFIY-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- HUXCOHMTWUSXGY-GAPIFECDSA-N Meclorisone dibutyrate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COC(=O)CCC)(OC(=O)CCC)[C@@]1(C)C[C@@H]2Cl HUXCOHMTWUSXGY-GAPIFECDSA-N 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
- 108010065028 Metabotropic Glutamate 5 Receptor Proteins 0.000 description 1
- 102100038357 Metabotropic glutamate receptor 5 Human genes 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- UEQUQVLFIPOEMF-UHFFFAOYSA-N Mianserin Chemical compound C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CC=C21 UEQUQVLFIPOEMF-UHFFFAOYSA-N 0.000 description 1
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- YXOLAZRVSSWPPT-UHFFFAOYSA-N Morin Chemical compound OC1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 YXOLAZRVSSWPPT-UHFFFAOYSA-N 0.000 description 1
- 101100038125 Mus musculus Rora gene Proteins 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- IDBPHNDTYPBSNI-UHFFFAOYSA-N N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide Chemical compound C1CN(CCN2C(N(CC)N=N2)=O)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 IDBPHNDTYPBSNI-UHFFFAOYSA-N 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- SATKYJFPJXMNIW-UHFFFAOYSA-N N1SCC=CC2=C1C=CC=C2 Chemical compound N1SCC=CC2=C1C=CC=C2 SATKYJFPJXMNIW-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 description 1
- 102100029409 Neuromedin-K receptor Human genes 0.000 description 1
- 102100029549 Neuropeptide Y receptor type 5 Human genes 0.000 description 1
- 101710198055 Neuropeptide Y receptor type 5 Proteins 0.000 description 1
- 102000029748 Neuropeptide Y2 receptor Human genes 0.000 description 1
- 102000028435 Neuropeptide Y4 receptor Human genes 0.000 description 1
- 108010002245 Neuropeptide Y4 receptor Proteins 0.000 description 1
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- ONBWJWYUHXVEJS-ZTYRTETDSA-N Normorphine Chemical compound C([C@@H](NCC1)[C@@H]2C=C[C@@H]3O)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 ONBWJWYUHXVEJS-ZTYRTETDSA-N 0.000 description 1
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- KYYIDSXMWOZKMP-UHFFFAOYSA-N O-desmethylvenlafaxine Chemical compound C1CCCCC1(O)C(CN(C)C)C1=CC=C(O)C=C1 KYYIDSXMWOZKMP-UHFFFAOYSA-N 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 229940123257 Opioid receptor antagonist Drugs 0.000 description 1
- 239000008896 Opium Substances 0.000 description 1
- 102000008108 Osteoprotegerin Human genes 0.000 description 1
- 108010035042 Osteoprotegerin Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 1
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 102000018886 Pancreatic Polypeptide Human genes 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 102100036893 Parathyroid hormone Human genes 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 101150017365 Per3 gene Proteins 0.000 description 1
- 229940080774 Peroxisome proliferator-activated receptor gamma agonist Drugs 0.000 description 1
- RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 description 1
- 201000011252 Phenylketonuria Diseases 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Natural products P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 206010036049 Polycystic ovaries Diseases 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108010076181 Proinsulin Proteins 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical class C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 208000002009 Pyruvate Dehydrogenase Complex Deficiency Disease Diseases 0.000 description 1
- 108010025832 RANK Ligand Proteins 0.000 description 1
- 102000014128 RANK Ligand Human genes 0.000 description 1
- 238000010357 RNA editing Methods 0.000 description 1
- 230000026279 RNA modification Effects 0.000 description 1
- 238000001069 Raman spectroscopy Methods 0.000 description 1
- ZTVQQQVZCWLTDF-UHFFFAOYSA-N Remifentanil Chemical compound C1CN(CCC(=O)OC)CCC1(C(=O)OC)N(C(=O)CC)C1=CC=CC=C1 ZTVQQQVZCWLTDF-UHFFFAOYSA-N 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 102000034527 Retinoid X Receptors Human genes 0.000 description 1
- 108010038912 Retinoid X Receptors Proteins 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- IEAKXXNRGSLYTQ-DEOSSOPVSA-N SSR 125543 Chemical compound C1=C(C)C(OC)=CC(Cl)=C1C1=C(C)SC(N(CC#C)[C@@H](CC2CC2)C=2C=C(F)C(C)=CC=2)=N1 IEAKXXNRGSLYTQ-DEOSSOPVSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 description 1
- 229940123185 Squalene epoxidase inhibitor Drugs 0.000 description 1
- 229940123495 Squalene synthetase inhibitor Drugs 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 102100037346 Substance-P receptor Human genes 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 101000983124 Sus scrofa Pancreatic prohormone precursor Proteins 0.000 description 1
- 102000043124 TIM family Human genes 0.000 description 1
- 108091054435 TIM family Proteins 0.000 description 1
- QLYKJCMUNUWAGO-GAJHUEQPSA-N Taranabant Chemical compound N([C@@H](C)[C@@H](CC=1C=CC(Cl)=CC=1)C=1C=C(C=CC=1)C#N)C(=O)C(C)(C)OC1=CC=C(C(F)(F)F)C=N1 QLYKJCMUNUWAGO-GAJHUEQPSA-N 0.000 description 1
- XBDYBAVJXHJMNQ-UHFFFAOYSA-N Tetrahydroanthracene Natural products C1=CC=C2C=C(CCCC3)C3=CC2=C1 XBDYBAVJXHJMNQ-UHFFFAOYSA-N 0.000 description 1
- 241000534944 Thia Species 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- ZROUQTNYPCANTN-UHFFFAOYSA-N Tiapamil Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC1(C=2C=C(OC)C(OC)=CC=2)S(=O)(=O)CCCS1(=O)=O ZROUQTNYPCANTN-UHFFFAOYSA-N 0.000 description 1
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 102100035140 Vitronectin Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- UVAZQQHAVMNMHE-BBRMVZONSA-N [(3s,4s)-1,3-dimethyl-4-phenylpiperidin-4-yl] propanoate Chemical compound C=1C=CC=CC=1[C@]1(OC(=O)CC)CCN(C)C[C@@H]1C UVAZQQHAVMNMHE-BBRMVZONSA-N 0.000 description 1
- MVLBCBPGBUAVJQ-CENSZEJFSA-N [(6s,8s,9r,10s,11s,13s,14s,16r,17r)-17-(chloromethylsulfanylcarbonyl)-6,9-difluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCCl)(OC(=O)CC)[C@@]2(C)C[C@@H]1O MVLBCBPGBUAVJQ-CENSZEJFSA-N 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- FBRAWBYQGRLCEK-UHFFFAOYSA-N [17-(2-chloroacetyl)-9-fluoro-10,13,16-trimethyl-3,11-dioxo-7,8,12,14,15,16-hexahydro-6h-cyclopenta[a]phenanthren-17-yl] butanoate Chemical compound C1CC2=CC(=O)C=CC2(C)C2(F)C1C1CC(C)C(C(=O)CCl)(OC(=O)CCC)C1(C)CC2=O FBRAWBYQGRLCEK-UHFFFAOYSA-N 0.000 description 1
- APERIXFHHNDFQV-UHFFFAOYSA-N [2-[2-[2-[bis(carboxymethyl)amino]-5-methylphenoxy]ethoxy]-4-[3,6-bis(dimethylamino)xanthen-9-ylidene]cyclohexa-2,5-dien-1-ylidene]-bis(carboxymethyl)azanium;chloride Chemical compound [Cl-].C12=CC=C(N(C)C)C=C2OC2=CC(N(C)C)=CC=C2C1=C(C=1)C=CC(=[N+](CC(O)=O)CC(O)=O)C=1OCCOC1=CC(C)=CC=C1N(CC(O)=O)CC(O)=O APERIXFHHNDFQV-UHFFFAOYSA-N 0.000 description 1
- UGEPSJNLORCRBO-UHFFFAOYSA-N [3-(dimethylamino)-1-hydroxy-1-phosphonopropyl]phosphonic acid Chemical compound CN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O UGEPSJNLORCRBO-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- MJMXSNHYUJBWKG-UHFFFAOYSA-N [Cl-].[SH3+].C Chemical compound [Cl-].[SH3+].C MJMXSNHYUJBWKG-UHFFFAOYSA-N 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 239000000370 acceptor Substances 0.000 description 1
- 229960002122 acebutolol Drugs 0.000 description 1
- GOEMGAFJFRBGGG-UHFFFAOYSA-N acebutolol Chemical compound CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(C(C)=O)=C1 GOEMGAFJFRBGGG-UHFFFAOYSA-N 0.000 description 1
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 1
- 229960000571 acetazolamide Drugs 0.000 description 1
- FIKSSPSBVSPVFU-WIKDFEFZSA-N acetic acid;(3s,6s,9s,12r,15s,18s)-9-(4-aminobutyl)-3-benzyl-15-[(4-hydroxyphenyl)methyl]-12-(1h-indol-3-ylmethyl)-1,18-dimethyl-6-propan-2-yl-1,4,7,10,13,16-hexazacyclooctadecane-2,5,8,11,14,17-hexone Chemical compound CC(O)=O.C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CC=2C=CC=CC=2)C(=O)N(C)[C@@H](C)C(=O)N1)=O)C(C)C)C1=CC=C(O)C=C1 FIKSSPSBVSPVFU-WIKDFEFZSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 229940037127 actonel Drugs 0.000 description 1
- 229940062328 actos Drugs 0.000 description 1
- 238000011374 additional therapy Methods 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229960005142 alclofenac Drugs 0.000 description 1
- ARHWPKZXBHOEEE-UHFFFAOYSA-N alclofenac Chemical compound OC(=O)CC1=CC=C(OCC=C)C(Cl)=C1 ARHWPKZXBHOEEE-UHFFFAOYSA-N 0.000 description 1
- DJHCCTTVDRAMEH-DUUJBDRPSA-N alclometasone dipropionate Chemical compound C([C@H]1Cl)C2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O DJHCCTTVDRAMEH-DUUJBDRPSA-N 0.000 description 1
- 229960004229 alclometasone dipropionate Drugs 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229940062527 alendronate Drugs 0.000 description 1
- 229960001391 alfentanil Drugs 0.000 description 1
- LSWBQIAZNGURQV-WTBIUSKOSA-N algestone acetonide Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)C)[C@@]1(C)CC2 LSWBQIAZNGURQV-WTBIUSKOSA-N 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000005089 alkenylaminocarbonyl group Chemical group 0.000 description 1
- 125000005090 alkenylcarbonyl group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 description 1
- 125000004849 alkoxymethyl group Chemical group 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 description 1
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
- 125000004691 alkyl thio carbonyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- 102000004139 alpha-Amylases Human genes 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229940024171 alpha-amylase Drugs 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- QAZIXAUMDFPQRW-UHFFFAOYSA-K aluminum;2-[4-(2-methylpropyl)phenyl]propanoate;hydroxide Chemical compound [Al+2]O.CC(C)CC1=CC=C(C(C)C([O-])=O)C=C1.CC(C)CC1=CC=C(C(C)C([O-])=O)C=C1 QAZIXAUMDFPQRW-UHFFFAOYSA-K 0.000 description 1
- 229940000806 amaryl Drugs 0.000 description 1
- NSZFBGIRFCHKOE-LFZVSNMSSA-N amcinafal Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(CC)(CC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O NSZFBGIRFCHKOE-LFZVSNMSSA-N 0.000 description 1
- 229950004850 amcinafal Drugs 0.000 description 1
- 229950003408 amcinafide Drugs 0.000 description 1
- QZNJPJDUBTYMRS-UHFFFAOYSA-M amfenac sodium hydrate Chemical compound O.[Na+].NC1=C(CC([O-])=O)C=CC=C1C(=O)C1=CC=CC=C1 QZNJPJDUBTYMRS-UHFFFAOYSA-M 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 229960002980 amitriptyline oxide Drugs 0.000 description 1
- ZPMKQFOGINQDAM-UHFFFAOYSA-N amitriptylinoxide Chemical compound C1CC2=CC=CC=C2C(=CCC[N+](C)([O-])C)C2=CC=CC=C21 ZPMKQFOGINQDAM-UHFFFAOYSA-N 0.000 description 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
- 229960000528 amlodipine Drugs 0.000 description 1
- 238000004082 amperometric method Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- RNLQIBCLLYYYFJ-UHFFFAOYSA-N amrinone Chemical compound N1C(=O)C(N)=CC(C=2C=CN=CC=2)=C1 RNLQIBCLLYYYFJ-UHFFFAOYSA-N 0.000 description 1
- 229960002105 amrinone Drugs 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 229960004238 anakinra Drugs 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- LKYQLAWMNBFNJT-UHFFFAOYSA-N anileridine Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC1=CC=C(N)C=C1 LKYQLAWMNBFNJT-UHFFFAOYSA-N 0.000 description 1
- 229960002512 anileridine Drugs 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 229950004699 anirolac Drugs 0.000 description 1
- HDNJXZZJFPCFHG-UHFFFAOYSA-N anitrazafen Chemical compound C1=CC(OC)=CC=C1C1=NN=C(C)N=C1C1=CC=C(OC)C=C1 HDNJXZZJFPCFHG-UHFFFAOYSA-N 0.000 description 1
- 229950002412 anitrazafen Drugs 0.000 description 1
- 229940098194 antabuse Drugs 0.000 description 1
- 230000002221 antabuse Effects 0.000 description 1
- 229930014669 anthocyanidin Natural products 0.000 description 1
- 150000001453 anthocyanidins Chemical class 0.000 description 1
- 235000008758 anthocyanidins Nutrition 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
- 229960004046 apomorphine Drugs 0.000 description 1
- ATALOFNDEOCMKK-OITMNORJSA-N aprepitant Chemical compound O([C@@H]([C@@H]1C=2C=CC(F)=CC=2)O[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CCN1CC1=NNC(=O)N1 ATALOFNDEOCMKK-OITMNORJSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 208000037849 arterial hypertension Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000005125 aryl alkyl amino carbonyl group Chemical group 0.000 description 1
- 125000005099 aryl alkyl carbonyl group Chemical group 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000005129 aryl carbonyl group Chemical group 0.000 description 1
- 125000005199 aryl carbonyloxy group Chemical group 0.000 description 1
- 125000005200 aryloxy carbonyloxy group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- MCGDSOGUHLTADD-UHFFFAOYSA-N arzoxifene Chemical compound C1=CC(OC)=CC=C1C1=C(OC=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 MCGDSOGUHLTADD-UHFFFAOYSA-N 0.000 description 1
- 229950005529 arzoxifene Drugs 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- VHGCDTVCOLNTBX-QGZVFWFLSA-N atomoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=CC=C1C VHGCDTVCOLNTBX-QGZVFWFLSA-N 0.000 description 1
- 229960002430 atomoxetine Drugs 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 229960001671 azapropazone Drugs 0.000 description 1
- WOIIIUDZSOLAIW-NSHDSACASA-N azapropazone Chemical compound C1=C(C)C=C2N3C(=O)[C@H](CC=C)C(=O)N3C(N(C)C)=NC2=C1 WOIIIUDZSOLAIW-NSHDSACASA-N 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 229960000794 baclofen Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229960000560 balsalazide disodium Drugs 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- UCJGJABZCDBEDK-UHFFFAOYSA-N bazedoxifene Chemical compound C=1C=C(OCCN2CCCCCC2)C=CC=1CN1C2=CC=C(O)C=C2C(C)=C1C1=CC=C(O)C=C1 UCJGJABZCDBEDK-UHFFFAOYSA-N 0.000 description 1
- 229960000817 bazedoxifene Drugs 0.000 description 1
- 229940092705 beclomethasone Drugs 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- ZPQPDBIHYCBNIG-UHFFFAOYSA-N befunolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=C1OC(C(C)=O)=C2 ZPQPDBIHYCBNIG-UHFFFAOYSA-N 0.000 description 1
- 229960004374 befunolol Drugs 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- FYJJXENSONZJRG-UHFFFAOYSA-N bencyclane Chemical compound C=1C=CC=CC=1CC1(OCCCN(C)C)CCCCCC1 FYJJXENSONZJRG-UHFFFAOYSA-N 0.000 description 1
- 229960000945 bencyclane Drugs 0.000 description 1
- 229960005149 bendazac Drugs 0.000 description 1
- BYFMCKSPFYVMOU-UHFFFAOYSA-N bendazac Chemical compound C12=CC=CC=C2C(OCC(=O)O)=NN1CC1=CC=CC=C1 BYFMCKSPFYVMOU-UHFFFAOYSA-N 0.000 description 1
- UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 1
- 229960005430 benoxaprofen Drugs 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 229960001689 benzydamine hydrochloride Drugs 0.000 description 1
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 239000002439 beta secretase inhibitor Substances 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N beta-methyl-butyric acid Natural products CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
- 229960004536 betahistine Drugs 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 229950000011 betaprodine Drugs 0.000 description 1
- 229960004324 betaxolol Drugs 0.000 description 1
- NWIUTZDMDHAVTP-UHFFFAOYSA-N betaxolol Chemical compound C1=CC(OCC(O)CNC(C)C)=CC=C1CCOCC1CC1 NWIUTZDMDHAVTP-UHFFFAOYSA-N 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 229920000080 bile acid sequestrant Polymers 0.000 description 1
- 229940096699 bile acid sequestrants Drugs 0.000 description 1
- 238000010378 bimolecular fluorescence complementation Methods 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- QRZAKQDHEVVFRX-UHFFFAOYSA-N biphenyl-4-ylacetic acid Chemical compound C1=CC(CC(=O)O)=CC=C1C1=CC=CC=C1 QRZAKQDHEVVFRX-UHFFFAOYSA-N 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229940028101 boniva Drugs 0.000 description 1
- 229960003679 brimonidine Drugs 0.000 description 1
- 235000019835 bromelain Nutrition 0.000 description 1
- 229960001780 bromelains Drugs 0.000 description 1
- 229950011622 broperamole Drugs 0.000 description 1
- XSEUMFJMFFMCIU-UHFFFAOYSA-N buformin Chemical compound CCCC\N=C(/N)N=C(N)N XSEUMFJMFFMCIU-UHFFFAOYSA-N 0.000 description 1
- 229960004111 buformin Drugs 0.000 description 1
- VCVQSRCYSKKPBA-UHFFFAOYSA-N bunitrolol Chemical compound CC(C)(C)NCC(O)COC1=CC=CC=C1C#N VCVQSRCYSKKPBA-UHFFFAOYSA-N 0.000 description 1
- 229950008581 bunitrolol Drugs 0.000 description 1
- HQIRNZOQPUAHHV-UHFFFAOYSA-N bupranolol Chemical compound CC1=CC=C(Cl)C(OCC(O)CNC(C)(C)C)=C1 HQIRNZOQPUAHHV-UHFFFAOYSA-N 0.000 description 1
- 229960000330 bupranolol Drugs 0.000 description 1
- 229960002495 buspirone Drugs 0.000 description 1
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 description 1
- 229960001113 butorphanol Drugs 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- 229950001261 camiglibose Drugs 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- KVLLHLWBPNCVNR-SKCUWOTOSA-N capromorelin Chemical compound C([C@@]12CN(CCC1=NN(C2=O)C)C(=O)[C@@H](COCC=1C=CC=CC=1)NC(=O)C(C)(C)N)C1=CC=CC=C1 KVLLHLWBPNCVNR-SKCUWOTOSA-N 0.000 description 1
- 229950004826 capromorelin Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 229960004484 carbachol Drugs 0.000 description 1
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 1
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 1
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 1
- KWEDUNSJJZVRKR-UHFFFAOYSA-N carbononitridic azide Chemical compound [N-]=[N+]=NC#N KWEDUNSJJZVRKR-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 125000004181 carboxyalkyl group Chemical group 0.000 description 1
- 230000007681 cardiovascular toxicity Effects 0.000 description 1
- 231100000060 cardiovascular toxicity Toxicity 0.000 description 1
- 239000004075 cariostatic agent Substances 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 229960003184 carprofen Drugs 0.000 description 1
- IVUMCTKHWDRRMH-UHFFFAOYSA-N carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 229960002320 celiprolol Drugs 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- CETPSERCERDGAM-UHFFFAOYSA-N ceric oxide Chemical compound O=[Ce]=O CETPSERCERDGAM-UHFFFAOYSA-N 0.000 description 1
- 229910000422 cerium(IV) oxide Inorganic materials 0.000 description 1
- 229960005110 cerivastatin Drugs 0.000 description 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 1
- MVCQKIKWYUURMU-UHFFFAOYSA-N cetilistat Chemical compound C1=C(C)C=C2C(=O)OC(OCCCCCCCCCCCCCCCC)=NC2=C1 MVCQKIKWYUURMU-UHFFFAOYSA-N 0.000 description 1
- 229950002397 cetilistat Drugs 0.000 description 1
- CKMOQBVBEGCJGW-UHFFFAOYSA-L chembl1200760 Chemical compound [Na+].[Na+].C1=C(C([O-])=O)C(O)=CC=C1N=NC1=CC=C(C(=O)NCCC([O-])=O)C=C1 CKMOQBVBEGCJGW-UHFFFAOYSA-L 0.000 description 1
- JQXXHWHPUNPDRT-BQVAUQFYSA-N chembl1523493 Chemical compound O([C@](C1=O)(C)O\C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2C=NN1CCN(C)CC1 JQXXHWHPUNPDRT-BQVAUQFYSA-N 0.000 description 1
- RNZOILMUIJSTSY-UHFFFAOYSA-N chembl16733 Chemical compound S1C(OCC)=NN=C1C1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 RNZOILMUIJSTSY-UHFFFAOYSA-N 0.000 description 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229960004782 chlordiazepoxide Drugs 0.000 description 1
- ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 229960001761 chlorpropamide Drugs 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001906 cholesterol absorption Effects 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 239000000064 cholinergic agonist Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 229950002545 cicloprofen Drugs 0.000 description 1
- YZFWTZACSRHJQD-UHFFFAOYSA-N ciglitazone Chemical compound C=1C=C(CC2C(NC(=O)S2)=O)C=CC=1OCC1(C)CCCCC1 YZFWTZACSRHJQD-UHFFFAOYSA-N 0.000 description 1
- 229950009226 ciglitazone Drugs 0.000 description 1
- 229960005025 cilazapril Drugs 0.000 description 1
- JQRZBPFGBRIWSN-YOTVLOEGSA-N cilazapril monohydrate Chemical compound O.C([C@@H](C(=O)OCC)N[C@@H]1C(N2[C@@H](CCCN2CCC1)C(O)=O)=O)CC1=CC=CC=C1 JQRZBPFGBRIWSN-YOTVLOEGSA-N 0.000 description 1
- KYXDNECMRLFQMZ-UHFFFAOYSA-N cimicoxib Chemical compound C1=C(F)C(OC)=CC=C1C1=C(Cl)N=CN1C1=CC=C(S(N)(=O)=O)C=C1 KYXDNECMRLFQMZ-UHFFFAOYSA-N 0.000 description 1
- 229950010851 cimicoxib Drugs 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- GPUVGQIASQNZET-CCEZHUSRSA-N cinnoxicam Chemical compound C=1C=CC=CC=1/C=C/C(=O)OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 GPUVGQIASQNZET-CCEZHUSRSA-N 0.000 description 1
- 230000002060 circadian Effects 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 229960001653 citalopram Drugs 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 238000007635 classification algorithm Methods 0.000 description 1
- 238000010224 classification analysis Methods 0.000 description 1
- 229950005384 cliprofen Drugs 0.000 description 1
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 description 1
- 229960004703 clobetasol propionate Drugs 0.000 description 1
- 229960005465 clobetasone butyrate Drugs 0.000 description 1
- 229960002286 clodronic acid Drugs 0.000 description 1
- HJKBJIYDJLVSAO-UHFFFAOYSA-L clodronic acid disodium salt Chemical compound [Na+].[Na+].OP([O-])(=O)C(Cl)(Cl)P(O)([O-])=O HJKBJIYDJLVSAO-UHFFFAOYSA-L 0.000 description 1
- 229960001214 clofibrate Drugs 0.000 description 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
- GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 1
- 229960003608 clomifene Drugs 0.000 description 1
- 229960003120 clonazepam Drugs 0.000 description 1
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- SJCRQMUYEQHNTC-UHFFFAOYSA-N clopirac Chemical compound CC1=CC(CC(O)=O)=C(C)N1C1=CC=C(Cl)C=C1 SJCRQMUYEQHNTC-UHFFFAOYSA-N 0.000 description 1
- 229950009185 clopirac Drugs 0.000 description 1
- 229940126523 co-drug Drugs 0.000 description 1
- 238000000749 co-immunoprecipitation Methods 0.000 description 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 208000035196 congenital hypomyelinating 2 neuropathy Diseases 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000000332 continued effect Effects 0.000 description 1
- 229940012193 contrave Drugs 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229950002276 cortodoxone Drugs 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 229960002104 cyanocobalamin Drugs 0.000 description 1
- 235000000639 cyanocobalamin Nutrition 0.000 description 1
- 239000011666 cyanocobalamin Substances 0.000 description 1
- 229950002213 cyclazocine Drugs 0.000 description 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 1
- ZHPBLHYKDKSZCQ-UHFFFAOYSA-N cyclooctylmethanol Chemical compound OCC1CCCCCCC1 ZHPBLHYKDKSZCQ-UHFFFAOYSA-N 0.000 description 1
- 108050004038 cystatin Proteins 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229960003834 dapagliflozin Drugs 0.000 description 1
- QAYICIQNSGETAS-UHFFFAOYSA-N dazomet Chemical compound CN1CSC(=S)N(C)C1 QAYICIQNSGETAS-UHFFFAOYSA-N 0.000 description 1
- 125000006612 decyloxy group Chemical group 0.000 description 1
- 125000005070 decynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 229960001145 deflazacort Drugs 0.000 description 1
- FBHSPRKOSMHSIF-GRMWVWQJSA-N deflazacort Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)=N[C@@]3(C(=O)COC(=O)C)[C@@]1(C)C[C@@H]2O FBHSPRKOSMHSIF-GRMWVWQJSA-N 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- 229960003662 desonide Drugs 0.000 description 1
- WBGKWQHBNHJJPZ-LECWWXJVSA-N desonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O WBGKWQHBNHJJPZ-LECWWXJVSA-N 0.000 description 1
- 229960002593 desoximetasone Drugs 0.000 description 1
- VWVSBHGCDBMOOT-IIEHVVJPSA-N desoximetasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@@H]2O VWVSBHGCDBMOOT-IIEHVVJPSA-N 0.000 description 1
- 229960001623 desvenlafaxine Drugs 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 229950000250 dexamethasone dipropionate Drugs 0.000 description 1
- CIWBQSYVNNPZIQ-PKWREOPISA-N dexamethasone dipropionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CIWBQSYVNNPZIQ-PKWREOPISA-N 0.000 description 1
- 229960001985 dextromethorphan Drugs 0.000 description 1
- XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 description 1
- 229960004193 dextropropoxyphene Drugs 0.000 description 1
- 229940089126 diabeta Drugs 0.000 description 1
- 201000009101 diabetic angiopathy Diseases 0.000 description 1
- 201000002249 diabetic peripheral angiopathy Diseases 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 229960002069 diamorphine Drugs 0.000 description 1
- 125000005266 diarylamine group Chemical group 0.000 description 1
- RAABOESOVLLHRU-UHFFFAOYSA-O diazenium Chemical compound [NH2+]=N RAABOESOVLLHRU-UHFFFAOYSA-O 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960003075 dibenzepin Drugs 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 229960004515 diclofenac potassium Drugs 0.000 description 1
- KXZOIWWTXOCYKR-UHFFFAOYSA-M diclofenac potassium Chemical compound [K+].[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl KXZOIWWTXOCYKR-UHFFFAOYSA-M 0.000 description 1
- 229960001193 diclofenac sodium Drugs 0.000 description 1
- 229960005081 diclofenamide Drugs 0.000 description 1
- GJQPMPFPNINLKP-UHFFFAOYSA-N diclofenamide Chemical compound NS(=O)(=O)C1=CC(Cl)=C(Cl)C(S(N)(=O)=O)=C1 GJQPMPFPNINLKP-UHFFFAOYSA-N 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229960002124 diflorasone diacetate Drugs 0.000 description 1
- BOBLHFUVNSFZPJ-JOYXJVLSSA-N diflorasone diacetate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H](C)[C@@](C(=O)COC(C)=O)(OC(C)=O)[C@@]2(C)C[C@@H]1O BOBLHFUVNSFZPJ-JOYXJVLSSA-N 0.000 description 1
- 229960004875 difluprednate Drugs 0.000 description 1
- 229950007956 diftalone Drugs 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- MUCZHBLJLSDCSD-UHFFFAOYSA-N diisopropyl fluorophosphate Chemical compound CC(C)OP(F)(=O)OC(C)C MUCZHBLJLSDCSD-UHFFFAOYSA-N 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- QIRAYNIFEOXSPW-UHFFFAOYSA-N dimepheptanol Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(O)CC)C1=CC=CC=C1 QIRAYNIFEOXSPW-UHFFFAOYSA-N 0.000 description 1
- 229950004655 dimepheptanol Drugs 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 229950010286 diolamine Drugs 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- HYPPXZBJBPSRLK-UHFFFAOYSA-N diphenoxylate Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 HYPPXZBJBPSRLK-UHFFFAOYSA-N 0.000 description 1
- 229960004192 diphenoxylate Drugs 0.000 description 1
- OCUJLLGVOUDECM-UHFFFAOYSA-N dipivefrin Chemical compound CNCC(O)C1=CC=C(OC(=O)C(C)(C)C)C(OC(=O)C(C)(C)C)=C1 OCUJLLGVOUDECM-UHFFFAOYSA-N 0.000 description 1
- 229960000966 dipivefrine Drugs 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 229960002563 disulfiram Drugs 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- 125000005411 dithiolanyl group Chemical group S1SC(CC1)* 0.000 description 1
- 229940110377 dl- arginine Drugs 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000000221 dopamine uptake inhibitor Substances 0.000 description 1
- 229960001393 dosulepin Drugs 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 229960005426 doxepin Drugs 0.000 description 1
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 1
- GZBONOYGBJSTHF-QLRNAMTQSA-N drocinonide Chemical compound C([C@@H]1CC2)C(=O)CC[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O GZBONOYGBJSTHF-QLRNAMTQSA-N 0.000 description 1
- 229950006082 drocinonide Drugs 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 229960002445 echothiophate iodide Drugs 0.000 description 1
- OVXQHPWHMXOFRD-UHFFFAOYSA-M ecothiopate iodide Chemical compound [I-].CCOP(=O)(OCC)SCC[N+](C)(C)C OVXQHPWHMXOFRD-UHFFFAOYSA-M 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000002101 electrospray ionisation tandem mass spectrometry Methods 0.000 description 1
- 229950007566 elzasonan Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 229940073621 enbrel Drugs 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229950002798 enlimomab Drugs 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 229950003801 epirizole Drugs 0.000 description 1
- XBRDBODLCHKXHI-UHFFFAOYSA-N epolamine Chemical compound OCCN1CCCC1 XBRDBODLCHKXHI-UHFFFAOYSA-N 0.000 description 1
- 229950008932 epolamine Drugs 0.000 description 1
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 description 1
- 229960004563 eprosartan Drugs 0.000 description 1
- 229950005127 erbumine Drugs 0.000 description 1
- 229950000206 estolate Drugs 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000002834 estrogen receptor modulator Substances 0.000 description 1
- 229960003399 estrone Drugs 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-L ethane-1,2-disulfonate Chemical compound [O-]S(=O)(=O)CCS([O-])(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-L 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- WGJHHMKQBWSQIY-UHFFFAOYSA-N ethoheptazine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCCN(C)CC1 WGJHHMKQBWSQIY-UHFFFAOYSA-N 0.000 description 1
- 229960000569 ethoheptazine Drugs 0.000 description 1
- 229950005098 ethoxzolamide Drugs 0.000 description 1
- OUZWUKMCLIBBOG-UHFFFAOYSA-N ethoxzolamide Chemical compound CCOC1=CC=C2N=C(S(N)(=O)=O)SC2=C1 OUZWUKMCLIBBOG-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- ULANGSAJTINEBA-UHFFFAOYSA-N ethyl n-(3-benzoylphenyl)-n-(trifluoromethylsulfonyl)carbamate Chemical compound CCOC(=O)N(S(=O)(=O)C(F)(F)F)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 ULANGSAJTINEBA-UHFFFAOYSA-N 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 229940009626 etidronate Drugs 0.000 description 1
- 229960001493 etofenamate Drugs 0.000 description 1
- CAHCBJPUTCKATP-FAWZKKEFSA-N etorphine Chemical compound O([C@H]1[C@@]2(OC)C=C[C@@]34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O CAHCBJPUTCKATP-FAWZKKEFSA-N 0.000 description 1
- 229950004155 etorphine Drugs 0.000 description 1
- IXSZQYVWNJNRAL-UHFFFAOYSA-N etoxazole Chemical compound CCOC1=CC(C(C)(C)C)=CC=C1C1N=C(C=2C(=CC=CC=2F)F)OC1 IXSZQYVWNJNRAL-UHFFFAOYSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 229940085363 evista Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 229960000192 felbinac Drugs 0.000 description 1
- 229960003580 felodipine Drugs 0.000 description 1
- 229950003579 fenamole Drugs 0.000 description 1
- 229960001395 fenbufen Drugs 0.000 description 1
- ZPAKPRAICRBAOD-UHFFFAOYSA-N fenbufen Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1C1=CC=CC=C1 ZPAKPRAICRBAOD-UHFFFAOYSA-N 0.000 description 1
- 229950006236 fenclofenac Drugs 0.000 description 1
- IDKAXRLETRCXKS-UHFFFAOYSA-N fenclofenac Chemical compound OC(=O)CC1=CC=CC=C1OC1=CC=C(Cl)C=C1Cl IDKAXRLETRCXKS-UHFFFAOYSA-N 0.000 description 1
- 229950003537 fenclorac Drugs 0.000 description 1
- 229960002602 fendiline Drugs 0.000 description 1
- 229950005416 fendosal Drugs 0.000 description 1
- HAWWPSYXSLJRBO-UHFFFAOYSA-N fendosal Chemical compound C1=C(O)C(C(=O)O)=CC(N2C(=CC=3C4=CC=CC=C4CCC=32)C=2C=CC=CC=2)=C1 HAWWPSYXSLJRBO-UHFFFAOYSA-N 0.000 description 1
- 229960002297 fenofibrate Drugs 0.000 description 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
- 229960001419 fenoprofen Drugs 0.000 description 1
- 229950002296 fenpipalone Drugs 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- 229960002679 fentiazac Drugs 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229950004322 flazalone Drugs 0.000 description 1
- BYZCJOHDXLROEC-RBWIMXSLSA-N fluazacort Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)=N[C@@]3(C(=O)COC(=O)C)[C@@]1(C)C[C@@H]2O BYZCJOHDXLROEC-RBWIMXSLSA-N 0.000 description 1
- 229950002335 fluazacort Drugs 0.000 description 1
- 229960004369 flufenamic acid Drugs 0.000 description 1
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 1
- 229950005288 flumizole Drugs 0.000 description 1
- OPYFPDBMMYUPME-UHFFFAOYSA-N flumizole Chemical compound C1=CC(OC)=CC=C1C1=C(C=2C=CC(OC)=CC=2)NC(C(F)(F)F)=N1 OPYFPDBMMYUPME-UHFFFAOYSA-N 0.000 description 1
- SMANXXCATUTDDT-QPJJXVBHSA-N flunarizine Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)N1CCN(C\C=C\C=2C=CC=CC=2)CC1 SMANXXCATUTDDT-QPJJXVBHSA-N 0.000 description 1
- 229960000326 flunarizine Drugs 0.000 description 1
- WEGNFRKBIKYVLC-XTLNBZDDSA-N flunisolide acetate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WEGNFRKBIKYVLC-XTLNBZDDSA-N 0.000 description 1
- 229960000588 flunixin Drugs 0.000 description 1
- NOOCSNJCXJYGPE-UHFFFAOYSA-N flunixin Chemical compound C1=CC=C(C(F)(F)F)C(C)=C1NC1=NC=CC=C1C(O)=O NOOCSNJCXJYGPE-UHFFFAOYSA-N 0.000 description 1
- 229960000469 flunixin meglumine Drugs 0.000 description 1
- MGCCHNLNRBULBU-WZTVWXICSA-N flunixin meglumine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.C1=CC=C(C(F)(F)F)C(C)=C1NC1=NC=CC=C1C(O)=O MGCCHNLNRBULBU-WZTVWXICSA-N 0.000 description 1
- XWTIDFOGTCVGQB-FHIVUSPVSA-N fluocortin butyl Chemical group C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)C(=O)OCCCC)[C@@]2(C)C[C@@H]1O XWTIDFOGTCVGQB-FHIVUSPVSA-N 0.000 description 1
- 229950008509 fluocortin butyl Drugs 0.000 description 1
- RMBPEFMHABBEKP-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2C3=C[CH]C=CC3=CC2=C1 RMBPEFMHABBEKP-UHFFFAOYSA-N 0.000 description 1
- 238000012921 fluorescence analysis Methods 0.000 description 1
- 238000000198 fluorescence anisotropy Methods 0.000 description 1
- 238000002060 fluorescence correlation spectroscopy Methods 0.000 description 1
- 238000002875 fluorescence polarization Methods 0.000 description 1
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 1
- 229960001629 fluorometholone acetate Drugs 0.000 description 1
- YRFXGQHBPBMFHW-SBTZIJSASA-N fluorometholone acetate Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@]2(F)[C@@H](O)C[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 YRFXGQHBPBMFHW-SBTZIJSASA-N 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 229950007253 fluquazone Drugs 0.000 description 1
- 229950003750 fluretofen Drugs 0.000 description 1
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 1
- 229960000289 fluticasone propionate Drugs 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- 229960004038 fluvoxamine Drugs 0.000 description 1
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 229940053641 forteo Drugs 0.000 description 1
- 229940001490 fosamax Drugs 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 229950008156 furaprofen Drugs 0.000 description 1
- 229950006099 furobufen Drugs 0.000 description 1
- 125000004612 furopyridinyl group Chemical group O1C(=CC2=C1C=CC=N2)* 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229960002870 gabapentin Drugs 0.000 description 1
- 229960003980 galantamine Drugs 0.000 description 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 1
- 229960000457 gallopamil Drugs 0.000 description 1
- 239000003540 gamma secretase inhibitor Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 102000054767 gene variant Human genes 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000004104 gestational diabetes Diseases 0.000 description 1
- 210000003731 gingival crevicular fluid Anatomy 0.000 description 1
- 230000009477 glass transition Effects 0.000 description 1
- 229950004153 gliamilide Drugs 0.000 description 1
- 229950000063 glicetanile Drugs 0.000 description 1
- 229960000346 gliclazide Drugs 0.000 description 1
- 229950002106 gliflumide Drugs 0.000 description 1
- 229960004346 glimepiride Drugs 0.000 description 1
- 229960001381 glipizide Drugs 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229940095884 glucophage Drugs 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 208000008605 glucosephosphate dehydrogenase deficiency Diseases 0.000 description 1
- 229940088991 glucotrol Drugs 0.000 description 1
- 229930182480 glucuronide Natural products 0.000 description 1
- 150000008134 glucuronides Chemical class 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- NFRPNQDSKJJQGV-UHFFFAOYSA-N glyhexamide Chemical compound C=1C=C2CCCC2=CC=1S(=O)(=O)NC(=O)NC1CCCCC1 NFRPNQDSKJJQGV-UHFFFAOYSA-N 0.000 description 1
- 229950008290 glyhexamide Drugs 0.000 description 1
- 229950011212 glymidine sodium Drugs 0.000 description 1
- NUQDEHHKOXSIEA-UHFFFAOYSA-N glymidine sodium Chemical compound [Na+].N1=CC(OCCOC)=CN=C1[N-]S(=O)(=O)C1=CC=CC=C1 NUQDEHHKOXSIEA-UHFFFAOYSA-N 0.000 description 1
- 229940120105 glynase Drugs 0.000 description 1
- 229950007246 glyoctamide Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000003324 growth hormone secretagogue Substances 0.000 description 1
- 229960004198 guanidine Drugs 0.000 description 1
- 229960002383 halcinonide Drugs 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 229950004611 halopredone acetate Drugs 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 238000005734 heterodimerization reaction Methods 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 description 1
- 229950000177 hibenzate Drugs 0.000 description 1
- 239000003395 histamine H3 receptor antagonist Substances 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 229940038661 humalog Drugs 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 150000002429 hydrazines Chemical class 0.000 description 1
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 1
- 229960000240 hydrocodone Drugs 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 1
- 229960001410 hydromorphone Drugs 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 229940015872 ibandronate Drugs 0.000 description 1
- 229950009183 ibufenac Drugs 0.000 description 1
- CYWFCPPBTWOZSF-UHFFFAOYSA-N ibufenac Chemical compound CC(C)CC1=CC=C(CC(O)=O)C=C1 CYWFCPPBTWOZSF-UHFFFAOYSA-N 0.000 description 1
- 229950005954 ibuprofen piconol Drugs 0.000 description 1
- 229960000934 ibutamoren Drugs 0.000 description 1
- 229950011445 ilonidap Drugs 0.000 description 1
- 238000005417 image-selected in vivo spectroscopy Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000007850 in situ PCR Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- MPGBPFMOOXKQRX-UHFFFAOYSA-N indenolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=C1C=CC2 MPGBPFMOOXKQRX-UHFFFAOYSA-N 0.000 description 1
- 229950008838 indenolol Drugs 0.000 description 1
- 229960004187 indoprofen Drugs 0.000 description 1
- 229950008443 indoxole Drugs 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 229960002068 insulin lispro Drugs 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 238000012739 integrated shape imaging system Methods 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 229950004204 intrazole Drugs 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000001871 ion mobility spectroscopy Methods 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 229960003317 isoflupredone acetate Drugs 0.000 description 1
- IFKPLJWIEQBPGG-UHFFFAOYSA-N isomethadone Chemical compound C=1C=CC=CC=1C(C(C)CN(C)C)(C(=O)CC)C1=CC=CC=C1 IFKPLJWIEQBPGG-UHFFFAOYSA-N 0.000 description 1
- 229950009272 isomethadone Drugs 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229940006445 isophane insulin Drugs 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 229960002479 isosorbide Drugs 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- QFGMXJOBTNZHEL-UHFFFAOYSA-N isoxepac Chemical compound O1CC2=CC=CC=C2C(=O)C2=CC(CC(=O)O)=CC=C21 QFGMXJOBTNZHEL-UHFFFAOYSA-N 0.000 description 1
- 229950011455 isoxepac Drugs 0.000 description 1
- YYUAYBYLJSNDCX-UHFFFAOYSA-N isoxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC=1C=C(C)ON=1 YYUAYBYLJSNDCX-UHFFFAOYSA-N 0.000 description 1
- 229950002252 isoxicam Drugs 0.000 description 1
- 229960004427 isradipine Drugs 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229960004752 ketorolac Drugs 0.000 description 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 description 1
- 229960001160 latanoprost Drugs 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000007942 layered tablet Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- BMPDWHIDQYTSHX-UHFFFAOYSA-N licarbazepine Chemical compound C1C(O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 BMPDWHIDQYTSHX-UHFFFAOYSA-N 0.000 description 1
- 229950004872 linogliride Drugs 0.000 description 1
- 239000002960 lipid emulsion Substances 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229960002394 lisinopril Drugs 0.000 description 1
- CZRQXSDBMCMPNJ-ZUIPZQNBSA-N lisinopril dihydrate Chemical compound O.O.C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 CZRQXSDBMCMPNJ-ZUIPZQNBSA-N 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 229960004391 lorazepam Drugs 0.000 description 1
- OXROWJKCGCOJDO-JLHYYAGUSA-N lornoxicam Chemical compound O=C1C=2SC(Cl)=CC=2S(=O)(=O)N(C)\C1=C(\O)NC1=CC=CC=N1 OXROWJKCGCOJDO-JLHYYAGUSA-N 0.000 description 1
- 229960002202 lornoxicam Drugs 0.000 description 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
- 229960004773 losartan Drugs 0.000 description 1
- DMKSVUSAATWOCU-HROMYWEYSA-N loteprednol etabonate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)OCCl)(OC(=O)OCC)[C@@]1(C)C[C@@H]2O DMKSVUSAATWOCU-HROMYWEYSA-N 0.000 description 1
- 229960003744 loteprednol etabonate Drugs 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 229960000994 lumiracoxib Drugs 0.000 description 1
- KHPKQFYUPIUARC-UHFFFAOYSA-N lumiracoxib Chemical compound OC(=O)CC1=CC(C)=CC=C1NC1=C(F)C=CC=C1Cl KHPKQFYUPIUARC-UHFFFAOYSA-N 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- GQVWFGYYMWLERN-UHFFFAOYSA-J magnesium;2-carboxyphenolate;2-hydroxyethyl(trimethyl)azanium;sulfate;tetrahydrate Chemical compound O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O.C[N+](C)(C)CCO.C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O GQVWFGYYMWLERN-UHFFFAOYSA-J 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 229940043353 maltol Drugs 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 229940013798 meclofenamate Drugs 0.000 description 1
- 229960003803 meclofenamic acid Drugs 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- 229950004994 meglitinide Drugs 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 229950008446 melinamide Drugs 0.000 description 1
- 229960001929 meloxicam Drugs 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960003134 mepindolol Drugs 0.000 description 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
- 229960004963 mesalazine Drugs 0.000 description 1
- OJGJQQNLRVNIKE-UHFFFAOYSA-N meseclazone Chemical compound O1C2=CC=C(Cl)C=C2C(=O)N2C1CC(C)O2 OJGJQQNLRVNIKE-UHFFFAOYSA-N 0.000 description 1
- 229950000701 meseclazone Drugs 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 1
- FLOSMHQXBMRNHR-DAXSKMNVSA-N methazolamide Chemical compound CC(=O)\N=C1/SC(S(N)(=O)=O)=NN1C FLOSMHQXBMRNHR-DAXSKMNVSA-N 0.000 description 1
- 229960004083 methazolamide Drugs 0.000 description 1
- RSSDZUNGAWCFPT-UHFFFAOYSA-N methyl 2-tetradecyloxirane-2-carboxylate Chemical compound CCCCCCCCCCCCCCC1(C(=O)OC)CO1 RSSDZUNGAWCFPT-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 229940050176 methyl chloride Drugs 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- NPZXCTIHHUUEEJ-CMKMFDCUSA-N metopon Chemical compound O([C@@]1(C)C(=O)CC[C@@H]23)C4=C5[C@@]13CCN(C)[C@@H]2CC5=CC=C4O NPZXCTIHHUUEEJ-CMKMFDCUSA-N 0.000 description 1
- 229950006080 metopon Drugs 0.000 description 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
- 229960002237 metoprolol Drugs 0.000 description 1
- 229940101566 miacalcin Drugs 0.000 description 1
- 229960003955 mianserin Drugs 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- MXWHMTNPTTVWDM-NXOFHUPFSA-N mitoguazone Chemical compound NC(N)=N\N=C(/C)\C=N\N=C(N)N MXWHMTNPTTVWDM-NXOFHUPFSA-N 0.000 description 1
- ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 235000007708 morin Nutrition 0.000 description 1
- 229960003251 morniflumate Drugs 0.000 description 1
- LDXSPUSKBDTEKA-UHFFFAOYSA-N morniflumate Chemical compound FC(F)(F)C1=CC=CC(NC=2C(=CC=CN=2)C(=O)OCCN2CCOCC2)=C1 LDXSPUSKBDTEKA-UHFFFAOYSA-N 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 229940113083 morpholine Drugs 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 230000005405 multipole Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- NKDJNEGDJVXHKM-UHFFFAOYSA-N n,2-dimethyl-4,5,6,7-tetrahydroindazol-3-amine Chemical compound C1CCCC2=NN(C)C(NC)=C21 NKDJNEGDJVXHKM-UHFFFAOYSA-N 0.000 description 1
- PWDYHMBTPGXCSN-VCBMUGGBSA-N n,n'-bis[3,5-bis[(e)-n-(diaminomethylideneamino)-c-methylcarbonimidoyl]phenyl]decanediamide Chemical compound NC(N)=N/N=C(\C)C1=CC(C(=N/N=C(N)N)/C)=CC(NC(=O)CCCCCCCCC(=O)NC=2C=C(C=C(C=2)C(\C)=N\N=C(N)N)C(\C)=N\N=C(N)N)=C1 PWDYHMBTPGXCSN-VCBMUGGBSA-N 0.000 description 1
- JFSYLINYOHTYGG-UHFFFAOYSA-N n-(2-methoxyethyl)methanesulfonamide Chemical compound COCCNS(C)(=O)=O JFSYLINYOHTYGG-UHFFFAOYSA-N 0.000 description 1
- KSWJWTKGCHLIIX-UHFFFAOYSA-N n-(2-methylphenyl)methanesulfonamide Chemical compound CC1=CC=CC=C1NS(C)(=O)=O KSWJWTKGCHLIIX-UHFFFAOYSA-N 0.000 description 1
- HWCORKBTTGTRDY-UHFFFAOYSA-N n-(4-chlorophenyl)-1,3-dioxo-4h-isoquinoline-4-carboxamide Chemical compound C1=CC(Cl)=CC=C1NC(=O)C1C2=CC=CC=C2C(=O)NC1=O HWCORKBTTGTRDY-UHFFFAOYSA-N 0.000 description 1
- LXOXCADHKCVBOZ-UHFFFAOYSA-N n-(5-chloro-2-methoxyphenyl)-2-[4-[[5-(2-methylpropyl)pyrimidin-2-yl]sulfamoyl]phenyl]acetamide Chemical compound COC1=CC=C(Cl)C=C1NC(=O)CC1=CC=C(S(=O)(=O)NC=2N=CC(CC(C)C)=CN=2)C=C1 LXOXCADHKCVBOZ-UHFFFAOYSA-N 0.000 description 1
- NAOMHYZHXZCARI-UHFFFAOYSA-N n-(furan-2-ylmethyl)-n-(2-methylprop-2-enyl)methanesulfonamide Chemical compound CC(=C)CN(S(C)(=O)=O)CC1=CC=CO1 NAOMHYZHXZCARI-UHFFFAOYSA-N 0.000 description 1
- KCRXNRVDKKRCJP-UHFFFAOYSA-N n-(furan-2-ylmethyl)-n-(oxiran-2-ylmethyl)methanesulfonamide Chemical compound C=1C=COC=1CN(S(=O)(=O)C)CC1CO1 KCRXNRVDKKRCJP-UHFFFAOYSA-N 0.000 description 1
- VQFSWBZLVFKIBN-UHFFFAOYSA-N n-(furan-2-ylmethyl)-n-[(2-methyloxiran-2-yl)methyl]methanesulfonamide Chemical compound C=1C=COC=1CN(S(C)(=O)=O)CC1(C)CO1 VQFSWBZLVFKIBN-UHFFFAOYSA-N 0.000 description 1
- MWYZWLQBGDDXSZ-UHFFFAOYSA-N n-(furan-2-ylmethyl)methanesulfonamide Chemical compound CS(=O)(=O)NCC1=CC=CO1 MWYZWLQBGDDXSZ-UHFFFAOYSA-N 0.000 description 1
- CKOLETHYECDWSS-KRWDZBQOSA-N n-[(1s)-1-(5-fluoro-2-methoxyphenyl)ethyl]-2-[4-[[5-(2-methylpropyl)pyrimidin-2-yl]sulfamoyl]phenyl]acetamide Chemical compound COC1=CC=C(F)C=C1[C@H](C)NC(=O)CC1=CC=C(S(=O)(=O)NC=2N=CC(CC(C)C)=CN=2)C=C1 CKOLETHYECDWSS-KRWDZBQOSA-N 0.000 description 1
- MQQJZPWSYVPWPF-QYZOEREBSA-N n-[2-[1-[[(1r,4r,5r)-5-bicyclo[2.2.1]hept-2-enyl]methylcarbamoylsulfamoyl]piperidin-4-yl]ethyl]-2-methoxypyridine-3-carboxamide Chemical compound COC1=NC=CC=C1C(=O)NCCC1CCN(S(=O)(=O)NC(=O)NC[C@H]2[C@@H]3C[C@@H](C=C3)C2)CC1 MQQJZPWSYVPWPF-QYZOEREBSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- BDQCDIWFPIDPQU-NDEPHWFRSA-N n-methyl-5-[4-[1-[(1r)-3-oxospiro[2-benzofuran-1,3'-pyrrolidine]-1'-carbonyl]cyclopropyl]phenyl]pyridine-2-carboxamide Chemical compound C1=NC(C(=O)NC)=CC=C1C1=CC=C(C2(CC2)C(=O)N2C[C@@]3(CC2)C2=CC=CC=C2C(=O)O3)C=C1 BDQCDIWFPIDPQU-NDEPHWFRSA-N 0.000 description 1
- NETZHAKZCGBWSS-CEDHKZHLSA-N nalbuphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 NETZHAKZCGBWSS-CEDHKZHLSA-N 0.000 description 1
- 229960000805 nalbuphine Drugs 0.000 description 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
- 229960004127 naloxone Drugs 0.000 description 1
- RHBRMCOKKKZVRY-ITLPAZOVSA-N naltrexone hydrochloride Chemical compound Cl.N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 RHBRMCOKKKZVRY-ITLPAZOVSA-N 0.000 description 1
- YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical compound C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- CDBRNDSHEYLDJV-FVGYRXGTSA-M naproxen sodium Chemical compound [Na+].C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CDBRNDSHEYLDJV-FVGYRXGTSA-M 0.000 description 1
- 229960003940 naproxen sodium Drugs 0.000 description 1
- 229950006890 naproxol Drugs 0.000 description 1
- LTRANDSQVZFZDG-SNVBAGLBSA-N naproxol Chemical compound C1=C([C@H](C)CO)C=CC2=CC(OC)=CC=C21 LTRANDSQVZFZDG-SNVBAGLBSA-N 0.000 description 1
- 229960001800 nefazodone Drugs 0.000 description 1
- VRBKIVRKKCLPHA-UHFFFAOYSA-N nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000009707 neogenesis Effects 0.000 description 1
- 229910052754 neon Inorganic materials 0.000 description 1
- GKAOGPIIYCISHV-UHFFFAOYSA-N neon atom Chemical compound [Ne] GKAOGPIIYCISHV-UHFFFAOYSA-N 0.000 description 1
- 229960002362 neostigmine Drugs 0.000 description 1
- LULNWZDBKTWDGK-UHFFFAOYSA-M neostigmine bromide Chemical compound [Br-].CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 LULNWZDBKTWDGK-UHFFFAOYSA-M 0.000 description 1
- OGZQTTHDGQBLBT-UHFFFAOYSA-N neramexane Chemical compound CC1(C)CC(C)(C)CC(C)(N)C1 OGZQTTHDGQBLBT-UHFFFAOYSA-N 0.000 description 1
- 229950004543 neramexane Drugs 0.000 description 1
- PUUSSSIBPPTKTP-UHFFFAOYSA-N neridronic acid Chemical compound NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O PUUSSSIBPPTKTP-UHFFFAOYSA-N 0.000 description 1
- 229950010733 neridronic acid Drugs 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 108010089579 neuropeptide Y2 receptor Proteins 0.000 description 1
- 229960001783 nicardipine Drugs 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 229950006046 nimazone Drugs 0.000 description 1
- 229960000965 nimesulide Drugs 0.000 description 1
- HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 229950006134 normorphine Drugs 0.000 description 1
- 229960001158 nortriptyline Drugs 0.000 description 1
- 229940098815 novolin n Drugs 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 229940127073 nucleoside analogue Drugs 0.000 description 1
- 230000030648 nucleus localization Effects 0.000 description 1
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Natural products C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 1
- XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 1
- 229960005017 olanzapine Drugs 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 229960004364 olsalazine sodium Drugs 0.000 description 1
- 229960005343 ondansetron Drugs 0.000 description 1
- 229960001027 opium Drugs 0.000 description 1
- 229940127017 oral antidiabetic Drugs 0.000 description 1
- 239000003538 oral antidiabetic agent Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229960004534 orgotein Drugs 0.000 description 1
- 108010070915 orgotein Proteins 0.000 description 1
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 1
- 229950003655 orpanoxin Drugs 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 239000002337 osmotic diuretic agent Substances 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 229960002739 oxaprozin Drugs 0.000 description 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 229960004570 oxprenolol Drugs 0.000 description 1
- 229960002085 oxycodone Drugs 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 229960005118 oxymorphone Drugs 0.000 description 1
- 229960000649 oxyphenbutazone Drugs 0.000 description 1
- CNDQSXOVEQXJOE-UHFFFAOYSA-N oxyphenbutazone hydrate Chemical compound O.O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=C(O)C=C1 CNDQSXOVEQXJOE-UHFFFAOYSA-N 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229950002286 pagoclone Drugs 0.000 description 1
- HIUPRQPBWVEQJJ-UHFFFAOYSA-N pagoclone Chemical compound C1=CC(Cl)=NC2=NC(N3C(C4=CC=CC=C4C3=O)CC(=O)CCC(C)C)=CC=C21 HIUPRQPBWVEQJJ-UHFFFAOYSA-N 0.000 description 1
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 1
- 229940046231 pamidronate Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229960004662 parecoxib Drugs 0.000 description 1
- TZRHLKRLEZJVIJ-UHFFFAOYSA-N parecoxib Chemical compound C1=CC(S(=O)(=O)NC(=O)CC)=CC=C1C1=C(C)ON=C1C1=CC=CC=C1 TZRHLKRLEZJVIJ-UHFFFAOYSA-N 0.000 description 1
- 238000010238 partial least squares regression Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000012567 pattern recognition method Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- NRNCYVBFPDDJNE-UHFFFAOYSA-N pemoline Chemical compound O1C(N)=NC(=O)C1C1=CC=CC=C1 NRNCYVBFPDDJNE-UHFFFAOYSA-N 0.000 description 1
- KQXKVJAGOJTNJS-HNNXBMFYSA-N penbutolol Chemical compound CC(C)(C)NC[C@H](O)COC1=CC=CC=C1C1CCCC1 KQXKVJAGOJTNJS-HNNXBMFYSA-N 0.000 description 1
- 229960002035 penbutolol Drugs 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 229960003820 pentosan polysulfate sodium Drugs 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 125000001151 peptidyl group Chemical group 0.000 description 1
- CYXKNKQEMFBLER-UHFFFAOYSA-N perhexiline Chemical compound C1CCCNC1CC(C1CCCCC1)C1CCCCC1 CYXKNKQEMFBLER-UHFFFAOYSA-N 0.000 description 1
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 description 1
- 229960002582 perindopril Drugs 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 229960000482 pethidine Drugs 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- ZQHYKVKNPWDQSL-KNXBSLHKSA-N phenazocine Chemical compound C([C@@]1(C)C2=CC(O)=CC=C2C[C@@H]2[C@@H]1C)CN2CCC1=CC=CC=C1 ZQHYKVKNPWDQSL-KNXBSLHKSA-N 0.000 description 1
- 229960000897 phenazocine Drugs 0.000 description 1
- 229960000964 phenelzine Drugs 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- ABOYDMHGKWRPFD-UHFFFAOYSA-N phenylmethanesulfonamide Chemical compound NS(=O)(=O)CC1=CC=CC=C1 ABOYDMHGKWRPFD-UHFFFAOYSA-N 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- ACVYVLVWPXVTIT-UHFFFAOYSA-M phosphinate Chemical compound [O-][PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-M 0.000 description 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 1
- 229930029653 phosphoenolpyruvate Natural products 0.000 description 1
- DTBNBXWJWCWCIK-UHFFFAOYSA-N phosphoenolpyruvic acid Chemical compound OC(=O)C(=C)OP(O)(O)=O DTBNBXWJWCWCIK-UHFFFAOYSA-N 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- DCWXELXMIBXGTH-QMMMGPOBSA-N phosphonotyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-QMMMGPOBSA-N 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 description 1
- 229960001697 physostigmine Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960001416 pilocarpine Drugs 0.000 description 1
- 229960002508 pindolol Drugs 0.000 description 1
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- HXEACLLIILLPRG-UHFFFAOYSA-N pipecolic acid Chemical compound OC(=O)C1CCCCN1 HXEACLLIILLPRG-UHFFFAOYSA-N 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 description 1
- 229960003073 pirfenidone Drugs 0.000 description 1
- 229960001369 piroxicam cinnamate Drugs 0.000 description 1
- 229960000851 pirprofen Drugs 0.000 description 1
- PIDSZXPFGCURGN-UHFFFAOYSA-N pirprofen Chemical compound ClC1=CC(C(C(O)=O)C)=CC=C1N1CC=CC1 PIDSZXPFGCURGN-UHFFFAOYSA-N 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229960000540 polacrilin potassium Drugs 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229940119528 pork insulin Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000003450 potassium channel blocker Substances 0.000 description 1
- 229940125422 potassium channel blocker Drugs 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- WVWZXTJUCNEUAE-UHFFFAOYSA-M potassium;1,2-bis(ethenyl)benzene;2-methylprop-2-enoate Chemical compound [K+].CC(=C)C([O-])=O.C=CC1=CC=CC=C1C=C WVWZXTJUCNEUAE-UHFFFAOYSA-M 0.000 description 1
- 238000004313 potentiometry Methods 0.000 description 1
- 229960001749 practolol Drugs 0.000 description 1
- DURULFYMVIFBIR-UHFFFAOYSA-N practolol Chemical compound CC(C)NCC(O)COC1=CC=C(NC(C)=O)C=C1 DURULFYMVIFBIR-UHFFFAOYSA-N 0.000 description 1
- 229960003089 pramipexole Drugs 0.000 description 1
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 description 1
- 229940096058 prandin Drugs 0.000 description 1
- VWBQYTRBTXKKOG-IYNICTALSA-M pravastatin sodium Chemical compound [Na+].C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC([O-])=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 VWBQYTRBTXKKOG-IYNICTALSA-M 0.000 description 1
- 229960001495 pravastatin sodium Drugs 0.000 description 1
- 238000007781 pre-processing Methods 0.000 description 1
- 229940095885 precose Drugs 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 229950008421 prednazate Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000001581 pretranslational effect Effects 0.000 description 1
- 229950004465 prifelone Drugs 0.000 description 1
- WAAVMZLJRXYRMA-UHFFFAOYSA-N prifelone Chemical compound CC(C)(C)C1=C(O)C(C(C)(C)C)=CC(C(=O)C=2SC=CC=2)=C1 WAAVMZLJRXYRMA-UHFFFAOYSA-N 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000019525 primary metabolic process Effects 0.000 description 1
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 1
- 229960003912 probucol Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 229950003795 prodolic acid Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 229960002466 proquazone Drugs 0.000 description 1
- JTIGKVIOEQASGT-UHFFFAOYSA-N proquazone Chemical compound N=1C(=O)N(C(C)C)C2=CC(C)=CC=C2C=1C1=CC=CC=C1 JTIGKVIOEQASGT-UHFFFAOYSA-N 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 201000005825 prostate adenocarcinoma Diseases 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 230000026447 protein localization Effects 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 229960001801 proxazole Drugs 0.000 description 1
- OLTAWOVKGWWERU-UHFFFAOYSA-N proxazole Chemical compound C=1C=CC=CC=1C(CC)C1=NOC(CCN(CC)CC)=N1 OLTAWOVKGWWERU-UHFFFAOYSA-N 0.000 description 1
- 238000010379 pull-down assay Methods 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 238000000009 pyrolysis mass spectrometry Methods 0.000 description 1
- 150000003233 pyrroles Chemical class 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 201000006473 pyruvate decarboxylase deficiency Diseases 0.000 description 1
- 208000015445 pyruvate dehydrogenase deficiency Diseases 0.000 description 1
- 238000005173 quadrupole mass spectroscopy Methods 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 1
- 229960004431 quetiapine Drugs 0.000 description 1
- 229960001455 quinapril Drugs 0.000 description 1
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- RCOBKSKAZMVBHT-TVQRCGJNSA-N radafaxine Chemical compound C[C@@H]1NC(C)(C)CO[C@@]1(O)C1=CC=CC(Cl)=C1 RCOBKSKAZMVBHT-TVQRCGJNSA-N 0.000 description 1
- 229950010561 radafaxine Drugs 0.000 description 1
- 238000005514 radiochemical analysis Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 229960004622 raloxifene Drugs 0.000 description 1
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 1
- 229960003401 ramipril Drugs 0.000 description 1
- 238000007637 random forest analysis Methods 0.000 description 1
- 229960003770 reboxetine Drugs 0.000 description 1
- CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 description 1
- 108091006084 receptor activators Proteins 0.000 description 1
- 239000002469 receptor inverse agonist Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 229940116176 remicade Drugs 0.000 description 1
- 229960003394 remifentanil Drugs 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 229960002354 repaglinide Drugs 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012465 retentate Substances 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 229960001487 rimexolone Drugs 0.000 description 1
- QTTRZHGPGKRAFB-OOKHYKNYSA-N rimexolone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CC)(C)[C@@]1(C)C[C@@H]2O QTTRZHGPGKRAFB-OOKHYKNYSA-N 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- 229960001534 risperidone Drugs 0.000 description 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 1
- 229960000311 ritonavir Drugs 0.000 description 1
- 229960004136 rivastigmine Drugs 0.000 description 1
- 229950001166 romazarit Drugs 0.000 description 1
- 229950000125 salcolex Drugs 0.000 description 1
- 108010068072 salmon calcitonin Proteins 0.000 description 1
- 229950009768 salnacedin Drugs 0.000 description 1
- 229960000953 salsalate Drugs 0.000 description 1
- 229950011197 sanguinarium chloride Drugs 0.000 description 1
- GIZKAXHWLRYMLE-UHFFFAOYSA-M sanguinarium chloride Chemical compound [Cl-].C1=C2OCOC2=CC2=C3[N+](C)=CC4=C(OCO5)C5=CC=C4C3=CC=C21 GIZKAXHWLRYMLE-UHFFFAOYSA-M 0.000 description 1
- PGKXDIMONUAMFR-AREMUKBSSA-N saredutant Chemical compound C([C@H](CN(C)C(=O)C=1C=CC=CC=1)C=1C=C(Cl)C(Cl)=CC=1)CN(CC1)CCC1(NC(C)=O)C1=CC=CC=C1 PGKXDIMONUAMFR-AREMUKBSSA-N 0.000 description 1
- 229950004387 saredutant Drugs 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 229950002093 seclazone Drugs 0.000 description 1
- 150000003335 secondary amines Chemical group 0.000 description 1
- 238000001004 secondary ion mass spectrometry Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 108010052231 seglitide Proteins 0.000 description 1
- 239000000849 selective androgen receptor modulator Substances 0.000 description 1
- 229950006250 sermetacin Drugs 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 239000012176 shellac wax Substances 0.000 description 1
- 125000005629 sialic acid group Chemical group 0.000 description 1
- 230000007727 signaling mechanism Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 229940112726 skelid Drugs 0.000 description 1
- JFBMSTWZURKQOC-UHFFFAOYSA-M sodium 2-amino-5-[(1-methoxy-2-methylindolizin-3-yl)carbonyl]benzoate Chemical compound [Na+].N12C=CC=CC2=C(OC)C(C)=C1C(=O)C1=CC=C(N)C(C([O-])=O)=C1 JFBMSTWZURKQOC-UHFFFAOYSA-M 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940056729 sodium sulfate anhydrous Drugs 0.000 description 1
- HVBBVDWXAWJQSV-UHFFFAOYSA-N sodium;(3-benzoylphenyl)-(difluoromethylsulfonyl)azanide Chemical compound [Na+].FC(F)S(=O)(=O)[N-]C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 HVBBVDWXAWJQSV-UHFFFAOYSA-N 0.000 description 1
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 1
- UISHOHGMISMAQN-UHFFFAOYSA-M sodium;2-[2-butyl-5-chloro-3-[(2-chlorophenyl)methyl]imidazol-4-yl]acetate Chemical compound [Na+].CCCCC1=NC(Cl)=C(CC([O-])=O)N1CC1=CC=CC=C1Cl UISHOHGMISMAQN-UHFFFAOYSA-M 0.000 description 1
- ZJXLSCXDGPDZOL-UHFFFAOYSA-M sodium;2-[5-(4-chlorobenzoyl)-1,4-dimethylpyrrol-2-yl]acetate;dihydrate Chemical compound O.O.[Na+].C1=C(CC([O-])=O)N(C)C(C(=O)C=2C=CC(Cl)=CC=2)=C1C ZJXLSCXDGPDZOL-UHFFFAOYSA-M 0.000 description 1
- KFSQDUBDCZTCRP-UHFFFAOYSA-M sodium;2-tetradecyloxirane-2-carboxylate;dihydrate Chemical compound O.O.[Na+].CCCCCCCCCCCCCCC1(C([O-])=O)CO1 KFSQDUBDCZTCRP-UHFFFAOYSA-M 0.000 description 1
- QUCDWLYKDRVKMI-UHFFFAOYSA-M sodium;3,4-dimethylbenzenesulfonate Chemical compound [Na+].CC1=CC=C(S([O-])(=O)=O)C=C1C QUCDWLYKDRVKMI-UHFFFAOYSA-M 0.000 description 1
- TVGNJNYKOTWAJQ-UHFFFAOYSA-M sodium;4-butyl-5-oxo-1,2-diphenylpyrazol-3-olate;propane-1,2,3-triol Chemical compound [Na+].OCC(O)CO.C=1C=CC=CC=1N1C(=O)C(CCCC)=C([O-])N1C1=CC=CC=C1 TVGNJNYKOTWAJQ-UHFFFAOYSA-M 0.000 description 1
- JQWYNJRCVYGLMO-GPPXSFHXSA-M sodium;5-[[(2r)-2-benzyl-3,4-dihydro-2h-chromen-6-yl]methyl]-1,3-thiazolidin-3-ide-2,4-dione Chemical compound [Na+].S1C(=O)[N-]C(=O)C1CC1=CC=C(O[C@@H](CC=2C=CC=CC=2)CC2)C2=C1 JQWYNJRCVYGLMO-GPPXSFHXSA-M 0.000 description 1
- AMCPCELVARAPHJ-UHFFFAOYSA-M sodium;5-[[4-[3-(5-methyl-2-phenyl-1,3-oxazol-4-yl)propanoyl]phenyl]methyl]-1,3-thiazolidin-3-ide-2,4-dione Chemical compound [Na+].CC=1OC(C=2C=CC=CC=2)=NC=1CCC(=O)C(C=C1)=CC=C1CC1SC(=O)[N-]C1=O AMCPCELVARAPHJ-UHFFFAOYSA-M 0.000 description 1
- AVERBMQHYOZACV-UHFFFAOYSA-M sodium;7-chloro-4-[(3,4-dichlorophenyl)carbamoyl]-1,1-dioxo-2,3-dihydro-1$l^{6}-benzothiepin-5-olate;hydrate Chemical compound O.[Na+].C1CS(=O)(=O)C2=CC=C(Cl)C=C2C([O-])=C1C(=O)NC1=CC=C(Cl)C(Cl)=C1 AVERBMQHYOZACV-UHFFFAOYSA-M 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000002708 spider venom Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010922 spray-dried dispersion Methods 0.000 description 1
- 239000004059 squalene synthase inhibitor Substances 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 235000011150 stannous chloride Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- DFVFTMTWCUHJBL-BQBZGAKWSA-N statine Chemical compound CC(C)C[C@H](N)[C@@H](O)CC(O)=O DFVFTMTWCUHJBL-BQBZGAKWSA-N 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229950005175 sudoxicam Drugs 0.000 description 1
- 229960004739 sufentanil Drugs 0.000 description 1
- GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical compound C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- PBCZLFBEBARBBI-UHFFFAOYSA-N sulfabenzamide Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC(=O)C1=CC=CC=C1 PBCZLFBEBARBBI-UHFFFAOYSA-N 0.000 description 1
- 229960004730 sulfabenzamide Drugs 0.000 description 1
- 125000001010 sulfinic acid amide group Chemical group 0.000 description 1
- 229960003329 sulfinpyrazone Drugs 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 238000006277 sulfonation reaction Methods 0.000 description 1
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- XTQHKBHJIVJGKJ-UHFFFAOYSA-N sulfur monoxide Chemical compound S=O XTQHKBHJIVJGKJ-UHFFFAOYSA-N 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 230000010741 sumoylation Effects 0.000 description 1
- 229960004492 suprofen Drugs 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 229940099093 symlin Drugs 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 description 1
- 229960001685 tacrine Drugs 0.000 description 1
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 229950005100 talmetacin Drugs 0.000 description 1
- 229960005262 talniflumate Drugs 0.000 description 1
- 229950005400 talosalate Drugs 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 238000010381 tandem affinity purification Methods 0.000 description 1
- 229950005022 taranabant Drugs 0.000 description 1
- 229950003441 tebufelone Drugs 0.000 description 1
- 229960002871 tenoxicam Drugs 0.000 description 1
- WZWYJBNHTWCXIM-UHFFFAOYSA-N tenoxicam Chemical compound O=C1C=2SC=CC=2S(=O)(=O)N(C)C1=C(O)NC1=CC=CC=N1 WZWYJBNHTWCXIM-UHFFFAOYSA-N 0.000 description 1
- 229960005460 teriparatide Drugs 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- 229950007324 tesicam Drugs 0.000 description 1
- 229950000997 tesimide Drugs 0.000 description 1
- 229950009970 tesofensine Drugs 0.000 description 1
- TUGDLVFMIQZYPA-UHFFFAOYSA-N tetracopper;tetrazinc Chemical compound [Cu+2].[Cu+2].[Cu+2].[Cu+2].[Zn+2].[Zn+2].[Zn+2].[Zn+2] TUGDLVFMIQZYPA-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 150000003566 thiocarboxylic acids Chemical class 0.000 description 1
- RSPCKAHMRANGJZ-UHFFFAOYSA-N thiohydroxylamine Chemical compound SN RSPCKAHMRANGJZ-UHFFFAOYSA-N 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 125000005503 thioxanyl group Chemical group 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 229950003137 tiapamil Drugs 0.000 description 1
- 229940019375 tiludronate Drugs 0.000 description 1
- 238000001269 time-of-flight mass spectrometry Methods 0.000 description 1
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 1
- 229950002345 tiopinac Drugs 0.000 description 1
- CSUNLSYSEQIDMO-UHFFFAOYSA-N tiprenolol Chemical compound CSC1=CC=CC=C1OCC(O)CNC(C)C CSUNLSYSEQIDMO-UHFFFAOYSA-N 0.000 description 1
- 229950004988 tiprenolol Drugs 0.000 description 1
- 229960003114 tixocortol pivalate Drugs 0.000 description 1
- BISFDZNIUZIKJD-XDANTLIUSA-N tixocortol pivalate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CSC(=O)C(C)(C)C)(O)[C@@]1(C)C[C@@H]2O BISFDZNIUZIKJD-XDANTLIUSA-N 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- 229960001017 tolmetin Drugs 0.000 description 1
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
- RFVJKWJDUQOEML-UHFFFAOYSA-N tolpyrramide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)N1CCCC1 RFVJKWJDUQOEML-UHFFFAOYSA-N 0.000 description 1
- 229950001469 tolpyrramide Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 229960004394 topiramate Drugs 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 description 1
- PHTUQLWOUWZIMZ-GZTJUZNOSA-N trans-dothiepin Chemical compound C1SC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 PHTUQLWOUWZIMZ-GZTJUZNOSA-N 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000037426 transcriptional repression Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229960003741 tranylcypromine Drugs 0.000 description 1
- 229960003991 trazodone Drugs 0.000 description 1
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- DBGVGMSCBYYSLD-UHFFFAOYSA-N tributylstannane Chemical compound CCCC[SnH](CCCC)CCCC DBGVGMSCBYYSLD-UHFFFAOYSA-N 0.000 description 1
- VATYWOIGKMMCMM-UHFFFAOYSA-N trichodimerol Natural products CC=CC=CC(=O)C1=C(O)C2(C)C3C(=C(O)C4(C)C1C5(C)OC4(O)C3(C)OC25O)C(=O)C=CC=CC VATYWOIGKMMCMM-UHFFFAOYSA-N 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 229950000451 triflumidate Drugs 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 125000005591 trimellitate group Chemical group 0.000 description 1
- BPLKQGGAXWRFOE-UHFFFAOYSA-M trimethylsulfoxonium iodide Chemical compound [I-].C[S+](C)(C)=O BPLKQGGAXWRFOE-UHFFFAOYSA-M 0.000 description 1
- 229960002431 trimipramine Drugs 0.000 description 1
- ZSCDBOWYZJWBIY-UHFFFAOYSA-N trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 description 1
- VMJFYMAHEGJHFH-UHFFFAOYSA-M triphenylsulfanium;bromide Chemical compound [Br-].C1=CC=CC=C1[S+](C=1C=CC=CC=1)C1=CC=CC=C1 VMJFYMAHEGJHFH-UHFFFAOYSA-M 0.000 description 1
- 239000003174 triple reuptake inhibitor Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- PSZXPGFNGPBEFR-UHFFFAOYSA-N trisodium butan-1-olate Chemical compound [Na+].[Na+].[Na+].CCCC[O-].CCCC[O-].CCCC[O-] PSZXPGFNGPBEFR-UHFFFAOYSA-N 0.000 description 1
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 1
- 229960004418 trolamine Drugs 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 1
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 238000004879 turbidimetry Methods 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical class C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 229960002004 valdecoxib Drugs 0.000 description 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 1
- 229960004751 varenicline Drugs 0.000 description 1
- JQSHBVHOMNKWFT-DTORHVGOSA-N varenicline Chemical compound C12=CC3=NC=CN=C3C=C2[C@H]2C[C@@H]1CNC2 JQSHBVHOMNKWFT-DTORHVGOSA-N 0.000 description 1
- 229960004688 venlafaxine Drugs 0.000 description 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- PJDFLNIOAUIZSL-UHFFFAOYSA-N vigabatrin Chemical compound C=CC(N)CCC(O)=O PJDFLNIOAUIZSL-UHFFFAOYSA-N 0.000 description 1
- 229960005318 vigabatrin Drugs 0.000 description 1
- 229960003740 vilazodone Drugs 0.000 description 1
- UXDQRXUZPXSLJK-UHFFFAOYSA-N vilazodone Chemical compound C1=CC(C#N)=C[C]2C(CCCCN3CCN(CC3)C=3C=C4C=C(OC4=CC=3)C(=O)N)=CN=C21 UXDQRXUZPXSLJK-UHFFFAOYSA-N 0.000 description 1
- 229960001255 viloxazine Drugs 0.000 description 1
- 229920001567 vinyl ester resin Polymers 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- YQNWZWMKLDQSAC-UHFFFAOYSA-N vortioxetine Chemical compound CC1=CC(C)=CC=C1SC1=CC=CC=C1N1CCNCC1 YQNWZWMKLDQSAC-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical group CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 238000003158 yeast two-hybrid assay Methods 0.000 description 1
- 238000001086 yeast two-hybrid system Methods 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
- 229950007802 zidometacin Drugs 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229960002769 zofenopril Drugs 0.000 description 1
- IAIDUHCBNLFXEF-MNEFBYGVSA-N zofenopril Chemical compound C([C@@H](C)C(=O)N1[C@@H](C[C@@H](C1)SC=1C=CC=CC=1)C(O)=O)SC(=O)C1=CC=CC=C1 IAIDUHCBNLFXEF-MNEFBYGVSA-N 0.000 description 1
- 229960004276 zoledronic acid Drugs 0.000 description 1
- 229960003516 zomepirac sodium Drugs 0.000 description 1
- 229940002005 zometa Drugs 0.000 description 1
- KNJNGVKTAFTUFL-OCMUWRIYSA-N ω-conotoxin Chemical compound N([C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]1C(N[C@@H](CSSC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H]1C(N[C@@H](CCCN=C(N)N)C(=O)N[C@H](CO)C(=O)NCC(=O)N[C@H](CCCCN)C(=O)N[C@H](CSSC1)C(N)=O)=O)=O)C(=O)[C@@H]1CSSC[C@@H](N)C(=O)N[C@H](CCCCN)C(=O)NCC(=O)N[C@H](CCCCN)C(=O)NCC(=O)N[C@H](C)C(=O)N[C@@H](CCCCN)C(=O)N1 KNJNGVKTAFTUFL-OCMUWRIYSA-N 0.000 description 1
- 108091058550 ω-conotoxin Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/86—Carbazoles; Hydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Addiction (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
Abstract
本文之主題係指向結構式I之含咔唑磺醯胺衍生物及其醫藥上可接受之鹽或水合物,其中據此說明變數R1、R2、R3、R4、R5、R6、R7、A、B、C、D、E、F、G、H、a和b。亦提供包含式I化合物之醫藥組成物用以治療Cry-介導之疾病或病症,諸如糖尿病、肥胖症、代謝症候群、庫欣氏(Cushing’s)症候群和青光眼。□
Description
本申請案主張在2012年5月11日申請之美國臨時申請案號61/645,918及在2013年3月12日申請之美國臨時申請案號61/778,176之優先權及權益,將該等內容以其全文併入本文以供參考。
在本論題中所引述之每個申請案和專利,以及在每個申請案和專利中所引述之各文件或參考文獻(包括在各頒予之專利的申訴期間;〝經申請案引述之文件〞),及對應於及/或主張該等申請案和專利之任一者的優先權之每個美國及前述申請案或專利,及在每個經申請案引述之文件中所引述或參考之每個文件藉此特意併入本文以供參考。該等文件或參考文獻更概括地在申請專利範圍前的參考文獻列表中或在論題本身中引述於本論題中;及每個該等文件或參考文獻(〝本文所引述之參考文獻〞),以及在每個本文所引述之參考文獻中所引述之各文件或參考文獻(包括任何製造者的說明書、指示等)藉此特意併入本文以供參考。藉由參考而併入本論題之文件可用於本發明的實施中。
本文所揭示之主題尤其關於含咔唑磺醯胺衍生物,含有該等化合物之醫藥組成物,彼等用於治療隱花色素介導之疾病或病症的方法,及彼等之製法。亦提供診斷、偵測或監控在接受本文所揭示之化合物和組成物的受驗者中之隱花色素依賴性疾病的進展之方法。
晝夜時鐘為內在計時機制,其控制許多生理過程的日常節律,諸如睡眠/喚醒行為、體溫、荷爾蒙分泌及新陳代謝(Takahashi,J.S.等人之Nat.Rev.Genet.2008,9,764;Green,C.B.等人之Cell,2008,134,728;Zhang,E.E.等人之Nat.Rev.Mol.Cell.Biol.2010,11,764)。晝夜節律係以細胞自主性方式經由時鐘基因的轉錄調控網絡而產生。在核心反饋迴路中,轉錄因子CLOCK和BMAL1活化週期(Per1和Per2)及隱花色素(Cry1和Cry2)基因的表現。在轉譯及核定位之後,PER及CRY蛋白質抑制CLOCK-BMAL1的功能,造成持續的節律基因表現。許多生理路徑係在晝夜時鐘的控制下(Panda,S.等人之Cell,2002,109,307),包括直接調控許多肝生理過程(Rey,G.等人之PLoS Biol.2011,9,e1000595;Bugge,A.等人之Genes Dev.2012,26,657)。
晝夜去同步化與受損的胰島素敏感性有關聯(Spiegel,
K.等人之J.Appl.Physiol.2005,99,2008;Spiegel,K.等人之Lancet,1999,354,1435),降低瘦素值及造成與糖尿病前狀態比較的高血糖症、高胰島素血症和餐後葡萄糖反應(Scheer,F.A.等人之Proc.Natl.Acad.Sci.USA,2009,106,4453)。許多全基因組(genome-wide)相關研究領先發現Cry2可具有調控哺乳類葡萄糖值的重要性(Dupuis,J.等人之Nat.Genet.2010,42,105;Liu,C.等人之PLoS One,2011,6,e21464;Barker,A.等人之Diabetes,2011,60,1805)。
血液中的葡萄糖濃度具有高節律性,因為內分泌胰腺的胰島素敏感性及胰島素分泌能力的變化(Polonsky,K.S.等人之N.Engl.J.Med.1988,318,1231)。Clock△19突變小鼠發展年齡依賴性高血糖症且該等動物亦發展易患有飲食誘發之肥胖症,具有不當的低濃度胰島素(Turek,F.W.等人之Science,2005,308,1043)且對胰島素治療顯現急遽下降的血糖反應,表明該等動物提高胰島素敏感性,因而掩飾彼等的β-細胞缺乏(Marcheva,B.等人之Nature,2010,466,627)。在小鼠中的Bmal1之肝特異性缺失造成受損的葡萄糖耐性及增加的胰島素敏感性(Lamia,K.A.等人之Proc.Natl.Acad.Sci.USA,2008,105,15172)。患有2型糖尿病的個體及甚至其尚未受疾病影響的一等親屬顯現改變的葡萄糖耐性節律(Boden,G.等人之Diabetes,1999,48,2182)。在患有2型糖尿病的人類中之Per2、Per3和Cry2表現亦明顯低於沒有疾病的人類(Stamenkovich,J.A.等人
之Metabolism,2012,61,978)。葡萄糖生成基因(gluconeogenic gene)磷酸烯醇(phosphoenol)丙酮酸羧基激酶(Pck1)及葡萄糖6-磷酸酶(G6pc)受到CRY及Bmal1基因調控子REV-ERB的控制(Zhang,E.E.等人之Nat.Med.2010,16,1152;Lamia,K.A.等人之Nature,2011,480,552;Yin,L.等人之Science,2007,318,1786)。葡萄糖生成作用受到多重傳訊機制的嚴格控制,而且以小鼠的研究揭露調節Cry1和Cry2可擾亂葡萄糖生成作用及調控血糖值(Zhang,E.E.等人之Nat.Med.2010,16,1152)。
在單一療法或組合療法的背景中,新型且經確立的口服抗糖尿病劑具有不均勻且有限的有效性。口服抗糖尿病療法忍受差且有限的血糖控制,或由於不可接受的副作用而忍受差的病患順從性,諸如水腫、體重增加或甚至更嚴重的併發症,如低血糖症。二甲雙胍(Metformin)(經取代之雙胍(biguanide))可引起腹瀉和胃腸道不適。最後,水腫、體重增加及在一些情況中的肝中毒和心血管毒性與一些噻唑啶-2,4-二酮抗糖尿病劑(例如,羅格列酮(Rosiglitazone)和皮格列酮(Pioglitazone))的投予有關聯。使用上述劑之二或多種的組合療法是常見的,但是通常只導致遞增改進的血糖控制。
Cry1和Cry2亦與糖皮質素受體(GR)交互作用,整體地改變對糖皮質素的轉錄反應(Lamia,K.A.等人之Nature,2011,480,552)。Cry1及/或Cry2的損失造成葡萄糖不耐性及本質上高的循環皮質酮值,示意降低與肝中增加之糖
皮質素轉活化結合的下視丘-腦垂體-腎上腺軸之抑制。Cry1和Cry2在基因組學上與Pck1啟動子中的糖皮質素反應成分以激素依賴方式締合,且經地塞米松(dexamethasone)-誘發之Pck1基因轉錄在隱花色素缺乏之肝中顯著地增加。此示意用於抑制發炎的糖皮質素之非所欲代謝副作用(例如,高血糖症、胰島素抗性和抑制腎上腺功能)可藉由將該等與可穩定Cry1及/或Cry2之劑組合而減輕。
本文的主題係關於隱花色素(Cry)調節化合物,包含Cry調節化合物之醫藥組成物及藉由投予Cry調節化合物來治療Cry-相關的疾病或病症之方法,諸如糖尿病、肥胖症、代謝症候群、庫欣氏症候群和青光眼。
在一個態樣中,本文所揭示之主題係指向式I化合物:
或其醫藥上可接受之鹽或水合物,其中:A、B、C、D、E、F、G和H之各者係獨立為N或C;
當A、B、C、D、E、F、G或H為C時,則R1和R2之各者係獨立選自H、鹵基、氰基、硝基、-CF3、-CHF2、-CH2F、三氟甲氧基、疊氮基、羥基、(C1-C6)烷氧基、(C1-C6)烷基、(C2-C6)烯基、(C2-C6)炔基、-(C=O)-R8、-(C=O)-O-R8、-O-(C=O)-R8、-NR8(C=O)-R10、-(C=O)-NR8R9、-NR8R9、-NR8OR9、-S(O)cNR8R9、-S(O)d(C1-C8)烷基、-O-SO2-R8、NR8-S(O)c、-(CR8R9)d(3-10)-員環烷基、-(CR8R9)e(C6-C10)芳基、-(CR8R9)e(4-10)-員雜環基、-(CR8R9)f(C=O)(CR8R9)e(C6-C10)芳基、-(CR8R9)f(C=O)(CR8R9)e(4-10)-員雜環基、-(CR8R9)eO(CR8R9)f(C6-C10)芳基、-(CR8R9)eO(CR8R9)f(4-10)-員雜環基、-(CR8R9)fS(O)d(CR8R9)e(C6-C10)芳基和-(CR8R9)fS(O)d(CR8R9)e(4-10)-員雜環基;R3和R5之各者係獨立選自H、氰基、-CF3、-CHF2、-CH2F、(C1-C6)烷基、(C2-C6)烯基、(C2-C6)炔基、-(C=O)-R8、-(C=O)-O-R8、-(C=O)-NR8R9、-S(O)cNR8R9、-S(O)d(C1-C8)烷基、-(CR8R9)d(3-10)-員環烷基、-(CR8R9)e(C6-C10)芳基、-(CR8R9)e(4-10)-員雜環基、-(CR8R9)f(C=O)(CR8R9)e(C6-C10)芳基、-(CR8R9)f(C=O)(CR8R9)e(4-10)-員雜環基、-(CR8R9)eO(CR8R9)f(C6-C10)芳基、-(CR8R9)eO(CR8R9)f(4-10)-員雜環基、
-(CR8R9)fS(O)d(CR8R9)e(C6-C10)芳基和-(CR8R9)fS(O)d(CR8R9)e(4-10)-員雜環基;其中R3基團之各者隨意地互相連結成4-12員單-或雙環狀環;其中R5基團之各者隨意地互相連結成4-12員單-或雙環狀環;R4為H、-CF3、-CHF2、-CH2F、(C1-C6)烷基、(C2-C6)烯基、(C2-C6)炔基、-(C=O)-R8、-(C=O)-O-R8、-(C=O)-NR8R9、-(CR8R9)d(3-10)-員環烷基、-(CR8R9)e(C6-C10)芳基、-(CR8R9)e(4-10)-員雜環基、-(CR8R9)f(C=O)(CR8R9)e(C6-C10)芳基、-(CR8R9)f(C=O)(CR8R9)e(4-10)-員雜環基、-(CR8R9)eO(CR8R9)f(C6-C10)芳基、-(CR8R9)eO(CR8R9)f(4-10)-員雜環基、-CR8R9)fS(O)d(CR8R9)e(C6-C10)芳基和-(CR8R9)fS(O)d(CR8R9)e(4-10)-員雜環基;R6為H、-CF3、-CHF2、-CH2F、(C1-C6)烷基、(C2-C6)烯基、(C2-C6)炔基、-(C=O)-R8、-(C=O)-O-R8、-(C=O)-NR8R9、-(CR8R9)d(3-10)-員環烷基、-(CR8R9)e(C6-C10)芳基、-(CR8R9)e(4-10)-員雜環基、-(CR8R9)f(C=O)(CR8R9)e(C6-C10)芳基、-(CR8R9)f(C=O)(CR8R9)e(4-10)-員雜環基、-(CR8R9)eO(CR8R9)f(C6-C10)芳基、-(CR8R9)eO(CR8R9)f(4-10)-員雜環基、
-(CR8R9)fS(O)d(CR8R9)e(C6-C10)芳基和-(CR8R9)fS(O)d(CR8R9)e(4-10)-員雜環基;其中R5與R6隨意地互相連結成4-12員單-或雙環狀環;R7為-CF3、-CHF2、-CH2F、(C1-C6)烷基、(C2-C6)烯基、(C2-C6)炔基、-(C=O)-R8、-(C=O)-O-R8、-NR8(C=O)-R10、-(C=O)-NR8R9、-NR8R9、-NR8OR9、-NR8-S(O)c、-(CR8R9)d(3-10)-員環烷基、-(CR8R9)e(C6-C10)芳基、-(CR8R9)e(4-10)-員雜環基、-(CR8R9)f(C=O)(CR8R9)e(C6-C10)芳基、-(CR8R9)f(C=O)(CR8R9)e(4-10)-員雜環基、-(CR8R9)eO(CR8R9)f(C6-C10)芳基、-(CR8R9)eO(CR8R9)f(4-10)-員雜環基、-(CR8R9)fS(O)d(CR8R9)e(C6-C10)芳基和-(CR8R9)fS(O)d(CR8R9)e(4-10)-員雜環基;其中R6與R7隨意地互相連結成4-12員單-或雙環狀環;R8、R9和R10之各者係獨立選自H、(C1-C6)烷基、-(CR11R12)e(3-10)-員環烷基、-(CR11R12)g(C6-C10)芳基和-(CR11R12)g(4-10)-員雜環基;前述R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12、R13、R14、R15和R16之(C1-C6)烷基、(3-10)-員環烷基、(C6-C10)芳基及(4-10)-員雜環基的任何碳原子係獨立隨意地經1至3個R14取代基取代,該取代基各自獨
立選自鹵基、氰基、硝基、-CF3、-CHF2、-CH2F、三氟甲氧基、疊氮基、羥基、-O-R15、-(CR8R9)e(C1-C6)烷氧基、(C1-C6)烷氧基、(C1-C6)烷基、(C2-C6)烯基、(C2-C6)炔基、-(C=O)-R11、-(C=O)-R15、-(C=O)-O-R11、-(C=O)-O-R15、-O-(C=O)-R11、-O-(C=O)-R15、-NR11(C=O)-R13、-(C=O)-NR11R12、-(C=O)-NR11R15、-NR11R12、-NR11R15、-NR11OR12、-NR11OR15、-S(O)cNR11R12、-S(O)cNR11R15、-S(O)d(C1-C6)烷基、-S(O)dR15、-O-SO2-R11、-O-SO2-R15、-NR11-S(O)c、-NR15-S(O)c、-(CR11R12)e(3-10)-員環烷基、-(CR11R12)e(C6-C10)芳基、-(CR11R12)e(4-10)-員雜環基、-(CR11R12)f(C=O)(CR11R12)e(C6-C10)芳基、-(CR11R12)f(C=O)(CR11R12)e(4-10)-員雜環基、-(CR11R12)eO(CR11R12)f(C6-C10)芳基、-(CR11R12)eO(CR11R12)f(4-10)-員雜環基、-(CR11R12)fS(O)d(CR11R12)e(C6-C10)芳基和-(CR11R12)fS(O)d(CR11R12)e(4-10)-員雜環基;前述R14之(C1-C6)烷基、(3-10)-員環烷基、(C6-C10)芳基及(4-10)-員雜環基的任何碳原子係獨立隨意地經取代1至3個R16取代基取代,該取代基各自獨立選自鹵基、氰基、硝基、-CF3、-CHF2、-CH2F、三氟甲氧基、疊氮基、(CH2)eOH、(C1-C6)烷氧基、(C1-C6)烷基、(C2-C6)烯基、(C2-C6)炔基、-(C=O)-R11、-(C=O)-R15、-(C=O)-O-R11、-(C=O)-O-R15、-O-(C=O)-R11、
-O-(C=O)-R15、-NR11(C=O)-R13、-(C=O)-NR11R12、-NR11R12和-NR11R15;前述R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R14和R15之(4-10)-員雜環基的任何氮原子係獨立隨意地經(C1-C6)烷基、(C2-C6)烯基、(C2-C6)炔基、-(C=O)-R11、-(C=O)-O-R11、-(C=O)-NR11R12、-(CR11R12)e(3-10)-員環烷基、-(CR11R12)e(C6-C10)芳基、-(CR11R12)e(4-10)-員雜環基、-(CR11R12)f(C=O)(CR11R12)e(C6-C10)芳基或-(CR11R12)f(C=O)(CR11R12)e(4-10)-員雜環基取代;R11、R12和R13之各者係獨立為H或(C1-C6)烷基;R15為-(CR11R12)e(3-10)-員環烷基、-(CR11R12)e(C6-C10)芳基或-(CR11R12)e(4-10)-員雜環基;a和b各自獨立為1、2、3或4;c為1或2;d為0、1或2;及e、f和g各自獨立為0、1、2、3、4或5。
在一些具體例中,A、B、C、D、E、F、G和H之各者為C;R1和R2之各者係獨立選自H或鹵基;R4為H或(C1-C6)烷基;R3和R5為H;R6為-CF3、-CHF2、-CH2F、(C1-C6)烷基、(C2-C6)烯基、(C2-C6)炔基、-(CR8R9)d(3-10)-員環烷基、-(CR8R9)e(C6-C10)芳基、-(CR8R9)e(4-10)-員雜環基、-(CR8R9)eO(CR8R9)f(C6-C10)芳基、-(CR8R9)eO(CR8R9)f(4-10)-員雜環基、
-(CR8R9)fS(O)d(CR8R9)e(C6-C10)芳基和-(CR8R9)fS(O)d(CR8R9)e(4-10)-員雜環基;R7為-CF3、-CHF2、-CH2F、(C1-C6)烷基、(C2-C6)烯基、(C2-C6)炔基、-(CR8R9)d(3-10)-員環烷基、-(CR8R9)e(C6-C10)芳基、-(CR8R9)e(4-10)-員雜環基、-(CR8R9)eO(CR8R9)f(C6-C10)芳基、-(CR8R9)eO(CR8R9)f(4-10)-員雜環基、-(CR8R9)fS(O)d(CR8R9)e(C6-C10)芳基和-(CR8R9)fS(O)d(CR8R9)e(4-10)-員雜環基;R8、R9、R10、R11、R12、R13、R14、R15、R16、a、b、c、d、e和f係如本文所定義。
在其他的具體例中,A、B、C、D、E、F、G和H之各者為C;R1和R2之各者係獨立選自H或鹵基;R4為H或(C1-C6)烷基;R3和R5為H;R6與R7互相連結成4-12員單-或雙環狀環;R8、R9、R10、R11、R12、R13、R14、R15、R16、a、b、c、d、e和f係如本文所定義。
在其他的具體例中,A、B、C、D、E、F、G和H之各者為C;R1和R2之各者係獨立選自H或鹵基;R4為H或(C1-C6)烷基;R3和一個R5為H;一個R5與R6互相連結成4-12員單-或雙環狀環;R7為-CF3、-CHF2、-CH2F、(C1-C6)烷基、(C2-C6)烯基、(C2-C6)炔基、-(CR8R9)d(3-10)-員環烷基、-(CR8R9)e(C6-C10)芳基、-(CR8R9)e(4-10)-員雜環基、-(CR8R9)eO(CR8R9)f(C6-C10)芳基、-(CR8R9)eO(CR8R9)f(4-10)-員雜環基、-(CR8R9)fS(O)d(CR8R9)e(C6-C10)芳基和
-(CR8R9)fS(O)d(CR8R9)e(4-10)-員雜環基;R8、R9、R10、R11、R12、R13、R14、R15、R16、a、b、c、d、e和f係如本文所定義。
在一些具體例中,式I化合物為在C-3上帶有(S)-組態或(R)-組態之單一鏡像異構物,其中A、B、C、D、E、F、G和H之各者為C;R1和R2之各者係獨立選自H或鹵基;R4為H或(C1-C6)烷基;R3和R5為H;R6為-CF3、-CHF2、-CH2F、(C1-C6)烷基、(C2-C6)烯基、(C2-C6)炔基、-(CR8R9)d(3-10)-員環烷基、-(CR8R9)e(C6-C10)芳基、-(CR8R9)e(4-10)-員雜環基、-(CR8R9)eO(CR8R9)f(C6-C10)芳基、-(CR8R9)eO(CR8R9)f(4-10)-員雜環基、-(CR8R9)fS(O)d(CR8R9)e(C6-C10)芳基和-(CR8R9)fS(O)d(CR8R9)e(4-10)-員雜環基;R7為-CF3、-CHF2、-CH2F、(C1-C6)烷基、(C2-C6)烯基、(C2-C6)炔基、-(CR8R9)d(3-10)-員環烷基、-(CR8R9)e(C6-C10)芳基、-(CR8R9)e(4-10)-員雜環基、-(CR8R9)eO(CR8R9)f(C6-C10)芳基、-(CR8R9)eO(CR8R9)f(4-10)-員雜環基、-(CR8R9)fS(O)d(CR8R9)e(C6-C10)芳基和-(CR8R9)fS(O)d(CR8R9)e(4-10)-員雜環基;R8、R9、R10、R11、R12、R13、R14、R15、R16、a、b、c、d、e和f係如本文所定義。
在本文所揭示之主題的其他具體例中,式I化合物為在C-3上帶有(S)-組態或(R)-組態之單一鏡像異構物,其中A、B、C、D、E、F、G和H之各者為C;R1和R2之
各者為係獨立選自H或鹵基;R4為H或(C1-C6)烷基;R3和R5為H;R6與R7互相連結成4-12員單-或雙環狀環;R8、R9、R10、R11、R12、R13、R14、R15、R16、a、b、c、d、e和f係如本文所定義。
本文所述之主題的其他具體例為選自由下列者所組成之群組的化合物:(S)-N-(3-(9H-咔唑-9-基)-2-羥丙基)-1,2-噻(thiazinane)-1,1-二氧化物;N-(3-(3,6-二氟-9H-咔唑-9-基)-2-羥丙基)-異噻唑啶-1,1-二氧化物;(S)-N-(3-(9H-咔唑-9-基)-2-羥丙基)異噻唑啶-1,1-二氧化物;2-(3-(9H-咔唑-9-基)-2-羥丙基)-5-氟-異噻唑啶-1,1-二氧化物;2-(3-(3,6-二氟-9H-咔唑-9-基)-2-羥丙基)-1,2,6-噻二-1,1-二氧化物;N-(3-(9H-咔唑-9-基)-2-羥丙基)-N-(1-甲基環戊基)甲烷磺醯胺;N-(3-(9H-咔唑-9-基)-2-羥丙基)異噻唑啶-1,1-二氧化物;N-(3-(9H-咔唑-9-基)-2-羥丙基)-2,3-二氫苯並[d]異噻唑-1,1-二氧化物;N-(3-(2,6-二氟-9H-咔唑-9-基)-2-羥丙基)-1,2-噻-1,1-二氧化物;2-(3-(9H-咔唑-9-基)-2-羥丙基)-1,2,6-噻二-1,1-二氧化
物;或其醫藥上可接受之鹽或水合物。
在另一態樣中,本文所述之化合物調節Cry1或Cry2。Cry1或Cry2之調節包括下列中之任一者:與Cry1或Cry2結合;抑制Cry1或Cry2之修飾;改變Cry1或Cry2定位;增加或降低Cry1或Cry2穩定性;增加或降低Cry1或Cry2與標靶之間的結合;增加或降低Cry1或Cry2活性;及增加或降低Cry1或Cry2標靶之活性。Cry1及/或Cry2之標靶包括但不受限於Per1、Per2、糖皮質素受體(GR)、CLOCK、BMAL1或CLOCK-BMAL1啟動子序列。
在另一態樣中,本文所述之主題提供包含根據申請專利範圍第1項之化合物或其醫藥上可接受之鹽或水合物及醫藥上可接受之載劑、佐劑或稀釋劑的醫藥組成物。在一些具體例中,醫藥組成物另外包含一或多種額外的治療劑。
在其他的態樣中,本發明提供治療在受驗者中的Cry-介導之疾病或病症之方法,其包含投予受驗者治療有效量之本文所述之醫藥組成物。在另外的態樣中,本發明提供減輕在受驗者中的Cry-介導之疾病或病症的徵候之方法,其包含投予受驗者治療有效量之本文所述之醫藥組成物。疾病或病症可選自由下列者所組成之群組:糖尿病、代謝症候群、胰島素抗性症候群、肥胖症、青光眼、庫欣氏症候群、精神病性抑鬱症、阿茲海默爾氏症、神經性疼痛、藥物濫用、骨質疏鬆症、癌症、黃斑變性和肌病變。在一
些具體例中,該方法可進一步包含投予受驗者一或多種額外的治療劑。
在另一態樣中,本發明提供監控在受驗者中的Cry-介導之疾病或病症的進展或預後之方法,其包含測量在第一時期在來自受驗者的第一樣品中的一或多種隱花色素之有效量;測量在第二時期在來自受驗者的第二樣品中的一或多種隱花色素之有效量;及比較在第一樣品中所偵測之一或多種隱花色素的量與在第二樣品中所偵測之一或多種隱花色素的量或參考值。在一些具體例中,監控包含評估在受驗者中發展Cry-介導之疾病或病症的風險變化。
受驗者可包含先前對Cry-介導之疾病或病症進行治療者、先前對Cry-介導之疾病或病症未進行治療者或先前未診斷出患有Cry-介導之疾病或病症者。樣品可為全血、血清、血漿、血細胞、內皮細胞、組織生檢、淋巴液、腹水液、間隙液、骨髓、腦脊髓液(CSF)、精液、唾液、黏液、痰、汗或尿。
在一些具體例中,第一樣品係取自對Cry-介導之疾病或病症進行治療前之受驗者及第二樣品係取自對Cry-介導之疾病或病症進行治療後之受驗者。在其他的具體例中,將受驗者以包含本文所揭示之式I化合物的醫藥組成物治療。在特定的具體例中,監控進一步包含選擇用於受驗者的治療及/或監控對Cry-介導之疾病或病症治療的有效性,其中對Cry-介導之疾病或病症的治療包含手術介入、投予單獨或與一或多種額外的治療劑組合的本文定義之醫
藥組成物、在投予單獨或與一或多種額外的治療劑組合的本文提供之醫藥組成物之後或之前的手術介入、或不採取進一步的行動。
在其他的具體例中,參考值包含指數值、從一或多種Cry-介導之疾病或病症風險預測演算法所導出之值、從未患有Cry-介導之疾病或病症的受驗者所導出之值、或從診斷出患有Cry-介導之疾病或病症的受驗者所導出之值。在一些具體例中,測量包含偵測一或多種隱花色素的存在或不存在、定量一或多種隱花色素的量、定性一或多種隱花色素的類型及評定一或多種隱花色素與標靶結合的能力。標靶可為Per1、Per2或CLOCK-BMAL1啟動子序列。如本文所揭示之Cry-介導之疾病或病症可選自由下列者所組成之群組:糖尿病、肥胖症、代謝症候群、胰島素抗性症候群、庫欣氏症候群,和青光眼、精神病性抑鬱症、阿茲海默爾氏症、神經性疼痛、藥物濫用、骨質疏鬆症、癌症、黃斑變性和肌病變。
除非另有其他定義,本文所使用之所有技術及科學術語具有與一般熟諳本發明所屬技藝之技術者普遍瞭解的相同意義。雖然與那些本文所述者類似或相等的方法及材料可用於實行本發明,但是下文說明適合的方法及材料。本文述及之所有發表案、專利申請案、專利及其他參考文獻特意併入其全文以供本文參考。在衝突的情況下,將以本發明書(包括定義)支配。另外,本文所述之材料、方法及實例僅為例證而已,並不想受到限制。
本發明的其他特色及優點將從以下的詳細說明及申請專利範圍顯而易見。
在整個本說明書中所述之特色、結構或特性可以任何適合的方式組合在一或多個具體例中。例如,在整個本說明書中所使用之詞組〝例示性具體例〞、〝實例性具體例〞、〝一些具體例〞或其他類似語言係指有關具體例所述之特別的特色、結構或特性可包括在本文所述之至少一個具體例中。因此,在整個本說明書中出現的詞組〝例示性具體例〞、〝實例性具體例〞、〝在一些具體例中〞、〝在其他的具體例中〞或其他類似語言未必全部係指相同群組之具體例,且可將所述之特色、結構或特性以任何適合的方式組合在一或多個具體例中。
為了促進對本發明的瞭解,將許多術語定義如下,本文所定義之術語具有一般熟諳與本文所述之主題相關領域之技術者普遍瞭解的意義。諸如〝a〞、〝an〞和〝the〞之術語不意欲僅指單數實體,而是包括總體類別,可使用其中特定的實例作為例證。本文之術語學係用於說明本文所述之主題的特定具體例,但是該等術語的使用不設限本文主題,除了在申請專利範圍中所概述者以外。
如本文所使用之術語〝包含(comprising)〞、〝包括(including)〞或〝具有〞係取其開放性的非限制意義。
如本文所使用之術語〝鹵基〞意指(除非另有其他指
示)氟、氯、溴或碘。
如本文所使用之術語〝烷基〞包括(除非另有其他指示)具有直鏈或支鏈部分的飽和單價烴基。
如本文所使用之術語〝烯基〞代表(除非另有其他指定)含有一或多個碳-碳雙鍵之從2至6個碳原子的單價直鏈或支鏈基團,且以乙烯基、1-丙烯基、2-丙烯基、2-甲基-1-丙烯基、1-丁烯基、2-丁烯基及類似者為實例。
如本文所使用之術語〝炔基〞代表含有一個碳-碳參鍵之從2至6個碳原子的單價直鏈或支鏈基團,且以乙炔基、1-丙炔基及類似者為實例。
如本文所使用之術語〝烷氧基〞包括(除非另有其他指示)O-烷基,其中烷基係如上文所定義。
術語〝Me〞意指甲基,及〝Et〞意指乙基。
如本文所使用之術語〝環烷基〞係指(除非另有其他指示)含有總共從3至10個碳原子的本文提及之非芳族、飽和或部分飽和、單環或稠合、螺旋或未稠合雙環或三環烴。環烷基的例證實例係衍生自下列者,但不限於此:
如本文所使用之術語〝芳基〞包括(除非另有其他指示)藉由移除一個氫原子而自芳族烴衍生之有機基團,諸
如苯基或萘基。
如本文所使用之術語〝(4-12)-員雜環基〞包括(除非另有其他指示)含有1至4個分別選自O、S和N之雜原子的芳族和非芳族雜環基團,其中各雜環基團具有從4-12個原子在其環系統中,且先決條件為該基團之環不含有兩個相鄰的O或S原子。非芳族雜環基團包括僅具有3個原子在其環系統中的基團,但是芳族雜環基團必須具有至少5個原子在其環系統中。雜環基團包括苯並-稠合環系統。3員雜環基團的實例為氮芫,4員環雜環基團的實例為四氫吖唉基(衍生自四氫吖唉)。5員雜環基團的實例為噻唑基,7員環的實例為氮呯基,及10員雜環基團的實例為喹啉基。非芳族雜環基團的實例為吡咯啶基、四氫呋喃基、二氫呋喃基、四氫噻吩基、四氫吡喃基、二氫吡喃基、四氫硫代吡喃基、哌啶基、嗎啉基、硫代嗎啉基、氧硫基(thioxanyl)、哌基、四氫吖唉基、氧呾基、硫呾基、高哌啶基、氧呯基、硫呯基、氧氮呯基、二氮呯基、噻氮呯基、1,2,3,6-四氫吡啶基、2-吡咯啉基、3-吡咯啉基、吲哚啉基、2H-吡喃基、4H-吡喃基、二噁烷基、1,3-二氧基、吡唑啉基、二硫基(dithianyl)、二噻基(dithiolanyl)、二氫吡喃基、二氫噻吩基、二氫呋喃基、吡唑啶基、咪唑啉基、咪唑啶基、3-氮雜雙環[3.1.0]己烷基、3-氮雜雙環[4.1.0]庚烷基、3H-吲哚基和喹基。芳族雜環基團的實例為吡啶基、咪唑基、嘧啶基、吡唑基、三唑基、吡基、四唑基、呋喃基、噻吩基、異噁唑基、噻
唑基、噁唑基、異噻唑基、吡咯基、喹啉基、異喹啉基、吲哚基、苯並咪唑基、苯並呋喃基、噌啉基、吲唑基、吲哚基、酞基、嗒基、三基、異吲哚基、喋啶基、嘌呤基、噁二唑基、噻二唑基、呋咕基、苯並呋咕基、苯並苯硫基、苯並噻唑基、苯並噁唑基、喹唑啉基、喹噁啉基、萘啶基和呋喃並吡啶基。從上文名單所衍生之前述基團可為經C-附著或經N-附著的此等可能性。例如,自吡咯所衍生之基團可為吡咯-1-基(經N-附著)或吡咯-3-基(經C-附著)。另外,自咪唑所衍生之基團可為咪唑-1-基(經N-附著)或咪唑-3-基(經C-附著)。4-12員雜環可隨意地在任何環碳、硫或氮原子上以每一環經一或兩個側氧基取代。其中2個環原子經側氧基部分取代之雜環基團的實例為1,1-二側氧基-硫代嗎啉基。4-12員雜環的其他例證實例係衍生自下列者,但不限於此:
如本文所使用之術語〝4-12員單-或雙環狀環〞代表(除非另有其他指示)環烷基、芳基和(4-12)-員雜環基團,
其中環烷基、芳基和(4-12)-員雜環基係如上文所定義。
如本文所使用之術語〝經取代〞意指將標出之原子上的任何一或多個氫原子以選自指定的基團置換,其先決條件為不超過標出之原子的正常價及取代得到穩定的化合物。當取代基為酮基(亦即=O)時,則在原子上的2個氫原子被置換。酮基取代基不存在於芳族部分上。如本文所使用之環雙鍵為在兩個相鄰的環原子之間形成的雙鍵(例如,C=C、C=N或N=N)。此等基團的非限制性實例包括(非限制)H、CH3、NO2、SO2N(CH3)2、SO2N((CH3)SO2)、COOH、COOCH3、CO(N(CH3))、烷基、烯基、炔基、芳基、芳烷基、環烷基、雜環基、烷基芳基、雜芳基、雜環烷基、烷氧基(亦即甲氧基、乙氧基等)、烷基羰氧基、芳基羰氧基、烷氧基羰氧基、芳氧基羰氧基、羧酸基、烷基羰基、烷基胺基羰基、芳烷基胺基羰基、烯基胺基羰基、烷基羰基、芳基羰基、芳烷基羰基、烯基羰基、烷氧基羰基、胺基羰基、烷硫基羰基、三氟甲基、五氟乙基、鹵素(亦即氯、氟、溴、碘)、氰基、硫基、醯胺基、醚、酯、羥基、羥烷基、飽和或不飽和脂肪酸、疊氮基、膦醯胺基、磺醯胺基、內醯胺、磷酸基、膦酸根、亞膦酸根、胺基(包括烷基胺基、二烷基胺基、芳基胺基、二芳基胺基和烷基芳基胺基)、醯基胺基(包括烷基羰基胺基、芳基羰基胺基、胺甲醯基和脲基)、脒基、亞胺基、胍基、氫硫基、烷硫基、芳硫基、硫代羧酸基、硫酸基、烷基亞磺醯基、磺酸根、胺磺醯基、磺醯胺基、硝基、氰基、疊氮基
等。
本文所揭示之主題提供調節一或多種隱花色素分子之含咔唑磺醯胺化合物。該等化合物具有式I中提出之通用結構:
或其醫藥上可接受之鹽或水合物,其中A、B、C、D、E、F、G和H之各者係獨立為N或C;當A、B、C、D、E、F、G或H為C時,則R1和R2之各者係獨立選自H、鹵基、氰基、硝基、-CF3、-CHF2、-CH2F、三氟甲氧基、疊氮基、羥基、(C1-C6)烷氧基、(C1-C6)烷基、(C2-C6)烯基、(C2-C6)炔基、-(C=O)-R8、-(C=O)-O-R8、-O-(C=O)-R8、-NR8(C=O)-R10、-(C=O)-NR8R9、-NR8R9、-NR8OR9、-S(O)cNR8R9、-S(O)d(C1-C8)烷基、-O-SO2-R8、NR8-S(O)c、-(CR8R9)d(3-10)-員環烷基、-(CR8R9)e(C6-C10)芳基、-(CR8R9)e(4-10)-員雜環基、-(CR8R9)f(C=O)(CR8R9)e(C6-C10)芳基、-(CR8R9)f(C=O)(CR8R9)e(4-10)-員雜環基、-(CR8R9)eO(CR8R9)f(C6-C10)芳基、
-(CR8R9)eO(CR8R9)f(4-10)-員雜環基、-(CR8R9)fS(O)d(CR8R9)e(C6-C10)芳基和-(CR8R9)fS(O)d(CR8R9)e(4-10)-員雜環基;R3和R5之各者係獨立選自H、氰基、-CF3、-CHF2、-CH2F、(C1-C6)烷基、(C2-C6)烯基、(C2-C6)炔基、-(C=O)-R8、-(C=O)-O-R8、-(C=O)-NR8R9、-S(O)cNR8R9、-S(O)d(C1-C8)烷基、-(CR8R9)d(3-10)-員環烷基、-(CR8R9)e(C6-C10)芳基、-(CR8R9)e(4-10)-員雜環基、-(CR8R9)f(C=O)(CR8R9)e(C6-C10)芳基、-(CR8R9)f(C=O)(CR8R9)e(4-10)-員雜環基、-(CR8R9)eO(CR8R9)f(C6-C10)芳基、-(CR8R9)eO(CR8R9)f(4-10)-員雜環基、-(CR8R9)fS(O)d(CR8R9)e(C6-C10)芳基和-(CR8R9)fS(O)d(CR8R9)e(4-10)-員雜環基;R3基團之各者隨意地互相連結成4-12員單-或雙環狀環;R5基團之各者隨意地互相連結成4-12員單-或雙環狀環;R4為H、-CF3、-CHF2、-CH2F、(C1-C6)烷基、(C2-C6)烯基、(C2-C6)炔基、-(C=O)-R8、-(C=O)-O-R8、-(C=O)-NR8R9、-(CR8R9)d(3-10)-員環烷基、-(CR8R9)e(C6-C10)芳基、-(CR8R9)e(4-10)-員雜環基、-(CR8R9)f(C=O)(CR8R9)e(C6-C10)芳基、-(CR8R9)f(C=O)(CR8R9)e(4-10)-員雜環基、
-(CR8R9)eO(CR8R9)f(C6-C10)芳基、-(CR8R9)eO(CR8R9)f(4-10)-員雜環基、-CR8R9)fS(O)d(CR8R9)e(C6-C10)芳基和-(CR8R9)fS(O)d(CR8R9)e(4-10)-員雜環基;R6為H、-CF3、-CHF2、-CH2F、(C1-C6)烷基、(C2-C6)烯基、(C2-C6)炔基、-(C=O)-R8、-(C=O)-O-R8、-(C=O)-NR8R9、-(CR8R9)d(3-10)-員環烷基、-(CR8R9)e(C6-C10)芳基、-(CR8R9)e(4-10)-員雜環基、-(CR8R9)f(C=O)(CR8R9)e(C6-C10)芳基、-(CR8R9)f(C=O)(CR8R9)e(4-10)-員雜環基、-(CR8R9)eO(CR8R9)f(C6-C10)芳基、-(CR8R9)eO(CR8R9)f(4-10)-員雜環基、-(CR8R9)fS(O)d(CR8R9)e(C6-C10)芳基和-(CR8R9)fS(O)d(CR8R9)e(4-10)-員雜環基;其中R5與R6隨意地互相連結成4-12員單-或雙環狀環;R7為-CF3、-CHF2、-CH2F、(C1-C6)烷基、(C2-C6)烯基、(C2-C6)炔基、-(C=O)-R8、-(C=O)-O-R8、-NR8(C=O)-R10、-(C=O)-NR8R9、-NR8R9、-NR8OR9、-NR8-S(O)c、-(CR8R9)d(3-10)-員環烷基、-(CR8R9)e(C6-C10)芳基、-(CR8R9)e(4-10)-員雜環基、-(CR8R9)f(C=O)(CR8R9)e(C6-C10)芳基、-(CR8R9)f(C=O)(CR8R9)e(4-10)-員雜環基、-(CR8R9)eO(CR8R9)f(C6-C10)芳基、
-(CR8R9)eO(CR8R9)f(4-10)-員雜環基、-(CR8R9)fS(O)d(CR8R9)e(C6-C10)芳基和-(CR8R9)fS(O)d(CR8R9)e(4-10)-員雜環基;其中R6與R7隨意地互相連結成4-12員單-或雙環狀環;R8、R9和R10之各者係獨立選自H、(C1-C6)烷基、-(CR11R12)e(3-10)-員環烷基、-(CR11R12)g(C6-C10)芳基和-(CR11R12)g(4-10)-員雜環基;前述R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12、R13、R14、R15和R16之(C1-C6)烷基、(3-10)-員環烷基、(C6-C10)芳基及(4-10)-員雜環基的任何碳原子係獨立隨意地經1至3個R14取代基取代,該取代基各自獨立選自鹵基、氰基、硝基、-CF3、-CHF2、-CH2F、三氟甲氧基、疊氮基、羥基、-O-R15、(C1-C6)烷氧基、-(CR8R9)e(C1-C6)烷氧基、(C1-C6)烷基、(C2-C6)烯基、(C2-C6)炔基、-(C=O)-R11、-(C=O)-R15、-(C=O)-O-R11、-(C=O)-O-R15、-O-(C=O)-R11、-O-(C=O)-R15、-NR11(C=O)-R13、-(C=O)-NR11R12、-(C=O)-NR11R15、-NR11R12、-NR11R15、-NR11OR12、-NR11OR15、-S(O)cNR11R12、-S(O)cNR11R15、-S(O)d(C1-C6)烷基、-S(O)dR15、-O-SO2-R11、-O-SO2-R15、-NR11-S(O)c、-NR15-S(O)c、-(CR11R12)e(3-10)-員環烷基、-(CR11R12)e(C6-C10)芳基、-(CR11R12)e(4-10)-員雜環基、-(CR11R12)f(C=O)(CR11R12)e(C6-C10)芳基、
-(CR11R12)f(C=O)(CR11R12)e(4-10)-員雜環基、-(CR11R12)eO(CR11R12)f(C6-C10)芳基、-(CR11R12)eO(CR11R12)f(4-10)-員雜環基、-(CR11R12)fS(O)d(CR11R12)e(C6-C10)芳基和-(CR11R12)fS(O)d(CR11R12)e(4-10)-員雜環基;前述R14之(C1-C6)烷基、(3-10)-員環烷基、(C6-C10)芳基及(4-10)-員雜環基的任何碳原子係獨立隨意地經取代1至3個R16取代基取代,該取代基各自獨立選自鹵基、氰基、硝基、-CF3、-CHF2、-CH2F、三氟甲氧基、疊氮基、(CH2)eOH、(C1-C6)烷氧基、(C1-C6)烷基、(C2-C6)烯基、(C2-C6)炔基、-(C=O)-R11、-(C=O)-R15、-(C=O)-O-R11、-(C=O)-O-R15、-O-(C=O)-R11、-O-(C=O)-R15、-NR11(C=O)-R13、-(C=O)-NR11R12、-NR11R12和NR11R15;前述R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R14和R15之(4-10)-員雜環基的任何氮原子係獨立隨意地經(C1-C6)烷基、(C2-C6)烯基、(C2-C6)炔基、-(C=O)-R11、-(C=O)-O-R11、-(C=O)-NR11R12、-(CR11R12)e(3-10)-員環烷基、-(CR11R12)e(C6-C10)芳基、-(CR11R12)e(4-10)-員雜環基、-(CR11R12)f(C=O)(CR11R12)e(C6-C10)芳基或-(CR11R12)f(C=O)(CR11R12)e(4-10)-員雜環基取代;R11、R12和R13之各者係獨立為H或(C1-C6)烷基;R15為-(CR11R12)e(3-10)-員環烷基、-(CR11R12)e(C6-
C10)芳基或-(CR11R12)e(4-10)-員雜環基;a和b各自獨立為1、2、3或4;c為1或2;d為0、1或2;及e、f和g各自獨立為0、1、2、3、4或5。
在式I化合物的例示性具體例中,A、B、C、D、E、F、G和H之各者為C;R1和R2之各者係獨立選自H或鹵基;R4為H或(C1-C6)烷基;R3和R5為H;R6為-CF3、-CHF2、-CH2F、(C1-C6)烷基、(C2-C6)烯基、(C2-C6)炔基、-(CR8R9)d(3-10)-員環烷基、-(CR8R9)e(C6-C10)芳基、-(CR8R9)e(4-10)-員雜環基、-(CR8R9)eO(CR8R9)f(C6-C10)芳基、-(CR8R9)eO(CR8R9)f(4-10)-員雜環基、-(CR8R9)fS(O)d(CR8R9)e(C6-C10)芳基和-(CR8R9)fS(O)d(CR8R9)e(4-10)-員雜環基;R7為-CF3、-CHF2、-CH2F、(C1-C6)烷基、(C2-C6)烯基、(C2-C6)炔基、-(CR8R9)d(3-10)-員環烷基、-(CR8R9)e(C6-C10)芳基、-(CR8R9)e(4-10)-員雜環基、-(CR8R9)eO(CR8R9)f(C6-C10)芳基、-(CR8R9)eO(CR8R9)f(4-10)-員雜環基、-(CR8R9)fS(O)d(CR8R9)e(C6-C10)芳基和-(CR8R9)fS(O)d(CR8R9)e(4-10)-員雜環基;R8、R9、R10、R11、R12、R13、R14、R15、R16、a、b、c、d、e和f係如本文所定義。
在一些具體例中,A、B、C、D、E、F、G和H之各
者為C;R1和R2之各者係獨立選自H或鹵基;R4為H或(C1-C6)烷基;R3和R5為H;R6與R7互相連結成4-12員單-或雙環狀環;R8、R9、R10、R11、R12、R13、R14、R15、R16、a、b、c、d、e和f係如本文所定義。
在其他的具體例中,A、B、C、D、E、F、G和H之各者為C;R1和R2之各者係獨立選自H或鹵基;R4為H或(C1-C6)烷基;R3和一個R5為H;一個R5與R6互相連結成4-12員單-或雙環狀環;R7為-CF3、-CHF2、-CH2F、(C1-C6)烷基、(C2-C6)烯基、(C2-C6)炔基、-(CR8R9)d(3-10)-員環烷基、-(CR8R9)e(C6-C10)芳基、-(CR8R9)e(4-10)-員雜環基、-(CR8R9)eO(CR8R9)f(C6-C10)芳基、-(CR8R9)eO(CR8R9)f(4-10)-員雜環基、-(CR8R9)fS(O)d(CR8R9)e(C6-C10)芳基和-(CR8R9)fS(O)d(CR8R9)e(4-10)-員雜環基;R8、R9、R10、R11、R12、R13、R14、R15、R16、a、b、c、d、e和f係如本文所定義。
在本文所揭示之主題的一些具體例,式I化合物為在C-3上帶有(S)-組態或(R)-組態之單一鏡像異構物,其中A、B、C、D、E、F、G和H之各者為C;R1和R2之各者係獨立選自H或鹵基;R4為H或(C1-C6)烷基;R3和R5為H;R6為-CF3、-CHF2、-CH2F、(C1-C6)烷基、(C2-C6)烯基、(C2-C6)炔基、-(CR8R9)d(3-10)-員環烷基、-(CR8R9)e(C6-C10)芳基、-(CR8R9)e(4-10)-員雜環基、-(CR8R9)eO(CR8R9)f(C6-C10)芳基、
-(CR8R9)eO(CR8R9)f(4-10)-員雜環基、-(CR8R9)fS(O)d(CR8R9)e(C6-C10)芳基和-(CR8R9)fS(O)d(CR8R9)e(4-10)-員雜環基;R7為-CF3、-CHF2、-CH2F、(C1-C6)烷基、(C2-C6)烯基、(C2-C6)炔基、-(CR8R9)d(3-10)-員環烷基、-(CR8R9)e(C6-C10)芳基、-(CR8R9)e(4-10)-員雜環基、-(CR8R9)eO(CR8R9)f(C6-C10)芳基、-(CR8R9)eO(CR8R9)f(4-10)-員雜環基、-(CR8R9)fS(O)d(CR8R9)e(C6-C10)芳基和-(CR8R9)fS(O)d(CR8R9)e(4-10)-員雜環基;R8、R9、R10、R11、R12、R13、R14、R15、R16、a、b、c、d、e和f係如本文所定義。
在其他的具體例中,式I化合物為在C-3上帶有(S)-組態或(R)-組態之單一鏡像異構物,其中A、B、C、D、E、F、G和H之各者為C;R1和R2之各者為係獨立選自H或鹵基;R4為H或(C1-C6)烷基;R3和R5為H;R6與R7互相連結成4-12員單-或雙環狀環;R8、R9、R10、R11、R12、R13、R14、R15、R16、a、b、c、d、e和f係如本文所定義。
在特定的具體例中,化合物可選自由下列者所組成之群組:(S)-N-(3-(9H-咔唑-9-基)-2-羥丙基)-1,2-噻-1,1-二氧化物;N-(3-(3,6-二氟-9H-咔唑-9-基)-2-羥丙基)-異噻唑啶-1,1-二氧化物;
(S)-N-(3-(9H-咔唑-9-基)-2-羥丙基)異噻唑啶-1,1-二氧化物;2-(3-(9H-咔唑-9-基)-2-羥丙基)-5-氟-異噻唑啶-1,1-二氧化物;2-(3-(3,6-二氟-9H-咔唑-9-基)-2-羥丙基)-1,2,6-噻二-1,1-二氧化物;N-(3-(9H-咔唑-9-基)-2-羥丙基)-N-(1-甲基環戊基)甲烷磺醯胺;N-(3-(9H-咔唑-9-基)-2-羥丙基)異噻唑啶-1,1-二氧化物;N-(3-(9H-咔唑-9-基)-2-羥丙基)-2,3-二氫苯並[d]異噻唑-1,1-二氧化物;N-(3-(2,6-二氟-9H-咔唑-9-基)-2-羥丙基)-1,2-噻-1,1-二氧化物;2-(3-(9H-咔唑-9-基)-2-羥丙基)-1,2,6-噻二-1,1-二氧化物;或其醫藥上可接受之鹽或水合物。
如本文所使用之術語〝醫藥上可接受〞係指不廢除本文所述之化合物的生物活性或性質且相對無毒性之材料,諸如載劑或稀釋劑,亦即可將材料投予個體而不引起非所欲生物效應或不以有害的方式與組成物含有的組份之任一者交互作用。
如本文所使用之術語〝醫藥上可接受之鹽〞係指保留特定化合物之自由酸和鹼的生物有效性且不為生物學或在其他方面非所欲之鹽。式I化合物的醫藥上可接受之鹽包括其酸加成鹽和鹼鹽。適合的酸加成鹽係從形成無毒性鹽
之酸類所形成。實例包括乙酸鹽、己二酸鹽、阿拉伯半乳糖磺酸鹽(arabogalactanesulfonate)、抗壞血酸鹽、天冬胺酸鹽、苯甲酸鹽、苯磺酸鹽、碳酸氫鹽/碳酸鹽、硫酸氫鹽/硫酸鹽、硼酸鹽、樟腦磺酸鹽、膽酸鹽、檸檬酸鹽、乙二磺酸鹽、依托鹽(estolate)、乙磺酸鹽(esylate)、甲酸鹽、反丁烯二酸鹽、半乳糖醛酸鹽(galacturonate)、葡庚糖酸鹽、葡萄糖酸鹽、葡萄糖醛酸鹽、麩胺酸鹽、六氟磷酸鹽、海苯酸鹽(hibenzate)、馬尿酸鹽(hippurate)、鹽酸鹽/氯化物、氫溴酸鹽/溴化物、氫碘酸鹽/碘化物、3-羥基-2-萘甲酸鹽、1-羥基-2-萘甲酸鹽、羥乙磺酸鹽、乳酸鹽、乳糖酸鹽、蘋果酸鹽、順丁烯二酸鹽、丙二酸鹽、杏仁酸鹽、甲烷磺酸鹽、甲基硫酸鹽、黏液酸鹽(mucate)、萘二磺酸鹽、萘酸鹽、2-萘磺酸鹽、菸鹼酸鹽、硝酸鹽、油酸鹽、乳清酸鹽、草酸鹽、棕櫚酸鹽、雙羥萘酸鹽、磷酸鹽/磷酸氫鹽/磷酸二氫鹽、蔗糖酸鹽、水楊酸鹽、硬脂酸鹽、琥珀酸鹽、磺基水楊酸鹽、酒石酸鹽、甲苯磺酸鹽、三氟乙酸鹽和色胺酸鹽。
適合的鹼鹽係從形成無毒性鹽之鹼類所形成。實例包括腺嘌呤、鋁、2-胺基-2-甲基丙-1-醇、精胺酸、苯明(benethamine)、苄星(benzathine)、鈣、膽鹼、胞嘧啶、二乙胺、二醇胺、依波拉明(epolamine)、爾布明(erbumine)、乙二胺、葡萄胺糖、甘胺酸、胍、鳥嘌呤、海巴明(hydrabamine)、離胺酸、鎂、葡甲胺(meglumine)、嗎啉、菸鹼醯胺、乙醇胺、鳥胺酸
(omithine)、哌、鉀、普鹵卡因、脯胺酸、吡哆醇、絲胺酸、銀、鈉、三乙醇胺、胺基丁三醇、酪胺酸、纈胺酸和鋅鹽。對適合的鹽之評論參閱“Handbook of Pharmaceutical Salts:Properties,Selection,and Use”by Stahl and Wermuth(Wiley-VCH,Weinheim,Germany,2002)。
式I化合物的醫藥上可接受之鹽可藉由將式I化合物與若適當的所欲酸或鹼之溶液混合在一起而輕易地製備。鹽可從溶液沉澱且以過濾收集或以蒸發溶劑而回收。在鹽中的離子化程度可從完全離子化至幾乎未離子化之間改變。
式I化合物亦可以各種已知為多晶型之結晶形式存在。多晶型包括相同成分組成之化合物以不同的晶體堆積排列。多晶型可具有不同的X-射線繞射圖案、紅外線光譜、熔點、密度、硬度、晶體形狀、光學和電性質、穩定性、溶劑化物和溶解度。各種因素(諸如再結晶溶劑、結晶速率和貯存溫度)可引起一種晶體形式成為優勢。
〝溶劑化物〞意欲指特定化合物的醫藥上可接受之溶劑化物形式,其保留該化合物的生物有效性。溶劑化物的實例包括與水、異丙醇、乙醇、甲醇、二甲亞碸、乙酸乙酯、乙酸或乙醇胺組合之本發明化合物。術語〝水合物〞係指其中溶劑為水之溶劑化物。術語〝醇化物〞係指其中溶劑為醇之溶劑化物。水合物係藉由一或多個水分子與一個分子物質之組合而形成,其中水保留其為H2O之分子
態。水合物的非限制性實例包括單水合物、二水合物等。
本發明化合物包括如本文定義之式I化合物、多晶型、前藥和其異構物(包括光學、幾何和互變異構物),以及經同位素標記之式I化合物。
本發明化合物可以前藥投予。因此,式I化合物之特定衍生物(其本身可具有些微或不具藥理活性)在投予身體內或身體上時可轉化成具有所欲活性之式I化合物,例如藉由水解裂解。此等衍生物被稱為〝前藥〞。更多關於前藥用途的資訊可於“Pro-drugs as Novel Delivery Systems,Vol.14,ACS Symposium Series(T.Higuchi and W.Stella)及“Bioreversible Carriers in Drug Design”,Pergamon Press,1987(Ed.E.B.Roche,American Pharmaceutical Association)中發現。前藥可以例如藉由將式I化合物中存在之適當的官能性以特定部分置換而製得,該特定部分被那些熟諳本技藝者稱為〝前-部分(pro-moieties)〞,如在例如H.Bundgaard之“Design of Prodrugs”(Elsevier,1985)中所述。
該等前藥的一些實例包括其中式I化合物含有羧酸官能性(-CO2H)的其酯前藥,例如以(C1-C8)烷基置換氫;其中式I化合物含有醇官能性(-OH)的其醚前藥,例如以(C1-C8)烷醯氧基甲基置換氫;及其中式I化合物含有二級胺基官能性(其中R不為H之-NHR)的其醯胺前藥,例如以(C1-C10)烷醯基置換氫。更多依照前述實例之置換基團的實例及其他前藥類型的實例為那些一般熟諳本技藝者所
知。
式I化合物含有一或多個不對稱碳原子。應瞭解所有對應於式I化合物之鏡像異構物及/或非鏡像異構物可以類似方法製備。式I化合物的所有光學異構物和立體異構物及其混合物皆被認為是在本發明的範圍內。本發明包括關於式I化合物的消旋物、一或多種鏡像異構物形式、一或多種非鏡像異構物形式或其混合物之用途。式I化合物亦可以互變異構物存在。本發明關於所有該等互變異構物及其混合物之用途。
在本發明化合物內含有的特定官能基可以生物電子等排基團取代,亦即具有類似於母基團之空間或電子要求,但是展現不同或改進之物理化學或其他性質的基團。適合的實例為那些熟諳本技藝者所熟知,且包括但不受限於在Patini等人之Chem Rev.1996,96,3147-3176及本文所引述之參考文獻中所述之部分。
包括在所主張的式I化合物之範圍內的是醫藥上可接受之酸加成鹽或鹼鹽,其中相對離子具有光學活性,例如D-乳酸鹽或L-離胺酸,或具有消旋性,例如DL-酒石酸鹽或DL-精胺酸。順式/反式異構物可以那些熟諳本技藝者熟知的慣例技術分離,例如層析術和分段結晶。製備/分離個別的鏡像異構物之慣例技術包括從適合的光學純前驅體之手性合成法或使用例如手性高壓液相層析術(HPLC)之消旋物(或鹽或衍生物之消旋物)解析。
另一選擇地,消旋物(或消旋物前驅體)可與適合的光
學活性化合物反應,例如醇,或在其中式I化合物含有酸或鹼部分之例子中的酸或鹼,諸如酒石酸或1-苯基乙胺。所得非鏡像異構物混合物可以層析術及/或分段結晶分離且非鏡像異構物可以熟諳技藝者熟知的方式轉化成對應之純鏡像異構物及/或非鏡像異構物。本發明的手性化合物(及其手性前驅物)可使用在不對稱樹脂上以含有從0至50%之異丙醇(通常為2至20%)及從0至5%之烷基胺(通常為0.1%之二乙胺)之烴(通常為庚烷或己烷)所組成之移動相的層析術(通常為HPLC)而以富含鏡像異構性-及/或非鏡像異構性形式獲得。濃縮溶析液供給富含之混合物。鏡像異構物及/或非鏡像異構物之混合物可以那些熟諳本技藝者已知的慣例技術分離。參見例如E.L.Eliel之“Stereochemistry of Organic Compounds”(Wiley,New York,1994)。
式I化合物可經同位素標記,其中將一或多個原子以具有相同的原子數,但是原子量或質量數與通常在自然界中發現的原子量或質量數不同的原子置換。適合於包括在本發明化合物內之同位素的實例包括下列者之同位素:氫(諸如2H和3H)、碳(諸如11C、13C和14C)、氯(諸如36Cl)、氟(諸如18F)、碘(諸如123I和125I)、氮(諸如13N和15N)、氧(諸如15O、17O和18O)、磷(諸如32P)及硫(諸如35S)。特定的經同位素標記之式I化合物(例如,那些併入放射活性同位素)有用於藥物及/或受質組織分布的研究。放射活性同位素氚(亦即3H)和碳-14(亦即14C)係鑑於彼等
容易併入及現成的偵測方式而對此目的特別有用。以重質同位素(諸如氘,亦即2H)取代可由於更大的代謝穩定性而供給特定的治療優勢,例如增加的活體內半生期或減少的劑量需求,而因此在某些情況中為較佳的。以正子放射同位素(諸如11C、18F、15O和13N)取代可用於檢查受質受體佔有率之正子發射斷層掃描(PET)研究。經同位素標記之式I化合物通常可藉由那些熟諳本技藝者已知的慣例技術或以類似於那些所附實例及製法中所述之方法使用適當的經同位素標記之試劑代替先前所使用的未經標記之試劑而製備。
本發明化合物調節Cry1及/或Cry2。如本文所使用之〝調節〞係指增加、降低或改變Cry1和Cry2功能、活性或固有特性。Cry1或Cry2之調節包括下列中之任一者:與Cry1或Cry2結合;抑制Cry1或Cry2之修飾;改變Cry1或Cry2定位;增加或降低Cry1或Cry2穩定性;增加或降低Cry1或Cry2與標靶之間的結合;增加或降低Cry1或Cry2活性;及增加或降低Cry1或Cry2標靶之活性,或其任何組合。Cry1及/或Cry2之標靶包括但不受限於Per1、Per2、糖皮質素受體(GR)、CLOCK、BMAL1或CLOCK-BMAL1啟動子序列。
Cry1和Cry2之調節包括:將本發明化合物與Cry1及/或Cry2經由直接交互作用或間接交互作用而結合。在一些態樣中,本發明化合物可與含有Cry1及/或Cry2之複合物結合。用於偵測小分子與蛋白質之間的交互作用之
方法為本技藝中已知,例如免疫沉澱技術、層析術和各種陣列格式。
Cry1和Cry2之固有特性(諸如轉譯後修飾、穩定性或定位)可以本發明化合物改變。Cry1和Cry2之轉譯後修飾可在測定Cry1和Cry2之活性、穩定性或細胞定位中扮演關鍵角色。一些研究顯示磷酸化可改變Cry1和Cry2穩定性。本發明化合物可防止或增加Cry1和Cry2之轉譯後修飾,例如磷酸化、泛蛋白化、乙醯化、糖化、核糖化或類泛素化(sumoylation)。偵測Cry1或Cry2之轉譯後修飾的方法可由熟諳本技藝者輕易地執行。此等偵測方法包括西方墨點法(western blot)和放射免疫檢定法。Cry1和Cry2係在特定的條件下定位至細胞核,例如在以Per1和Per2之雜二聚合反應時。一旦在細胞核內時,Cry1和Cry2係從開始轉錄起扮演分裂細胞核CLOCK-BMAL1複合物的角色,從而向下調控對維持晝夜擺動至關重要的負反饋迴路中之晝夜節律基因。蛋白質定位可由本技藝者輕易地測定,例如以免疫螢光、亞細胞分級和西方墨點檢定法。Cry1和Cry2之向下調控亦為晝夜擺動的關鍵且在轉錄和蛋白質值下介導。Cry1和Cry2穩定性可以本技藝中已知以及那些在實例5-8中所提出之方法測量。
如本文所使用之Cry1和Cry2活性包括在Cry1或Cry2與標靶之間的結合及下游Cry1或Cry2標靶之活性。本發明化合物可增加或降低在Cry1或Cry2與標靶之間的結合。與Cry1及/或Cry2結合之標靶為本技藝中已
知且包括Per1、Per2、糖皮質素受體、CLOCK-BMAL1啟動子序列和VEGF啟動子序列。在本文述及之Cry1和Cry2標靶亦包括那些尚未鑑定之標靶。在Cry1或Cry2與標靶之間的結合可以例如免疫沉澱技術、酵母雙雜交技術(yeast two-hybrid)、親和力層析術測定。Cry1或Cry2標靶之下游活性包含經CLOCK-BMAL1-介導之轉錄、Cry1或Cry2與CLOCK-BMAL-1啟動子之結合、Cry1或Cry2與VEGF啟動子之結合、Per1或Per2定位或穩定性、CLOCK-BMAL1二聚合反應、CLOCK-BMAL1標靶基因之表現,諸如Cry1、Cry2、Per1、Per2、Rev-erb α和β、Rora、TIM蛋白質及VEGF。偵測啟動子活性之方法可以染色質免疫沉澱技術、電泳遷移率變動檢定法(electrophoretic mobility shift assay)或啟動子-螢光素酶檢定法決定,如實例3和4中所述。測定標靶基因表現之方法包括可以一般熟諳本技藝者輕易地執行的基因表現分析和微陣列。
在本文所揭示之主題的其他態樣中,本發明提供醫藥組成物,其包含根據式I之化合物及醫藥上可接受之載劑、佐劑或稀釋劑。製備具有特定量之活性化合物的各種醫藥組成物之方法為那些熟諳本技藝者已知或顯而易見的。另外,那些一般熟諳本技藝者熟悉調配及投予技術。此等論題係於例如Goodman and Gilman之“The Pharmaceutical Basis of Therapeutics”,current edition,Pergamon Press;及“Remington’s Pharmaceutical Sciences”,
current edition,Mack Publishing,Co.,Easton,PA中討論。該等技術可用在本文所述之方法和組成物的適當態樣和具體例中。醫藥組成物較佳地在GMP條件下製造。以下的實例僅以例證為目的而提供,並不意謂充當為本發明的限制。
因為本文所述之化合物意欲用在醫藥組成物中,所以可輕易地瞭解較佳地分別提供實質上純形式的該等化合物,例如至少50%之純度,至少55%之純度,至少60%之純度,至少65%之純度,至少70%之純度,至少75%之純度,至少80%之純度,至少85%,至少90%之純度,至少95%之純度,至少96%之純度,至少97%之純度,至少98%之純度或至少99%之純度。本文所提供之百分比係以重量為基準之重量。不純的化合物製劑可用於製備醫藥組成物中所使用之更純的形式;該等不太純的化合物製劑應該含有至少1%,更適合為至少5%,例如10至49%之式I化合物。
可將式I化合物提供在適合用於治療Cry介導之疾病的局部、經口、經鼻、經眼、經黏膜、經直腸、經陰道和非經腸用醫藥調配物中。本發明化合物可以錠劑或膠囊、油性或水性懸浮液、可含錠、片劑、粉末、顆粒、乳液、糖漿或酏劑經口投予。經口使用之組成物可包括一或多種用於調味、增甜、著色及保存之劑,以便製造醫藥上精緻且美味之製劑。錠劑可含有醫藥上可接受之賦形劑、載劑、稀釋劑和佐劑作為製造此等錠劑之輔助劑。如本技藝
所習知,該等錠劑可以醫藥上可接受之腸溶性包衣包膜,諸如單硬脂酸甘油酯或二硬脂酸甘油酯,以延遲在胃腸道中崩解及吸收,以提供較長時間的持續作用。差的水溶性化合物之溶解速率可藉由使用噴霧乾燥之分散液而提高,諸如那些Takeuchi,H.等人之J.Pharm.Pharmacol.1987,39,769-773所述者。
經口使用之調配物可呈硬明膠膠囊形式,其中將活性成分與惰性固體稀釋劑混合,例如碳酸鈣、磷酸鈣或高嶺土。該等調配物亦可呈軟明膠膠囊形式,其中將活性成分與水或油介質混合,諸如花生油、液態石蠟或橄欖油。
水性懸浮液正常含有與適合於製造水性懸浮液的賦形劑摻合之活性成分。此等賦形劑可為懸浮劑,諸如Kolliphor、羧甲基纖維素鈉、甲基纖維素、羥丙基甲基纖維素、藻酸鈉、聚乙烯吡咯啶酮、黃蓍膠和阿拉伯膠;分散或潤濕劑,其可為天然生成之磷脂(諸如卵磷脂)、環氧乙烷與長鏈脂肪酸的縮合產物(例如,聚氧乙烯硬脂酸酯)、環氧乙烷與長鏈脂族醇的縮合產物(諸如十七乙烯氧十六醇)、環氧乙烷與自脂肪酸和已醣醇所衍生之部分酯的縮合產物(諸如聚氧乙烯山梨糖醇單油酸酯)或與自脂肪酸和已醣醇酐所衍生之部分酯的縮合產物(諸如聚氧乙烯山梨糖醇酐單油酸酯)。
醫藥組成物可呈無菌可注射用水性或油性懸浮液形式。此懸浮液可根據已知的方法調配成水性等滲壓溶液或懸浮液,及栓劑可從脂肪乳液或懸浮液製備。可將組成物
滅菌及/或含有佐劑(諸如保存、穩定、潤濕或乳化劑)、溶液促進劑、調控滲透壓之鹽及/或緩衝劑。另外,組成物亦可含有其他在治療上有價值之物質。無菌可注射用製劑亦可調配成在非經腸可接受之無毒性稀釋劑或溶劑中的懸浮液,例如在1,3-丁二醇中的溶液。在可接受之媒劑和溶劑之中,可使用水、林格氏(Ringers)溶液和氯化鈉等滲壓溶液。可就此目的而使用任何無刺激性固定油,包括合成的單-或二甘油酯。另外,發現脂肪酸(諸如油酸)在可注射劑之製法中的用途。
式I化合物亦可以使藥物經直腸投予的栓劑形式投予。該等組成物可藉由將藥物與適合的無刺激性賦形劑混合而製備,該賦形劑在約25℃下為固體,但在直腸溫度下為液體及因此在直腸中熔融而釋出藥物。此等材料包括可可脂和甘油酯。
例如,將含有本發明化合物之乳霜、軟膏、膠凍溶液或懸浮液用於局部或穿透皮膚用製劑。適合於穿透皮膚施予之調配物包括有效量之本發明化合物與載劑。載劑可包括藥理上可接受之可吸收性溶劑,以幫助通過宿主皮膚。例如,穿透皮膚裝置係呈繃帶形式,其包括背襯元件、含有化合物與隨意的載劑之儲庫、以經控制及預定的速率在延長的期間內輸送活性成分至宿主皮膚之隨意的速率控制障壁及使裝置固定於皮膚之構件。亦可使用基質穿透皮膚調配物及電離子透入裝置。適合於局部施予例如皮膚和眼睛之調配物較佳為本技藝熟知的水溶液、軟膏、乳霜或凝
膠。此等可含有溶解劑、穩定劑、等滲壓增強劑、緩衝劑和保存劑。
活性化合物可以保護化合物免於從體內快速消除之醫藥上可接受之載劑製備,諸如控制型釋放調配物,包括植入物和微膠囊化輸送系統。可使用生物可降解之生物可相容性聚合物,諸如乙烯乙酸乙烯酯、聚酐、聚乙醇酸、膠蛋白、聚原酯和聚乳酸。此等調配物之製備方法為那些熟諳本技藝者顯而易見。
亦可將式I化合物製備成微脂粒輸送系統,諸如小單層狀泡囊、大單層狀泡囊及多層狀泡囊。微脂粒可從各種磷脂形成,諸如膽固醇、硬脂基胺或磷脂醯膽鹼。
任一活性醫藥成分或二者之適合的延長型釋放形式可為基質錠劑或膠囊組成物。適合的基質形成材料包括例如蠟(例如,棕櫚蠟、蜂蠟、石蠟、地蠟、蟲膠臘、脂肪酸和脂肪醇)、油、硬化油或脂(例如,硬化萊服子油、蓖麻油、牛脂、棕櫚油和大豆油)及聚合物(例如,羥丙基纖維素、聚乙烯吡咯啶酮、羥丙基甲基纖維素和聚乙二醇)。其他適合的基質製錠材料為微結晶纖維素、粉末狀纖維素、羥丙基纖維素、乙基纖維素與其他載劑,及填充劑。錠劑亦可含有顆粒、包膜之粉末或小粒。錠劑亦可經多層化。多層化錠劑在活性成分具有顯著不同的藥物動力輪廓時尤其較佳。可將成品錠劑隨意地包膜或不包膜。
包膜組成物典型地含有不溶性基質聚合物(佔包膜組成物重量之約15-85%)及水溶性材料(例如,佔包膜組成
物重量之約15-85%)。可隨意地使用或包括腸衣聚合物(佔包膜組成物重量之約1至99%)。適合的水溶性材料包括聚合物,諸如聚乙二醇、羥丙基纖維素、羥丙基甲基纖維素、聚乙烯吡咯啶酮、聚乙烯醇,及單體材料,諸如糖(例如,乳糖、蔗糖、果糖、甘露醇和類似者)、鹽(例如,氯化鈉、氯化鉀和類似者)、有機酸(例如,反丁烯二酸、琥珀酸、乳酸和酒石酸)及其混合物。適合的腸衣聚合物包括羥丙基甲基纖維素、乙酸酯琥珀酸酯、羥丙基甲基纖維素、酞酸酯、聚乙烯基乙酸酯酞酸酯、纖維素乙酸酯酞酸酯、纖維素乙酸酯偏苯三酸酯、蟲膠、玉米蛋白和含有羧基之聚甲基丙烯酸酯。
包膜組成物可根據包膜摻合物之性質而塑化,諸如主要組份或組份之混合物的玻璃轉換溫度或用於塗覆包膜組成物之溶劑。適合的塑化劑之添加量可佔包膜組成物重量之從0至50%且包括例如酞酸二乙酯、檸檬酸酯、聚乙二醇、甘油、乙醯化甘油酯、乙醯化檸檬酸酯、癸二酸二丁酯和蓖麻油。若必要時,包膜組成物可包括填充劑。填充劑之量可以包膜組成物總重量為基準計為1至約99重量%且可為不溶性材料,諸如二氧化矽、二氧化鈦、滑石、高嶺土、氧化鋁、澱粉、粉末狀纖維素、MCC或波拉克林鉀(polacrilin potassium)。包膜組成物可以在有機溶劑或水性溶劑或其混合物中的溶液或乳膠塗覆。若塗覆溶液,則溶劑可以溶解之固體總重量為基準計從約25-99重量%之量存在。適合的溶劑為水、低碳醇、低碳氯化
烴、酮或其混合物。若塗覆乳膠,則溶劑可以乳膠中的聚合物材料數量為基準計從約25-97重量%之量存在。溶劑主要可為水。本發明化合物之劑量值等於約0.5毫克/公斤體重至約100毫克/公斤體重或在該等之間的任何遞增量。較佳的劑量率係介於約30毫克/公斤體重與約100毫克/公斤體重之間。總日劑量可以單次或分次劑量投予。式I化合物之適合的治療劑量可在以每天每公斤接受者體重計1微克(μg)至1000毫克(mg)之範圍內及在該等之間的任何遞增量,諸如1,2,3,5,10,25,50,75,100,200,300,400,500,600,700,800,900或1000微克(1毫克);2,3,5,10,25,50,75,100,200,300,400,500,600,700,800,900或1000毫克。然而,應瞭解對特定病患之特定劑量值將取決於許多因素而定,包括欲投予之特別化合物的活性、年齡、體重、一般的健康狀態、性別、飲食、投予時間、投予途徑、分泌速率、藥物組合及進行治療之特別疾病的嚴重性。
劑量制度可經調整以提供最優的所欲反應。例如,可投予單一藥丸,可隨時間投予幾個分次劑量,或按治療情況的迫切需求所指示而依比例減少或增加劑量。尤其最好調配容易投予且劑量均勻的單位劑型之非經腸組成物。如本文所使用之單位劑型係指適合於欲治療之哺乳類受驗者的單一式劑量的物理離散單元;各單元含有經計算與所需之醫藥載劑締合而產生所欲治療效應的預定數量之活性化合物。本發明之單位劑量的規格係由且直接取決於下列者
予以制定:(a)治療劑之獨有特性及欲達成之特別的治療或預防效應,及(b)在化合此活性化合物以治療個體中的敏感性之技藝中的固有限制。因此,熟諳本技藝者可基於本文所提供之揭示內容而理解劑量及給藥制度係依照治療技藝中熟知的方法調整。亦即最大耐受劑量可輕易確立,且亦可測定提供病患可偵測之治療利益的有效量,如可投予各劑以提供病患可偵測之治療利益的時間性需求。據此,雖然在本文舉例特定的劑量及投予制度,但是該等實例不以任何方式限制在實行本發明時可提供病患的劑量及投予制度。
在本文所揭示之主題的另一態樣中,本發明提供治療Cry-介導之疾病或病症的方法,其包含投予治療有效量之根據如上文前述具體例之任一者中所述的式I之化合物。本發明較佳的具體例為根據前述具體例之方法,其中以不正常的Cry值為特徵之疾病或病症係選自下列者所組成之群組:糖尿病、代謝症候群、胰島素抗性症候群、肥胖症、青光眼、庫欣氏症候群、精神病性抑鬱症、阿茲海默爾氏症、神經性疼痛、藥物濫用、骨質疏鬆症、癌症、黃斑變性和肌病變。又另一較佳的具體例為根據前述具體例之方法,其中Cry-介導之疾病或病症為糖尿病、代謝症候群、胰島素抗性症候群、肥胖症、庫欣氏症候群、青光眼、精神病性抑鬱症、阿茲海默爾氏症、神經性疼痛、藥物濫用、骨質疏鬆症、癌症、黃斑變性或肌病變。特別佳的癌症為固體腫瘤癌症或類上皮癌,包括但不受限於:肺
癌、腦癌、胰腺癌、頭部和頸部癌(例如,鱗狀細胞癌)、乳癌、大腸癌、肝癌、胃癌、腎癌、卵巢癌、攝護腺癌或腺癌。其他較佳的癌症為那些具有VEGF表現增加、血管生成增加或缺氧性腫瘤之癌症。
如本文所使用之術語〝投予(administer、administering、administration)〞及類似者係指可使用而能夠將化合物或組成物輸送至所欲生物作用位置之方法。該等方法包括但不受限於經口、非經腸、局部、黏膜、眼睛、眼內、陰道和直腸投予。那些熟諳本技藝者熟悉可由本文所述之化合物及方法使用的投予技術,例如在Goodman and Gilman,The Pharmacological Basis of Therapeutics(目前版本);Pergamon;及Remington's,Pharmaceutical Sciences(目前版本),Mack Publishing Co.,Easton,Pa中的討論。如本文所使用之醫藥組成物的〝非經腸投予〞包括以物理侵害受驗者組織為特徵的任何投予途徑及經由侵害組織投予醫藥組成物。非經腸投予因此包括但不受限於藉由注射組成物、經由手術切口施予組成物、經由組織穿透非手術傷口施予組成物及類似者而投予醫藥組成物。非經腸投予特別預期包括但不受限於皮下、腹膜內,肌肉內,胸骨內注射和腎透析輸注技術。
在本發明的上下文中的〝受驗者〞較佳為哺乳類。哺乳類可為人類、非人類靈長類動物、小鼠、大鼠、狗、貓、馬或牛、但不限於該等實例。除了人類以外的哺乳類最好可被用作為代表Cry-介導之疾病或病症的動物模式之
受驗者,諸如ob/ob小鼠。受驗者可為雄性或雌性。受驗者可為先前診斷或鑑定出患有Cry-介導之疾病或病症且隨意地已接受或正接受疾病或病症之治療介入或治療者。另一選擇地,受驗者亦可為未於先前診斷出患有Cry-介導之疾病或病症者。例如,受驗者可為顯出Cry-介導之疾病或病症的一或多種風險因子之受驗者,或未顯出Cry-介導之疾病或病症的風險因子之受驗者,或有Cry-介導之疾病或病症的徵候之受驗者。受驗者亦可為正遭遇或處於發展Cry-介導之疾病或病症的風險者,或正遭遇或處於發展Cry-介導之疾病或病症復發的風險者。受驗者亦可為先前已對Cry-介導之疾病或病症進行治療者,無論單獨或與其他治療劑、手術或前述之任何組合方式組合投予本文所揭示之化合物和組成物。
〝Cry-介導之疾病或病症〞可包括而不限於糖尿病(包括而不限於胰島素依賴性〝I型〞糖尿病、非胰島素依賴性〝II型〞糖尿病、妊娠糖尿病和糖尿病-相關之併發症,如糖尿病性神經病變,糖尿病性視網膜病變,糖尿病性心肌病變,糖尿病性腎病變,牙周疾病和糖尿病性酮症酸中毒)、代謝症候群、胰島素抗性症候群、肥胖症、青光眼、庫欣氏症候群、精神病性抑鬱症、阿茲海默爾氏症、神經性疼痛、藥物濫用、骨質疏鬆症、癌症、黃斑變性和肌病變。
如本文所使用之術語〝治療(treating、treat或treatment〞包括預防性(例如,預防)、緩和性、輔助性和
治療性治療。例如,如本文所使用之治療2型糖尿病意指患有2型糖尿病或處於患有2型糖尿病風險之病患可根據本文所述之方法治療。關於接受預防性治療之病患,造成預防性治療之疾病狀態的發生率降低為預防性治療的可測量結果。
如本文所使用之術語〝減輕(alleviating或alleviate)〞說明使病症之徵兆或徵候的嚴重性降低、減低或抑制之方法。重要的是可使徵候減輕而未消除。在較佳的具體例中,投予本發明的醫藥組成物導致徵候消除,然而消除卻非必要的。本文所述之化合物或醫藥組成物之治療有效量預期使徵候的嚴重性降低。
如本文所使用之術語〝徵候〞被定義為疾病、生病、受傷或身體中似乎不正常之跡象。徵候係由正經歷徵候之個體所感受或察覺,但是別人不可能輕易察覺。其他係由保健或臨床專家定義。
如本文所使用之術語〝代謝症候群〞意指(除非另有其他指示)牛皮癬、糖尿病、傷口癒合、發炎、神經變性疾病、半乳糖血症、楓糖尿症、苯丙酮尿症、高肌胺酸血症、胸腺嘧啶-尿嘧啶尿(thymine uraciluria),速復利尿症(sulfinuria)、異戊酸血症、酵母丙胺酸尿症、4-羥基丁酸尿症、葡萄糖-6-磷酸脫氫酶缺乏症和丙酮酸脫氫酶缺乏症。
如本文所使用之術語〝肥胖症〞或〝肥胖〞通常係指個體超過他/她的年齡、性別和身高的平均體重之至少約
20-30%。在技術上而言,〝肥胖〞對男性係定義為個體的體指數大於27.8公斤/平方公尺及對女性係定義為個體的體指數大於27.3公斤/平方公尺。那些熟諳本技術者可輕易地確認本發明方法不限於那些落在上述標準內的個體。實際上,本發明方法最好亦可施行於落在該等傳統標準外的個體,例如那些可能有肥胖症傾向者。
如本文所使用之術語〝發炎性病症〞係指諸如類風濕性關節炎、僵直性脊椎炎、乾癬性關節炎、牛皮癬、軟骨鈣化症、痛風、發炎性腸道疾病、潰瘍性結腸炎、克隆氏病(Crohn's disease)、纖維變性肌痛和惡病質之病症。
如本文所使用之詞組〝治療有效量〞係指由研究者、獸醫、醫生或其他人員探索而誘出組織、系統、動物或人類之生物或醫學反應的藥物或醫藥劑之量。
如本文所使用之詞組〝對降低血液葡萄糖值有效之量〞係指足以提供足夠高的循環濃度以達到所欲效應之化合物值。此濃度典型地落在約10nM到至多2μM之範圍內;以在約100nM到至多500nM之範圍內的濃度較佳。如先前所述,因為落在上文提出之式I定義範圍內的不同化合物之活性可能有極大的變化,且因為受驗個體在徵候嚴重性上可出現寬廣的變異,所以應由執業者測定受驗者對治療的反應及據此變更劑量。
如本文所使用之詞組〝胰島素抗性〞係指在整個體內或個別組織內(諸如骨骼肌組織、心肌組織、脂肪組織或肝臟組織)對胰島素作用之敏感度降低。胰島素抗性可發
生在很多患有或未患有糖尿病之個體中。
如本文所使用之詞組〝胰島素抗性症候群〞係指包括胰島素抗性、高胰島素血症、非胰島素依賴性糖尿病(NIDDM)、動脈性高血壓、中央性(內臟)肥胖症和血脂異常症之發病群。
本發明化合物亦可用於治療與葡萄糖利用受損及胰島素抗性有關聯的其他代謝性病症,包括NIDDM之主要的晚期併發症,諸如糖尿病血管病變、動脈粥樣硬化症、非酒精性皮脂腺肝炎(NASH)、非酒精性脂肪肝疾病、糖尿病性腎病變、糖尿病性神經病變和糖尿病性眼部併發症,諸如視網膜病變、白內障形成和青光眼,及許多與NIDDM結合的其他併發症,包括血脂異常症、葡萄糖皮質素誘發之胰島素抗性、多囊性卵巢症候群、肥胖症、高血糖症、高脂血症、高膽固醇血症、高三酸甘油酯血症、高胰島素血症和高血壓。該等病況的簡單說明可於任何醫學字典中取得,例如“Stedman’s Medical Dictionary”(Xth Ed.)。
本所揭示之化合物和組成物可以治療有效量與本文定義之一或多種額外的治療劑組合投予。例如,增效效應可以治療Cry-介導之疾病或病症中所使用之其他物質發生。在本發明化合物連同其他療法一起投予時,共同投予之化合物的劑量當然係取決於所使用之共同藥物的類型、所使用之特定藥物、欲治療之病況等等而變更。
如本文所使用之可交換使用的術語〝組合治療〞、
〝組合療法〞、〝組合之治療〞或〝組合性治療〞係指以至少兩種不同的治療劑治療個體。如本文所使用之術語〝共同投予〞或〝組合投予〞或類似者意謂包含經選擇之治療劑類投予單一受驗者且意欲包括其中治療劑類沒必要以相同的投予途徑或相同時間投予之治療制度。術語〝醫藥組合〞意謂從混合或組合一種以上的活性成分所生成之產物且包括活性成分的固定和非固定組合二者。〝固定組合〞意謂活性成分(例如,本文所揭示之化合物和額外的治療劑)皆以單一實體或劑量同時投予病患。〝非固定組合〞意謂活性成分(例如,本文所揭示之化合物和額外的治療劑)皆沒有特定的時間限制同時、並行或相繼以單獨的實體投予病患,其中此投予係以2種化合物的治療有效量提供至病患體內。非固定組合亦適用於雞尾酒療法,例如投予3或更多種活性成分。
用於治療糖尿病、代謝症候群、肥胖症、胰島素抗性症候群、糖尿病併發症或癌症之治療劑包括而不限於下列者:胰島素、降血糖劑、抗發炎劑、降脂劑、抗高血壓藥,諸如鈣通道阻斷劑、β-腎上腺素能受體阻斷劑、環加氧酶-2抑制劑、血管緊張素系統抑制劑、ACE抑制劑、腎素抑制劑、化療劑,放射療法、激素調節劑,免疫調節劑、抗血管生成劑、與其他常見的危險因子修飾劑。
胰島素包括短效型式,諸如胰島素lispro rDNA來源:HUMALOG(1.5毫升,10毫升,Eli Lilly and Company,Indianapolis,Ind.)、胰島素注射(常規型胰島素)
型式牛肉和豬肉(常規ILETIN I,Eli Lilly)、人類:rDNA:HUMULIN R(Eli Lilly)、NOVOLIN R(Novo Nordisk)、半合成:VELOSULIN人類(Novo Nordisk)、rDNA人類,經緩衝:VELOSULIN BR,豬肉:常規型胰島素(Novo Nordisk)、純化豬肉:豬肉常規型ILETIN II(Eli Lilly)、常規型純化豬肉胰島素(Novo Nordisk)和常規型(經濃縮)ILETIN II U-500(500單位/毫升,Eli Lilly);中效型式,諸如胰島素鋅懸浮液,牛肉和豬肉:LENTE ILETIN G I(Eli Lilly)、人類rDNA:HUMULIN L(Eli Lilly)、NOVOLIN L(Novo Nordisk)、純化豬肉:LENTE ILETIN II(Eli Lilly)、低精蛋白(Isophane)胰島素懸浮液(NPH):牛肉和豬肉:NPH ILETIN I(Eli Lilly)、人類rDNA:HUMULIN N(Eli Lilly)、Novolin N(Novo Nordisk)、純化豬肉:豬肉NPH Iletin II(Eli Lilly)、NPH-N(Novo Nordisk);及長效型式,諸如胰島素鋅懸浮液,延長型(ULTRALENTE,Eli Lilly)、人類rDNA:HUMULIN U(Eli Lilly)。
降血糖劑包括而不限於磺醯脲類:乙磺環已脲(Acetohexamide)(Dymelor)、氯磺丙脲(Chlorpropamide)(Diabinese)、甲苯磺丁脲(Tolbutamide)(Orinase);第二代磺醯脲類:格列吡嗪(Glipizide)(Glucotrol,Glucotrol XL)、甘布若(Glyburide)(Diabeta;Micronase;Glynase)、格列美脲(Glimepiride)(Amaryl);雙胍類:二甲雙胍(Glucophage);
α-葡萄糖苷酶抑制劑:阿卡波糖(Acarbose)(Precose)、米格列醇(Miglitol)(Glyset);噻唑啶二酮類:羅格列酮(Avandia)、皮格列酮(Actos)、曲格列酮(Troglitazone)(Rezulin);格替耐類(Meglitinides):瑞巴葛耐(Repaglinide)(Prandin);及其他降血糖劑,諸如阿卡波糖、丁福明(Buformin)、布他沙明鹽酸鹽(Butoxamine Hydrochloride)、卡格列波糖(Camiglibose)、環格列酮(Ciglitazone)、恩格列酮鈉(Englitazone Sodium)、達格列酮鈉(Darglitazone Sodium)、依託福明鹽酸鹽(Etoformin Hydrochloride)、格列胺脲(Gliamilide)、格列波脲(Glibomuride)、格列他尼(Glicetanile)、格列齊特鈉(Gliclazide Sodium)、格列氟胺(Gliflumide)、胰高血糖素(Glucagon)、格列己脲(Glyhexamide)、格列嘧啶鈉(Glymidine Sodium)、格列辛脲(Glyoctamide)、格列帕脲(Glyparamide)、利諾格列(Linogliride)、利諾格列反丁烯二酸鹽、帕莫酸甲酯(Methyl Palmoxirate)、帕莫酸鈉(Palmoxirate Sodium)、吡咯格列酒石酸鹽(Pirogliride Tartrate)、人類胰島素原、司格列肽乙酸鹽(Seglitide Acetate)、妥拉磺脲(Tolazamide)、甲苯磺吡胺(Tolpyrramide)、唑泊司他(Zopolrestat)。
抗發炎劑包括阿氯芬酸(Alclofenac)、阿氯米松二丙酸鹽(Alclometasone Dipropionate)、阿孕奈德(Algestone Acetonide)、α-澱粉酶、安西法爾(Amcinafal)、安西非特(Amcinafide)、胺芬酸鈉(Amfenac Sodium)、胺普立糖鹽
酸鹽(Amiprilose Hydrochloride)、阿那白滯素(Anakinra)、阿尼羅酸(Anirolac)、阿尼紮芬(Anitrazafen)、阿紮丙宗(Apazone)、巴柳氮二鈉(Balsalazide Disodium)、苄達酸(Bendazac)、苯噁洛芬(Benoxaprofen)、苄達明鹽酸鹽(Benzydamine Hydrochloride)、菠蘿蛋白酶(Bromelains)、溴哌莫(Broperamole)、布地奈德(Budesonide)、卡洛芬(Carprofen)、環洛芬(Cicloprofen)、辛噴他宗(Cintazone)、克利洛芬(Cliprofen)、氯倍他索丙酸鹽(Clobetasol Propionate)、氯倍他松丁酸鹽(Clobetasone Butyrate)、氯吡酸(Clopirac)、氯硫卡松丙酸鹽(Cloticasone Propionate)、可米松乙酸鹽(Cormethasone Acetate)、可托多松(Cortodoxone)、地夫可特(Deflazacort)、地奈德(Desonide)、去羥米松(Desoximetasone)、地塞米松二丙酸鹽(Dexamethasone Dipropionate)、雙氯芬酸鉀(Diclofenac Potassium)、雙氯芬酸鈉、二氟拉松二乙酸鹽(Diflorasone Diacetate)、二氟米酮鈉(Diflumidone Sodium)、二氟尼柳(Diflunisal)、二氟潑尼酯(Difluprednate)、地弗他酮(Diftalone)、二甲亞碸、羥西奈德(Drocinonide)、恩甲羥松(Endrysone)、恩莫單抗(Enlimomab)、依諾利康鈉(Enolicam Sodium)、依匹唑(Epirizole)、依託度酸(Etodolac)、依託芬那酯(Etofenamate)、聯苯乙酸(Felbinac)、非那莫(Fenamole)、芬布芬(Fenbufen)、芬氯酸(Fenclofenac)、苯克洛酸(Fenclorac)、芬度柳(Fendosal)、芬吡帕酮(Fenpipalone)、
芬替酸(Fentiazac)、呋拉紮酮(Flazalone)、氟紮可特(Fluazacort)、氟芬那酸(Flufenamic Acid)、氟米唑(Flumizole)、氟尼縮松乙酸鹽(Flunisolide Acetate)、氟尼辛(Flunixin)、氟尼辛葡甲胺(Flunixin Meglumine)、氟可汀丁酯(Fluocortin Butyl)、氟米龍乙酸鹽(Fluorometholone Acetate)、氟喹宗(Fluquazone)、氟比洛芬(Flurbiprofen)、氟瑞托芬(Fluretofen)、氟替卡松丙酸鹽(Fluticasone Propionate)、呋喃洛芬(Furaprofen)、呋羅布芬(Furobufen)、哈西奈德(Halcinonide)、鹵倍他索丙酸鹽(Halobetasol Propionate)、鹵潑尼松乙酸鹽(Halopredone Acetate)、異丁芬酸(Ibufenac)、布洛芬(Ibuprofen)、布洛芬鋁、布洛芬吡甲酯(Ibuprofen Piconol)、伊洛達普(Ilonidap)、吲哚美辛(Indomethacin)、吲哚美辛鈉、吲哚洛芬(Indoprofen)、吲哚克索(Indoxole)、吲四唑(Intrazole)、異氟潑尼龍乙酸鹽(Isoflupredone Acetate)、伊索克酸(Isoxepac)、伊索昔康(Isoxicam)、酮洛芬(Ketoprofen)、洛非咪唑鹽酸鹽(Lofemizole Hydrochloride)、氯諾昔康(Lornoxicam)、氯替潑諾(Loteprednol Etabonate)、甲氯芬那酸鈉(Meclofenamate Sodium)、甲氯芬那酸(Meclofenamic Acid)、甲氯松二丁酸鹽(Meclorisone Dibutyrate)、甲芬那酸(Mefenamic Acid)、美塞拉明(Mesalamine)、美西拉宗(Meseclazone)、磺庚甲潑尼龍(Methylprednisolone Suleptanate)、嗎尼氟酯(Morniflumate)、萘丁美酮(Nabumetone)、萘普生
(Naproxen)、萘普生鈉、萘普索(Naproxol)、尼馬宗(Nimazone)、奧沙拉嗪鈉(Olsalazine Sodium)、奧古蛋白(Orgotein)、奧帕諾辛(Orpanoxin)、奧沙普嗪(Oxaprozin)、羥保泰松(Oxyphenbutazone)、瑞尼托林鹽酸鹽(Paranyline Hydrochloride)、戊聚糖聚硫酸鈉(Pentosan Polysulfate Sodium)、保泰松甘油酸鈉(Phenbutazone Sodium Glycerate)、吡非尼酮(Pirfenidone)、吡羅昔康(Piroxicam)、吡羅昔康肉桂酸鹽、吡羅昔康乙醇胺(Piroxicam Olamine)、吡洛芬(Pirprofen)、潑那紮特(Prednazate)、普立非酮(Prifelone)、普羅度酸(Prodolic Acid)、普羅喹宗(Proquazone)、普羅沙唑(Proxazole)、普羅沙唑檸檬酸鹽、利美索龍(Rimexolone)、氯馬紮利(Romazarit)、柳膽來司(Salcolex)、沙那西定(Salnacedin)、雙水楊酯(Salsalate)、水楊酸酯、血根氯銨(Sanguinarium Chloride)、司克拉宗(Seclazone)、絲美辛(Sermetacin)、舒多昔康(Sudoxicam)、舒林酸(Sulindac)、舒洛芬(Suprofen)、他美辛(Talmetacin)、他尼氟酯(Talniflumate)、他洛柳酯(Talosalate)、特丁非隆(Tebufelone)、替尼達普(Tenidap)、替尼達普鈉、替諾昔康(Tenoxicam)、替昔康(Tesicam)、特西嘧胺(Tesimide)、特唑達明(Tetrydamine)、硫平酸(Tiopinac)、替可的松特戊酸鹽(Tixocortol Pivalate)、托美丁(Tolmetin)、托美丁鈉、三氯奈德(Triclonide)、三氟米酯(Triflumidate)、齊多美辛(Zidometacin)、糖皮質素、佐美酸鈉(Zomepirac
Sodium)。重要的抗發炎劑為阿司匹林(aspirin)。
其他的抗發炎劑為細胞激素抑制劑,包括細胞激素拮抗劑(例如,IL-6受體拮抗劑)、氮雜烷基溶血磷脂(AALP)和腫瘤壞死因子-α(TNF-α)抑制劑,諸如抗-TNF-α抗體、可溶性TNF受體、TNF-α、反義核酸分子、多價脒基腙(guanylhydrazone)(CNI-1493)、N-乙醯半胱胺酸、己酮可可鹼(pentoxiphylline)、己酮可可鹼(oxpentifylline)、碳環核苷類似物、小分子S9a、RP 55778(TNF-α合成抑制劑)、地塞比諾(Dexanabinol)(HU-211)、MDL 201,449A(9-[(IR,3R)-反式-環戊-3-醇]腺嘌呤)和木黴醇(trichodimerol)(BMS-182123)。其他的TNF-α抑制劑包括依那西普(Etanercept)(ENBREL,Immunex,Seattle)和因福利美(Infliximab)(REMICADE,Centocor,Malvern,Pa.)。
降脂劑包括吉非羅齊(gemfibrozil)、考來烯胺(cholystyramine)、考來替泊(colestipol)、菸鹼酸和HMG-CoA還原酶抑制劑。可用於投予或與根據本發明的其他劑共同投予之HMG-CoA還原酶抑制劑包括但不受限於辛伐他汀(simvastatin)(美國專利案號4,444,784)、洛伐他汀(lovastatin)(美國專利案號4,231,938)、普伐他汀鈉(pravastatin sodium)(美國專利案號4,346,227)、氟伐他汀(fluvastatin)(美國專利案號4,739,073)、阿托伐他汀(atorvastatin)(美國專利案號5,273,995)和西立伐他汀(cerivastatin)。
鈣通道阻斷劑包括二氫吡啶,諸如硝苯地平
(nifedipine);苯基烷基胺,諸如維拉帕米(verapamil);及苯并噻氮呯(benzothiazepine),諸如地爾硫卓(diltiazem)。其他的鈣通道阻斷劑包括但不受限於胺力農(amrinone)、胺氯地平(amlodipine)、苄環烷(bencyclane)、非洛地平(felodipine)、芬地林(fendiline)、氟桂利嗪(flunarizine)、伊拉地平(isradipine)、尼卡地平(nicardipine)、尼莫地平(nimodipine)、哌克昔林(perhexilene)、戈洛帕米(gallopamil)、噻帕米(tiapamil)和噻帕米類似物(諸如1993RO-11-2933)、苯妥英(phenytoin)、巴比妥鹽(barbiturate)和肽類強啡肽(dynorphin)、ω-芋螺毒素和ω-漏斗網蛛毒素(omega-agatoxin)及類似者及/或其醫藥上可接受之鹽。
β-腎上腺素能受體阻斷劑包括但不受限於阿替洛爾(atenolol)、醋丁洛爾(acebutolol)、阿普洛爾(alprenolol)、苯呋洛爾(befunolol)、倍他洛爾(betaxolol)、布尼洛爾(bunitrolol)、卡替洛爾(carteolol)、塞利洛爾(celiprolol)、海沙洛爾(hedroxalol)、茚諾洛爾(indenolol)、拉貝洛爾(labetalol)、左布諾洛爾(levobunolol)、甲吲洛爾(mepindolol)、美替普洛(methypranol)、美提哆(metindol)、美托洛爾(metoprolol)、美唑洛爾(metrizoranolol)、氧烯洛爾(oxprenolol)、吲哚洛爾(pindolol)、普萘洛爾(propranolol)、普拉洛爾(practolol)、索他洛爾(sotalolnadolol)、替普洛爾(tiprenolol)、托嗎洛爾
(tomalolol)、噻嗎洛爾(timolol)、布拉洛爾(bupranolol)、噴布洛爾(penbutolol)、三甲普爾(trimepranol)、2-(3-(1,1-二甲基乙基)-胺基-2-羥基丙氧基)-3-吡啶甲腈HCl、1-丁基胺基-3-(2,5-二氯苯氧基)-2-丙醇、1-異丙基胺基-3-(4-(2-環丙基甲氧基乙基)苯氧基)-2-丙醇、3-異丙基胺基-1-(7-甲基二氫化茚-4-氧基)-2-丁醇、2-(3-第三丁基胺基-2-羥基-丙硫基)-4-(5-胺甲醯基-2-噻吩基)噻唑、7-(2-羥基-3-第三丁基胺基丙氧基)苯酞(phthalide)。上文鑑定之化合物可以異構物混合物或以其各自的左旋或右旋形式使用。
許多選擇性COX-2抑制劑為本技藝中已知且包括但不受限於下列者所述之COX-2抑制劑:美國專利案號5,474,995、美國專利案號5,521,213、美國專利案號5,536,752、美國專利案號5,550,142、美國專利案號5,552,422、美國專利案號5,604,253、美國專利案號5,604,260、美國專利案號5,639,780、美國專利案號5,677,318、美國專利案號5,691,374、美國專利案號5,698,584、美國專利案號5,710,140、美國專利案號5,733,909、美國專利案號5,789,413、美國專利案號5,817,700、美國專利案號5,849,943、美國專利案號5,861,419、美國專利案號5,922,742、美國專利案號5,925,631和美國專利案號5,643,933。許多上文鑑定之COX-2抑制劑為選擇性COX-2抑制劑之前藥且包括那些在WO 95/00501、WO 95/18799和1995年12月12日頒予之美國專利案號5,474,995中所述者。
血管緊張素II拮抗劑的實例包括:肽化合物(例如,沙拉新(saralasin),[(San1)(Val5)(Ala8)]血管緊張素-(1-8)八肽和相關類似物);經N-取代之咪唑-2-酮(美國專利案號5,087,634);咪唑乙酸鹽衍生物,包括2-N-丁基-4-氯-1-(2-氯苄基)咪唑-5-乙酸(參見Long等人之J.Pharmacol.Exp.Ther.247(1),1-7(1988));4,5,6,7-四氫-1H-咪唑並[4,5-c]吡啶-6-羧酸和類似衍生物(美國專利案號4,816,463);N2-四唑β-葡糖苷酸類似物(美國專利案號5,085,992);經取代之吡咯、吡唑及三唑(美國專利案號5,081,127);酚和雜環衍生物,諸如1,3-咪唑(美國專利案號5,073,566);咪唑并-稠合7員環雜環(美國專利案號5,064,825);肽(例如,美國專利案號4,772,684);血管緊張素II之抗體(例如,美國專利案號4,302,386);及芳烷基咪唑化合物,諸如經聯苯-甲基取代之咪唑(例如,1988年1月20日之EP 253,310)、ES8891(N-嗎啉基乙醯基-(-1-萘基)-L-丙醯胺基-1-(4-噻唑基)-L-丙醯胺基(35,45)-4-胺基-3-羥基-5-環己戊醯基-N-己醯胺,Sankyo Company,Ltd.,Tokyo,Japan)、SKF108566(E-α-2-[2-丁基-1-(羧苯基)甲基]-1H-咪唑-5-基[亞甲基]-2-噻吩丙酸,Smith Kline Beecham Pharmaceuticals,Pa.)、氯沙坦(Losartan)(DUP753/MK954,DuPont Merck Pharmaceutical Company)、瑞米吉侖(Remikirin)(RO42-5892,F.Hoffman LaRoche AG)、A2促效劑(Marion Merrill Dow)和特定的非肽雜環(G.D.Searle and Company)。
血管緊張素轉化酵素(ACE)抑制劑包括胺基酸和其衍生物、肽(包括二肽及三肽)和ACE抗體,其係藉由抑制ACE活性來介入腎素-血管緊張素系統,從而降低或消除增壓物質血管緊張素II之形成。其他的ACE抑制劑包括醯基巰基和巰基烷醯基脯胺酸,諸如卡托普利(captopril)(美國專利案號4,105,776)和佐芬普利(zofenopril)(美國專利案號4,316,906);羧烷基二肽,諸如依那普利(enalapril)(美國專利案號4,374,829)、賴諾普利(lisinopril)(美國專利案號4,374,829)、喹那普利(quinapril)(US Patent Number 4,344,949)、雷米普利(ramipril)(美國專利案號4,587,258)和培哚普利(perindopril)(美國專利案號4,508,729);羧烷基二肽模擬劑,諸如西拉普利(cilazapril)(美國專利案號4,512,924)和苯那普利(benazapril)(美國專利案號4,410,520);膦基烷醯基脯胺酸,諸如福辛普利(fosinipril)(美國專利案號4,337,201)和群多普利(trandolopril)。
腎素抑制劑包括胺基酸和其衍生物、肽和其衍生物及腎素抗體。其他的腎素抑制劑包括肽之脲衍生物(美國專利案號5,116,835)、經非肽鍵連接之胺基酸(美國專利案號5,114,937)、二-和三-肽衍生物(美國專利案號5,106,835)、胺基酸和其衍生物(美國專利案號5,104,869和5,095,119)、二醇磺醯胺和亞磺醯基(美國專利案號5,098,924)、經修飾之肽(美國專利案號5,095,006)、肽基β-胺基醯基胺基二醇胺甲酸酯(美國專利案號5,089,471)、
吡咯咪唑酮(美國專利案號5,075,451)、含氟和氯斯他汀(statine)或斯他通(statone)之肽(美國專利案號5,066,643)、肽基胺基二醇(美國專利案號5,063,208和4,845,079)、N-嗎啉基衍生物(美國專利案號5,055,466)、胃蛋白酶抑制劑衍生物(美國專利案號4,980,283)、N-雜環醇(美國專利案號4,885,292)、腎素之單株抗體(美國專利案號4,780,401)及各種其他肽和其類似物(美國專利案號5,071,837、5,064,965、5,063,207、5,036,054、5,036,053、5,034,512和4,894,437)。
有用於治療糖尿病和相關病症的其他治療劑包括但不受限於脂肪酶抑制劑,諸如西替利司他(Cetilistat)(ATL-962);合成胰澱素類似物,諸如普蘭林肽(Symlin pramlintide)(有或沒有重組瘦體素);鈉-葡萄糖共同轉運體2(SGLT2)抑制劑,如舍吉洛嗪(sergliflozin)(869682;KGT-1251)、YM543、達帕洛嗪(dapagliflozin)、GlaxoSmithKline分子189075和Sanofi-Aventis分子AVE2268;雙脂肪三酸甘油酯脂肪酶和PI3激酶活化劑,如阿地維爾(Adyvia)(ID 1101);神經肽Y2、Y4及Y5受體之拮抗劑,如Nastech分子PYY3-36、人類激素PYY3-36之合成類似物和胰腺多肽(7TM分子TM30338);Shionogi分子S-2367;大麻鹼CB1受體拮抗劑,諸如利莫納班(rimonabant)(Acomplia)、他蘭那特(taranabant)、CP-945,598、Solvay分子SLV319、Vernalis分子V24343;激素,如油醯基-雌酮;血清素、多巴胺和去甲
腎上腺素之抑制劑(在本技藝中亦稱為三重單胺再吸收抑制劑),如特索芬辛(tesofensine)(Neurosearch分子NS2330);去甲腎上腺素和多巴胺再吸收之抑制劑,如康曲維(Contrave)(安非他酮(bupropion)加鴉片拮抗劑納曲酮(naltrexone))和依賽利爾(Excalia)(安非他酮加抗痙攣劑唑尼沙胺(zonisaminde));1型11β-羥基類固醇脫氫酶(11b-HSD1)之抑制劑,如Incyte分子INCB13739;皮質醇合成抑制劑,諸如酮康唑(ketoconazole)(DiObex分子DIO-902);葡萄糖生成抑制劑,諸如Metabasis/Daiichi分子CS-917;葡糖激酶活化劑,如Roche分子R1440;蛋白質酪胺酸磷酸酶-1B之反義抑制劑,諸如ISIS 113715;以及其他劑,如NicOx分子NCX 4016;胃泌素和表皮生長因子(EGF)類似物之注射劑,諸如胰島新生療法(Islet Neogenesis Therapy)(E1-I.N.T.);倍他司汀(betahistine)(Obecure分子OBE101);膽酸螯合劑(例如,貴舒醇散(cholestyramine)和考來替泊(colestipol))、維生素B3(亦稱為菸鹼酸(nicotinic acid或niacin))、維生素B6(吡哆醇)、維生素B12(氰基鈷胺素)、纖維酸衍生物(例如,吉非貝齊(gemfibrozil)、克洛貝特(clofibrate)、芬諾貝特(fenofibrate)和苯札貝特(benzafibrate))、普羅布考(probucol)、硝基甘油和膽固醇吸收抑制劑(例如,β-麥固醇和醯基CoA-膽固醇醯基轉移酶(ACAT)抑制劑,諸如甲亞油醯胺(melinamide))、HMG-CoA合成酶抑制劑、鯊烯環氧酶抑制劑和鯊烯合成酶抑制劑。
常用於治療疼痛(包括神經性疼痛)之止痛劑的實例包括而不限於類鴉片或非類鴉片止痛劑。適合的類鴉片止痛劑包括但不受限於嗎啡、海洛因、氫嗎啡酮(hydromorphone)、氫可酮(hydrocodone)、氧化嗎啡酮(oxymorphone)、氧可酮(oxycodone)、美托酮(metopon)、阿波莫芬(apomorphine)、normorphine、愛托啡因(etorphine)、布普羅啡(buprenorphine)、麥佩里定(meperidine)、洛哌丁胺(lopermide)、阿尼利定(anileridine)、氫氮卓乙酯(ethoheptazine)、匹米尼定(piminidine)、倍他羅定(betaprodine)、地芬諾醋(diphenoxylate)、芬坦尼(fentanil)、舒芬坦尼(sufentanil)、阿芬坦尼(alfentanil)、瑞密芬坦尼(remifentanil)、左旋嗎汎(levorphanol)、右美沙芬(dextromethorphan)、芬那佐辛(phenazocine)、潘他唑辛(pentazocine)、環佐辛(cyclazocine)、美沙酮(methadone)、異美沙酮(isomethadone)和普帕西芬(propoxyphene)。適合的非類鴉片止痛劑包括但不受限於阿司匹靈(aspirin)、塞內昔布(celecoxib)、羅非考昔(rofecoxib)、雙氯芬酸(diclofenac)、地夫西納(diflusinal)、依託度酸(etodolac)、非諾洛芬(fenoprofen)、氟比洛芬(flurbiprofen)、布洛芬(ibuprofen)、酮洛芬(ketoprofen)、吲哚美辛(indomethacin)、酮咯酸(ketorolac)、美洛芬(meclofenamate)、甲芬那酸(mefanamic acid)、萘丁美酮
(nabumetone)、萘普生(naproxen)、吡羅昔康(piroxicam)和舒林酸(sulindac)。
常用於治療青光眼之治療劑的實例包括膽鹼能促效劑(例如,毛果芸香鹼(pilocarpine)和卡巴膽鹼(carbachol))、膽鹼酯酶抑制劑(例如,毒扁豆鹼(physostigmine)、新斯地明(neostigmine)、地美銨(demacarium)、碘化二乙氧磷醯硫膽鹼(echothiophate iodide)和氟磷酸二異丙酯(isofluorophate))、碳酸酐酶抑制劑(例如,乙醯唑醯胺(acetazolamide)、二氯酚醯胺(dichlorphenamide)、美唑醯胺(methazolamide)、優唑醯胺(ethoxzolamide)和道唑醯胺(dorzolamide))、非選擇性腎上腺素能促效劑(例如,腎上腺素和雙特戊醯腎上腺素(dipivefrin))、α2-選擇性腎上腺素能促效劑(例如,安普尼定(apraclonidine)和布莫尼定(brimonidine))、β-阻斷劑(例如,噻嗎洛爾(timolol)、貝他唑爾(betazolol)、左布諾洛爾(levobunolol)、卡替洛爾(carteolol)和美替洛爾(metipranolol))、前列腺素類似物(例如,樂通舒特(latanoprost))及滲透性利尿劑(例如甘油、甘露醇和異山梨糖醇);皮質類固醇,諸如貝克拉米松(beclomethasone)、甲基腎上腺皮質酮、倍它米松(betamethasone)、普德尼松(predinisone)、腎上腺皮質酮、地塞米松、氟替卡松(fluticasone)和氫皮質酮,及皮質類固醇類似物,諸如布第耐德(budesonide)。
常用於治療阿茲海默爾氏症之治療劑的實例包括β-分泌酶抑制劑或γ-分泌酶抑制劑;甘胺酸傳輸抑制劑、tau
磷酸化抑制劑;Aβ寡聚物形成阻斷劑;p25/CDK5抑制劑;HMG-CoA還原酶抑制劑;PPARγ促效劑,諸如皮格列酮和羅格列酮;NK1/NK3受體拮抗劑;NSAID,包括布洛芬(ibuprofen);維生素E;抗澱粉樣蛋白抗體,包括抗澱粉樣蛋白人類單株抗體;COX-2抑制劑;抗發炎化合物,諸如(R)-氟比洛芬;CB-1受體拮抗劑或CB-1受體反向促效劑;抗體,諸如多西環素(doxycycline)和利福平(rifampin);N-甲基-D-天冬胺酸鹽(NMDA)受體拮抗劑,諸如美金剛(memantine)和奈拉美生(neramexane);NR2B拮抗劑;雄性素受體調節劑;乙醯基膽鹼酯酶抑制劑,諸如加蘭他敏(galantamine)、雷斯替明(rivastigmine)、冬尼培唑(donepezil)和塔克林(tacrine);mGluR5調節劑;生長激素促泌素,諸如伊布莫侖(ibutamoren)、伊布莫侖甲磺酸鹽和卡普莫林(capromorelin);組織胺H3拮抗劑;AMPA促效劑;PDE IV抑制劑;GABAA反向促效劑;GABAA α5受體配體;GABAB受體配體;鉀通道阻斷劑;神經元菸鹼促效劑;P-450抑制劑,諸如利托那伯(ritonavir)。
常用於治療情感性病症(諸如抑鬱症)之治療劑的實例包括而不限於阿米替林(amitriptyline)、阿米替林氧化物、地昔帕明(desipramine)、二苯西平(dibenzepin)、度硫平(dosulepin)、多塞平(doxepin)、氯咪帕明(chloroimipramine)、咪帕明(imipramine)、去甲替林(nortriptyline)、米安色林(mianserin)、馬普替林
(maprotiline)、曲米帕明(trimipramine)、CP-122721、艾扎索南(elzasonan)、PD-171729、MK-869、DOV-216303、DOV-21947、利卡西平(licarbazepine)、安非布他酮(amfebutamone)、瑞達法辛(radafaxine)、維拉佐酮(vilazodone)、GSK-679769、GW-597599、NS-2359、GSK-876008、普拉克索(pramipexole)、度洛西汀(duloxetine)、阿托莫西汀(atomoxetine)、LY-628535、去甲文拉法辛(desvenlafaxine)、依地普蘭(escitalopram)、LU-AA21004、沙瑞度坦(saredutant)、SR-58611、SSR-149415、SSR-146977、嗎氯貝胺(moclobemide)、R-673、R-1204、BMS-469458、DPC-368、Org-34517、Org-34850、CRH受體抑制劑、ONO-2333Ms、NBI-876008、AAG-561、NBI-34041、DPC-368、PD-171729、SSR-125543、維洛沙秦(viloxazine)、曲唑酮(trazodone)、奈法唑酮(nefazodone)、米氮平(mirtazapine)、文拉法辛(venlafaxine)、瑞波西汀(reboxetine)、反苯環丙胺(tranylcypromine)、溴法羅明(brofaromine)、嗎氯貝胺(moclobemide)、西它普蘭(citalopram)、依地普蘭(escitalopram)、帕羅西汀(paroxetine)、氟西汀(fluoxetine)、氟伏沙明(fluvoxamine)、舍曲林(sertraline)、Hypericum(St.John's Wort)、阿普唑侖(alprazolam)、氯硝西泮(clonazepam)、地西泮(diazepam)、勞拉西泮(lorazepam)、哈拉西泮(halazepam)、氯二氮環氧化物(chlordiazepoxide)及其他藥
物,諸如丁螺環酮(buspirone)、可樂定(clonidine)、帕戈隆(pagoclone)、利培酮(risperidone)、奧氮平(olanzapine)、喹硫平(quetiapine)、齊拉西酮(ziprasidone)、塞內昔布(celecoxib)、吡羅昔康(piroxicam)、帕瑞昔布(parecoxib)、伐地昔布(valdecoxib)、PMI-001、PH-686464、SC-58236、依託昔布(etoricoxib)、羅芬昔布(rofecoxib)、L-776967、路密拉昔布(lumiracoxib)、GW-406381、GW-644784、美洛希肯(meloxicam)、SVT-2016、PAC-10649、CS-706、LAS-34475、西密昔布(cimicoxib)、A-183827.0或尼美舒利(nimesulide)。
常用於治療成癮和藥物濫用之治療劑的實例包括而不限於苯乙肼(phenelzine)、苯烷基肼(美國專利案號4,786,653)、二硫弗蘭(disulfiram)(“Antabuse”)、2-亞胺基-5-苯基-4-噁唑啶酮、α-甲基-對-酪胺酸或鐮孢菌酸、哌衍生物(美國專利案號4,325,952)、結合三環抗抑鬱藥物之可樂定(美國專利案號4,788,189)、γ-哌哢,諸如美特醇(maltol)或乙基美特醇(美國專利案號4,276,890)、乙醯高牛磺酸鹽(acamprosate)、加巴噴丁(gabapentin)、胺己烯酸(vigabatrin)、氯苯胺丁酸(baclofen)、N-乙醯基半胱胺酸、諾坎(nocaine)、摩丹那啡(modanafil)、帕羅西汀(paroxetine)、安非他酮(bupropion)、米氮平(mirtazapine)、托吡酯(topiramate)、昂丹司瓊(ondansetron)、瓦倫克林(varenicline)、類鴉片受體拮抗
劑,諸如那曲酮(naltrexone)、納洛酮(naloxone)、那美啡(nalmephine)、安塔頌(antaxone)、L-α-乙醯基美沙醇(methadol)、潘他唑新(pentazocine)、布托啡諾(butorphanol)、那布啡(nalbuphine)、丁丙諾啡(buprenorphine)和美沙酮(methadone)。
常用於骨質疏鬆症治療且可調節骨礦質含量之治療劑的實例包括但不受限於雙膦酸鹽,諸如阿侖膦酸鹽(alendronate)(Fosamax®)、利塞膦酸鹽(risedronate)(Actonel®)、依替膦酸鹽(etidronate)(Didronel®)、帕米膦酸鹽(pamidronate)、替魯膦酸鹽(tiludronate)(Skelid®)、氯膦酸鹽(clodronate)(Bonefos®;Loron®)、奈利膦酸鹽(neridronate)、歐帕膦酸鹽(olpadronate)、唑來膦酸鹽(zoledronate)(Zometa®)和依半膦酸鹽(ibandronate)(Boniva®);選擇性雌性素受體調節劑(SERMs),諸如雷諾昔芬(raloxifene)(Evista®)、阿佐昔芬(arzoxifene)、氯米芬(clomifene)、巴多昔芬(bazedoxifene)、拉索昔芬(lasofoxifene)、奧美昔芬(ormeloxifene)、他莫昔芬(tamoxifen)和托瑞米芬(toremifine);合成代謝療法,諸如特立帕太(teriparatide)(Forteo®;重組之副甲狀腺激素)和雷奈酸鍶(strontium ranelate);及副甲狀腺激素的重組之肽片段、雌性素/助孕酮替代療法、單株抗體、核因子kB配體之受體活化劑(RANKL)的抑制劑,諸如地諾單抗
(denosumab)、護骨因子(osteoprotegerin)和抑胃肽(Pepstatin)A;細胞自溶酵素K之抑制劑,諸如但不限於OST-4077(呋喃-2-羧酸-(1-{1-[4-氟-2-(2-側氧-吡咯啶-1-基)-苯基]-3-側氧-哌啶-3-基胺甲醯基}-環己基)-醯胺)、亮肽素(leupeptin)、Cbz-Phe-Ala-CHN2、Cbz-Leu-Leu-Leu-醛、血清胱抑素(cystatin)、不可逆式半胱胺酸蛋白酶抑制劑,如肽鹵甲基酮、肽二偶氮甲基酮和環氧化物;靜態不可逆式半胱胺酸蛋白酶抑制劑,諸如醯氧基甲基酮;氮雜肽、Michael受體,如肽乙烯酯、碸和磺酸酯;可逆式半胱胺酸蛋白酶抑制劑,諸如肽醛、a-酮酯和a-酮醯胺、肽甲基酮及其羥基、烷氧基、芳氧基、烷硫基和芳硫基衍生物;1,3-雙-(醯基胺基)-2-丙酮、1,3-雙-(醯基肼基)-羰基、醯基胺基-吡唑酮、哌啶酮和噻酮(thiazone)-羰基-醯肼、整合素Avb3之拮抗劑(在本技藝中亦稱為玻連蛋白(vitronectin))、鈣受體拮抗性(calcilytic)化合物(增加PTH分泌之Ca2+受體拮抗劑)、抑鈣素(MiacalcinÒ);硝酸鹽,包括但不受限於單硝酸異山梨酯(isosorbide mononitrate)(ISMO)或硝基甘油軟膏(NTG);及膳食補充劑,諸如鈣和維生素D;及其組合。
本發明的另一具體例為以測量從受驗者取得之樣品中的時鐘基因(例如,Cry1和Cry2)表現值為基準鑑定需要治療的病患之方法(Bjarnason,G.A.等人之Am.J.Pathol.2001,158,1793;Akashi,M.等人之Proc.Natl.Acad.Sci.USA,2010,107,15643)。在從受驗者取得之樣品中所測量
之人類時鐘基因(包括Cry1和Cry2)的節律mRNA表現輪廓表明晝夜時鐘存在於末梢組織中(Mohawk,J.A.等人之Ann.Rev.Neurosci.2012,Epub ahead of print)。在該等樣品中的晝夜時鐘相關基因之表現經證明在白天期間變更。而且,在末梢血液單核細胞中的時鐘基因(例如,Cry1和Cry2)表現圖案在人類中係因疾病(諸如肥胖症)而改變(Tahira,K.等人之Arch.Med.Sci.2011,7,933)。在末梢單核血液細胞中的時鐘基因(例如,Cry1和Cry2)表現之變化可與血清瘦素、脂聯素(adiponectin)、胰島素和hsCRP值、血漿脂質、葡萄糖、褪黑激素和皮質醇值有關聯,及在動物中與組織中的時鐘基因(例如,Cry1和Cry2)表現有關聯,包括肝、脂肪、胰腺和骨骼肌。藉由接觸自以式I化合物治療之受驗者取得的樣品及測量節律mRNA或蛋白質表現輪廓可鑑定需要治療的病患且可評定藥理活性。在其他的具體例中,可評定一或多種隱花色素之活性,例如隱花色素與標靶(諸如Per1、Per2、糖皮質素受體(GR)或含有Cry識別位置之啟動子序列,諸如CLOCK-BMAL1啟動子)結合的能力。
據此,本文所揭示之主題的一個態樣係關於監控在受驗者中的Cry-介導之疾病或病症的進展或預後之方法,其包含測量在第一時期在來自受驗者的第一樣品中的一或多種隱花色素之有效量;測量在第二時期在來自受驗者的第二樣品中的一或多種隱花色素之有效量;及比較在第一樣品中所偵測之一或多種隱花色素的量與在第二樣品中所偵
測之一或多種隱花色素的量或參考值。
〝診斷(Diagnosis、diagnose)〞或〝預後(prognose、prognosis)〞不受限於明確或幾乎明確判定個體患有疾病,但亦包括判定個體與健康的個體或一般大眾比較而具有增加患有或發展疾病的可能性。
如本文所使用之〝表現〞和〝表現值〞包括但不受限於下列中之一或多者:基因轉錄成前驅mRNA;前驅mRNA之剪接和其他處理,以產生成熟mRNA;mRNA穩定性;成熟mRNA轉譯成蛋白質(包括密碼子使用和tRNA可用性);及若必要時就適當的表現及功能而將轉譯產物糖化及/或其他修飾。
術語〝公式〞、〝演算法〞和〝模式〞為取得一或多個連續或分類輸入(本文稱為〝參數〞)且計算輸出值(有時稱為〝指數〞或〝指數值〞)的任何數學方程式、演算、分析或程式化過程、或統計技術。〝演算法〞的非限制性實例包括總和、比率和回歸運算子,諸如係數或冪、值轉換和標準化(包括而不限於以諸如性別、年齡、體指數或種族性之臨床參數為基準的那些標準化方案)、規則和準則、統計分類模式及以歷史群組培植(trained)之神經網路。在測量如本文所定義之Cry特別使用線性和非線性方程及統計分類分析,使受驗者樣品中所偵測之Cry值與發展Cry-介導之疾病或病症的受驗者風險之間的關係〝互相關聯〞。
〝測量(measuring或measurement)〞意謂評定在臨床
或受驗者所得樣品內的指定物質之存在、不存在、數量或量(其可為有效量),包括此等物質的定性或定量濃度值之導出,或以其他方式評估受驗者臨床參數的值或分類。測量(measurement或measuring)亦可包含核定類型資格及鑑定物質。測量(measurement或measuring)亦可包含一或多種Cry與標靶結合之能力,其中標靶可為週期基因或蛋白質Per1和Per2、糖皮質素受體(GR)或CLOCK-BMAL1基因之啟動子區域。Cry之測量可用於診斷、偵測或鑑定受驗者中的Cry-介導之疾病或病症,監控受驗者中的Cry-介導之疾病或病症的進展或預後,預測受驗者中的Cry-介導之疾病或病症的復發,或使受驗者歸類為具有發展Cry-介導之疾病或病症或Cry-介導之疾病或病症復發的低風險或高風險。
在本發明上下文中的〝風險〞係關於事件在特定的時間期限內發生的概率,如Cry-介導之疾病或病症的發展,且可指受驗者的〝絕對〞風險或〝相對〞風險。絕對風險可參考相關時間群體之測量後的實際觀測或參考自相關時間期間後之統計學有效的歷史群體所發展之指數值來測量。相對風險係指受驗者之絕對風險與低風險群體之絕對風險或平均群組風險比較之比率,其可視臨床風險因子如何評定而改變。對無轉變亦常使用勝算比(odds ratios),就給定之試驗結果的正面事件對負面事件之比例(勝算係根據公式p/(1-p),其中p為事件概率及(1-p)為未發生事件之概率)。可在本發明上下文中評定的替代之連續測量
包括發展Cry-介導之疾病或病症或進展至不同階段的Cry-介導之疾病或病症的時間(包括Cry-介導之疾病或病症的進展或發展)及治療轉變風險降低率。
在本文所揭示之主題的上下文之〝風險評估〞或〝風險之評估〞包含預測可能發生事件或疾病狀態之概率、勝算或可能性,事件發生或自一種疾病狀態轉變成另一種疾病狀態(亦即自〝正常〞狀況轉變成發展Cry-介導之疾病或病症的處於風險狀況,或自處於風險狀況轉變成Cry-介導之疾病或病症,或發展成復發的疾病或病症)之比率。風險評估亦可包含參考先前所測量之群組的絕對或相對關係預測Cry-介導之疾病或病症的其他指數。本發明方法可用於進行轉變成Cry-介導之疾病或病症的風險之連續或分類測量,因此診斷及定義被確定為處於發展疾病或病症風險的受驗者分類之風險譜。在分類方案中,本發明可用於辨別正常與處於風險之受驗者群體。在其他的具體例中,本發明可因此用於辨別處於風險狀況與疾病狀況之受驗者,或疾病狀況與正常之受驗者。
如本文所使用之〝樣品〞為自受驗者分離之生物樣品,且可包括(以實例說明而非限制)全血、血清、血漿、血細胞、內皮細胞、組織生檢、淋巴液、腹水液、間隙液(亦稱為〝細胞外液〞且包含細胞之間的空間中所見之液體,尤其包括齒齦裂隙液)、骨髓、精液、腦脊髓液(CSF)、唾液、黏液、痰、汗、尿或任何其他分泌液、排泄液或其他體液。
〝統計顯著性〞意謂變化大於可預期單獨由機會所發生之情況(其可為〝偽陽性〞)。統計顯著性可以本技藝中已知的任何方法測定。常使用的顯著性測量值包括p-值,其代表獲得至少與給定之數據點一樣極端的結果之概率,假定數據點為單獨機會的結果。結果通常在p-值為0.05或以下時被視為高顯著性。
Cry-介導之疾病或病症的風險可藉由測量在樣品(例如,取自受驗者之樣品)中之一或多種隱花色素的〝有效量〞及比較有效量與參考值而偵測,常利用數學演算法或公式使得來自多樣個體的結果之資料組合成單一測量值。可隨意地選擇經鑑定為具有Cry-介導之疾病或病症風險增加之受驗者接受治療制度或治療介入,諸如投予作為單一療法的本文定義之式I化合物或與一或多種額外的治療劑組合投予,或實施手術介入(其可在單獨或與額外的治療劑或其他療法組合投予式I化合物之後或之前)。
用於偵測樣品中的該等隱花色素之方法具有許多應用。例如,可測量一或多種隱花色素有助於Cry-介導之疾病或病症的診斷或預後。在另一實例中,用於偵測隱花色素之方法可用於監控在受驗者中對Cry-介導之疾病或病症的反應。在另一實例中,該方法可用於檢定及鑑定在活體內或試管內調節隱花色素表現之化合物。
本發明可用於進行轉變成Cry-介導之疾病或病症的風險之連續或分類測量,因此診斷及定義被確定為處於發展疾病或病症風險的受驗者分類之風險譜。在分類方案中,
本發明方法可用於辨別正常與處於風險之受驗者群體。在其他的具體例中,本發明可因此用於辨別處於風險與疾病之受驗者,或疾病與正常之受驗者。此等不同用途可能需要不同組合的個體小組或輪廓、數學演算法及/或截止點,但是就意欲用途而言接受相同的前述精度測量。
處於風險之受驗者的鑑定能夠選擇及開始各種治療介入或治療制度,以便延遲、降低或防止受驗者轉變成Cry-介導之疾病或病症。隱花色素蛋白質、核酸、多型態、代謝物或其他分析物之有效量值亦供與受監控之治療過程。在此方法中,生物樣品可由接受Cry-介導之疾病或病症之治療制度(例如,治療性治療)的受驗者提供。治療制度可包括但不受限於手術介入及以用在經診斷或鑑定患有Cry-介導之疾病或病症的受驗者之治療劑(例如,本文所述之式I化合物)治療。若有要求,生物樣品係在治療前、期間或後的各種時間點自受驗者獲得。例如,藉由比較受驗者之隱花色素輪廓與參考之隱花色素輪廓來測定疾病狀況可重複一次以上,其中受驗者輪廓可自每次取得的單獨樣品獲得,重複此方法。樣品可在指定的時間間隔自受驗者取得,諸如4小時、8小時、12小時、24小時、48小時、72小時或由那些熟諳本技藝者可執行的任何適合的時間間隔。
受驗者之基因組成差別可導致其代謝可調節Cry-介導之疾病或病症的徵候或風險因子之各種藥物的相對能力之差別。患有Cry-介導之疾病或病症或處於發展Cry-介導
之疾病或病症的風險之受驗者可隨年齡、種族性和其他參數而改變。據此,同時測量單獨及與已知用於藥物代謝的基因因子組合的如本文定義之一或多種隱花色素的有效量給與預定值的可預測性,其在所選擇之受驗者中測試的假定治療或預防劑適合於受驗者中治療或預防Cry-介導之疾病或病症。
為了鑑定適合於特定的受驗者之治療劑或藥物,亦可將來自受驗者之試驗樣品暴露於治療劑或藥物,且可測定隱花色素蛋白質、核酸、多型態、剪接變異體、代謝物或其他分析物中之一或多者之值或活性。亦可測量受影響或與一或多種隱花色素直接或間接結合的其他基因或蛋白質(例如,Per1、Per2、GR、CLOCK-BMAL1啟動子等)。可將一或多種隱花色素值與自處理Cry-介導之疾病或病症的受驗者(例如,治療或暴露於治療劑或藥物)之前及之後的受驗者所導出之樣品比較,或可與自一或多個由於此治療或暴露而顯示風險因子改進的受驗者所導出之樣品比較。
核酸可以熟諳本技藝者已知的許多方式自樣品獲得,例如萃取方法(包括例如溶劑萃取)、親和力純化及離心。選擇性沉澱亦可純化核酸。亦可利用層析術方法,包括凝膠過濾、離子交換、選擇性吸附或親和力結合。核酸可為例如RNA、DNA或可合成為cDNA。核酸可使用本技藝中熟知的微陣列技術偵測,例如Affymetrix陣列及接著以多維尺度技術。參見R.Ekins,R.and Chu,F.w.(1999)Trends Biotechnol.17:217-218;D.D.Shoemaker等人之
(2001)Nature 409(6822):922-927和美國專利案號5,750,015。
若有要求時,可以例如預分級來製備樣品,以提高一或多種隱花色素之可偵測性。預分級方法包括例如Cibacron藍色瓊脂糖層析術、大小排除層析術、離子交換層析術、肝素層析術、凝集素層析術、親和力層析術、單鏈DNA親和力層析術、連續萃取、凝膠電泳和液相層析術。分析物亦可在偵測前修飾。樣品可藉由移除大量存在或可干擾樣品中的關注分子偵測之蛋白質而預分級。例如,在血清樣品中,血清白蛋白係大量存在且可混淆一或多種隱花色素之分析。因此,血清樣品可藉由使用例如受質移除血清白蛋白而預分級,該受質包含特異性地結合血清白蛋白之吸附劑,可使用親和力管柱或抗血清白蛋白抗體。
在其他的具體例中,在樣品中的關注分子可以高解析電泳分離,例如一或二-維凝膠電泳。可將份分離且以氣相離子光譜法進一步分析。較佳地使用二-維凝膠電泳產生點(包括一或多種隱花色素)的二維陣列。參見例如Jungblut and Thiede,(1997)Mass Spectr.Rev.16:145-162。二-維凝膠電泳可使用本技藝中已知的方法執行。參見例如Deutscher ed.,Methods in Enzymology vol.182。樣品典型地可藉由例如等電集聚而分離,在樣品中的一或多種隱花色素在該期間內以pH梯度分離,直到該等隱花色素到達彼之淨電荷為零之點為止(亦即等電點)。此第一
分離步驟導致一維陣列。在一維陣列中的分子係使用通常與第一分離步驟中所使用者不同的技術進一步分離。例如,在第二維中,以等電集聚分離的關注分子係使用聚丙烯醯胺凝膠進一步分離,諸如在十二烷基硫酸鈉存在下的聚丙烯醯胺凝膠電泳(SDS-PAGE)。SDS-PAGE凝膠容許以分子質量為基準進一步分離。二-維凝膠電泳典型地可分離在複雜的混合物中的分子質量範圍從1000-200,000 Da之化學上不同的關注分子。
在二維陣列中的關注分子可使用本技藝中已知的任何適合方法偵測。例如,可標示或染色凝膠中的關注分子(例如,染上Coomassie藍或銀色)。若凝膠電泳產生對應於本發明的一或多種隱花色素之分子量的點時,則可將點切離且以例如氣相離子光譜法、質譜法或高性能液相層析術進一步分析。另一選擇地,含有關注分子的凝膠可藉由施予電場而轉移至惰性薄膜。接著將薄膜上大致對應於關注分子之分子量的點以例如氣相離子光譜法、質譜法或HPLC分析。
可在分析前隨意地修飾關注分子,以改進其解析或測定其本體。例如,樣品可在分析前接受蛋白分解消化。可使用任何蛋白酶。有可能分裂蛋白質成為許多離散片段的蛋白酶(諸如酪胺酸)特別有用。從消化生成之片段可作為關注分子的指紋起作用,因而能間接偵測樣品。此在有關注分子具有可能混淆較佳分子(亦即討論中的隱花色素)之類似的分子質量時特別有用。蛋白分解碎斷亦有用於高分
子量分子,因為較小的分子更容易以質譜法解析。在另一實例中,分子可經修飾以改進偵測解析度。例如,可使用神經胺酶(neuraminidase)從糖蛋白移除末端唾液酸殘基,以改進與陰離子吸附劑(例如,陽離子交換陣列)的結合及改進偵測解析度。在另一實例中,分子可藉由附著與另一分子實體特異性地結合的特定分子量標籤及進一步區分該等分子而予以修飾。在偵測此等經修飾的關注分子之後,分子本體可隨意地藉由配對蛋白質數據庫(例如,SwissProt)中的經修飾之變體的物理和化學特性而進一步測定。
一經補獲在受質(例如,生物晶片或抗體)上時,可使用任何適合的方法(諸如那些本文所述之方法)以及本技藝中已知的其他方法測量在樣品中的一或多種隱花色素。此等分子的實際測量值或量可使用本技藝中已知的任何方法測定。該等方法包括而不限於質譜法(例如,雷射脫附/電離質譜法)、螢光(例如,夾心(sandwich)免疫檢定法)、表面電漿子共振(surface plasmon resonance)、橢圓光度法和原子力顯微鏡法。該方法可另外包括下列中之一或多者:微陣列、PCR方法、質譜法(包括例如且不限於ESI-MS、ESI-MS/MS、ESI-MS/(MS)n、基質輔助之雷射脫附電離飛行時間(matrix-assisted laser desorption ionization time-of-flight)質譜法(MALDI-TOF-MS)、表面增強之雷射脫附/電離飛行時間(surface-enhanced laser desorption/ionization time-of-flight)質譜法(SELDI-TOF-MS)、矽上脫附/電離法
(desorption/ionization on silicon)(DIOS)、次級離子質譜法(SIMS)、四極桿-飛行時間(quadrupole time-of-flight)(Q-TOF)、大氣壓化學電離質譜法(APCI-MS)、APCI-MS/MS、APCI-(MS)n、大氣壓光致電離(atmospheric pressure photoionization)質譜法(APPI-MS)、APPI-MS/MS和APPI-(MS)n、四極桿質譜法、傅里葉變換(Fourier transform)質譜法(FTMS)和離子陷質譜法)、核酸晶片、北方墨點雜交(Northern blot hybridization)、TMA、SDA、NASBA、PCR、即時PCR、逆轉錄酶PCR、即時逆轉錄酶PCR、原位PCR、與質譜法結合的層析分離、使用固定抗體之蛋白質捕獲或傳統的免疫檢定法。參見例如美國專利案號5,723,591、5,801,155和6,084,102及Higuchi,1992和1993。PCR檢定法可在例如多槽孔盤格式或晶片中進行,諸如BioTrove OPEN ARRAY晶片(BioTrove,Woburn,MA)。
例如,在對應於隱花色素之序列數據庫登錄內的序列可用於建構在例如北方墨點雜交分析或特別且較佳地定量擴增特異性核酸序列之方法中用於偵測RNA序列之探針。下列者作為另一實例:序列可用於建構引子,其特異性地或選擇性地與隱花色素序列雜交且用於在例如以擴增為基準之偵測方法(諸如以逆轉錄為基準之聚合酶鏈反應(RT-PCR),例如定量性即時RT-PCR)中擴增此等序列。當基因表現的改變與基因擴增、缺失、多晶型和突變相關聯時,則在試驗與參考群組中的序列比較係藉由比較在受驗
者與參考細胞群組中的經檢查之DNA序列的相對量來進行。當述及核酸時,則如本文所使用之術語〝特異性地(或選擇性地)雜交〞係指決定核酸存在於異質核酸群組中的結合反應。因此,在指定的檢定條件下,特定的核酸探針(包括抑制性核酸)可與特別的關注核酸結合或雜交至少兩倍於背景值且實質上不以大量與樣品中存在的其他核酸結合或雜交。
隱花色素值亦可以免疫檢定法測定。抗體可為如本文詳細討論的前述者之單株、多株、嵌合或片段,且偵測反應產物的步驟可以任何適合的免疫檢定法進行。當述及蛋白質或肽時,則詞組與抗體〝特異性地(或選擇性地)結合〞或〝特異性(或選擇性)免疫反應〞係指決定蛋白質存在於異質蛋白質群組中的結合反應。因此,在指定的免疫檢定條件下,特定的抗體與特別的蛋白質結合至少兩倍於背景值且實質上不以大量與樣品中存在的其他蛋白質結合。在此等條件下與抗體的特異性結合可能需要選擇對特別的蛋白質具有特異性之抗體。例如,可選擇對來自特定物種(諸如大鼠、小鼠或人類)之隱花色素產生的多株抗體,僅獲得與隱花色素而不與除了隱花色素之多晶型變體和對偶基因以外的其他蛋白質具有特異性免疫反應的那些多株抗體。此選擇可藉由除去與來自其他物種之隱花色素交叉反應的抗體來達成。
依照本發明進行的免疫檢定法可為均質性檢定法或異質性檢定法。在均質性檢定法中,免疫反應通常包含特異
性抗體(例如,抗-隱花色素蛋白質抗體)、標記之分析物及關注的樣品。在抗體與標記之分析物結合時,可直接或間接修飾自標記產生之訊號。免疫反應或其反應程度的偵測二者可在均質性溶液中進行。可使用之免疫化學標記包括自由基、放射性同位素、螢光染料、酵素、噬菌體或輔酵素。
在異質性檢定法中,試劑通常為樣品、抗體及產生可偵測訊號之方式。可使用如上述之樣品。可將抗體固定在支撐物(諸如珠,諸如蛋白質A和蛋白質G瓊脂糖珠)、板或載玻片上,且與懷疑含有抗原之樣本於液相中接觸。接著將支撐物從液相分離,且使用產生可偵測訊號之方式檢查支撐物相或液相的此可偵測訊號。訊號與樣品中存在的分析物有關。用於產生可偵測訊號之方式包括使用可偵測標記。例示之可偵測標記包括磁珠(例如,DYNABEADSTM)、螢光染料、酵素(例如,馬辣根過氧化物(horse radish peroxide)、鹼性磷酸酶和ELISA中常使用的其他酵素)、放射性標記(例如,35S、125I、131I)和螢光標記(例如,螢光素、Alexa、綠螢光蛋白質、玫瑰紅),及依照已知技術的比色標記(諸如膠體金或有色玻璃或塑膠珠)。
另一選擇地,在樣品中的關注分子可使用間接檢定法偵測,其中例如使用第二標記之抗體偵測經結合之隱花色素-特異性抗體,及/或在競爭或抑制檢定法中偵測,其中例如將與隱花色素獨特的抗原決定區結合之單株抗體同時
以混合物培育。例如,若欲偵測之抗原含有第二結合位置,則與該位置結合之抗體可與可偵測基團共軛且在分離步驟之前添加至液相反應溶液中。在固體支撐物上存在的可偵測標記表明抗原存在於試驗樣品中。測量抗體-抗原複合物的量或存在之方法包括例如偵測螢光、發光、化學發光、吸收、反射率、透光率、雙折射率或折射率(例如,表面電漿子共振、橢圓光度法、共振反射鏡法、光柵耦合波導法或干涉量度法)。光學方法包括顯微鏡(共焦和非共焦二者)、影像法和非影像法。電化學方法包括電位測定法和電流測定法。無線電頻率方法包括多極共振光譜法。適合的免疫檢定法之實例包括但不受限於免疫墨點法(例如,西方墨點法、狹縫墨點檢定法)、免疫沈澱法、免疫螢光法、化學發光法、電化學發光(ECL)或酵素連結之免疫檢定法(例如,酵素連結之免疫吸附檢定法(ELISA)和放射免疫檢定法(RIA))。通常參見E.Maggio,Enzyme-Immunoassay,(1980)(CRC Press,Inc.,Boca Raton,Fla.);亦參見美國專利案號4,727,022、4,659,678、4,376,110、4,275,149、4,233,402和4,230,767。該等方法亦說明於例如Methods in Cell Biology:Antibodies in Cell Biology,volume 37(Asai,ed.1993);Basic and Clinical Immunology(Stites & Terr,eds.,7th ed.1991);和Harlow & Lane之前述參考中。將所有該等併入以供參考。
免疫檢定法可用於測定一或多種隱花色素存在或不存在於樣品中以及在樣品中的數量。抗體-標識複合物的量
可藉由與標準物比較來測定。標準物可為例如已知的化合物或樣品中存在的另一已知的蛋白質。如上文所述,不需要以絕對單位測量一或多種隱花色素的試驗量,只要測量單位可與對照組比較即可。
蛋白質常存在於以可偵測之不同質量為特徵的複數種不同形式之樣品中。該等形式可源自於轉譯前和轉譯後修飾之任一者或二者。經轉譯前修飾之形式包括對偶基因變體、切片變體和RNA編輯形式。經轉譯後修飾之形式包括源自於蛋白分解裂解(例如,母體蛋白質之片段)、糖化、磷酸化、脂質化、氧化、甲基化、胱胺酸化、磺酸化和乙醯化之形式。抗體亦可用於偵測蛋白質、多肽、突變和多晶型之轉譯後修飾,諸如酪胺酸磷酸化、蘇胺酸磷酸化、絲胺酸磷酸化、糖化(例如,O-GlcNAc)。該等抗體特別偵測關注之蛋白質或蛋白質類中的磷酸化胺基酸,且可用於本文所述之免疫墨點、免疫螢光及ELISA檢定法中。該等抗體為那些熟諳本技藝者所熟知且可於市場上取得。轉譯後修飾亦可使用在反射器基質輔助之雷射脫附電離飛行時間質譜法(MALDI-TOF)中的介穩態離子測定(Wirth,U.等人之(2002)Proteomics 2(10):1445-51)。包括特異性蛋白質及其所有經修飾形式之蛋白質的聚集在本文稱為〝蛋白質叢〞。包括特異性蛋白質本身的特異性蛋白質之所有經修飾形式的聚集在本文稱為〝經修飾之蛋白質叢〞。任何隱花色素的經修飾形式本身亦可用於本文所揭示之方法中。在特定的情況中,經修飾形式可展現比本文
提出之特定形式更好的診斷識別能力。經修飾形式可以本技藝中已知的任何方法開始偵測。
另一選擇地,可測量隱花色素蛋白質和核酸代謝物。術語〝代謝物〞包括代謝過程的任何化學或生化產物,諸如以生物分子(例如,蛋白質、核酸、碳水化合物或脂質)處理、裂解或消耗所產生之任何化合物。代謝物可以熟諳本技藝者已知的各種方式偵測,包括折射率光譜法(RI)、紫外線光譜法(UV)、螢光分析、放射性化學分析、近紅外線光譜法(近-IR)、核磁共振光譜法(NMR)、光散射分析(LS)、質譜法、熱解質譜法、散射測濁法、分散拉曼(Raman)光譜法、與質譜法組合的氣相層析術、可與質譜法組合的液相層析術(包括高性能液相層析術(HPLC))、與質譜法組合的基質輔助之雷射脫附電離飛行時間(MALDI-TOF)、與質譜法組合的離子噴霧光譜法、毛細管電泳、離子移動光譜法、表面增強之雷射脫附/電離法(SELDI)、光學方法、電化學方法、原子力顯微鏡法、無線電頻率方法、表面電漿子共振、橢圓光度法、NMR和IR偵測。(參見國際申請發表案WO 04/056456和WO 04/088309,將各者以其全文特此併入以供參考)。關於此點,其他的分析物可使用上述偵測方法或熟諳之技術人員已知的其他方法測量。例如,尤其可使用螢光染料偵測樣品中的循環鈣離子(Ca2+),諸如Fluo系列、Fura-2A、Rhod-2。其他的代謝物可以類似方式使用經特定設計或定製以偵測此等代謝物之試劑偵測。
Cry-介導之疾病或病症可包含一或多種隱花色素的活性改變或一或多種隱花色素與標靶結合的能力。不想受到理論的限制,咸信隱花色素蛋白質與週期蛋白質Per 1及/或Per2結合成雜二聚物,其接著與CLOCK-BMAL1基因之啟動子區域結合,以促進反饋迴路中的轉錄壓制,其可與數種代謝過程衝突。因此,根據本發明方法測量一或多種隱花色素之有效量可包含評定Cry蛋白質與Per1及/或Per2、糖皮質素受體(GR)或那些熟諳本技藝者已知的Cry之其他結合標靶結合的能力增加或降低。可以本技藝中已知的任何方法方便測量蛋白質-蛋白質交互作用,包括共同免疫沉澱技術、酵母雙雜交檢定法、表面電漿子共振、雙分子螢光互補作用、串聯親和力純化法、噬菌體展現法、螢光偏振/各向異性、雙偏振干涉量度法、螢光相關光譜法、螢光共振能量轉移及類似者。
一或多種隱花色素的活性亦可藉由與DNA序列(亦即CLOCK-BMAL1基因或含有以一或多種隱花色素識別之結合位置的其他基因之啟動子區域)結合的能力增加或降低來測量。〝啟動子〞、〝啟動子序列〞或〝啟動子區域〞係指能夠結合細胞中的RNA聚合酶,開始轉錄下游(3’方向)編碼序列之DNA序列,由此控制其表現。以定義本發明為目的,啟動子序列係在3’端上以轉譯開始位置為界且向上游延展伸(5’方向),以包括在大於背景的可偵測值開始轉錄所必要之最少數目的鹼基或成分。在啟動子序列內發現負責RNA聚合酶結合之轉錄開始位置(藉由例如以核
酸酶S1映射而合宜地界定)以及蛋白質結合域(一致序列)。啟動子全部可衍生自天然基因或由自然界發現的不同啟動子所衍生之不同成分所組成,或甚至包含合成DNA片段。在大部分的情況中,調控序列的真實邊界尚未完全界定,不同長度的DNA片段可能具有相同的啟動子活性。
CLOCK-BMAL1啟動子(或含有Cry之結合或識別位置的任何其他啟動子區域)〝可操作地連結〞至報導子基因。術語〝可操作地連結〞係指核酸序列締合在單一核酸片段上,使得其中一者的功能受另一者影響。例如,當啟動子能夠影響編碼序列的表現時(亦即編碼序列係在啟動子之轉錄控制下),該啟動子可操作地連結該編碼序列。編碼序列係以正義或反義定向可操作地連結至調控序列。術語〝報導子基因〞意謂編碼能夠基於報導子基因的效應而經鑑定之鑑定因子的核酸,其中使用該效應追蹤關注核酸的遺傳性、鑑定遺傳關注核酸的細胞或有機體及/或測量基因表現誘發或轉錄。在本技藝中已知且使用之報導子基因的實例包括:螢光素酶(Luc)、綠螢光蛋白質(GFP)、鹼性磷酸酶(ALP)、氯黴素乙醯轉移酶(CAT)、β-半乳糖苷酶(LacZ)、β-葡糖醛酸糖苷酶(Gus)及類似者。可選擇之標識基因亦被認為是報導子基因。啟動子-報導子基因結構可包含在轉移或轉染至細胞中的質體或表現載體中。報導子基因的表現可藉由測定基因產物的活性(例如,在使用上文例示之報導子基因的例子中之酵素活性)來偵測。
術語〝質體〞係指常帶有不為細胞中心代謝的一部分之基因且通常呈環狀雙股DNA分子形式的額外染色體成分。此等成分可為單-或雙-股DNA或RNA之線性、環狀或超螺旋的自主複製序列、基因組整合序列、噬菌體或核苷酸序列,其可衍生自任何來源,其中一些核苷酸序列已接合或重組成獨特的結構,其能夠將經選擇之基因產物的啟動子片段和DNA序列與適當的3'未轉譯序列一起引入細胞中。術語〝表現載體〞意謂經設計在轉變至宿主之後能夠表現插入之核酸序列之載體、質體或媒劑。載體可以本技藝中已知的方法引入所欲宿主細胞中,例如轉染、電穿孔、微注射、轉導、細胞融合、DEAE葡聚糖、磷酸鈣沉澱、脂質體轉染(溶酶體融合)、使用基因槍或DNA載體轉運蛋白。可使用任何細胞進行報導子檢定法,諸如原核生物細胞或真核細胞。細胞較佳地可為細菌細胞、真菌細胞、酵母細胞、線蟲細胞、昆蟲細胞、魚細胞、植物細胞、禽細胞、動物細胞和哺乳類細胞。細胞可為原代細胞或可以連續傳代的細胞系。例示性細胞和細胞系為那些熟諳本技者所知。
測量一或多種隱花色素與DNA序列結合的活性或能力之其他方法包括染色質免疫沉澱檢定法、電泳遷移率變動檢定法、DNA下拉(pull-down)檢定法、微量盤捕獲和偵測及類似者。
接著可測定隱花色素蛋白質、核酸、多晶型、代謝物或其他分析物之有效量值,或隱花色素蛋白質或直接或間
接與隱花色素蛋白質結合的標靶之活性,且與參考值比較,例如對照組受驗者或已知疾病狀況之群組,或指數值或基準值。參考樣品或指數值或基準值可自一或多位已暴露於治療之受驗者取得或導出,或可自一或多位處於發展Cry-介導之疾病或病症的低風險之受驗者取得或導出,或可自由於暴露於治療而顯示疾病風險因子改進之受驗者取得或導出。另一選擇地,參考樣品或指數值或基準值可自一或多位未暴露於治療之受驗者取得或導出。例如,樣品可自接受Cry-介導之疾病或病症的初步治療及監控治療進展之疾病或病症的後續治療之受驗者收集。在一些具體例中,第一樣品可自第一時期之受驗者取得,例如在以單獨或與一或多種額外的治療劑組合的如本文定義之式I化合物治療之前,接著測量或偵測如本文所述之一或多種隱花色素(或隱花色素標靶)。隨後,第二樣品可自第二時期之受驗者取得,例如在以單獨或與一或多種額外的治療劑組合的如本文定義之式I化合物治療之後,及測量一或多種隱花色素或隱花色素標靶。可在整個治療過程期間的任何時間間隔取得任何數目的樣品,以評定其有效性。
參考值亦可包含自諸如那些本文所揭示之群組研究的風險預測演算法或經計算之指數導出之值。在本上下文中的相似術語為〝對照〞,其可為正常受驗者或沒有疾病的受驗者(諸如不可偵測出Cry-介導之疾病或病症)中之正常受驗者的可比較樣品中存在的隱花色素之平均或中間量。對照量係在與測量試驗量相同或實質上相似的實驗條件下
測量。關聯性可考慮在試驗樣品中存在或不存在的隱花色素及在對照組中的相同分子之偵測頻率。關聯性可同時考慮此等因素以幫助疾病狀況的測定。
不患有Cry-介導之疾病或病症及可能不預期發展Cry-介導之疾病或病症的那些受驗者的參考輪廓亦可根據本文所揭示之方法製備。一或多種隱花色素的測量亦可用於產生自患有Cry-介導之疾病或病症的受驗者取得之〝受驗者輪廓〞。可將受驗者輪廓與參考輪廓比較,以診斷或鑑定處於發展Cry-介導之疾病或病症的風險之受驗者,監控疾病的進展以及疾病進展速率,及監控治療方式或病患處理的有效性。
可將本發明的參考和受驗者輪廓納入機器可讀取媒體中,諸如但不受限於類比或數位磁帶,尤其如那些以VCR、CD-ROM、DVD-ROM、USB快閃媒體可讀取之磁帶。此等機器可讀取媒體亦可含有額外的試驗結果,諸如而不限於臨床參數及傳統的實驗室風險因子之測量。另一選擇地或另外,機器可讀取媒體亦可包含受驗者資訊,諸如醫學病史和任何相關的家族病史。機器可讀取媒體亦可含有與其他風險演算法及經計算之指數(諸如那些本文所述者)有關的資訊。
在本文所揭示之方法的任一者中,來自樣品的數據可從偵測裝置直接提供至含有診斷演算法之電腦中。另一選擇地,所獲得的數據可以人工或經由自動化裝置提供至含有診斷演算法的個別電腦中。據此,本發明的具體例包括
涉及使隱花色素的偵測與Cry-介導之疾病或病症的可能診斷互相關聯之方法。關聯性可考慮在樣品中與對照量(例如,在未偵測出Cry-介導之疾病或病症的正常受驗者中)相比的一或多種隱花色素之量(向上或向下調控隱花色素)。關聯性可考慮在試驗樣品中存在或不存在的隱花色素及在對照組中的相同分子之偵測頻率。關聯性可同時考慮此等因素以幫助測定受驗者是否患有Cry-介導之疾病或病症。
數據分析可包括測定所偵測之標識的訊號強度(例如,波峰高度)及移除〝離群值〞(偏離預定統計分佈之數據)的步驟。可將觀測之波峰標準化,此為由此計算相對於一些參考值的各波峰高度之方法。例如,參考值可為以儀器及化學物質(例如,能量吸收分子)所產生的背景雜訊,將其標度設定為零。可將對各關注分子所偵測之訊號強度以所欲標度的相對強度形式(例如,100)顯現。另一選擇地,標準物(例如,血清蛋白質)可與樣品一起引入,使得標準物之波峰可用作為參考值,以計算從所偵測之各關注分子觀測的訊號之相對強度。
所得數據可轉變或轉換成各種顯現用格式。在一種稱為〝光譜視圖或滯留圖(retentate map)〞之格式中,可顯現標準的光譜視圖,其中該視圖描述在各特定分子量下到達偵測器之分子數量。在稱為〝波峰圖〞的另一格式中,僅從光譜視圖保留波峰高度和質量資訊,得到更勻稱的影像及能更輕易地察看具有分子量幾乎相同的關注分子。在
稱為〝凝膠視圖(gel view)〞的又另一格式中,可將來自波峰視圖的各質量轉換成以各波峰高度為基準之灰階影像,得到類似於電泳凝膠上的譜帶之外觀。在稱為〝3-D重疊圖〞的又另一格式中,可將數個光譜重疊以研究相對波峰高度的微妙變化。在稱為〝差異圖視圖(difference map view)〞的又另一格式中,可比較二或多個光譜,合宜地突顯在樣品之間向上-或向下-調控之獨特的關注分子。可以視覺比較來自任何兩種樣品的輪廓(光譜)。在可使用Spotfire Scatter圖的又另一格式中,其中將偵測之關注分子以點繪製在圖中,其中圖的一個軸代表所偵測之隱花色素的視分子量及另一個軸代表所偵測之隱花色素的訊號強度。就各樣品而言,可將偵測之關注分子及存在於樣品中的分子量儲存於電腦可讀取媒體中。接著將此數據與對照或參考輪廓或參考值(例如,在對照組(例如,在未偵測出Cry-介導之疾病或病症的受驗者)中所偵測之分子輪廓或數量)比較。
在本文所揭示之方法中所產生之數據可使用利用分類模式的圖案識別方法分類。在一些具體例中,使用樣品(諸如〝已知樣品〞)所產生的數據接著可用於〝培植(train)〞分類模式。〝已知樣品〞為預分類之樣品(例如,疾病或沒有病)。使用已知樣品所產生之數據接著可用於〝培植〞分類模式。〝已知樣品〞為預分類之樣品。可用於形成分類模式之數據可稱為〝培植數據組〞。一經培植時,分類模式可識別在使用未知樣品所產生之數據的圖
案。接著可使用分類模式分類未知樣品。此可用於例如預測特定的生物樣品是否與特定的生物狀況有關聯(例如,生病相對於沒有生病)。用於形成分類模式的培植數據組可包含原始數據或預處理之數據。在一些具體例中,原始數據可自飛行時間光譜或質譜獲得,且接著可以任何適合的方式隨意地〝預處理〞。預處理步驟(諸如該等上述者)可用於減少用以培植分類模式之數據量。
分類模式可使用任何適合的統計分類(或〝學習(learning))〞方法形成,該方法嘗試將大量數據以數據中存在的客觀參數為基準分出類別。分類方法可為督導式或未督導式分類。督導式或非督導式分類法的實例說明於Jain,“Statistical Pattern Recognition:A Review”,IEEE Transactions on Pattern Analysis and Machine Intelligence,Vol.22,No.1,January 2000中,將其全文併入本文以供參考。在督導式分類中,含有已知種類的實例之培植數據提交至學習機制,其學習用以界定各個已知分類的多組關係。接著可將新數據應用至學習機制,其接著使用習得之關係分類新數據。
督導式分類法的實例包括線性回歸法(例如,多重線性回歸(MLR)、偏最小平方(PLS)回歸和主成分回歸(PCR))、二進制決策樹(例如,遞歸分割法,諸如CART-分類和回歸樹)、類神經網路,諸如倒傳遞網路(back propagation networks)、判別分析(例如,貝氏(Bayesian)分類器或費雪(Fischer)分析)、邏輯分類器及支撐向量分類
器(support vector classifiers)(支撐向量機)。較佳的督導式分類法為遞歸分割法(美國專利申請發表案號20020138208)。非督導式分類嘗試以培植數據組中的相似性為基準學習分類,而不預分類導出培植數據組的光譜。非督導式學習方法包括群集(cluster)分析。群集分析嘗試將數據分成〝群集〞或組別,理論上其具有的成員應該彼此非常相似及與其他群集之成員不相似。於是使用一些距離度量測量相似性,其測量數據項目之間的距離且將彼此更接近的數據項目群集在一起。群集技術包括MacQueen氏K-平均演算法及Kohonen氏自我組織圖(Self-Organizing Map)演算法。宣稱用於分類生物資訊的學習演算法說明於例如國際申請發表案號WO 01/31580及美國專利申請發表案號20020193950、20030004402和20030055615中。另一分類法包含使用非線性版本的統一化最大可分性分析(Unified Maximum Separability Analysis)(〝USMA〞)分類器之多變量預測模式。USMA分類器的細節說明於美國專利申請發表案號20030055615中。
其他的分類演算法及公式尤其包括但不受限於主成分分析(PCA)、交叉關聯性、因子旋轉、邏輯回歸(LogReg)、線性判別分析(LDA)、特徵基因線性判別分析(Eigengene Linear Discriminant Analysis)(ELDA)、隨機森林法(RF)、遞歸分割樹(RPART)以及其他相關的決策樹分類技術、縮小重心(Shrunken Centroids)(SC)、StepAIC、
Kth-最近相鄰(Kth-Nearest Neighbor)、加強(Boosting)、決策樹、神經網路、貝氏網路、支撐向量機、留一法(Leave-One-Out)(LOO)、10倍交叉驗證法(10-Fold CV)和隱式馬爾可夫模式(Hidden Markov Models)。
一或多種隱花色素的偵測及關聯性亦可使用任何適合的方式分析,包括套裝軟體,例如Applied Maths、GenExploreTM、2-向群集分析、主成分分析、判別分析、自我組織圖;BioDiscovery,Inc.,Los Angeles,California(ImaGeneTM,以MatLab®為動力之特殊影像處理和數據擷取軟體;GeneSight:階層式群集(hierarchical clustering)、類神經網路(SOM)、主成分分析、時間序(time series);AutoGeneTM;CloneTrackerTM);GeneData AG(Basel,Switzerland);在MIT’s Whitehead Genome Center之分子圖案識別網址;Rosetta Inpharmatics,Kirkland,Washington.ResolverTM表現數據分析系統(Expression Data Analysis System);Scanalytics,Inc.,Fairfax,VA.。其微陣列系列能使研究員獲取、視覺化、處理且分析基因表現微陣列數據;TIGR(基因組研究機構(The Institute for Genome Research))提供陣列分析的軟體工具。例如,亦參見Eisen and Brown,(1999)Methods Enzymol.303:179-205。
在認定疾病狀況之方法的特定具體例中,該方法進一步包含以疾病或病症狀況為基準處理或修改受驗者的臨床治療。例如,若本發明方法的結果不具決定性或有必要確
認狀況的理由時,則醫生可安排更多試驗(例如,CT掃描、PET掃描、MRI掃描、PET-CT掃描、X-射線、組織生檢、血液試驗)。另一選擇地,若狀況表明治療是適當的,則醫生可列出治療受驗者的計劃。在其他事例中,受驗者可接受代替或除了手術以外的治療性治療(諸如投予治療劑,諸如單獨或與一或多種額外的治療劑組合的本文定義之式I化合物)。不可能擔保進一步的作用。而且,若結果顯示已為成功的治療,則維持治療或不進一步處理可為必要的。
本文所揭示之主題亦提供在受驗者的臨床治療之後再測量隱花色素的此等方法。在該等例子中,使用該等方法監控Cry-介導之疾病或病症狀況,例如對治療的反應、疾病的緩解或疾病的進展。該等方法可在受驗者接受每次治療之後重複,容許醫生追蹤治療過程的有效性。若結果顯示治療沒效,則可據此改變治療過程。
本發明提供認定疾病狀況及/或偵測或診斷疾病之套組,其中套組可用於偵測一或多種隱花色素。例如,套組可用於偵測本文所述的隱花色素中之任一者或多者,一或多種隱花色素係差別地存在於疾病受驗者或正常受驗者之樣品中。本發明套組具有許多應用。例如,套組可用在本文所述的本發明方法中之任一者中,諸如尤其用於區分受驗者是否患有Cry-介導之疾病或病症或具有否定的診斷,因此有助於診斷。在另一實例中,可使用套組鑑定用以調節一或多種隱花色素表現的化合物,調節一或多種隱花色
素活性(亦即影響一或多種隱花色素與標靶(諸如Per1、Per2、糖皮質素受體(GR)或以隱花色素識別之啟動子序列,諸如CLOCK-BMAL1啟動子或任何其他的啟動子序列)結合之能力)的化合物,該鑑定係使用Cry-介導之疾病或病症的試管內或活體內動物模式。在另一實例中,可使用套組鑑定如本文所定義之一或多種隱花色素蛋白質的結合標靶。
本發明套組可包括偵測試劑,例如以同源核酸序列(諸如與核酸的一部分互補之寡核苷酸序列、引子或適體)特異性地鑑定一或多種隱花色素核酸之核酸,或以一起封裝的核酸編碼之蛋白質的抗體。寡核苷酸可為基因之片段。寡核苷酸可為單股或雙股。例如,寡核苷酸長度可為200個、150個、100個、50個、25個、10個或更少的核苷酸。另一選擇地,偵測試劑可為與一或多種隱花色素蛋白質或其標靶特異性地或選擇性地結合的一或多種抗體。套組可含有在單獨容器中的核酸或抗體(已與固體基質結合或與使彼等與基質結合之試劑單獨封裝)、對照調配物(陽性及/或陰性)及/或可偵測之標記(尤其諸如螢光素、綠螢光蛋白質、玫瑰紅、花青染料、Alexa染料、螢光素酶、放射性標記)。用於進行檢定及與疾病狀況的關聯性之說明書可包括在套組中(例如,書面形式、卡帶、VCR、CD-ROM等)。
例如,可將偵測試劑固定在固體基質(諸如多孔條帶)上以形成至少一個偵測位置。多孔條帶的測量或偵測區域
可包括複數個含有核酸之位置。試驗條帶亦可含有用於陰性及/或陽性對照組之位置。另一選擇地,對照位置可位於與試驗條帶不同的條帶上。不同的偵測位置可隨意地含有不同的固定核酸量,例如在第一偵測位置上的量較高及在隨後位置上的量較低。在添加試驗樣品時,顯現可偵測訊號之位置的數目提供在樣品中存在的隱花色素量之數量指示。偵測位置可呈任何適合的可偵測形狀配置且典型地呈跨越試驗條帶寬度的棒或點形狀。受質陣列可在例如固體基質上,例如在美國專利案號5,744,305中所述之〝晶片〞。另一選擇地,受質陣列可為溶液陣列,例如xMAP(Luminex,Austin,TX)、Cyvera(Illumina,San Diego,CA)、CellCard(Vitra Bioscience,Mountain View,CA)和Quantum Dots’Mosaic(Invitrogen,Carlsbad,CA)。套組亦可含有用於擴增或分離樣品DNA之試劑及/或酵素。套組可包括用於即時PCR之試劑(例如,TaqMan探針及/或引子)及酵素。
在一些具體例中,套組包含:(a)受質,在其上包含吸附劑,其中吸附劑包留或以另外方式適合於結合隱花色素,及(b)藉由將樣品與吸附劑接觸及偵測由吸附劑保留之隱花色素來偵測隱花色素的說明書。在一些具體例中,套組可包含溶析劑(作為替代物或與說明書組合)或製造溶析劑的說明書,其中吸附劑與溶析劑的組合容許使用氣相離子光譜法偵測隱花色素。
在其他的具體例中,套組可包含第一受質,在其上包
含吸附劑(例如,具有吸附劑功能之粒子),及第二受質,在其上可安置第一受質以形成探針,該探針可移出及插入機器中,諸如氣相離子光譜計。在其他的具體例中,套組可包含單一受質,其呈具有吸附劑在受質上的探針形式,該探針可移出及插入機器中。在又另一具體例中,套組可另外包含預分級離心管(例如,Cibacron藍色瓊脂糖管柱、抗-HSA瓊脂糖管柱、K-30大小排除管柱、Q-陰離子離心管柱、單股DNA管柱、凝集素管柱等)。在另一具體例中,套組包含(a)與一或多種隱花色素特異性地結合之抗體;及(b)偵測試劑。抗體可為例如針對隱花色素基因之基因產物的抗體。
套組可隨意地另外包含標準或對照資訊,使得試驗樣品可與對照資訊標準比較,以測定樣品中所偵測之一或多種隱花色素的試驗量是否為與診斷Cry-介導之疾病或病症一致的診斷量。
雖然已於上文詳細說明一些變化,但是其他的修改或添加是可行的。特別可提供除了那些本文所提出者以外的進一步特色及/或變化。例如,上文所述之實施可引導出所揭示之特色的各種組合和子組合及/或上文所揭示之許多進一步特色的組合和子組合。另外,本文所述之邏輯流程不需要特定的所示順序或相繼順序來達成所欲結果。其他的具體例可在申請專利的範圍內。
以下的反應流程:反應流程I、II和III描述式I化合物之合成方法。在製備式I化合物之通用方法中,變數R1、R2、R3、R4、R5、R6、R7、a和b係如先前以式I化合物所定義,除非另有其他陳述。本文所述之反應流程意欲提供在許多提出之實例的製備作用中所使用之方法的一般說明。然而,從實驗章節所提出之詳細說明顯見所使用之製備模式更進一步延伸本文所述之一般程序。特別注意根據流程所製備之化合物可進一步修改,以提供在本發明範圍內的新實例。在以下實例中所使用之試劑和中間物係自市場上取得或可由那些熟諳有機合成技藝者根據標準的文獻程序製備。
以下的反應流程I描述式I化合物之合成法。在適當的溶劑中(諸如N,N-二甲基甲醯胺或N,N-二甲基乙醯胺),在約0℃至150℃之溫度範圍內以適當的式VII之咔唑經約5分鐘至24小時期間處理經適當取代之式VI之溴化物衍生物,以提供對應的式V之環氧乙烷化合物。以式VI之溴化物衍生物與式VII之咔唑反應來提供式V化合物的較佳條件包括在N,N-二甲基甲醯胺中,在0℃至室溫下,在氫氧化鉀的存在下進行20至24小時反應,接著進行萃取整理。在適當的溶劑中(諸如乙醇),在約室溫至150℃之溫度範圍內以適當的式IV之胺經約5分鐘至24小時期間處理式V化合物,以提供對應的式III之胺基醇
化合物。以式V之環氧乙烷化合物反應來提供式III化合物的較佳條件包括在乙醇中,在40℃下進行20至24小時反應,接著進行萃取整理。另一選擇地,式V之環氧乙烷化合物可與式IV之胺在適當的溶劑中(諸如乙醇),在微波照射下反應,以提供式III化合物。在適當的溶劑中(諸如二氯甲烷),在0℃至150℃之溫度範圍內以適當的式II之磺醯氯經約5分鐘至24小時期間處理式III化合物,以提供對應的式I之磺醯胺化合物。以式III之胺基醇化合物與式II之磺醯氯反應來提供式I化合物的較佳條件包括在二氯甲烷中,在0℃至室溫下,在三乙胺或吡啶的存在下進行1至24小時反應,接著進行萃取整理。
以下的反應流程II描述式I化合物之替代合成法。在適當的溶劑中(諸如N,N-二甲基甲醯胺或N,N-二甲基乙
醯胺),在0℃至150℃之溫度範圍內以適當的式VIII之磺醯胺經約5分鐘至24小時期間處理經適當取代之式V之環氧乙烷衍生物,以提供對應的式I之磺醯胺化合物。以式V之環氧乙烷化合物與式VIII之磺醯胺反應來提供式I化合物的較佳條件包括在N,N-二甲基甲醯胺中,在室溫至70℃下,在氫化鈉的存在下進行20至24小時反應。另一選擇地,式V之環氧乙烷化合物可與式VIII之磺醯胺在適當的溶劑中(諸如N,N-二甲基乙醯胺),在100℃下,在碳酸銫的存在下反應20至24小時。
以下的反應流程III描述式I化合物之替代合成法。在適當的溶劑中(諸如二氯甲烷),在0℃至150℃之溫度範圍內以適當的式II之磺醯氯經約5分鐘至24小時期間處理式IV之胺化合物,以提供對應的式VIII之磺醯胺化合物。以式IV之胺化合物與式II之磺醯氯反應來提供式VIII化合物的較佳條件包括在二氯甲烷中,在0℃至室溫下,在三乙胺或吡啶的存在下進行1至24小時反應,接著進行萃取整理。在適當的溶劑中(諸如N,N-二甲基甲醯胺或N,N-二甲基乙醯胺),在0℃至150℃之溫度範圍內以
適當的式X之溴化物經約5分鐘至24小時期間處理式VIII化合物,以提供對應的式IX之環氧乙烷化合物。以式VIII之磺醯胺化合物與式X之溴化物反應來提供式IX化合物的較佳條件包括在N,N-二甲基甲醯胺中,在室溫至70℃下,在氫化鈉的存在下進行20至24小時反應。在適當的溶劑中(諸如N,N-二甲基甲醯胺或N,N-二甲基乙醯胺),在0℃至150℃之溫度範圍內以適當的式VII之咔唑經約5分鐘至24小時期間處理式IX化合物,以提供對應的式I之磺醯胺化合物。以式IX之環氧乙烷化合物與式VII之咔唑反應來提供式I化合物的較佳條件包括在N,N-二甲基甲醯胺中,在室溫至115℃下,在碳酸銫的存在下進行1至24小時反應。另一選擇地,式IX之環氧乙烷化合物可與式VII之咔唑在適當的溶劑中(諸如N,N-二甲基甲醯胺),在微波照射下反應,以提供式I化合物。
以下的反應流程IV描述式I化合物之替代合成法。在適當的溶劑中(諸如二氯甲烷),在0℃至150℃之溫度範圍內以適當的式II之磺醯氯經約5分鐘至24小時期間處理式XIV之胺基酯化合物,以提供對應的式XIII之磺醯胺化合物。以式XIV之胺基酯化合物與式II之磺醯氯反應來提供式XIII化合物的較佳條件包括在二氯甲烷中,在0℃至室溫下,在三乙胺的存在下進行1至24小時反應,接著進行萃取整理。在適當的溶劑中(諸如四氫呋喃),在0℃至150℃之溫度範圍內以適當的還原劑經約5分鐘至24小時期間處理式XIII化合物,以提供對應的式XII之醇化合物。還原式XIII之酯化合物來提供式XII化合物的較佳條件包括在四氫呋喃中,在0℃至室溫下,在氫化鋰鋁的存在下進行1至24小時反應,接著進行萃取整理。在適當的溶劑中(諸如二氯甲烷),在0℃至150℃之溫度範圍內以適當的氧化劑經約5分鐘至24小時期間處理式XII化合物,以提供對應的式XI之醛化合物。氧化式XII之醇化合物來提供式XI化合物的較佳條件包括在二氯甲烷中,在0℃至室溫下,在迪斯-馬丁過碘烷(Dess-Martin periodinane)的存在下進行24至48小時反應,接著進行過濾。在適當的溶劑中(諸如二甲亞碸),在0℃至150℃之溫度範圍內以碘化三甲基亞碸鎓鹽(trimethylsulfoxonium iodide)經約5分鐘至24小時期間處理式XI化合物,以提供對應的式IX之環氧乙烷化合物。轉化式XI之醛化合物來提供式IX化合物的較佳條件包括
在二甲亞碸中,在0℃至室溫下,在碘化三甲基亞碸鎓鹽和氫化鈉的存在下進行2至24小時反應,接著進行萃取整理。在適當的溶劑中(諸如N,N-二甲基甲醯胺或N,N-二甲基乙醯胺),在0℃至150℃之溫度範圍內以適當的式VII之咔唑經約5分鐘至24小時期間處理式IX化合物,以提供對應的式I之磺醯胺化合物。以式IX之環氧乙烷化合物與式VII之咔唑反應來提供式I化合物的較佳條件包括在N,N-二甲基甲醯胺中,在室溫至115℃下,在碳酸銫的存在下進行1至24小時。另一選擇地,式IX之環氧乙烷化合物可與式VII之咔唑在適當的溶劑中(諸如N,N-二甲基甲醯胺),在微波照射下反應,以提供式I化合物。
以下的反應流程V描述式I化合物之替代合成法。在
適當的溶劑中(諸如N,N-二甲基甲醯胺或N,N-二甲基乙醯胺),在0℃至150℃之溫度範圍內以適當的式VIII之磺醯胺經約5分鐘至24小時期間處理經適當取代之式XV或XVI之環氧乙烷衍生物,以提供對應的式I之磺醯胺化合物。以式XV或XVI之環氧乙烷化合物與式VIII之磺醯胺反應來提供式I化合物的較佳條件包括在N,N-二甲基甲醯胺中,在室溫至70℃下,在氫化鈉的存在下進行20至24小時反應。另一選擇地,式XV或XVI之環氧乙烷化合物可與式VIII之磺醯胺在適當的溶劑中(諸如N,N-二甲基甲醯胺),在100℃下,在碳酸銫的存在下反應20至24小時。
在本文所述之反應流程中,應瞭解在用於製備式I化合物之中間物中的羥基若必要時可以那些熟諳本技藝者已知的習用基團保護。例如,可將含有羥基之中間物保護成
對應的第三丁基二甲基矽烷基醚及接著以氟化四-正丁基銨處理而去保護,以提供自由羥基衍生物。適合的保護基及移除彼等之方法例證在T.W.Greene and P.G.M.Wuts的第三版之“Protective Groups in Organic Synthesis”(Wiley & Sons,1999)中。
1H核磁共振(NMR)光譜在所有的例子中皆與提出之結構一致。特性化學位移(δ)係以距四甲基矽烷低磁場的每百萬份之份數提出,使用習用的縮寫命名主要波峰:例如s:單峰;d:二重峰;t:三重峰;q:四重峰;m:多重峰;br:寬峰。質譜(m/z)係使用電噴灑離子化(ESI)或大氣壓化學離子化(APCI)記錄。在使用薄層層析術(TLC)時,其係指使用矽膠60 F254板之矽膠TLC,Rf為在TLC板上由化合物行進之距離除以由溶劑前沿行進之距離。HPLC係指高性能液相層析術。
以下的特定實例係以例證為目的而納入,並不被解釋為對本發明的限制。
將無水甲苯(18毫升)中的碘苯(1.42公克,7毫莫耳)、乙酸鈀(II)(0.079公克,0.35毫莫耳)、2,2'-雙(二苯
膦基)-1,1'-聯萘(0.217公克,0.35毫莫耳)、碳酸銫(6.8公克,21毫莫耳)、2-氟苯胺(0.777公克,7毫莫耳)裝入反應容器中。在氮氛圍下,將混合物在115℃下加熱24小時。將冷卻的混合物以水和醚稀釋。將有機層分離,以飽和水性氯化鈉清洗,乾燥(無水硫酸鈉),過濾且濃縮成殘餘物。將粗製產物以矽膠管柱層析術純化(在己烷中的0-30%之乙酸乙酯),得到成為澄清油的所欲產物(1.1公克,81%)。1H NMR(CDCl3,300MHz)δ 7.36-7.29(m,3H),7.20-7.14(m,3H),7.09-7.00(m,2H),6.88-6.85(m,1H),5.82(br s,1H)。ESI m/z:188.2(M+H)。
將2-氟-N-苯基苯胺(0.4公克,2.1毫莫耳)、二乙酸鈀(0.025公克,0.1毫莫耳)、碳酸鉀(0.030公克,0.21毫莫耳)及三甲基乙酸(1.8公克)裝入反應容器中,將容器放置在氧氣球下且在120℃下加熱。在48小時及72小時添加額外份量的二乙酸鈀(0.025公克,0.1毫莫耳)且將混合物加熱4天。將冷卻的反應混合物以二氯甲烷稀釋,以飽和水性碳酸鈉清洗,乾燥(無水硫酸鈉),經由矽膠墊過濾且濃縮。將粗製產物以矽膠管柱層析術純化(在己烷中的
5-30%之二氯甲烷),得到成為白色固體的所欲產物(0.181公克,46%)。1H NMR(d6-DMSO,300MHz)δ 11.65(s,1H),8.13-8.11(dd,1H,J=0.6,7.5Hz),7.94-7.91(d,1H,J=7.8Hz),7.50-7.38(m,2H),7.25-7.07(m,3H)。HPLC分析(C18,在H2O+0.1%之三氟乙酸中的5-95%之乙腈經20分鐘:滯留時間,在254奈米之面積%):9.65分鐘,100%。
將水(2毫升)中的2-氯-5-氟硝基苯(0.175公克,1毫莫耳)、苯基硼酸(0.134公克,1.1毫莫耳)、碳酸鈉(0.317公克,3毫莫耳)、二乙酸鈀(0.009公克,0.04毫莫耳)、溴化四丁基銨(0.322公克,1毫莫耳)裝入微波反應容器中。將混合物在微波反應器中加熱至165℃經7.5分鐘。將反應冷卻且倒入醚和0.1N水性氫氧化鈉中。將醚層以飽和水性氯化鈉清洗,乾燥(無水硫酸鈉),過濾且濃縮。將粗製產物以矽膠管柱層析術純化(在己烷中的5-30%之二氯甲烷),得到成為淡黃色油的所欲產物(0.179公克,82%)。1H NMR(CDCl3,300MHz)δ 7.62-7.58(dd,1H,J=2.7,8.1Hz),7.46-7.40(m,4H),7.38-7.34(m,1H),7.31-
7.26(m,2H)。HPLC分析(C18,在H2O+0.1%之三氟乙酸中的5-95%之乙腈經20分鐘滯留時間,在254奈米之面積%):9.95分鐘,96.3%。
將無水1,2-二氯苯(1.5毫升)中的4-氟-2-硝基-1,1'-聯苯(0.170公克,0.78毫莫耳)及三苯膦(0.513公克,1.9毫莫耳)之溶液在微波反應器中加熱至175℃經8小時。將冷卻的混合物在真空中濃縮且以管柱層析術純化(在己烷中的7-50%之二氯甲烷),得到灰白色固體(0.129公克,89%)。1H NMR(CDCl3,300MHz)δ 8.06(br s,1H),8.03-7.95(m,2H),7.43-7.39(m,2H),7.26-7.21(m,1H),7.12-7.08(dd,1H,J=2.3,9.3Hz),7.00-6.93(m,1H)。HPLC分析:(C18,在H2O+0.1%之三氟乙酸中的5-95%之乙腈經20分鐘滯留時間,在254奈米之面積%):9.67分鐘,98.8%。
將吡啶(2.2毫升,27毫莫耳)及三氟甲烷磺酸酐(2.7毫升,16毫莫耳)添加至無水二氯甲烷(44毫升)中的4-氟酚(1.5公克,13.3毫莫耳)之0℃溶液中。容許溶液緩慢溫熱至周圍溫度且攪拌16小時。將溶液以醚稀釋且以兩次1N水性氫氯酸、飽和水性碳酸氫鈉和飽和水性氯化鈉溶液連續清洗。將有機溶液乾燥(無水硫酸鈉),過濾且濃縮,得到黃褐色液體(3.2公克,99%)。1H NMR(CDCl3,300MHz)δ 7.28-7.24(m,2H),7.16-7.11(m,2H)。
將無水甲苯(7.5毫升)中的三氟甲烷磺酸4-氟苯酯(0.753公克,3毫莫耳)、苯胺(0.307公克,3.3毫莫耳)、乙酸鈀(0.067公克,0.3毫莫耳)、碳酸銫(1.17公克,3.6毫莫耳)與2-二環己膦基-2’,4’,6’-三異丙基聯苯(0.215公克,0.45毫莫耳)之混合物放置在氮環境中,抽氣且以氮氣回充兩次,並在100℃下加熱2小時。將乙酸(25毫升)
添加至冷卻的反應混合物中,將反應放置在氧環境(氣球)下且在100℃下加熱48小時。將混合物濃縮成殘餘物,溶解在乙酸乙酯中,以飽和水性碳酸氫鈉和飽和氯化鈉溶液清洗,乾燥(無水硫酸鈉),過濾且濃縮。將粗製產物以矽膠管柱層析術純化,得到成為黃褐色固體的所欲產物(0.1公克,18%)。1H NMR(d6-DMSO,300MHz)δ 11.26(s,1H),8.11-8.08(d,1H,J=7.5Hz),7.94-7.90(dd,1H,J=2.4,9.3Hz),7.47-7.35(m,3H),7.23-7.10(m,2H)。
將無水甲苯(28毫升)中的2-氯-3-氟苯胺(1.5公克,10.3毫莫耳)、乙酸鈀(II)(0.140公克,0.62毫莫耳)、2,2'-雙(二苯膦基)-1,1'-聯萘(0.386公克,0.62毫莫耳)、碳酸銫(6.7公克,20.6毫莫耳)及碘苯(2.1公克,10.3毫莫耳)裝入反應容器中。將容器以氮氣沖洗且將混合物在回流下加熱24小時。將混合物冷卻,以二氯甲烷稀釋,經二氧化矽墊過濾,濃縮且以管柱層析術純化(在己烷中的10-50%之二氯甲烷),得到成為澄清液體的所欲產物(1.24公克,54%)。1H NMR(CDCl3,300MHz)δ 7.38-7.32(m,
2H),7.20-7.19(m,2H),7.16-6.98(m,3H),6.67-6.61(m,1H),6.17(br s,1H)。ESI m/z:222.1(M+H)。HPLC分析:(C18,在H2O+0.1%之三氟乙酸中的5-95%之乙腈經20分鐘滯留時間,在254奈米之面積%):11.03分鐘,98.6%。
將無水N,N-二甲基乙醯胺(6.7毫升)中的2-氯-3-氟-N-苯基苯胺(0.300公克,1.3毫莫耳)、碳酸鉀(0.374公克,2.7毫莫耳)、二乙酸鈀(0.024公克,0.1毫莫耳)、四氟硼酸三環己基鏻(0.079公克,0.2毫莫耳)之混合物抽氣且以氬氣回充,並在150℃下加熱45分鐘。將混合物冷卻,以乙酸乙酯和水稀釋。將有機層以水和飽和水性氯化鈉清洗,乾燥(無水硫酸鈉),過濾且濃縮。將粗製產物以矽膠管柱層析術純化(在己烷中的7-50%之醚),得到灰白色固體(0.06公克,24%)。1H NMR(CDCl3,300MHz)δ 8.23-8.20(d,1H,J=7.8Hz),8.10(br s,1H),7.48-7.25(m,4H),7.20-7.17(d,1H,J=8.1Hz),6.95-6.89(dd,1H,J=7.8,9.9Hz)。HPLC分析:(C18,在H2O+0.1%之三氟乙酸中的5-95%之乙腈經20分鐘滯留時間,在254奈米之面
積%):9.84分鐘,96.5%。
將粉末狀氫氧化鉀(3.36公克,60毫莫耳)添加至無水N,N-二甲基甲醯胺(50毫升)中的咔唑(8.36公克,50毫莫耳)之溶液中且在周圍溫度下攪拌1小時。將反應混合物在冰浴中冷卻且添加表溴醇(10.3毫升,125毫莫耳)。移除冰浴且將反應在室溫下攪拌20小時。將混合物分溶在乙酸乙酯與水之間。將有機層以水和飽和水性氯化鈉溶液連續清洗,乾燥(無水硫酸鈉),過濾且濃縮。將粗製材料以己烷濕磨且自乙酸乙酯/己烷再結晶,得到成為白色針狀物的所欲產物(6.41公克,58%產率)。將第二收成晶體自母液結晶,得到額外產物(1.2公克,11%)。1H NMR(CDCl3,300MHz)δ 8.11-8.08(m,2H),7.46-7.44(m,4H),7.28-7.25(m,2H),4.68-4.62(dd,1H,J=3.1,15.8Hz)4.45-4.38(dd,1H,J=4.8,15.9Hz),3.37(m,1H),2.84-2.81(dd,1H,J=4.2,4.3Hz),2.60-2.57(dd,1H,J=2.5,5.0Hz)。HPLC分析:(C18,在H2O+0.1%之三氟乙酸中的5-95%之乙腈經20分鐘滯留時間,在254奈米之面積%):7.83分鐘,98.7%。
將85%之水性氫氧化鉀(0.95公克,14.4毫莫耳)添加至無水N,N-二甲基甲醯胺(20毫升)中的咔唑(2.0公克,12毫莫耳)之攪拌溶液中且將混合物在室溫下攪拌1小時。將混合物在冰浴中冷卻且添加(R)-(-)-2-(氯甲基)環氧乙烷(2.77公克,29.9毫莫耳)。將混合物在室溫下攪拌隔夜且接著分溶在水與乙酸乙酯之間。將有機層以飽和水性氯化鈉清洗,乾燥(無水硫酸鈉),過濾且濃縮。將殘餘物自乙酸乙酯/己烷再結晶而純化,以供給成為白色晶體的所欲產物(0.8公克,30%)。1H NMR(300MHz,CDCl3)δ 8.10(d,2H,J=7.5Hz),7.55-7.40(m,4H),7.32-7.22(m,2H),4.66(dd,1H,J=15.9,3.3Hz),4.43(dd,1H,J=15.9,4.8Hz),3.38(m,1H),2.83(t,1H,J=4.5Hz),2.60(dd,1H,J=4.8,2.4Hz)。
將85%之水性氫氧化鉀(2.171公克,32.9毫莫耳)添加至無水N,N-二甲基甲醯胺(20毫升)中的咔唑(5.0公克,29.9毫莫耳)之攪拌溶液中且將混合物在室溫下攪拌1小時。將混合物在冰浴中冷卻且添加(S)-(+)-表氯醇(4.68毫升,59.8毫莫耳)。將混合物在室溫下攪拌隔夜且接著分溶在水與乙酸乙酯之間。將有機層以飽和水性氯化鈉清洗,乾燥(無水硫酸鈉),過濾且濃縮。將殘餘物以矽膠管柱層析術純化(30%之二氯甲烷/己烷)以供給成為白色固體的所欲產物(3.9公克,58%)。[α]D-10.4(c 1.92,CHCl3)。1H NMR(300MHz,CDCl3)δ 8.10(d,2H,J=7.5Hz),7.60-7.40(m,4H),7.35-7.20(m,2H),4.64(dd,1H,J=15.9,3.3Hz),4.41(dd,1H,J=15.9,4.8Hz),3.37(m,1H),2.82(t,1H,J=4.2Hz),2.59(dd,1H,J=4.5,2.4Hz)。
將呋喃甲基胺(5.3毫升,60毫莫耳)及乙醇(11毫升)之溶液中的9-(環氧乙烷-2-基甲基)-9H-咔唑(2.97公克,13.3毫莫耳)之懸浮液在Biotage Initiator微波反應器中加熱至110℃經15分鐘。將所得溶液以甲醇稀釋且在冰浴中冷卻,以沉澱白色固體。將固體溶解在最少量的熱甲醇中而再結晶且緩慢冷卻,得到成為細結晶狀白色固體的所欲產物(2.4公克,57%)。1H NMR(CDCl3,300MHz)δ 8.10-8.08(d,2H,J=8.1Hz),7.46-7.44(m,3H),7.32-7.25(m,4H),6.29-6.27(dd,1H,J=1.8,3.3Hz),6.11-6.10(d,1H,J=3Hz),4.39-4.38(d,1H,J=2.1Hz),4.37(d,1H,J=0.9Hz),4.21-4.17(m,1H),3.75(s,2H),2.85-2.79(dd,1H,J=3.8,12.3Hz),2.69-2.62(dd,1H,J=8.4,12.3Hz),2.00(br s,2H)。ESI m/z:321.1(M+H)。HPLC分析:(C18,在水+0.1%之三氟乙酸中的10-90%之乙腈經10分鐘滯留時間,在254奈米之面積%):6.1分鐘,99.0%。
將第三丁基二甲基矽烷基氯(2.117公克,14.0毫莫耳)添加至無水二氯甲烷(50毫升)中的1-(9H-咔唑-9-基)-
3-((呋喃-2-基甲基)胺基)丙-2-醇(1.80公克,5.6毫莫耳)及咪唑(1.912公克,28.1毫莫耳)之攪拌溶液中。將反應混合物在70℃下攪拌隔夜。將反應混合物以飽和水性氯化鈉和飽和水性碳酸鈉清洗,乾燥(無水硫酸鈉),過濾且濃縮。將殘餘物以矽膠管柱層析術純化(在己烷中的0-40%之乙酸乙酯),以供給成為濃稠油的產物(2.4公克,98%)。1H NMR(300MHz,CDCl3)δ 8.08(d,2H,J=7.8Hz),7.53-7.40(m,4H),7.37(d,1H,J=1.5Hz),7.22(t,2H,J=7.2Hz),6.32(dd,1H,J=3.3,1.8Hz),6.16(d,1H,J=3.3Hz),4.56(dd,1H,J=14.4,6.0Hz),4.41-4.22(m,2H),3.85與3.75(dd,2H,J=14.4,14.4Hz),2.74(dd,1H,J=12.0,4.5Hz),2.61(dd,1H,J=12.0,3.6Hz),1.60(br s,2H),0.80(s,9H),-0.13(s,3H),-0.42(s,3H)。ESI m/z:435.2[M+H]。
將甲烷磺醯氯(3.2毫升,42毫莫耳)緩慢添加至無水二氯甲烷(110毫升)中的呋喃甲基胺(4.2公克,43.2毫莫耳)及三乙胺(6毫升,43毫莫耳)之攪拌溶液中。將反應在周圍溫度下攪拌隔夜且接著以乙酸乙酯稀釋。將有機溶液以三次1N水性氫氯酸、飽和水性碳酸氫鈉和飽和水性氯
化鈉溶液連續清洗,乾燥(無水硫酸鈉)且過濾。將溶液在減壓下濃縮,得到成為黃褐色液體的所欲產物(6.6公克,89%)。1H NMR(CDCl3,300MHz)δ 7.39-7.38(m,1H),6.33-6.31(m,2H),5.02(br s,1H),4.33-4.31(d,2H,J=6Hz)。
將甲烷磺醯氯(2.0毫升,25.8毫莫耳)緩慢添加至0℃下在無水二氯甲烷(100毫升)及N,N-二異丙基乙胺(8.54毫升,51.7毫莫耳)中的2-甲氧基乙胺(2.67毫升,31.0毫莫耳)之攪拌溶液中。將反應混合物緩慢溫熱至室溫且攪拌隔夜。將混合物濃縮且將殘餘物以矽膠管柱層析術純化(在己烷中的0-100%之乙酸乙酯),以供給成為無色油的產物(2.8公克,71%)。1H NMR(300MHz,CDCl3)δ 4.66(br s,1H),3.54(t,2H,J=4.8Hz),3.39(s,3H),6.37-3.29(m,2H),3.00(s,3H)。
將磺苯甲醯亞胺(1公克,5.5毫莫耳)添加至以外部冰浴保持在0℃之無水四氫呋喃(30毫升)中的氫化鋰鋁(0.414公克)之冷溶液中。容許反應溫熱至周圍溫度且攪拌隔夜。將反應以添加的水及2.5M水性硫酸中止。將混合物經由矽藻土過濾且以乙酸乙酯清洗。將有機層以1M水性硫酸清洗,乾燥(無水硫酸鎂),過濾且濃縮,以供給灰白色固體(0.75公克,81%)。1H NMR(CDCl3,300MHz)δ 7.81-7.78(d,1H,J=7.8Hz),7.64-7.59(dt,1H,J=1.2,7.5Hz),7.52-7.49(dt,1H,J=0.75,7.5Hz),7.41-7.37(d,1H,J=8.1Hz),4.8(br s,1H),4.55-4.54(d,1H,J=3.6Hz)。
標題化合物係使用WO 98/32438 A1中所述之方法製備。將氯化錫(II)(19.3公克,86毫莫耳)添加至無水乙酸乙酯(250毫升)中的2-硝基-α-甲苯磺醯氯(5.1公克,21.6毫莫耳)之溶液中。將反應在70℃下攪拌隔夜,接著倒在冰上且以飽和水性碳酸氫鈉中和。將溶液經由矽藻土過濾,以乙酸乙酯萃取且將有機層濃縮。將無水二氯甲烷(200毫升)及三乙胺(5毫升)添加至粗製殘餘物中。將溶液
在室溫下攪拌隔夜且在減壓下濃縮。產物係藉由矽膠管柱層析術(在己烷中的30-100%之乙酸乙酯)及接著自二氯甲烷/己烷再結晶而獲得,得到白色固體(0.24公克,6.5%)。1H NMR(CDCl3,300MHz)δ 7.30-7.22(m,2H),7.07-7.02(t,1H,J=7.4Hz),6.89-6.86(dd,1H,J=0.6,8.1Hz),6.66(br s,1H),4.39(s,1H)。
標題化合物係根據Bravo,R.D.等人之Synth.Commun.2002,32,3675中所述之方法製備。將無水二氯乙烷(23毫升)中的α-甲苯磺醯胺(1公克,5.8毫莫耳)和1,3,5-三噁烷(0.175公克,1.9毫莫耳)及amberlyst 15 H+樹脂(3.7公克)裝入燒瓶中。將混合物在80℃下攪拌隔夜,然後將樹脂濾出且以二氯甲烷清洗。將有機溶液濃縮,以供給白色固體(0.848公克,79%)。1H NMR(d6-DMSO,300MHz)δ 7.41-7.37(t,1H,J=6.8Hz),7.30-7.24(m,2H),7.19-7.16(m,1H),7.12-7.09(m,1H),4.42-4.40(d,2H,J=6.6Hz),4.35(s,2H)。
標題化合物係根據WO 2008/073956 A2中所述之方法合成。將無水二氯甲烷(40毫升)中的甲烷磺醯氯(3.4毫升,44毫莫耳)之溶液逐滴添加至無水二氯甲烷(80毫升)中的2-胺基苯甲醇(5公克,40.6毫莫耳)及無水吡啶(16毫升,203毫莫耳)之攪拌溶液中。將所得混合物在室溫下攪拌24小時,濃縮至1/3體積且以乙酸乙酯稀釋。將有機溶液以兩次1N水性氫氯酸、水、飽和水性碳酸氫鈉和飽和水性氯化鈉溶液連續清洗,乾燥(無水硫酸鈉),過濾且濃縮。將粗製殘餘物通過以乙酸乙酯/己烷清洗之矽膠墊,得到黃色油(6.1公克,75%)。1H NMR(CDCl3,300MHz)δ 7.84(br s,1H),7.53(d,1H,J=8.1Hz),7.36-7.30(dt,1H,J=1.5,7.8Hz),7.25-7.21(dd,1H,J=1.5,7.8Hz),7.16-7.11(dt,1H,J=1.2,7.5Hz),4.77-4.75(d,2H,J=5.1Hz),3.04(s,3H),2.60(t,1H,J=5.2Hz)。
標題化合物係根據WO 2008/073956 A2所述之方法合成。將二氧化錳(85% Aldrich,17公克)添加至無水二氯甲
烷(68毫升)中的N-(2-(羥甲基)苯基)甲烷磺醯胺(3.44公克,17.1毫莫耳)之溶液中且將混合物在周圍溫度下攪拌隔夜。添加額外的二氧化錳(1.6公克)且將混合物在30℃下攪拌8小時。將混合物經由以二氯甲烷清洗之矽藻土過濾且將有機溶液濃縮。將粗製殘餘物以矽膠管柱層析術純化(在己烷中的40-60%之乙酸乙酯),得到白色固體(2.1公克,62%)。1H NMR(CDCl3,300MHz)δ 10.59(br s,1H),9.91(s,1H),7.75-7.59(m,3H)7.28-7.23(t,1H,J=7.5Hz),3.12(s,3H)。
標題化合物係根據WO 2008/073956 A2所述之方法合成。將碳酸銫(6.5公克,20毫莫耳)及4-甲氧基苯甲基氯(2.7毫升,20毫莫耳)添加至無水乙腈(45毫升)中的N-(2-甲醯基苯基)甲烷磺醯胺(2.0公克,10毫莫耳)之溶液中。將混合物加熱至50℃且攪拌48小時,以乙酸乙酯稀釋,經由矽藻土過濾且濃縮。將粗製產物以矽膠管柱層析術純化(在己烷中的50-100%之二氯甲烷),得到產物(0.9公克,31%)。1H NMR(CDCl3,300MHz)δ 7.40-7.32(m,2H),7.28-7.24(m,3H),7.16-7.11(m,2H),6.85-6.81(m,
3H),5.15(s,2H),3.77(s,3H)。
標題化合物係根據WO 2008/073956 A2所述之方法合成。將三氟乙酸(18毫升)添加至無水二氯甲烷中的1-(4-甲氧基苯甲基)-1H-苯並[c][1,2]噻2,2-二氧化物(0.9公克,3毫莫耳)之溶液中。將混合物在室溫下攪拌5小時且接著在減壓下濃縮。將粗製產物以矽膠管柱層析術純化(在己烷中的25-70%之乙酸乙酯),得到白色固體(0.6公克,72%)。1H NMR(CDCl3,300MHz)δ 7.43-7.38(m,2H),7.29(m,1H),7.20-7.14(dt,1H,J=1.2,7.5Hz),7.02-6.99(d,1H,J=7.8Hz),6.78-6.75(dd,1H,J=2.4,10.5Hz)。
將無水甲醇(6毫升)中的1H-苯並[c][1,2]噻2,2-二氧化物(0.381公克,2.1毫莫耳)及10%之鈀/碳(0.05公克)
之溶液放置在以氫氣填充之氣球下且在室溫下攪拌17小時。將混合物經由矽藻土過濾且濃縮,得到白色固體(0.366公克,95%)。1H NMR(CDCl3,300MHz)δ 7.25-7.16(m,2H),7.07-7.01(m,1H),6.76-6.73(d,1H,J=8.4Hz),3.51-3.46(t,2H,J=6.8Hz),3.34-3.29(br t,1H,J=6.9Hz)。
將N,N-二異丙基乙胺(8.6毫升,52.1毫莫耳)緩慢添加至0℃下在無水二氯甲烷(50毫升)中的4-氯苯磺醯氯(5.0公克,23.7毫莫耳)及2-溴乙胺氫溴酸鹽(5.4公克,26.3毫莫耳)之攪拌混合物中且將混合物在0℃下攪拌1小時。將反應混合物以水、2N水性氫氯酸、飽和水性碳酸鈉和飽和水性氯化鈉連續清洗。將有機層乾燥(無水硫酸鈉),過濾且在真空中濃縮,以供給白色固體(7公克,99%)。1H NMR(300MHz,CDCl3)δ 7.82(d,2H,J=8.7Hz),7.52(d,2H,J=8.7Hz),4.96(s,1H),3.50-3.30(m,4H)。
將N-(2-溴乙基)-4-氯苯磺醯胺(2.80公克,9.4毫莫耳)及無水苯(50毫升)裝入配備有冷凝器及橡膠隔板的雙頸燒瓶中。將反應容器脫氣且以氬氣回充,並接著加熱至回流。在回流下使用注射幫浦經8小時緩慢添加在無水苯(25毫升)中的氫化三丁基錫(5.05毫升,18.8毫莫耳)及2,2’-偶氮雙(2-甲基丙腈)(0.77公克,4.7毫莫耳)之溶液且將混合物再回流12小時。在冷卻之後,將反應混合物濃縮且將殘餘物以矽膠管柱層析術(在二氯甲烷中的0-40%之乙酸乙酯)及接著以製備性TLC(1:2之己烷中的乙酸乙酯烷)純化,以供給成為白色泡沫的純產物(0.085公克,4%)。1H NMR(300MHz,CDCl3)δ 7.77(d,1H,J=8.4Hz),7.37(dd,1H,J=8.1,2.1Hz),7.26(s,1H),4.47(t,1H,J=7.5Hz),3.83(dt,2H,J=7.5,6.0Hz),3.00(t,2H,J=6.0Hz)。
將氫化鈉(60%之礦油懸浮液,0.524公克,13.1毫莫耳)分批添加至38毫升無水N,N-二甲基甲醯胺(38毫升)中
的N-(呋喃-2-基甲基)甲烷磺醯胺(2.0公克,11.4毫莫耳)之0℃溶液中,容許所得混合物溫熱至室溫且攪拌1小時。緩慢添加表溴醇(1.2毫升,14.3毫莫耳),且將反應在室溫下攪拌3小時及在70℃下攪拌16小時。將反應冷卻,以乙酸乙酯稀釋且以兩次水和一次飽和水性氯化鈉溶液連續清洗。將有機層乾燥(無水硫酸鈉),過濾且在減壓下濃縮。將粗製殘餘物以矽膠管柱層析術純化(在己烷中的25-60%之乙酸乙酯),得到淡黃色液體(2.2公克,84%)。1H NMR(CDCl3,300MHz)δ 7.40-7.39(m,1H),6.37-6.35(m,2H),4.64-4.50(br dd,2H,J=25.8,16.5Hz),3.61-3.55(m,1H),3.22-3.12(m,2H),2.82(s,3H),2.82-2.79(m,1H),2.62-2.60(m,1H)。ESI(m/z):232.0(M+H)。
將氫化鈉(60%之礦油懸浮液,0.284公克,7.1毫莫耳)分批添加至無水N,N-二甲基甲醯胺(12毫升)中的N-(呋喃-2-基甲基)甲烷磺醯胺(1.0公克,5.7毫莫耳)之攪拌溶液中,將其以外部冰浴保持在0℃。移除冰浴且將混合物在周圍溫度下攪拌50分鐘。添加一份3-溴-2-甲基丙烷
(1.15公克,8.6毫莫耳)且將所得混合物在65℃下攪拌隔夜,然後以乙酸乙酯稀釋。將有機層以水和飽和水性氯化鈉溶液連續清洗,乾燥(無水硫酸鈉),過濾且濃縮。將粗製材料以矽膠管柱層析術純化(在己烷中的0-50%之乙酸乙酯),得到澄清液體(1.24公克,95%)。1H NMR(CDCl3,300MHz)δ 7.41-7.40(m,1H),6.38-6.34(m,1H),6.29-6.28(m,1H),5.03-5.00(m,2H),4.37(s,2H),3.73(s,2H),2.76(s,3H),1.77(s,3H)。
將3-氯過苯甲酸(70%,2.1公克,8.6毫莫耳)添加至無水二氯甲烷(20毫升)中的N-(呋喃-2-基甲基)-N-(2-甲基烯丙基)甲烷磺醯胺(1.0公克,4.3毫莫耳)之攪拌溶液中。將混合物在周圍溫度下攪拌2小時及在40℃下攪拌18小時。將混合物以二氯甲烷稀釋且以飽和水性亞硫酸鈉、飽和水性碳酸氫鈉和飽和水性氯化鈉溶液連續清洗。將有機層乾燥(無水硫酸鈉),過濾且濃縮。將粗製殘餘物以矽膠管柱層析術純化(在己烷中的10-60%之乙酸乙酯),得到澄清油(0.278公克,26%)。1H NMR(CDCl3,
300MHz)δ 7.40-7.35(dd,1H,J=0.9,1.8Hz),6.33-6.30(m,2H),4.52-4.51(m,2H),3.48-3.43(d,1H,J=15Hz),3.13-3.09(d,1H,J=15Hz),2.73-2.72(d,1H,J=4.5Hz),2.70(s,3H),2.62-2.61(d,1H,J=4.5Hz),1.35(s,3H)。
將甲烷磺醯氯(2.3毫升,30毫莫耳)緩慢添加至無水二氯甲烷(75毫升)中的D/L-脯胺酸甲酯鹽酸鹽(5.0公克,30.2毫莫耳)及三乙胺(8.4毫升,60毫莫耳)之攪拌溶液中。將反應在周圍溫度下攪拌隔夜且接著以乙酸乙酯稀釋。將有機層以水、兩次1N水性氫氯酸、飽和水性碳酸氫鈉和飽和水性氯化鈉溶液連續清洗,乾燥(無水硫酸鈉)且過濾。將溶液在減壓下濃縮,得到成為黃褐色液體的所欲產物(4.45公克,72%)。1H NMR(CDCl3,300MHz)δ 4.53-4.49(dd,1H,J=8.7,3.6Hz),3.75(s,3H),3.57-3.54(m,1H),3.52-3.42(m,1H),3.01(s,3H),2.32-2.22(m,1H),2.11-1.98(m,3H)。
將無水四氫呋喃(10毫升)中的1-(甲基磺醯基)吡咯啶-2-羧酸甲酯(1.1公克,4.6毫莫耳)緩慢添加至以外部冰浴保持在0℃之無水四氫呋喃(10毫升)中的氫化鋰鋁(0.259公克,6.8毫莫耳)之攪拌懸浮液中。在15分鐘之後,移除冰浴,且容許反應溫熱至周圍溫度及再攪拌1小時。將混合物冷卻至0℃且逐滴添加水(1毫升),接著添加15%之水性氫氧化鈉(1毫升)和水(3毫升)。將混合物在室溫下攪拌15分鐘,接著添加硫酸鎂且再攪拌。將混合物經由矽藻土過濾,以醚清洗三次且將合併的有機部分在減壓下濃縮,以供給黃色油(0.7公克,77%)。1H NMR(CDCl3,300MHz)δ 3.78-3.57(m,3H),3.49-3.36(m,2H),2.87(s,3H),2.64(br s,1H),2.09-1.82(m,4H)。
將迪斯-馬丁過碘烷(1.7公克,4毫莫耳)添加至無水二氯甲烷(20毫升)中的(1-(甲基磺醯基)吡咯啶-2-基)甲醇(0.570公克,3.18毫莫耳)之溶液中。將反應攪拌24小時且添加第二部分的迪斯-馬丁過碘烷(1公克,2.3毫莫
耳)。將所得懸浮液攪拌24小時,過濾且濃縮。將粗製殘餘物以矽膠管柱層析術純化(在二氯甲烷中的1-15%之乙酸乙酯),以提供白色蠟狀固體(0.44公克,78%)。1H NMR(CDCl3,300MHz)δ 9.58(d,1H,J=1.2Hz),4.25-4.20(td,1H,J=6.9,1.2Hz),3.55-3.44(m,2H),2.97(s,3H),2.21-2.13(m,2H),2.05-1.90(m,2H)。
將無水二甲亞碸(0.750毫升)添加至碘化三甲基亞碸鎓鹽(0.187公克,0.85毫莫耳)及氫化鈉(60%之礦油懸浮液,0.034公克,0.85毫莫耳)中且將所得懸浮液攪拌1小時。將無水四氫呋喃(1毫升)中的1-(甲基磺醯基)吡咯啶-2-甲醛(0.100公克,0.56毫莫耳)添加至攪拌溶液中且將混合物在室溫下攪拌2小時。添加飽和水性氯化鈉(3毫升)且將混合物以乙酸乙酯萃取(3×30毫升)。將合併的有機物乾燥(無水硫酸鈉),過濾且在減壓下濃縮,得到含有粗製產物之二甲亞碸溶液(0.473公克),將其直接用於下一步驟中。
將甲烷磺醯氯(4.0公克,35毫莫耳)緩慢添加至無水二氯甲烷(88毫升)中的甲基哌啶酸乙酯(pipecolinate)(5.5公克,35毫莫耳)及三乙胺(4.9毫升,35毫莫耳)之攪拌溶液中。將反應在周圍溫度下攪拌隔夜且接著以乙酸乙酯稀釋。將有機層以水、兩次1N水性氫氯酸、飽和水性碳酸氫鈉和飽和水性氯化鈉溶液連續清洗,乾燥(無水硫酸鈉)且過濾。將溶液在減壓下濃縮,得到成為黃褐色液體的所欲產物(6.9公克,84%)。1H NMR(CDCl3,300MHz)δ 4.72-4.71(br d,1H,J=3.6Hz),4.24-4.16(qd,2H,J=6.9,2.6Hz),3.74-3.68(m,1H),3.22-3.13(td,1H,J=12.3,3.0Hz),2.93(s,3H),2.31-2.25(m,1H),1.83-1.51(m,5H),1.32-1.27(td,3H,J=7.0,0.6Hz),3.52-3.42(m,1H),3.01(s,3H),2.32-2.22(m,1H),2.11-1.98(m,3H)。ESI(m/z):235.9(M+H)。
將無水四氫呋喃(40毫升)中的1-(甲基磺醯基)哌啶-2-羧酸乙酯(6.9公克,29.3毫莫耳)緩慢添加至以外部冰浴
保持在0℃之無水四氫呋喃(80毫升)中的氫化鋰鋁(1.5公克,40毫莫耳)之攪拌懸浮液中。在15分鐘之後,移除冰浴,容許反應溫熱至周圍溫度且再攪拌4.5小時。將混合物冷卻至0℃,且逐滴添加水(1.5毫升)及接著添加水性氫氧化鈉(1.5毫升)和水(4.5毫升)。將混合物在室溫下攪拌15分鐘,接著添加硫酸鎂且再攪拌。將混合物經由矽藻土過濾,以醚清洗三次且將合併的有機部分在減壓下濃縮。將粗製殘餘物通過以乙酸乙酯清洗的矽膠墊,得到成為澄清液體的所欲產物(4.9公克,87%)。1H NMR(CDCl3,300MHz)δ 4.06-4.03(m,1H),3.96-3.92(dd,1H,J=11.1,9.3Hz),3.73-3.68(br d,1H,J=14.1Hz),3.61-3.56(dd,1H,J=11.1,4.8Hz),3.12-3.03(br t,1H,J=12.1Hz),2.96(s,3H),2.17(br s,1H),1.74-1.47(m,6H)。
將迪斯-馬丁過碘烷(21公克,50毫莫耳)添加至無水二氯甲烷(125毫升)中的(1-(甲基磺醯基)哌啶-2-基)甲醇(4.9公克,25.4毫莫耳)之溶液中。將反應攪拌24小時,過濾且在真空中濃縮。將粗製殘餘物以矽膠管柱層析術純化(在己烷中的25-75%之乙酸乙酯),以提供白色蠟狀固
體(1.1公克,24%產率)。1H NMR(CDCl3,300MHz)δ 9.56(s,1H),4.61-4.58(br d,1H,J=6.3Hz),3.75-3.68(m,1H),3.13-3.04(td,1H,J=12.0,3.2Hz),2.97(s,3H),2.33-2.22(m,1H),1.89-1.55(m,4H),1.27-1.21(m,1H)。
將正丁基鋰(在己烷中的2.5N,1.96毫升,4.92毫莫耳)添加至無水四氫呋喃(10毫升)中的溴化三苯基鏻(1.76公克,4.92毫莫耳)之冷懸浮液中,將其以外部冷浴保持在-78℃。容許混合物溫熱至0℃且攪拌1小時,接著冷卻至-78℃。添加在無水四氫呋喃(5毫升)中的1-(甲基磺醯基)哌啶-2-甲醛(0.626公克,3.28毫莫耳)。將所得混合物在-78℃下攪拌10分鐘,接著溫熱至0℃且攪拌3小時。添加飽和水性氯化鈉(10毫升)且將混合物以乙酸乙酯萃取(3×50毫升)。將合併的有機物乾燥(無水硫酸鈉),過濾且在減壓下濃縮。將粗製殘餘物以矽膠管柱層析術純化(在己烷中的25-70%之乙酸乙酯),以提供澄清油(0.369公克,60%)。1H NMR(CDCl3,300MHz)δ 6.08-5.97(m,1H),5.33-5.26(m,2H),4.52(br s,1H),3.69-3.63(m,1H),3.05-3.00(m,1H),2.81(s,3H),1.86-1.55(m,6H)。
將純化之3-氯過苯甲酸(100%,1.0公克,6毫莫耳)添加至無水二氯甲烷(10毫升)中的1-(甲基磺醯基)-2-乙烯基哌啶(0.369公克,2.0毫莫耳)之溶液中。將反應在室溫下攪拌65小時。將反應混合物過濾,添加飽和水性亞硫酸鈉且將兩相溶液攪拌5分鐘。將混合物以乙酸乙酯稀釋且將有機層以飽和水性碳酸氫鈉和飽和水性氯化鈉溶液連續清洗,乾燥(無水硫酸鈉),過濾且濃縮。將粗製產物以矽膠管柱層析術純化(在己烷中的30-60%之乙酸乙酯),得到白色半固體(0.128公克,31%)。1H NMR(CDCl3,300MHz)δ 3.78-3.74(br d,1H,J=13.2Hz),3.66-3.61(m,1H),3.37-3.32(m,1H),3.24-3.15(m,1H),2.98(s,3H),2.88-2.85(dd,1H,J=4.8,4.2Hz),2.68-2.66(dd,1H,J=4.8,2.6Hz),1.81-1.60(m,6H)。ESI(m/z):205.9(M+H)。
將1-溴-4-氟苯(6.011公克,34.4毫莫耳)、2-氯-4-氟苯胺(5.000公克,34.3毫莫耳)、Xantphos(0.795公克,1.4毫莫耳)、無水甲苯(200毫升)及第三丁醇鈉(4.952公克,51.5毫莫耳)裝入圓底燒瓶中。將混合物脫氣及以氮氣填充,接著添加參(二亞苯甲基丙酮)二鈀(0)(0.944公克,1.0毫莫耳)且將反應在氮氣下於100℃下攪拌16小時。在冷卻至室溫之後,將混合物經由矽藻土過濾且將濾餅以二氯甲烷清洗。將過濾物濃縮且將殘餘物以矽膠層析術純化(0-20%之乙酸乙酯/己烷),以供給淡黃色油(5.63公克,68%)。1H NMR(300MHz,CDCl3)δ 7.14(dd,1H,J=8.4,3.0Hz),7.12-6.98(m,5H),6.88(td,1H,J=8.7,3.0Hz),5.80(br s,1H)。
將第三丁醇鈉(7.218公克,75.1毫莫耳)、2-氯-4-氟-N-(4-氟苯基)苯胺(3.600公克,15.0毫莫耳)、四氟硼酸三-第三丁基鏻(0.305公克,1.1毫莫耳)、二乙酸鈀(0.169公克,0.8毫莫耳)及無水1,4-二噁烷(80毫升)裝入反應管
中。將管在氮氣下密封且在110℃之油浴中加熱20小時。在冷卻至室溫之後,將混合物以2M水性氫氯酸(90毫升)處理且以二氯甲烷萃取(3×50毫升)。將合併的有機層以飽和水性氯化鈉清洗,乾燥(無水硫酸鈉)且在真空中濃縮。將殘餘物以矽膠層析術純化(20-50%之二氯甲烷/己烷)。將固體以己烷沖洗且乾燥,以供給成為白色粉末的純化合物(1.1公克,36%)。1H NMR(300MHz,CDCl3)δ 7.99(br s,1H),7.67(dd,2H,J=8.7,2.4Hz),7.36(dd,2H,J=8.7,4.2Hz),7.19(td,2H,J=9.0,2.4Hz)。
將85%之氫氧化鉀(0.195公克,3.0毫莫耳)添加至0℃下在N,N-二甲基甲醯胺(5毫升)中的3,6-二氟-9H-咔唑(0.500公克,2.5毫莫耳)之攪拌溶液中且將混合物攪拌1小時。添加表溴醇(0.407毫升,4.9毫莫耳),將混合物緩慢溫熱至室溫且攪拌16小時。將混合物分溶在水與乙酸乙酯之間。將有機層以飽和水性氯化鈉清洗,乾燥(無水硫酸鈉),過濾且在真空中濃縮。將殘餘物以矽膠層析術純化(10-50%之二氯甲烷/己烷),以供給成為白色固體的
所欲產物(0.575公克,90%)。1H NMR(300MHz,CDCl3)δ 7.69(dd,2H,J=8.7,2.7Hz),7.39(dd,2H,J=9.0,3.9Hz),7.24(td,2H,J=9.0,2.7Hz),4.68(dd,1H,J=15.9,3.0Hz),4.33(dd,1H,J=15.9,5.1Hz),3.35(m,1H),2.84(t,1H,J=4.5Hz),2.55(dd,1H,J=4.8,2.4Hz)。
將水(10毫升)中的2-氯-5-氟硝基苯(0.878公克,5.0毫莫耳)、4-氟苯基硼酸(0.770公克,5.5毫莫耳)、碳酸鈉(1.590公克,15.0毫莫耳)、二乙酸鈀(0.045公克,0.2毫莫耳)、溴化四丁銨(1.612公克,5.0毫莫耳)裝入微波反應容器中。將混合物在微波反應器加熱至165℃經10分鐘。將反應冷卻至室溫且倒入二乙醚及0.1N水性氫氧化鈉中。將有機層以飽和水性氯化鈉清洗,乾燥(無水硫酸鈉),過濾且在真空中濃縮。將殘餘物以矽膠層析術純化(10-30%之二氯甲烷/己烷),得到成為黃色固體的所欲產物(0.61公克,52%)。1H NMR(CDCl3,300MHz)δ 7.61(dd,1H,J=8.1,2.7Hz),7.44-7.30(m,2H),7.30-7.21(m,2H),7.16-7.07(m,2H)。
將無水1,2-二氯苯(5毫升)中的4,4'-二氟-2-硝基-1,1'-聯苯(0.580公克,2.5毫莫耳)及三苯膦(1.617公克,6.2毫莫耳)之溶液在微波反應器中加熱至175℃經4小時。將混合物冷卻至室溫且在高真空下濃縮成黑色殘餘物。將將粗製產物以矽膠層析術純化(5-50%之二氯甲烷/己烷),以供給成為淺棕色粉末的產物(0.41公克,82%)。1H NMR(CDCl3,300MHz)δ 8.10(br s,1H),7.93(dd,2H,J=8.7,5.4Hz),7.11(dd,2H,J=9.3,2.4Hz),6.99(ddd,2H,J=9.6,9.0,2.4Hz)。
將85%之氫氧化鉀(0.156公克,2.4毫莫耳)添加至0℃下在N,N-二甲基甲醯胺(5毫升)中的2,7-二氟-9H-咔唑
(0.400公克,2.0毫莫耳)之攪拌溶液中且將混合物攪拌1小時。添加表溴醇(0.326毫升,3.9毫莫耳),將混合物緩慢溫熱至室溫且攪拌16小時。將混合物分溶在水與乙酸乙酯之間。將有機層以飽和水性氯化鈉清洗,乾燥(無水硫酸鈉),過濾且在真空中濃縮。將殘餘物以矽膠層析術純化(10-50%之二氯甲烷/己烷),以供給成為白色固體的所欲產物(0.47公克,92%)。1H NMR(300MHz,CDCl3)δ 7.93(dd,2H,J=8.4,5.4Hz),7.14(dd,2H,J=9.9,2.4Hz),6.99(td,2H,J=9.0,2.4Hz),4.60(dd,1H,J=15.9,2.7Hz),4.25(dd,1H,J=15.9,5.1Hz),3.35(m,1H),2.86(t,1H,J=4.5Hz),2.57(dd,1H,J=4.8,2.7Hz)。
將水(10毫升)及1,4-二噁烷(1毫升)中的2-氯-3-氟硝基苯(1.500公克,8.5毫莫耳)、4-氟苯基硼酸(1.315公克,9.4毫莫耳)、碳酸鈉(2.717公克,25.6毫莫耳)、二乙酸鈀(0.077公克,0.3毫莫耳)、溴化四丁銨(2.755公克,8.5毫莫耳)裝入微波反應容器中。將混合物在微波反應容器中加熱至100℃經1小時。將反應冷卻至室溫且倒入二乙醚及0.1N水性氫氧化鈉中。將有機層以飽和水性
氯化鈉清洗,乾燥(無水硫酸鈉),過濾且在真空中濃縮。將殘餘物以矽膠層析術純化(10-30%之二氯甲烷/己烷),得到成為黃色固體的所欲產物(1.15公克,57%)。1H NMR(CDCl3,300MHz)δ 7.70(dt,1H,J=8.4,1.5Hz),7.51(td,1H,J=8.4,5.4Hz),7.41(td,1H,J=8.4,1.2Hz),7.35-7.26(m,2H),7.22-7.11(m,2H)。
將無水1,2-二氯苯(2毫升)中的2,4'-二氟-6-硝基-1,1'-聯苯(1.100公克,4.7毫莫耳)及三苯膦(3.067公克,11.7毫莫耳)之溶液在微波反應器中加熱至175℃經4小時。將混合物冷卻至室溫且在真空中濃縮。接著將粗製殘餘物以矽膠層析術純化(5-50%之二氯甲烷/己烷),以供給成為白色固體的產物(0.84公克,88%)。1H NMR(CDCl3,300MHz)δ 8.17(br s,1H),8.12(dd,1H,J=8.7,5.1Hz),7.33(td,1H,J=8.1,5.1Hz),7.20(d,1H,J=8.1Hz),7.12(dd,1H,J=9.3,2.4Hz),7.02(td,1H,J=9.3,2.4Hz),6.93(dd,1H,J=9.6,7.8Hz)。
將85%之氫氧化鉀(0.207公克,3.1毫莫耳)添加至0℃下在N,N-二甲基甲醯胺(5毫升)中的2,5-二氟-9H-咔唑(0.530公克,2.6毫莫耳)之攪拌溶液中且將混合物攪拌1小時。添加表溴醇(0.432毫升,5.2毫莫耳),將混合物緩慢溫熱至室溫且攪拌16小時。將混合物分溶在水與乙酸乙酯之間。將有機層以飽和水性氯化鈉清洗,乾燥(無水硫酸鈉),過濾且在真空中濃縮。將殘餘物以矽膠層析術純化(10-50%之二氯甲烷/己烷)以供給成為白色固體的所欲產物(0.59公克,87%)。1H NMR(300MHz,CDCl3)δ 8.13(dd,1H,J=8.7,5.7Hz),7.38(td,1H,J=8.1,5.4Hz),7.23(d,1H,J=8.4Hz),7.15(dd,1H,J=9.6,2.1Hz),7.03(ddd,1H,J=9.6,9.0,2.4Hz),6.95(ddd,1H,J=9.9,8.1,0.6Hz),4.64(dd,1H,J=15.9,3.0Hz),4.31(dd,1H,J=15.9,5.1Hz),3.36(m,1H),2.85(t,1H,J=4.5Hz),2.57(dd,1H,J=4.5,2.4Hz)。
將1-溴-4-氟苯(4.809公克,27.5毫莫耳)、2-氯-5-氟苯胺(4.000公克,27.5毫莫耳)、Xantphos(0.636公克,1.1毫莫耳)、無水甲苯(100毫升)及第三丁醇鈉(3.961公克,41.2毫莫耳)裝入圓底燒瓶中。將混合物脫氣及以氬氣填充,接著添加參(二亞苯甲基丙酮)二鈀(0)(0.755公克,0.8毫莫耳)且將反應在氬氣下於110℃下攪拌5小時。在冷卻至室溫之後,將混合物以水處理且以二乙醚萃取。將有機層以飽和水性氯化鈉清洗,乾燥(無水硫酸鎂),過濾且在真空中濃縮。將殘餘物以矽膠層析術純化(0-20%之乙酸乙酯/己烷),以供給成為無色油的產物(5.75公克,87%)。1H NMR(300MHz,CDCl3)δ 7.27(dd,1H,J=9.0,5.4Hz),7.23-7.03(m,4H),6.71(dd,1H,J=10.8,2.4Hz),6.47(td,1H,J=8.1,3.0Hz),6.09(br s,1H)。
將第三丁醇鈉(11.429公克,118.9毫莫耳)、2-氯-5-氟-N-(4-氟苯基)苯胺(5.700公克,23.8毫莫耳)與無水1,4-二噁烷(120毫升)之混合物脫氣且以氬氣回充。添加四氟硼酸三-第三丁基鏻(0.483公克,1.7毫莫耳)及二乙酸鈀(0.267公克,1.2毫莫耳)且將混合物在110℃之油浴中攪拌20小時。在冷卻至室溫之後,將混合物以2M水性氫氯酸(90毫升)處理且以二氯甲烷萃取(3×50毫升)。將合併的有機層以飽和水性氯化鈉清洗,乾燥(無水硫酸鈉),過濾且在真空中濃縮。將殘餘物以矽膠層析術純化(20-50%之二氯甲烷/己烷)。將固體以己烷沖洗且乾燥,以供給成為白色粉末的純化合物(0.80公克,17%)。1H NMR(300MHz,CDCl3)δ 8.05(br s,1H),7.94(dd,1H,J=8.7,5.7Hz),7.67(dd,1H,J=8.7,2.7Hz),7.35(dd,1H,J=9.0,4.5Hz),7.14(td,1H,J=9.0,2.7Hz),7.11(dd,1H,J=9.3,2.4Hz),6.98(ddd,1H,J=9.3,8.4,2.4Hz)。
將85%之氫氧化鉀(0.179公克,2.7毫莫耳)添加至0℃下在N,N-二甲基甲醯胺(5毫升)中的2,6-二氟-9H-咔唑(0.460公克,2.3毫莫耳)之攪拌溶液中且將混合物攪拌1
小時。添加表溴醇(0.375毫升,4.5毫莫耳),將混合物緩慢溫熱至室溫且攪拌16小時。將混合物分溶在水與乙酸乙酯之間。將有機層以飽和水性氯化鈉清洗,乾燥(無水硫酸鈉),過濾且在真空中濃縮。將殘餘物以矽膠層析術純化(10-50%之二氯甲烷/己烷),以供給成為白色固體的所欲產物(0.55公克,94%)。1H NMR(300MHz,CDCl3)δ 7.95(dd,1H,J=8.7,5.7Hz),7.68(dd,1H,J=8.7,2.7Hz),7.38(dd,1H,J=8.7,4.2Hz),7.20(td,1H,J=9.0,2.7Hz),7.13(dd,1H,J=9.9,2.1Hz),6.98(ddd,1H,J=9.6,9.0,2.4Hz),4.64(dd,1H,J=15.9,2.7Hz),4.29(dd,1H,J=15.9,5.1Hz),3.35(m,1H),2.85(t,1H,J=4.5Hz),2.56(dd,1H,J=4.8,2.4Hz)。
將肆(三苯膦)鈀(0)(0.394公克,0.3毫莫耳)添加至氬氣下的2-溴-3-氟硝基苯(1.500公克,6.8毫莫耳)、2-氟苯基硼酸(1.145公克,8.2毫莫耳)、N,N-二甲基甲醯胺(50毫升)及2.0M水性碳酸鉀(10毫升)之溶液中。將混合物在110℃下攪拌16小時。在冷卻至室溫之後,將混合物以乙酸乙酯(100毫升)稀釋且以飽和水性氯化鈉清洗,乾
燥(無水硫酸鈉),過濾且在真空中濃縮。將殘餘物以矽膠層析術純化(0-30%之二氯甲烷/己烷),以供給淡黃色固體(0.780公克,49%)。1H NMR(300MHz,CDCl3)δ 7.86(dt,1H,J=7.8,1.2Hz),7.56(td,1H,J=8.1,5.7Hz),7.52-7.40(m,2H),7.35-7.15(m,3H)。
將無水1,2-二氯苯(1.5毫升)中的2,2'-二氟-6-硝基-1,1'-聯苯(0.740公克,3.1毫莫耳)及三苯膦(2.063公克,7.9毫莫耳)之溶液在微波反應器中加熱至175℃經3小時。將混合物冷卻至室溫且以矽膠層析術純化(5-50%之二氯甲烷/己烷),以供給成為白色固體的產物(0.28公克,44%)。1H NMR(CDCl3,300MHz)δ 8.26(br s,1H),7.39(tt,2H,J=8.1,2.4Hz),7.22(d,2H,J=8.1Hz),6.97(dt,2H,J=8.1,5.1Hz)。
將85%之氫氧化鉀(0.105公克,1.6毫莫耳)添加至0℃下在N,N-二甲基甲醯胺(5毫升)中的4,5-二氟-9H-咔唑(0.270公克,1.3毫莫耳)之攪拌溶液中且將混合物攪拌1小時。添加表溴醇(0.220毫升,2.7毫莫耳),將混合物緩慢溫熱至室溫且攪拌4小時。將混合物分溶在水與乙酸乙酯之間。將有機層以飽和水性氯化鈉清洗,乾燥(無水硫酸鈉),過濾且在真空中濃縮。將殘餘物以矽膠層析術純化(10-50%之二氯甲烷/己烷),以供給成為白色固體的所欲產物(0.315公克,91%)。1H NMR(300MHz,CDCl3)δ 7.45(tt,2H,J=8.1,2.4Hz),7.25(d,2H,J=8.1Hz),6.99(dt,2H,J=9.9,4.2Hz),4.68(dd,1H,J=15.9,3.0Hz),4.38(dd,1H,J=15.9,5.1Hz),3.37(m,1H),2.85(t,1H,J=4.5Hz),2.57(dd,1H,J=4.5,2.4Hz)。
將肆(三苯膦)鈀(0)(0.394公克,0.3毫莫耳)添加至氬氣下的2-溴-4-氟硝基苯(1.500公克,6.8毫莫耳)、2-氟苯基硼酸(1.145公克,8.2毫莫耳)、N,N-二甲基乙醯胺(50毫升)及2.0M水性碳酸鉀(10毫升)之溶液中。將混合物
在110℃下攪拌6小時。在冷卻至室溫之後,將混合物分溶在乙酸乙酯(100毫升)與水之間。將有機層以飽和水性氯化鈉清洗,乾燥(無水硫酸鈉),過濾且在真空中濃縮。將殘餘物以矽膠層析術純化(0-30%之二氯甲烷/己烷),以供給淺黃色油(1.5公克,94%)。1H NMR(300MHz,CDCl3)δ 8.12(dd,1H,J=9.0,5.1Hz),7.44(m,1H),7.34(td,1H,J=7.5,2.1Hz),7.31-7.10(m,4H)。
將無水1,2-二氯苯(5毫升)中的2',5-二氟-2-硝基-1,1'-聯苯(1.400公克,6.0毫莫耳)及三苯膦(3.903公克,14.9毫莫耳)之溶液在微波反應器中加熱至175℃經4小時。將混合物冷卻至室溫且以矽膠層析術純化(5-50%之二氯甲烷/己烷),以供給成為淺棕色固體的產物(0.62公克,51%)。1H NMR(CDCl3,300MHz)δ 8.12(br s,1H),7.87(dd,1H,J=9.0,2.4Hz),7.41-7.31(m,2H),7.24-7.15(m,2H),6.91(dd,1H,J=10.2,8.1Hz)。
將85%之氫氧化鉀(0.117公克,1.8毫莫耳)添加至0℃下在N,N-二甲基甲醯胺(5毫升)中的3,5-二氟-9H-咔唑(0.300公克,1.5毫莫耳)之攪拌溶液中且將混合物攪拌1小時。添加表溴醇(0.244毫升,3.0毫莫耳),將混合物緩慢溫熱至室溫且攪拌4小時。將混合物分溶在水與乙酸乙酯之間。將有機層以飽和水性氯化鈉清洗,乾燥(無水硫酸鈉),過濾且在真空中濃縮。將殘餘物以矽膠層析術純化(10-50%之二氯甲烷/己烷),以供給成為灰白色固體的所欲產物(0.36公克,94%)。1H NMR(300MHz,CDCl3)δ 7.88(dd,1H,J=8.7,2.7Hz),7.46-7.36(m,2H),7.29-7.20(m,2H),6.92(dd,1H,J=9.9,7.8Hz),4.68(dd,1H,J=15.9,3.0Hz),4.35(dd,1H,J=15.9,5.1Hz),3.36(m,1H),2.85(t,1H,J=4.5Hz),2.56(dd,1H,J=4.5,2.7Hz)。
將乙烷磺醯氯(2.967公克,23.1毫莫耳)緩慢添加至0
℃下在無水乙腈(60毫升)及三乙胺(7.056毫升,50.8毫莫耳)中的3-氯丙胺鹽酸鹽(3.000公克,23.1毫莫耳)之攪拌溶液中。將反應混合物緩慢溫熱至室溫且攪拌16小時。以過濾移除三乙胺鹽酸鹽且將濾餅以四氫呋喃清洗。將過濾物濃縮,將殘餘物溶解在乙酸乙酯中且以飽和水性碳酸氫鈉和飽和水性氯化鈉清洗,乾燥(無水硫酸鈉),過濾且濃縮,以供給鹵基磺醯胺中間物(4.35公克),將其溶解在無水四氫呋喃(60毫升)中且冷卻至-30℃。在添加二異丙胺(0.584公克,5.8毫莫耳)及1,10-啡啉(0.010公克)之後,經由滴液漏斗經30分鐘期間緩慢添加在己烷中的n-BuLi溶液(50毫莫耳,2.5M),維持-30℃至-10℃之內部溫度。將所得溶液經2小時緩慢溫熱至0℃。在0℃下再2小時之後,將反應以添加2N水性氫氯酸(pH調整至5)中止。在添加飽和水性氯化鈉之後,將混合物以乙酸乙酯萃取。將有機層以飽和水性氯化鈉清洗,乾燥(無水硫酸鎂),過濾且濃縮,以供給成為黃色油的產物(2.73公克,79%)。1H NMR(300MHz,CDCl3)δ 4.20(br s,1H),3.54-3.28(m,2H),3.06(m,1H),2.13(m,1H),1.98(m,1H),1.77(m,1H),1.65(m,1H),1.41(d,3H,J=6.6Hz)。
將水(15毫升)中的4-溴-1-丁烯(3.000公克,22.2毫莫耳)與亞硫酸鈉(3.356公克,26.6毫莫耳)之混合物在回流下加熱16小時。在冷卻至室溫之後,將水溶液以二乙醚清洗且在真空中濃縮,以供給白色粉末,將其在真空下於100℃下乾燥,得到粗製丁-3-烯-1-磺酸與鹽之混合物(約6.2公克),接著將其以磷醯氯(20.7毫升,222.2毫莫耳)處理。將混合物在130℃下加熱6小時且接著濃縮。將殘餘物以乙腈(50毫升)處理且在0℃下緩慢引入氨氣。將混合物在0℃下攪拌1小時,接著以水稀釋且以乙酸乙酯萃取(100毫升)。將有機層以飽和水性氯化鈉清洗,乾燥(無水硫酸鈉),過濾且濃縮,以供給黃色油(2.1公克,70%)。1H NMR(300MHz,CDCl3)δ 5.85(m,1H),5.19(d,1H,J=17.4Hz),5.15(d,1H,J=9.9Hz),4.69(br s,2H),3.24(t,2H,J=7.5Hz),2.65(q,2H,J=7.5Hz)。
將乙酸銠(II)(0.80公克)添加至氬氣及室溫下的丁-3-烯-1-磺醯胺(1.300公克,9.6毫莫耳)、氧碘基苯二乙酸酯(3.252公克,10.1毫莫耳)、氧化鋁(1.030公克,10.1毫莫耳)與二氯甲烷(50毫升)之混合物中。將所得懸浮液在40℃下劇烈攪拌5小時。將混合物經由矽藻土墊過濾且將
濾餅以二氯甲烷清洗。將過濾物蒸發且將殘餘物以矽膠層析術純化(0-100%之乙酸乙酯/己烷),以供給成為白色固體的產物(0.61公克,48%)。1H NMR(300MHz,CDCl3)δ 3.21(m,1H),3.15(dt,1H,J=13.2,4.5Hz),2.82(m,1H),2.72-2.62(m,2H),2.49(dd,1H,J=5.1,2.4Hz),2.31(dd,1H,J=4.5,3.0Hz)。
將2-硫雜-1-氮雜雙環[3.1.0]己烷2,2-二氧化物(0.600公克,4.5毫莫耳)、對-甲苯磺酸水合物(0.086公克,0.5毫莫耳)與甲醇(50毫升)之混合物在室溫下攪拌3天。將反應濃縮且將殘餘物以矽膠層析術純化(0-100%之乙酸乙酯/己烷),以供給成為白色固體的產物(0.56公克,75%)。1H NMR(300MHz,CDCl3)δ 4.43(br s,1H),3.65-3.40(m,2H),3.40(s,3H),3.36-3.23(m,2H),3.08(dt,1H,J=13.5,3.9Hz),2.50-2.23(m,2H)。
將礦油中的60%之氫化鈉(0.718公克,17.9毫莫耳)添加至0℃下在無水N,N-二甲基甲醯胺(30毫升)中的咔唑(2.500公克,15.0毫莫耳)之攪拌溶液中且將混合物在0℃下攪拌1小時。添加3-氯-3-甲基-1-丁炔(2.300公克,22.4毫莫耳),將反應混合物在0℃下攪1小時,接著緩慢溫熱至室溫且攪拌16小時。將混合物分溶在水與乙酸乙酯之間。將有機層以飽和水性氯化鈉清洗,乾燥(無水硫酸鈉),過濾且在真空中濃縮。將殘餘物以矽膠層析術純化(10-70%之二氯甲烷/己烷),以供給成為淺棕色固體的所欲產物(1.7公克,49%)。1H NMR(300MHz,CDCl3)δ 8.10(d,2H,J=7.5Hz),8.04(d,2H,J=8.7Hz),7.41(td,2H,J=8.1,1.5Hz),7.24(t,2H,J=7.5Hz),2.67(s,1H),2.28(s,6H)。
將9-(2-甲基丁-3-炔-2-基)-9H-咔唑(1.600公克,6.9毫莫耳)、喹啉(0.810毫升,6.9毫莫耳)、苯(70.0毫升)與
5%之鈀/硫酸鋇(0.190公克)之混合物在氫氛圍及室溫下攪拌。一旦消耗所欲氫量時(~45分鐘),停止反應,經由矽藻土過濾且將過濾物在真空中濃縮。將殘餘物以矽膠層析術純化(0-20%之二氯甲烷/己烷),以供給成為無色油的所欲產物(1.55公克,96%)。1H NMR(300MHz,CDCl3)δ 8.10(d,2H,J=7.5Hz),7.81(d,2H,J=8.4Hz),7.35(t,2H,J=8.1Hz),7.21(t,2H,J=7.5Hz),6.41(dd,1H,J=17.7,10.5Hz),5.32-5.20(m,2H),2.06(s,6H)。
將4%之四氧化鋨溶液(0.540毫升,0.1毫莫耳)添加至乙腈(10毫升)及水(3毫升)中的9-(2-甲基丁-3-烯-2-基)-9H-咔唑(0.400公克,1.7毫莫耳)及4-甲基嗎啉N-氧化物(0.398公克,3.4毫莫耳)之攪拌溶液中。將混合物在室溫下攪拌48小時。將反應濃縮且將殘餘物分溶在乙酸乙酯與水之間。將有機層以飽和水性氯化鈉清洗,乾燥(無水硫酸鈉),過濾且濃縮,得到黃色固體(0.43公克,94%)。1H NMR(300MHz,CDCl3)δ 8.10(d,2H,J=7.5Hz),7.84(d,2H,J=8.4Hz),7.37(t,2H,J=7.5Hz),7.23(t,2H,J=7.5Hz),4.84(m,1H),3.80-3.50(m,2H),2.30(br s,
1H),2.11(s,3H),2.05(s,3H),1.82(br s,1H)。ESI m/z:269.8(M+H)。
將對-甲苯磺醯氯(0.609公克,3.2毫莫耳)緩慢添加至0℃下在吡啶(5.0毫升,61.8毫莫耳)及二氯甲烷(5毫升)中的3-(9H-咔唑-9-基)-3-甲基丁-1,2-二醇(0.430公克,1.6毫莫耳)之攪拌溶液中。將反應混合物溫熱至室溫且攪拌16小時。將混合物濃縮且將殘餘物溶解在乙酸乙酯中。將有機相以飽和水性氯化鈉、1N水性氫氯酸和接著飽和水性碳酸氫鈉清洗,乾燥(無水硫酸鈉),過濾且濃縮,以供應粗製甲苯磺酸酯(0.650公克)。將碳酸鉀(0.255公克,1.8毫莫耳)添加至0℃下在甲醇(20毫升)中的粗製甲苯磺酸酯(0.650公克,1.5毫莫耳)之攪拌混合物中。將所得混合物在0℃下攪拌2小時且接著緩慢溫熱至室溫。將混合物濃縮且將殘餘物分溶在水與乙酸乙酯之間。將有機層以飽和水性氯化鈉清洗,乾燥(無水硫酸鈉),過濾且在真空中濃縮。將殘餘物以矽膠層析術純化(0-50%之二氯甲烷/己烷),以供給成為白色固體的所欲產物(0.295公克,76%)。1H NMR(300MHz,CDCl3)δ 8.10(d,2H,J=
7.5Hz),7.91(d,2H,J=8.7Hz),7.39(t,2H,J=7.5Hz),7.23(t,2H,J=7.5Hz),3.66(m,1H),3.09(t,1H,J=4.2Hz),2.98(m,1H),1.96(s,3H),1.86(s,3H)。
將礦油中的60%之氫化鈉(1.981公克,49.5毫莫耳)添加至0℃下在無水N,N-二甲基甲醯胺(30毫升)中的1,3-丙烷磺內醯胺(2.000公克,16.5毫莫耳)之攪拌溶液中且將混合物在0℃下攪拌1小時。添加3-氯-3-甲基-1-丁炔(2.300公克,22.4毫莫耳),將反應混合物在0℃下攪拌1小時,接著緩慢溫熱至室溫且攪拌16小時。將反應小心地以水中止且以乙酸乙酯萃取。將有機層以飽和水性氯化鈉清洗,乾燥(無水硫酸鈉)且在真空中濃縮。將殘餘物以矽膠層析術純化(0-70%之乙酸乙酯/己烷),以供給成為黃色油的所欲產物(1.35公克,44%)。1H NMR(300MHz,CDCl3)δ 3.52(t,2H,J=6.6Hz),3.23(t,2H,J=7.5Hz),2.46(s,1H),2.42-2.28(m,2H),1.74(s,6H)。
將2-(2-甲基丁-3-炔-2-基)-異噻唑啶-1,1-二氧化物(1.350公克,7.2毫莫耳)、喹啉(0.852毫升,7.2毫莫耳)、苯(70.0毫升)與5%之鈀/硫酸鋇(0.20公克)之混合物在氫氛圍及室溫下攪拌。一旦消耗所欲氫量時(~1小時),停止反應,經由矽藻土過濾且將過濾物濃縮。將殘餘物以矽膠層析術純化(0-70%之乙酸乙酯/己烷),以供給成為淡黃色油的含有約40%喹啉之產物(2.22公克)。1H NMR(300MHz,CDCl3)δ 6.04(dd,1H,J=17.4,10.5Hz),5.16(d,1H,J=17.4Hz),5.15(d,1H,J=10.8Hz),3.29(t,2H,J=6.6Hz),3.21(t,2H,J=7.5Hz),2.35-2.20(m,2H),1.56(s,6H)。
製法66:2-(2-(環氧乙烷-2-基)丙-2-基)-異噻唑啶-1,1-二氧化物
將4%之四氧化鋨溶液(1.007毫升,0.2毫莫耳)添加至乙腈(10毫升)及水(3毫升)中的60%之2-(2-甲基丁-3-烯-2-基)異噻唑啶1,1-二氧化物(1.0公克,3.2毫莫耳)、
4-甲基嗎啉N-氧化物(0.743公克,6.3毫莫耳)之攪拌溶液中。將混合物在室溫下攪拌48小時。將反應濃縮且將殘餘物分溶在乙酸乙酯與水之間。將有機層以飽和水性氯化鈉清洗,乾燥(無水硫酸鈉),過濾且濃縮,得到粗製二元醇。將對-甲苯磺醯氯(0.111公克,0.6毫莫耳)緩慢添加至0℃下在吡啶(1.0毫升,12.4毫莫耳)及二氯甲烷(2毫升)中的2-(3,4-二羥基-2-甲基丁-2-基)-異噻唑啶-1,1-二氧化物(0.065公克,0.3毫莫耳)之攪拌溶液中。將反應混合物溫熱至室溫且攪拌16小時。將混合物濃縮且將殘餘物溶解在乙酸乙酯中。將有機相以飽和水性氯化鈉、1N水性氫氯酸、飽和水性碳酸氫鈉清洗,乾燥(無水硫酸鈉),過濾且濃縮,以供給粗製甲苯磺酸酯(0.040公克)。將碳酸鉀(0.048公克,0.3毫莫耳)添加至0℃下在甲醇(5毫升)中的粗製甲苯磺酸酯(0.040公克,0.1毫莫耳)之攪拌混合物中,且將混合物在0℃下攪拌2小時及接著緩慢溫熱至室溫。將混合物濃縮且將殘餘物分溶在水與乙酸乙酯之間。將有機層以飽和水性氯化鈉清洗,乾燥(無水硫酸鈉),過濾且濃縮,得到粗製環氧化物(0.02公克),使用未進一步純化之粗製物。
將85%之氫氧化鉀(0.780公克,11.8毫莫耳)添加至0℃下在N,N-二甲基甲醯胺(50毫升)中的3,6-二氟-9H-咔唑(2.0公克,9.8毫莫耳)之攪拌溶液中且將混合物攪拌1小時。添加2-(氯甲基)-2-甲基環氧乙烷(2.098公克,19.7毫莫耳),將混合物緩慢溫熱至室溫且攪拌16小時。將混合物分溶在水與乙酸乙酯之間。將有機層以飽和水性氯化鈉清洗,乾燥(無水硫酸鈉),過濾且在真空中濃縮。將殘餘物以矽膠層析術純化(10-50%之二氯甲烷/己烷),以供給成為白色固體的所欲產物(1.7公克,63%)。1H NMR(300MHz,CDCl3)δ 7.68(dd,2H,J=8.4,2.4Hz),7.41(dd,2H,J=9.0,4.2Hz),7.23(td,2H,J=9.0,2.4Hz),4.62與4.22(AB,2H,J=15.6Hz),2.71 & 2.66(AB,2H,J=4.5Hz),1.33(s,3H)。
將甲烷磺醯氯(1.571毫升,20.3毫莫耳)緩慢添加至0
℃下在二氯甲烷(30毫升)中的2-胺基丙烷(1.200公克,20.3毫莫耳)、N,N-二異丙基乙胺(3.355毫升,20.3毫莫耳)及吡啶(1.642毫升,20.3毫莫耳)之攪拌溶液中。將反應混合物緩慢溫熱至室溫且攪拌16小時。將混合物濃縮且將殘餘物以矽膠層析術純化(0-80%之乙酸乙酯/己烷),以供給低熔融固體的產物(2.7公克,97%)。1H NMR(300MHz,CDCl3)δ 4.25(br s,1H),3.67(m,1H),2.99(s,3H),1.27(d,6H,J=6.6Hz)。
將甲烷磺醯氯(1.627毫升,21.0毫莫耳)緩慢添加至0℃下在二氯甲烷(30毫升)中的環丙胺(1.200公克,21.0毫莫耳)、N,N-二異丙基乙胺(3.474毫升,21.0毫莫耳)及吡啶(1.700毫升,21.0毫莫耳)之攪拌溶液中。將反應混合物緩慢溫熱至室溫且攪拌16小時。將混合物濃縮且將殘餘物以矽膠層析術純化(0-80%之乙酸乙酯/己烷),以供給成為低熔融固體的產物(2.7公克,95%)。1H NMR(300MHz,CDCl3)δ 4.86(br s,1H),3.02(s,3H),2.60(m,1H),0.85-0.65(m,4H)。
將甲烷磺醯氯(0.435毫升,5.6毫莫耳)緩慢添加至0℃下在二氯甲烷(10毫升)中的環丁胺(0.400公克,5.6毫莫耳)、N,N-二異丙基乙胺(0.930毫升,5.6毫莫耳)及吡啶(0.455毫升,5.6毫莫耳)之攪拌溶液中。將反應混合物緩慢溫熱至室溫且攪拌16小時。將混合物濃縮且將殘餘物以矽膠層析術純化(0-80%之乙酸乙酯/己烷),以供給成為低熔融固體的產物(0.82公克,98%)。1H NMR(300MHz,CDCl3)δ 4.62(br s,1H),3.94(m,1H),2.94(s,3H),2.50-2.30(m,2H),2.10-1.85(m,2H),1.85-1.60(m,2H)。
將無水四氫呋喃(10毫升)中的1,1-(偶氮二羰基)二哌啶(1.874公克,7.4毫莫耳)之溶液逐滴添加至無水四氫呋喃(20毫升)中的1,3-丙烷磺內醯胺(0.6公克,4.95毫莫耳)、三苯膦(1.95公克,7.4毫莫耳)及2,4-二甲氧基苯甲醇(1.0公克,6.2毫莫耳)之0℃溶液中。將所得溶液在0
℃下攪拌3小時,溫熱至室溫且再攪拌16小時。將溶液在減壓下濃縮且懸浮在乙酸乙酯/己烷中,以沉澱白色固體。以過濾移出固體且將過濾物以矽膠層析術純化(25-70%之乙酸乙酯/己烷),得到淡黃色油(0.505公克)。1H NMR(CDCl3,300MHz)δ 7.31-7.28(dd,1H,J=0.6,7.8Hz),6.49-6.44(m,2H),4.17(s,2H),3.81(s,3H),3.80(s,3H),3.19-3.13(m,4H),2.32-2.23(m,2H)。
將正丁基鋰(11.5毫升,在己烷中的2.5N)緩慢添加至在氮氛圍下且冷卻至-78℃之無水四氫呋喃(200毫升)中的2-(2,4-二甲氧基苯甲基)-異噻唑啶-1,1-二氧化物(4.0公克,14.7毫莫耳)之溶液中且將所得溶液攪拌1.5小時。經30分鐘緩慢添加冷卻至0℃之無水四氫呋喃(60毫升)中的N-氟苯磺醯亞胺(10.5公克,33毫莫耳)之溶液,在-78℃下攪拌3小時,接著溫熱至室溫且再攪拌2.5小時。添加飽和水性氯化銨(250毫升)且將混合物以乙酸乙酯(250毫升)萃取。將有機層以飽和水性氯化鈉清洗,乾燥(無水硫酸鈉),過濾且在真空中濃縮。將粗製產物以二乙
醚萃取,經由燒結之玻璃濾器過濾,以移除不可溶產物。將固體以少量二氯甲烷萃取,將過濾物通過矽膠塞(以50%之乙酸乙酯/己烷清洗)且與二乙醚萃取物合併。將合併的有機溶液濃縮且以矽膠層析術純化(20-60%之乙酸乙酯/己烷)。將此材料以製備性HPLC進一步純化(具有乙腈/水梯度之C18管柱),得到低熔融黃褐色固體(0.519公克)。1H NMR(CDCl3,300MHz)δ 7.24-7.21(d,1H,J=7.5Hz),6.49-6.44(m,2H),5.51-5.31(ddd,1H,J=1.8,5.1,54Hz),4.44-4.39(d,1H,J=2.7Hz),4.20-4.15(d,1H,J=2.7Hz),3.82(s,3H),3.81(s,3H),3.27-3.18(m,2H),2.65-2.35(m,2H)。HPLC分析:(C18,在水+0.1%之三氟乙酸中的25-95%之乙腈經10分鐘滯留時間,在254奈米之面積%):7.51分鐘,97%。
將三氟乙酸(25毫升)添加至冷卻至0℃之二氯甲烷(50毫升)中的2-(2,4-二甲氧基苯甲基)5-氟-異噻唑啶-1,1-二氧化物(0.519公克,1.9毫莫耳)之溶液中。將溶液在0℃下攪拌2.5小時且在真空中濃縮。將粗製產物以矽膠層析術純化(20-70%之乙酸乙酯/己烷),得到黃褐色固體(0.212公克)。1H NMR(CDCl3,300MHz)δ 5.52-5.50(ddd,1H,J
=1.5,4.5,53.1Hz),4.57(br s,1H),3.57-3.33(m,2H),2.78-2.48(m,2H)。
將無水吡啶(4.75毫升,58.7毫莫耳)添加至無水二乙醚中的2,4-二甲氧基苯甲醇(4.94公克,29.3毫莫耳)之0.5M溶液中。將混合物冷卻至0℃,經5-10分鐘緩慢添加亞硫醯氯(5.98毫升,80.7毫莫耳)且將反應在0℃下攪拌1.5小時。將反應混合物倒入冰水(120毫升)中且將層分離。將水層以二乙醚萃取(2×60毫升)且將合併的有機層以冰水(60毫升)和飽和水性氯化鈉:飽和水性碳酸氫鈉之5:1溶液(2×60毫升)清洗,乾燥(無水硫酸鈉),過濾且濃縮成~5毫升液體。將粗製溶液溶解在苯(200毫升)中且再濃縮成10-15毫升液體,將其立即用於下一步驟中。將無水N,N-二甲基甲醯胺(50毫升)中的1,4-丁烷磺內醯胺(2.800公克,20.7毫莫耳)冷卻至0℃且以小份量添加氫化鈉,在0℃下攪拌5分鐘及在室溫下攪拌1小時。反應變成泥漿,冷卻至0℃且添加在苯中的1-(氯甲基)-2,4-二甲氧基苯之溶液,在0℃下攪拌,緩慢溫熱至室溫且攪拌16
小時。將混合物倒入水(300毫升)中且以乙酸乙酯萃取(3x)。將合併的有機層以水、飽和水性氯化鈉清洗,乾燥(無水硫酸鈉),過濾且在真空中濃縮。將粗製材料以矽膠層析術純化(15-60%之乙酸乙酯/己烷),得到白色固體(4.78公克)。1H NMR(300MHz,CDCl3)δ 7.28-7.25(d,1H,J=8.4Hz),6.48-6.45(dd,1H,J=2.4,8.1Hz),6.43-6.42(d,1H,J=2.1Hz),4.29(s,2H),3.79(s,6H),3.31-3.27(m,2H),3.04-3.00(m,2H),2.18-2.15(m,2H),1.60-1.56(m,2H)。HPLC分析:(C18,在水+0.1%之三氟乙酸中的25-99%之乙腈經10分鐘滯留時間,在254奈米之面積%):6.93分鐘,98%。
將無水四氫呋喃(250毫升)中的2-(2,4-二甲氧基苯甲基)-1,2-噻-1,1-二氧化物(4.780公克,16.8毫莫耳)冷卻至-78℃且逐滴添加正丁基鋰(13毫升,在己烷中的2.5N)。將反應在-78℃下攪拌1小時且經20分鐘逐滴添加在無水四氫呋喃(50毫升)中的N-氟苯磺醯亞胺(11.885公克,37.7毫莫耳)之溶液。將所得溶液在-78℃下攪拌3
小時及在室溫下攪拌1小時。將反應混合物倒入飽和水性氯化銨中且以乙酸乙酯萃取(2x)。將合併的有機層以水、飽和水性氯化鈉清洗,乾燥(無水硫酸鈉),過濾且在減壓下濃縮。將粗製殘餘物以乙酸乙酯/己烷萃取,濾出固體沉澱物且將溶液濃縮。將粗製材料以矽膠層析術(20-60%之乙酸乙酯/己烷),接著以製備性HPLC(C18,25-95%之乙腈/水+0.1%之二乙胺)純化,得到淡黃色油(0.99公克)。1H NMR(300MHz,CDCl3)δ 7.26-7.24(d,1H,J=8.1Hz),6.49-6.46(dd,1H,J=8.1,2.4Hz),6.44-6.43(d,1H,J=2.4Hz),5.35-5.16(m,1H),4.55-4.37(dd,2H,J=15.0,38.4Hz),3.81(s,3H),3.80(s,3H),3.50-3.46(m,1H),3.26-3.22(m,1H),2.60-2.42(m,2H),2.02-1.97(m,1H),1.47-1.39(m,1H)。19F NMR(CDCl3,400MHz)δ -156.7(t,1F,J=42Hz)。HPLC分析:(C18,在水+0.1%之三氟乙酸中的10-95%之乙腈經20分鐘滯留時間,在254奈米之面積%):13.5分鐘,97%。
將二氯甲烷(40毫升)中的2-(2,4-二甲氧基苯甲基)-6-氟-1,2-噻-1,1-二氧化物(0.532公克,1.8毫莫耳)冷卻至0℃。添加三氟乙酸(25毫升)且將所得紅色溶液在0℃
下攪拌1.5小時,在減壓下濃縮。將粗製產物以矽膠層析術純化(20-70%之乙酸乙酯/己烷),得到澄清液體(0.213公克,79%)。1H NMR(300MHz,CDCl3)δ 5.35-5.33(dd,0.5H,J=5.0,2.4Hz),5.19-5.17(t,0.5H,J=3.6Hz),4.76(br s,1H),3.52-3.32(m,2H),2.56-2.40(m,2H),1.91-1.81(m,1H),1.59-1.52(m,1H)。
將己烷中的2.5N正丁基鋰(1.262毫升,3.2毫莫耳)緩慢添加至冷卻至-78℃之無水四氫呋喃(30毫升)中的2-(2,4-二甲氧基苯甲基)-6-氟-1,2-噻-1,1-二氧化物(0.500公克,1.8毫莫耳)之溶液中。將溶液在-78℃下攪拌1小時,經10分鐘緩慢添加在無水四氫呋喃(5毫升)中的N-氟苯磺醯亞胺(1.243公克,3.9毫莫耳)之溶液且將混合物在-78℃下攪拌3小時及在室溫下攪拌3小時。將反應混合物倒入飽和水性氯化銨中且以乙酸乙酯萃取(2x)。將合併的有機層以水、飽和水性氯化鈉清洗,乾燥(無水硫酸鈉),過濾且在真空中濃縮。將粗製產物以矽膠層析術純化(15-60%之乙酸乙酯/己烷),得到黃色油(0.09公
克)。1H NMR(CDCl3,300MHz)δ 7.25-7.21(d,1H,J=8.4Hz),6.50-6.47(dd,1H,J=2.4,8.4Hz),6.45-6.44(d,1H,J=2.4Hz),4.43(s,2H),3.82(s,3H),3.81(s,3H),3.38-3.37(t,2H,J=5.1Hz),2.58-2.45(m,2H),2.00-1.92(m,2H)。
將三氟乙酸(4毫升)添加至二氯甲烷(7毫升)中的2-(2,4-二甲氧基苯甲基)-6,6-二氟-1,2-噻-1,1-二氧化物(0.090公克,0.3毫莫耳)之溶液中且將所得紅色溶液在室溫下攪拌3小時。將混合物在真空中濃縮,以供給粗製殘餘物。將粗製產物以矽膠層析術純化(10-60%之乙酸乙酯/己烷),得到澄清油(0.034公克)。1H NMR(CDCl3,300MHz)δ 4.85(br s,1H),3.46-3.40(m,2H),2.60-2.47(m,2H),2.01-1.93(m,2H)。
將2-丙烷磺醯氯(1.0毫升,8.9毫莫耳)緩慢添加至0℃下在吡啶(10毫升)中的呋喃甲基胺(1.040公克,10.7毫莫耳)之攪拌溶液中。將反應混合物溫熱至室溫且攪拌16小時。將混合物濃縮且將殘餘物溶解在乙酸乙酯中。將有機層以1N水性氫氯酸、飽和水性碳酸氫鈉、飽和水性氯化鈉清洗,乾燥(無水硫酸鈉),過濾且在真空中濃縮。將殘餘物以矽膠層析術純化(0-50%之乙酸乙酯/己烷),以供給成為淡黃色濃稠油的產物(0.84公克,46%)。1H NMR(300MHz,CDCl3)δ 7.40(dd,1H,J=1.8,0.9Hz),6.35(dd,1H,J=3.3,1.8Hz),6.29(d,1H,J=3.3Hz),4.42(br s,1H),4.33(d,2H,J=5.7Hz),3.08(m,1H),1.35(d,6H,J=6.9Hz)。
將三氟甲烷磺醯氯(1.300公克,7.7毫莫耳)緩慢添加至0℃下在吡啶(10毫升)中的呋喃甲基胺(0.899公克,9.3毫莫耳)之攪拌溶液中。將反應混合物溫熱至室溫且攪拌16小時。將混合物濃縮且將殘餘物溶解在乙酸乙酯中。將有機層以1N水性氫氯酸、飽和水性碳酸氫鈉、飽和水
性氯化鈉清洗,乾燥(無水硫酸鈉),過濾且在真空中濃縮。將殘餘物以矽膠層析術純化(0-50%之乙酸乙酯/己烷),以供給成為淡黃色油的產物(1.5公克,85%)。1H NMR(300MHz,CDCl3)δ 7.43(dd,1H,J=1.8,0.9Hz),6.38(dd,1H,J=3.3,1.8Hz),6.36(d,1H,J=3.3Hz),5.10(br s,1H),4.48(s,2H)。
將環己烷磺醯氯(0.500公克,2.7毫莫耳)緩慢添加至0℃下在吡啶(5毫升)中的呋喃甲基胺(0.319公克,3.3毫莫耳)之攪拌溶液中。將反應混合物溫熱至室溫且攪拌16小時。將混合物濃縮且將殘餘物溶解在乙酸乙酯中。將有機層以1N水性氫氯酸、飽和水性碳酸氫鈉、飽和水性氯化鈉清洗,乾燥(無水硫酸鈉),過濾且在真空中濃縮。將殘餘物以矽膠層析術純化(0-50%之乙酸乙酯/己烷),以供給成為白色固體的產物(0.325公克,49%)。1H NMR(300MHz,CDCl3)δ 7.40(dd,1H,J=1.8,0.9Hz),6.35(dd,1H,J=3.3,2.1Hz),6.30(d,1H,J=3.0Hz),4.43(m,1H),4.32(d,2H,J=5.7Hz),2.75(tt,1H,J=12.0,3.3Hz),2.15-2.05(m,2H),1.95-1.80(m,2H),1.70(m,1H),
1.60-1.40(m,2H),1.30-1.10(m,3H)。
將四氫呋喃-3-磺醯氯(0.250公克,1.5毫莫耳)緩慢添加至0℃下在吡啶(2毫升)中的呋喃甲基胺(0.171公克,1.8毫莫耳)之攪拌溶液中。將反應混合物溫熱至室溫且攪拌16小時。將混合物濃縮且將殘餘物溶解在乙酸乙酯中。將有機層以1N水性氫氯酸、飽和水性碳酸氫鈉、飽和水性氯化鈉清洗,乾燥(無水硫酸鈉),過濾且在真空中濃縮。將殘餘物以矽膠層析術純化(0-50%之乙酸乙酯/己烷),以供給成為濃稠油的產物(0.220公克,65%)。1H NMR(300MHz,CDCl3)δ 7.41(s,1H),6.36(dd,1H,J=3.3,2.1Hz),6.31(d,1H,J=3.3Hz),4.68(t,1H,J=5.4Hz),4.36(d,2H,J=6.0Hz),4.05(dd,1H,J=10.2,5.7Hz),4.02-3.78(m,3H),3.65(m,1H),2.36-2.10(m,2H)。
將胺基磺醯胺(2.282公克,23.7毫莫耳)添加至吡啶(20毫升)中的1,3-二胺基丙烷(1.0毫升,11.9毫莫耳)之攪拌混合物中。將混合物在120℃之油浴中加熱16小時。在冷卻至室溫之後,將混合物濃縮且將殘餘物分溶在乙酸乙酯與飽和水性氯化鈉之間。將有機層以1N水性氫氯酸、飽和水性氯化鈉清洗,乾燥(無水硫酸鈉),過濾且濃縮,以供給白色固體(0.085公克,5%)。1H NMR(300MHz,CDCl3)δ 4.26(br s,2H),3.70-3.50(m,4H),1.80-1.60(m,2H)。
將胺基磺醯胺(1.877公克,19.5毫莫耳)添加至吡啶(20毫升)中的N-甲基-1,3-二胺基丙烷(1.70毫升,16.3毫莫耳)之攪拌混合物中。將混合物在120℃之油浴中加熱16小時。在冷卻至室溫之後,將混合物濃縮且將殘餘物分溶在乙酸乙酯與飽和水性氯化鈉之間。將有機層以1N水性氫氯酸、飽和水性氯化鈉清洗,乾燥(無水硫酸鈉),過濾且濃縮,以供給無色油(1.3公克,53%)。1H NMR(300MHz,CDCl3)δ 4.11(br s,1H),3.60-3.48(m,2H),3.32(t,2H,J=5.7Hz),2.78(s,3H),1.85-1.72(m,2H)。
將無水甲苯(65毫升)中的97%之順式與反式的3-甲氧基環己烷羧酸之混合物(1.50公克,9.5毫莫耳)、疊氮磷醯二苯酯(2.043毫升,9.5毫莫耳)與三乙胺(1.582毫升,11.4毫莫耳)之混合物在回流下加熱3小時。將混合物冷卻至0℃,添加三甲基矽烷酸鈉(18.964毫升在四氫呋喃中的1M溶液,19.0毫莫耳)且將混合物在室溫下攪拌30分鐘。將反應以5%之水性檸檬酸(100毫升)中止,攪拌,在減壓下濃縮至約一半的體積,以二乙醚清洗(2x),以氫氧化鈉調整至鹼性pH且以二氯甲烷萃取(3x)。將合併的有機層以飽和水性氯化鈉清洗,乾燥(無水硫酸鈉),過濾且在真空中濃縮。將粗製材料以矽膠層析術純化(5-12%之甲醇/二氯甲烷),得到部分純化之材料。將殘餘物溶解在二氯甲烷中且以1N水性氫氯酸萃取(3x)。將合併的水層以15%之水性氫氧化鈉調整至鹼性pH且以二氯甲烷萃取(3x)。將合併的有機部分乾燥(無水硫酸鈉),過濾,濃縮,懸浮在己烷/二氯甲烷中且過濾。濃縮有機物得到黃色液體(0.272公克)。1H NMR(300MHz,CDCl3)(非鏡像異構物之混合物)δ 3.52(m,1H),3.28(s,3H),2.99
(m,1H),1.95-1.00(m,10H)。
將無水甲苯(10毫升)中的7-氧雜雙環[2.2.1]庚烷-2羧酸(0.233公克,1.6毫莫耳)、三乙胺(0.273毫升,2.0毫莫耳)與疊氮磷醯二苯酯(0.353毫升,1.6毫莫耳)之混合物在回流溫度下加熱3小時,接著冷卻至0℃,添加三甲基矽烷酸鈉(3.278毫升在四氫呋喃中的1M溶液,3.3毫莫耳)且在室溫下攪拌1小時。添加5%之水性檸檬酸溶液(15毫升)且將混合物在減壓下濃縮至約一半的體積。將混合物以二乙醚清洗(2x)和以乙酸乙酯清洗一次,將水層以15%之水性氫氧化鈉調整至鹼性pH且以二氯甲烷萃取(3x)。將合併的有機層以飽和水性氯化鈉清洗(+3滴氫氧化鈉),乾燥(無水硫酸鈉),過濾且濃縮,得到澄清液體(0.121公克)。1H NMR(300MHz,CDCl3)(非鏡像異構物之混合物)δ 4.6-4.14(m,2H),3.48-3.42(m,1H),2.21-0.86(m,8H)。
將二乙基胺基三氟化硫(2.170毫升,16.4毫莫耳)逐滴添加至無水二氯甲烷(9毫升)中的(3-側氧環丁基)胺甲酸苯甲酯(0.900公克,4.1毫莫耳)之溶液中。將所得溶液在室溫下攪拌16小時。將混合物倒入冷飽和水性碳酸氫鈉中且攪拌5分鐘。將混合物以二氯甲烷萃取(3x)且將合併的有機層以水、飽和水性氯化鈉連續清洗,乾燥(無水硫酸鈉),過濾且在真空中濃縮。將粗製產物以矽膠層析術純化(5-30%之乙酸乙酯/己烷),得到黃褐色固體(0.6公克)。1H NMR(300MHz,CDCl3)δ 7.36-7.34(m,5H),5.10(s,2H),4.99(br m,1H),4.10(m,1H),2.97(m,2H),2.48(m,2H)。
將甲醇(8毫升)中的(3,3-二氟環丁基)胺甲酸苯甲酯(0.600公克,2.5毫莫耳)及10%之鈀/碳(0.350公克,50%濕)之懸浮液放置在氫氛圍下。在24小時之後,添加額
外的10%之鈀/碳(0.25公克,50%濕)且將混合物再攪拌24小時。將反應混合物經由矽藻土過濾,以甲醇清洗且將濃縮氫氯酸(0.3毫升)添加至甲醇溶液中。將粗製溶液在真空下濃縮,得到灰白色半固體(0.303公克)。1H NMR(d6-DMSO,300MHz)δ 8.61(br s,3H),3.65-3.58(m,1H),2.93-2.81(m,4H)。
將雙(乙腈)二氯-鈀(II)(0.231公克,1.0毫莫耳)及胺甲酸苯甲酯(1.497公克,9.9毫莫耳)添加至無水二氯甲烷(15毫升)中的2-環己烯-1-酮(1.442公克,15.0毫莫耳)之溶液中且在氮氣下攪拌24小時。將反應混合物經由矽膠墊過濾,以乙酸乙酯清洗且在真空中濃縮。將粗製產物以矽膠層析術純化(20-65%之乙酸乙酯/己烷),得到淡黃色低熔融固體(1.9公克)。1H NMR(300MHz,CDCl3)δ 7.34(m,5H),5.09(s,2H),4.81(br s,1H),3.99(br s,1H),2.73(m,1H),2.36-2.26(m,3H),2.11-1.97(m,2H),1.67-1.64(m,2H)。ESI m/z:248.0(M+H)。
將Deoxo-Fluor®(1.1毫升)添加至無水二氯乙烷(8毫升)中的(3-側氧環己基)胺甲酸苯甲酯(1.0公克,4毫莫耳)之溶液中且將混合物在密封的容器中以65℃加熱16小時。將混合物冷卻至0℃且添加冷飽和水性碳酸氫鈉。將混合物以乙酸乙酯萃取(3x)且將合併的有機層以飽和水性氯化鈉清洗,乾燥(無水硫酸鈉),過濾且在真空中濃縮。將粗製產物以矽膠層析術純化(5-40%之乙酸乙酯/己烷),得到白色固體(0.435公克)。1H NMR(300MHz,CDCl3)δ 7.41-7.28(m,5H),5.09(s,2H),4.89(br s,1H),3.92(br s,1H),2.34(m,1H),2.05-1.67(m,6H),1.40(m,1H)。ESI(m/z):269.9(M+H)。
將10%之鈀/碳(0.4公克,50%濕)添加至甲醇(25毫升)中的4%之甲酸中的(3,3-二氟環己基)胺甲酸苯甲酯(0.43公克,1.6毫莫耳)之懸浮液中。將所得混合物在氫氛圍下攪拌20小時。將混合物經由矽藻土過濾,以甲醇
清洗且在真空下濃縮,得到灰白色固體(0.3公克)。1H NMR(d6-DMSO,300MHz)δ 8.36(s,1H),3.03(m,1H),2.97(m,1H),1.97-1.63(m,5H),1.39-1.22(m,2H)。19F NMR(d6-DMSO,400MHz)-60.33--60.97(d,1F,J=252Hz),-70.73--71.54(dt,1F,J=252,36Hz)。ESI(m/z)136.2(M+H)。
將無水四氫呋喃(85毫升)中的2-胺基環己醇(3.524公克,30.6毫莫耳)之溶液冷卻至0℃且分批添加三乙胺(3.402毫升,24.5毫莫耳)及接著苯甲氧基羰基N-琥珀醯亞胺(6.100公克,24.5毫莫耳)。將所得混合物在0℃下攪拌,緩慢溫熱至室溫且攪拌16小時。將混合物以水和乙酸乙酯稀釋,將有機層分離且以1N水性氫氯酸(2x)、飽和水性碳酸氫鈉,飽和水性氯化鈉連續清洗,乾燥(無水硫酸鈉),過濾且在真空中濃縮。將粗製產物以矽膠層析術純化(25-60%之乙酸乙酯/己烷),得到白色固體(4.2公克)。1H NMR(400MHz,CDCl3)δ 7.35(m,5H),5.09(m,3H),3.96(m,1H),3.67(m,1H),1.82-1.28(m,8H)。
瓊斯(Jones)試劑之製備如下:將三氧化鉻(1.7公克)懸浮在硫酸(1.7毫升)中,將其添加至冷水(13毫升)中,以製得此活性溶液。
將瓊斯試劑經數分鐘逐滴添加至丙酮(15毫升)中的(2-羥基環己基)胺甲酸苯甲酯(4.200公克,16.8毫莫耳)之溶液(以室溫水浴冷卻反應)且將反應混合物在室溫下攪拌2.5小時。添加飽和水性碳酸鈉溶液及接著添加飽和水性碳酸氫鈉溶液,直到溶液調整至中性pH為止,且將所得混合物以乙酸乙酯萃取(3x)。將合併的有機層以飽和水性氯化鈉清洗,乾燥(無水硫酸鈉),過濾且在真空中濃縮。將粗製產物以矽膠層析術純化(10-50%之乙酸乙酯/己烷),得到澄清液體(3.3公克)。1H NMR(300MHz,CDCl3)δ 7.36-7.29(m,5H),5.75(br s,1H),5.10(s,2H),4.29-4.25(m,1H),2.65(m,1H),2.57-2.50(m,1H),2.43-2.33(m,1H),2.17-2.10(m,1H),1.88-1.60(m,3H),1.48-1.34(m,1H)。ESI(m/z):248.0(M+H)。
將二乙基胺基三氟化硫(2毫升)添加至無水二氯甲烷(20毫升)中的(2-側氧環己基)胺甲酸苯甲酯(1.25公克,5.0毫莫耳)之溶液中且將所得溶液在室溫下攪拌16小時。將反應混合物冷卻至0℃且倒入冷飽和水性碳酸氫鈉中。將混合物以乙酸乙酯萃取(3x)且將有機層以飽和水性碳酸氫鈉、飽和水性氯化鈉清洗,乾燥(無水硫酸鈉),過濾且在真空中濃縮。將粗製產物以矽膠層析術純化(5-55%之乙酸乙酯/己烷),得到黃色固體。將此材料自二乙醚/己烷再結晶,得到白色固體(0.227公克)。1H NMR(CDCl3,300MHz)δ 7.41-7.25(m,5H),5.17-5.07(m,2H),4.99(m,1H),3.99-3.85(m,1H),2.20-2.16(m,1H),2.00(m,1H),1.78-1.38(m,6H)。ESI(m/z):269.9(M+H)。
將10%之鈀/碳(0.15公克,50%濕)添加至甲醇(10毫升)中的4%之甲酸中的(2,2-二氟環己基)胺甲酸酯(0.200公克,0.7毫莫耳)之溶液中。將反應混合物在氫氛圍下攪拌18小時,經由矽藻土過濾,以甲醇清洗且在真空下濃縮,得到灰白色固體(0.1公克)。1H NMR(d6-DMSO,300MHz)δ 8.21(s,1H),3.03-2.95(m,1H),2.07-2.04(m,1H),
1.76-1.34(m,7H)。ESI(m/z):136.2(M+H)。
將甲烷磺醯氯(1.309毫升,16.9毫莫耳)逐滴添加至無水二氯甲烷(30毫升)中的1-丙胺(1.0公克,16.9毫莫耳)及三乙胺(2.587毫升,18.6毫莫耳)之0℃的冷卻溶液中。容許反應混合物緩慢溫熱至室溫且攪拌16小時。將混合物以乙酸乙酯稀釋且以1.0N水性氫氯酸、飽和水性碳酸氫鈉、飽和水性氯化鈉連續清洗,乾燥(無水硫酸鈉),過濾且濃縮,得到純產物(1.730公克,75%)。1H NMR(CDCl3,300MHz)δ 4.49(br s,1H),3.12-3.08(q,2H,J=7.5Hz),1.67-1.54(六重峰,2H,J=7.5Hz),0.99-0.94(t,3H,J=7.5Hz)。
將三乙胺(2.587毫升,18.6毫莫耳)及甲烷磺醯氯(1.309毫升,16.9毫莫耳)逐滴添加至無水二氯甲烷(20毫升)中的乙胺(0.763公克,16.9毫莫耳)之0℃的冷卻溶液
中。容許混合物緩慢溫熱至室溫且攪拌16小時。將所得混合物以乙酸乙酯稀釋且以1N水性氫氯酸(2x)、飽和水性碳酸氫鈉和飽和水性氯化鈉連續清洗。將有機層乾燥(無水硫酸鈉),過濾且濃縮,得到半固體(0.633公克,30%)。1HNMR(CDCl3,300MHz)δ 4.60(br s,1H),3.21-3.12(qd,2H,J=6.0,7.2Hz),1.28-1.19(t,3H,J=7.2Hz)。
將胺基磺醯胺(1.867公克,19.4毫莫耳)添加至吡啶(20毫升)中的N-甲基乙二胺(1.200公克,16.2毫莫耳)之攪拌混合物中。將混合物在120℃之油浴中加熱16小時。在冷卻至室溫之後,將混合物濃縮且將殘餘物分溶在乙酸乙酯與飽和水性氯化鈉之間。將有機層以1N水性氫氯酸、飽和水性氯化鈉清洗,乾燥(無水硫酸鈉),過濾且濃縮,以供給無色油(0.61公克,28%)。1H NMR(300MHz,CDCl3)δ 4.30(br s,1H),3.53(m,2H),3.40(m,2H),2.76(s,3H)。
將胺基磺醯胺(1.919公克,20.0毫莫耳)添加至吡啶(20毫升)中的N-苯甲基乙二胺(2.000公克,13.3毫莫耳)之攪拌混合物中。將混合物在120℃之油浴中加熱16小時。在冷卻至室溫之後,將混合物濃縮且將殘餘物分溶在乙酸乙酯與飽和水性氯化鈉之間。將有機層以1N水性氫氯酸、飽和水性氯化鈉清洗,乾燥(無水硫酸鈉),過濾且濃縮。將殘餘物以矽膠層析術純化(0-80%之乙酸乙酯/己烷),以供給成為淺黃色濃稠油的產物(1.4公克,50%)。1H NMR(300MHz,CDCl3)δ 7.40-7.30(m,5H),4.38(br s,1H),4.20(s,2H),3.50(q,2H,J=6.6Hz),3.29(t,2H,J=6.6Hz)。
將甲醇(20毫升)中的2-苯甲基-1,2,5-噻二唑啶-1,1-二氧化物(1.000公克,4.7毫莫耳)與20%之氫氧化鈀(0.200公克)之混合物在氫氛圍下(1大氣壓)攪拌16小時。將混合物經由矽藻土過濾且將過濾物濃縮,以供給白色固體(0.570公克,99%)。1H NMR(300MHz,d6-DMSO)δ 6.68
(s,2H),3.30-3.25(m,4H)。
將正丁基鋰(1.725毫升在己烷中的2.5N溶液,4.3毫莫耳)逐滴添加至無水四氫呋喃(29毫升)中的2-(2,4-二甲氧基苯甲基)異噻唑啶-1,1-二氧化物(0.600公克,2.2毫莫耳)之-78℃溶液中。將反應混合物在-78℃下攪拌1小時,添加碘甲烷(0.688毫升,11.1毫莫耳)且將所得混合物在-78℃下攪拌2.5小時及在室溫下攪拌30分鐘。將混合物倒入飽和水性氯化銨中且以乙酸乙酯萃取。將有機層以飽和水性氯化鈉清洗,乾燥(無水硫酸鈉),過濾且在真空中濃縮。將粗製材料以矽膠層析術純化(20-60%之乙酸乙酯/己烷),得到成為澄清油的產物(0.3公克)。1H NMR(CDCl3,300MHz)δ 7.25-7.22(d,1H,J=8.1Hz),6.48-6.43(m,2H),4.27-4.13(q,2H,J=14.1Hz),3.80(s,3H),3.79(s,3H),3.25-3.02(m,3H),2.43-2.32(m,1H),1.95-1.83(m,1H),1.42-1.40(d,3H,J=6.6Hz)。
使用上述程序亦獲得成為澄清油的標題化合物(0.237公克)。1H NMR(CDCl3,300MHz)δ 7.26-7.23(d,1H,J=7.8Hz),6.48-6.43(m,2H),4.23(s,2H),3.80(s,6H),3.07-3.03(t,2H,J=7.1Hz),2.10-2.05(t,2H,J=6.9Hz),1.42(s,3H)。
將三氟乙酸(5.000毫升,67.3毫莫耳)添加至二氯甲烷(10毫升)中的2-(2,4-二甲氧基苯甲基)-5-甲基異噻唑啶-1,1-二氧化物(0.292公克,1.0毫莫耳)之0℃溶液中,將所得紅色溶液在0℃下攪拌3小時且在真空中濃縮。將粗製產物以矽膠層析術純化(30-75%之乙酸乙酯/己烷),得到澄清油(0.117公克,90%)。1HNMR(CDCl3,300MHz)4.38(br s,1H),3.38-3.32(m,2H),3.21-3.14(m,1H),2.60-2.47(m,1H),2.13-2.00(m,1H),1.43-1.40(d,3H,J=7.2Hz)。
將三氟乙酸(3.591毫升,48.3毫莫耳)添加至二氯甲烷(10毫升)中的2-(2,4-二甲氧基苯甲基)-5,5-二甲基異噻唑啶-1,1-二氧化物(0.220公克,0.7毫莫耳)之0℃溶液中,將所得紅色溶液在0℃下攪拌3小時且在真空中濃縮。將粗製產物以矽膠層析術純化(20-80%之乙酸乙酯/己烷),得到澄清油(0.087公克,86%)。1HNMR(300MHz,CDCl3)δ 4.61(br s,1H),3.32-3.26(td,2H,J=5.1,7.1Hz),2.25-2.20(t,2H,J=7.2Hz),1.43(s,6H)。
將二氯甲烷(10毫升)中的2-氯乙烷磺醯氯(5.000公克,30.7毫莫耳)之溶液緩慢添加至無水二氯甲烷(50毫升)中的烯丙胺(1.926公克,33.7毫莫耳)及三乙胺(12.789毫升,92.0毫莫耳)之0℃的冷卻溶液中。容許所得混合物溫熱至室溫且攪拌4小時。將混合物以1N水性氫氯酸(2x)、水、飽和水性氯化鈉連續萃取,乾燥(無水硫酸
鈉),過濾且濃縮,得到黃色液體。1H NMR(300MHz,CDCl3)δ 6.57-6.48(dd,1H,J=9.9,16.8Hz),6.28-6.22(d,1H,J=16.8Hz),5.96-5.92(d,1H,J=9.6Hz),5.90-5.77(m,1H),5.30-5.29(m,1H),5.24-5.17(m,1H),4.44(br s,1H),3.69-3.64(tt,2H,J=1.5,6.0Hz)。
將無水二氯甲烷(7毫升)中的N-烯丙基乙烯磺醯胺(0.700公克,4.8毫莫耳)之溶液放置在氬氣下且添加(1,3-雙(2,4,6-三甲基苯基)-2-亞咪唑啶基)二氯(苯基亞甲基)(三環己膦)釕(0.02公克)。將混合物在回流下加熱且以30分鐘間隔添加額外部分的(1,3-雙(2,4,6-三甲基苯基)-2-亞咪唑啶基)二氯(苯基亞甲基)(三環己膦)釕(每次0.02公克),直到已添加總共0.1公克(2.5莫耳%)為止。將反應回流總共6小時,冷卻至室溫且在真空中濃縮。將粗製材料以矽膠層析術純化(50-100%之乙酸乙酯/己烷),得到棕色油(0.46公克)。1H NMR(CDCl3,300MHz)δ 6.90-6.86(dt,1H,J=2.4,6.6Hz),6.75-6.6.71(dt,1H,J=2.4,6.3Hz),4.92(br s,1H),4.15-4.12(m,2H)。
將甲醇中的25%之甲醇鈉(0.181公克,0.8毫莫耳)添加至甲醇(1毫升)中的2,3-二氫異噻唑-1,1-二氧化物(0.100公克,0.8毫莫耳)之溶液中且將溶液在60℃下攪拌2小時及在70℃下攪拌3小時。將混合物濃縮且懸浮在1N水性氫氯酸中。將水性混合物以乙酸乙酯萃取(3x),將有機層乾燥(無水硫酸鈉),過濾且在真空中濃縮。將粗製材料以矽膠層析術純化(0-6%之甲醇/二氯甲烷),得到產物(0.011公克,13%)。1H NMR(300MHz,CDCl3)δ 4.53(br s,1H),4.33-4.29(m,1H),3.48-3.30(m,3H),3.37(s,3H),3.19-3.13(m,1H)。13C NMR(100MHz,CDCl3)δ 80.8,57.1,53.3,48.7。
將正丁基鋰(14.973毫升在己烷中的2.5N溶液,37.4毫莫耳)緩慢添加至冷卻至-78℃之無水四氫呋喃(225毫升)中的2-(2,4-二甲氧基苯甲基)5-氟異噻唑啶-1,1-二氧化
物(5.700公克,19.7毫莫耳)之溶液且將所得深橘色/紅色溶液攪拌1小時。經30分鐘緩慢添加在無水四氫呋喃(60毫升)中的N-氟苯磺醯胺(14.6公克,46.3毫莫耳)之溶液,在-78℃下攪拌3小時及在室溫下攪拌2.5小時。將反應倒入飽和水性氯化銨中,以乙酸乙酯稀釋且將有機層分離。將有機層以飽和水性氯化鈉清洗,乾燥(無水硫酸鈉),過濾且在真空中濃縮。將粗製材料懸浮在二氯甲烷中且經由矽膠墊過濾,以二氯甲烷清洗且將溶液濃縮。將粗製材料以矽膠層析術(20-75%之乙酸乙酯/己烷)及接著以製備性HPLC(C18,32-95%之乙腈/水經17分鐘)純化,得到黃褐色油(0.106公克,2%)。1H NMR(CDCl3,300MHz)δ 7.21-7.18(d,1H,J=8.4Hz),6.49-6.45(m,2H),4.28(s,2H),3.82(s,3H),3.14(s,3H),3.19-3.15(m,2H),2.70-2.55(m,2H)。
將三氟乙酸(2.182毫升,29.4毫莫耳)添加至二氯甲烷(6毫升)中的2-(2,4-二甲氧基苯甲基)-5,5-二氟異噻唑啶-1,1-二氧化物(0.100公克,0.3毫莫耳)之0℃溶液中。將所得紅色/紫色溶液在0℃下攪拌3.5小時且在真空中濃縮。將粗製材料以矽膠層析術純化(30-75%之乙酸乙酯/己
烷),得到黃褐色油(0.036公克)。1H NMR(CDCl3,300MHz)δ 4.78(br s,1H),3.46-3.40(q,2H,J=6.6Hz),2.79-2.65(m,2H)。19F NMR(CDCl3,282MHz)-105.96--106.07(t,J=15.4Hz)。
將甲醇(100毫升)及2N水性硫酸(50毫升)中的2-(2-甲基丁-3-炔-2-基)異噻唑啶-1,1-二氧化物(3.500公克,18.7毫莫耳)與氧化汞(II)(0.810公克,3.7毫莫耳)之混合物在90℃下加熱3小時。將反應混合物經由矽藻土過濾且將過濾物在真空中濃縮。將殘餘物以水處理且以乙酸乙酯萃取。將有機層以飽和水性氯化鈉清洗,乾燥(無水硫酸鈉),過濾且在真空中濃縮。將殘餘物以矽膠層析術純化(0-100%之乙酸乙酯/己烷),以供給成為黃色油的所欲產物(1.65公克,43%)。1H NMR(300MHz,CDCl3)δ 3.38(t,2H,J=6.6Hz),3.21(t,2H,J=7.5Hz),2.42-2.30(m,2H),2.28(s,3H),1.60(s,6H)。
將碘化三甲基亞碸鎓鹽(0.214公克,1.0毫莫耳)添加至氮氣下在無水二甲亞碸(5毫升)中的氫化鈉(在礦油中的60%之溶液,0.039公克,1.0毫莫耳)之攪拌懸浮液中。將混合物在70℃下攪拌1小時及接著冷卻至室溫。添加3-(1,1-二氧基異噻唑啶-2-基)-3-甲基丁-2-酮(0.100公克,0.5毫莫耳)且將反應混合物在室溫下攪拌16小時及接著在70℃下加熱4小時。將混合物冷卻至0℃,以水中止且以乙酸乙酯萃取。將有機層以飽和水性氯化鈉清洗,乾燥(無水硫酸鈉),過濾且在真空中濃縮。將殘餘物以矽膠層析術純化(0-80%之乙酸乙酯/己烷),以供給成為濃稠油的產物(0.065公克,61%)。1H NMR(300MHz,CDCl3)δ 3.52-3.12(m,4H),2.76(d,1H,J=4.5Hz),2.54(d,1H,J=4.5Hz),2.42-2.20(m,2H),1.60(s,3H),1.43(s,3H),1.35(s,3H)。
將甲烷磺醯氯(0.095毫升,1.2毫莫耳)添加至吡啶(1毫升)中的1-甲基-環丁胺鹽酸鹽(0.100公克,0.8毫莫耳)之攪拌溶液中。將反應混合物在室溫下攪拌16小時。將混合物以乙酸乙酯稀釋且以2N水性氫氯酸、飽和水性碳酸氫鈉、飽和水性氯化鈉清洗,乾燥(無水硫酸鈉),過濾且濃縮,以供給成為棕色油的產物(0.090公克,67%)。1H NMR(300MHz,CDCl3)δ 4.49(br s,1H),3.03(s,3H),2.40-2.25(m,2H),2.12-2.00(m,2H),1.95-1.75(m,2H),1.58(s,3H)。
將甲烷磺醯氯(0.108毫升,1.4毫莫耳)添加至吡啶(1毫升)中的1-甲基環丙-1-胺鹽酸鹽(0.100公克,0.9毫莫耳)之攪拌溶液中。將反應混合物在室溫下攪拌16小時。將混合物以乙酸乙酯稀釋且以2N水性氫氯酸、飽和水性碳酸氫鈉、飽和水性氯化鈉清洗,乾燥(無水硫酸鈉),過濾且濃縮,以供給成為黃色油的產物(0.105公克,76%)。1H NMR(300MHz,CDCl3)δ 4.68(br s,1H),3.02(s,3H),1.50(s,3H),1.02-0.94(m,2H),0.71-0.64(m,2H)。
將甲烷磺醯氯(0.095毫升,1.2毫莫耳)添加至吡啶(1毫升)中的3-甲基環丁胺鹽酸鹽(0.100公克,0.8毫莫耳)之攪拌溶液中。將反應混合物在室溫下攪拌16小時。將混合物以乙酸乙酯稀釋且以2N水性氫氯酸、飽和水性碳酸氫鈉、飽和水性氯化鈉清洗,乾燥(無水硫酸鈉),過濾且濃縮,以供給成為棕色固體的產物(0.125公克,93%)。使用未進一步純化之該材料。
將甲烷磺醯氯(0.095毫升,1.2毫莫耳)添加至吡啶(1毫升)中的2-甲基環戊胺鹽酸鹽(0.100公克,0.7毫莫耳)之攪拌溶液中。將反應混合物在室溫下攪拌16小時。將混合物以乙酸乙酯稀釋且以2N水性氫氯酸、飽和水性碳酸氫鈉、飽和水性氯化鈉清洗,乾燥(無水硫酸鈉),過濾且濃縮,以供給成為棕色固體的產物(0.100公克,84
%)。使用未進一步純化之該材料。
將2-氯乙烷磺醯氯(0.734毫升,7.0毫莫耳)緩慢添加至0℃下在二氯甲烷(20毫升)中的2-甲基丙-2-烯-1-胺(0.500公克,7.0毫莫耳)、N,N-二異丙基乙胺(3.486毫升,21.1毫莫耳)及N,N-4-二甲基胺基吡啶(0.043公克,0.4毫莫耳)之攪拌溶液中。將反應混合物緩慢溫熱至室溫且攪拌16小時。將混合物濃縮且將殘餘物以矽膠層析術純化(0-80%之乙酸乙酯/己烷),以供給成為無色油的產物(0.59公克,52%)。1H NMR(300MHz,CDCl3)δ 6.54(dd,1H,J=16.5,9.6Hz),6.27(d,1H,J=16.5Hz),5.96(d,1H,J=9.6Hz),4.97(s,1H),4.93(s,1H),4.37(br s,1H),3.60(d,2H,J=6.3Hz),1.79(s,3H)。
將無水二氯甲烷(10毫升)中的N-(2-甲基烯丙基)乙烯磺醯胺(0.700公克,4.3毫莫耳)之溶液在氬氣下攪拌且添
加(1,3-雙(2,4,6-三甲基苯基)-2-亞咪唑啶基)二氯(苯基亞甲基)(三環己膦)釕(0.02公克)。將混合物在回流下加熱且以30分鐘間隔添加額外部分的(1,3-雙(2,4,6-三甲基苯基)-2-亞咪唑啶基基)二氯(苯基亞甲基)(三環己膦)釕(每次0.02公克),直到已添加總共0.1公克(2.5莫耳%)為止。將反應回流總共72小時,冷卻至室溫且在真空中濃縮。將粗製材料以矽膠層析術純化(0-100%之乙酸乙酯/己烷),以供給成為棕色油的所欲產物(0.380公克,66%)。1H NMR(CDCl3,300MHz)δ 6.45(s,1H),4.55(br s,1H),3.99(m,2H),2.06(s,3H)。
將甲醇(10毫升)中的4-甲基-2,3-二氫異噻唑-1,1-二氧化物(0.380公克,2.9毫莫耳)與20%之氫氧化鈀/碳(0.050公克)之混合物在氫氛圍下攪拌2小時。將混合物經由矽藻土過濾且將過濾物濃縮,以供給成為棕色油的產物(0.385公克,100%)。1H NMR(300MHz,CDCl3)δ 4.25(br s,1H),3.53(m,1H),3.34(dd,1H,J=12.0,7.5Hz),3.05-2.70(m,3H),1.27(d,3H,J=6.6Hz)。
將甲烷磺醯氯(0.169毫升,2.2毫莫耳)添加至吡啶(1毫升)中的1-胺基-1-甲基環戊烷鹽酸鹽(0.165公克,1.2毫莫耳)之攪拌溶液中。將反應混合物在室溫下攪拌16小時且接著濃縮。將混合物以乙酸乙酯稀釋且以1N水性氫氯酸、飽和水性碳酸氫鈉、飽和水性氯化鈉清洗,乾燥(無水硫酸鈉),過濾且濃縮,以供給成為棕色油的產物(0.100公克,46%)。1H NMR(300MHz,CDCl3)δ 4.27(br s,1H),3.04(s,3H),2.00-1.60(m,8H),1.50(s,3H)。
將甲烷磺醯氯(0.144毫升,1.9毫莫耳)添加至吡啶(1毫升)中的3-甲氧基環己胺(0.200公克,1.5毫莫耳)之攪拌溶液中。將反應混合物在室溫下攪拌16小時且接著濃縮。將混合物以乙酸乙酯稀釋且以1N水性氫氯酸、飽和水性碳酸氫鈉、飽和水性氯化鈉清洗,乾燥(無水硫酸鈉),過濾且濃縮,以供給成為棕色油的產物(0.140公
克,44%)。使用未進一步純化之該材料。
將氰基硼氫化鈉(7.466公克,118.8毫莫耳)添加至無水甲醇(250毫升)中的環丁酮(5.830公克,83.2毫莫耳)、乙二胺(39.711毫升,594.0毫莫耳)、乙酸(34.006毫升,594.0毫莫耳)及4埃分子篩(25公克)之溶液中。將混合物攪拌48小時,過濾,以移除固體且在真空中濃縮。將殘餘物溶解在3N水性氫氧化鈉(300毫升)中且以二氯甲烷萃取(3×500毫升)。將合併的有機層以鹼性飽和水性氯化鈉清洗,乾燥(無水硫酸鈉),過濾且濃縮,得到粗製產物。將材料真空蒸餾,得到成為澄清液體的所欲產物(4.8公克,50%)。1H NMR(300MHz,CDCl3)δ 3.24-3.17(m,1H),2.76-2.72(t,2H,J=6.0Hz),2.57-2.53(td,2H,J=0.8,6.0Hz),2.23-2.14(m,2H),1.71-1.58(m,4H),1.22(br s,3H)。
將氰基硼氫化鈉(2.839公克,45.2毫莫耳)添加至無水甲醇(113毫升)中的環戊酮(2.000毫升,22.6毫莫耳)、乙二胺(10.860公克,180.7毫莫耳)、乙酸(10.345毫升,180.7毫莫耳)及4埃分子篩(10公克)之溶液中。將混合物攪拌48小時,過濾,以移除固體且在真空中濃縮。將殘餘物溶解在3N水性氫氧化鈉(150毫升)中且以二氯甲烷萃取(3×300毫升)。將合併的有機層以鹼性飽和水性氯化鈉清洗,乾燥(無水硫酸鈉),過濾且濃縮,得到粗製產物。將材料真空蒸餾,得到成為澄清液體的所欲產物(1.0公克,35%)。1H NMR(300MHz,CDCl3)δ 3.08-2.99(五重峰,1H,J=6.8Hz),2.80-2.76(t,2H,J=5.9Hz),2.65-2.61(t,2H,J=5.9Hz),1.87-1.77(m,2H),1.72-1.60(m,2H),1.57-1.46(m,2H),1.35-1.24(m,5H)。
將氰基硼氫化鈉(8.017公克,127.6毫莫耳)添加至無水甲醇(250毫升)中的環己酮(6.260公克,63.8毫莫耳)、乙二胺(42.640毫升,637.8毫莫耳)、乙酸(36.515毫升,637.8毫莫耳)及4埃分子篩(25公克)之溶液中。將混合物攪拌48小時,過濾,以移除固體且在真空中濃縮。將殘餘物溶解在3N水性氫氧化鈉(150毫升)中且以二氯甲烷
萃取(3×300毫升)。將合併的有機層以鹼性飽和水性氯化鈉清洗,乾燥(無水硫酸鈉),過濾且濃縮,得到粗製產物。將材料真空蒸餾,得到成為澄清液體的所欲產物(4.1公克,45%)。1H NMR(300MHz,CDCl3)δ 2.80-2.76(td,2H,J=0.9,6.0Hz),2.68-2.64(td,2H,J=0.9,6.0Hz),2.43-2.34(m,1H),1.89-1.83(m,2H),1.74-1.70(m,2H),1.62-1.57(m,1H),1.32-0.98(m,8H)。
將環丁胺(5.90毫升,59.8毫莫耳)在室溫下經15分鐘逐滴添加至甲醇(7毫升)中的丙烯腈(4.76公克,89.7毫莫耳)之溶液中。將混合物在室溫下攪拌30分鐘及在回流下1小時,冷卻至室溫,在減壓下濃縮。所欲產物係在真空下蒸餾而獲得,以提供澄清液體(7.7公克,98%)。1H NMR(CDCl3,300MHz)δ 3.29-3.21(m,1H),2.88-2.83(t,2H,J=6.6Hz),2.50-2.46(t,2H,J=6.6Hz),2.26-2.20(m,2H),1.76-1.63(m,4H),1.30(br s,1H)。
將無水二乙醚(40毫升)中的3-(環丁基胺基)丙腈(5.000公克,40.3毫莫耳)之溶液經45分鐘逐滴添加至無水二乙醚(120毫升)中的氫化鋰鋁(3.056公克,80.5毫莫耳)之冷卻(0℃)懸浮液中。將反應混合物在室溫下攪拌15分鐘及在回流下4小時,冷卻至室溫且攪拌1小時。將混合物冷卻至0℃且劇烈攪拌,同時逐滴添加水(3.1毫升),接著添加15%之水性氫氧化鈉(3.1毫升)及最後添加水(9.3毫升)。將所得泥漿溫熱至室溫,攪拌15分鐘且添加無水硫酸鎂,再攪拌15分鐘。以過濾移出固體材料,以溫的二氯甲烷清洗多次且將過濾物在減壓下濃縮,得到成為淡黃色液體的所欲產物(3.44公克,66%)。1H NMR(CDCl3,300MHz)3.14(m,1H),2.69-2.62(m,2H),2.53-2.45(m,2H),2.13-2.10(m,2H),1.56-1.48(m,6H),1.33(br s,3H)。
將環戊胺(5.794毫升,58.7毫莫耳)在室溫下逐滴添加至甲醇(7毫升)中的丙烯腈(5.79毫升,88.1毫莫耳)之溶液中。將溶液在室溫下攪拌30分鐘及在回流下1小時,冷卻至室溫且在減壓下濃縮。所欲產物係在真空下蒸
餾而獲得,以提供澄清液體(7.4公克,91%)。1H NMR(CDCl3,300MHz)δ 3.14-3.04(五重峰,1H,J=6.3Hz),2.91-2.87(t,2H,J=6.9Hz),2.53-2.48(td,2H,J=0.9,6.9Hz),1.88-1.78(m,2H),1.73-1.49(m,4H),1.36-1.24(m,2H),1.19(br s,1H)。
將無水二乙醚(40毫升)中的3-(環戊基胺基)丙腈(6.000公克,43.4毫莫耳)之溶液經45分鐘逐滴添加至無水二乙醚(150毫升)中的氫化鋰鋁(3.295公克,86.8毫莫耳)之冷卻(0℃)懸浮液中。將反應混合物在室溫下攪拌15分鐘及在回流下4小時,冷卻至室溫且攪拌1小時。將混合物冷卻至0℃且劇烈攪拌,同時逐滴添加水(3.4毫升),接著添加15%之水性氫氧化鈉(3.4毫升)及最後添加水(10.2毫升)。將所得泥漿溫熱至室溫,攪拌15分鐘且添加無水硫酸鎂,再攪拌15分鐘。以過濾移出固體材料,以溫的二氯甲烷清洗多次且將過濾物在減壓下濃縮,得到成為澄清油的所欲產物(4.5公克,73%)。1H NMR(CDCl3,300MHz)δ 3.05-2.96(五重峰,1H,J=6.6Hz),2.74-2.71(t,2H,J=6.6Hz),2.68-2.58(t,2H,J=6.9Hz),1.85-1.68(m,2H),1.62-1.42(m,6H),1.34(br s,3H),
1.30-1.21(m,2H)。
製法128至138係根據以下的通用程序製備:將胺基磺醯胺(1.2當量)添加至無水吡啶中的二胺(1.0當量,0.5M)之攪拌溶液中。將混合物在密封的管中以120-125℃加熱18-24小時。在冷卻至室溫之後,將混合物在減壓下濃縮且將殘餘物分溶在乙酸乙酯與水之間。將有機層以1N水性氫氯酸(2x)、飽和水性氯化鈉連續清洗,乾燥(無水硫酸鈉),過濾且在減壓下濃縮,以供給所欲產物。產物通常不經任何額外的純化而直接用於下一步驟中。
將甲烷磺醯氯(0.650毫升,8.4毫莫耳)逐滴添加至無水二氯甲烷(55毫升)中的1-(9H-咔唑-9-基)-3-((呋喃-2-基甲基)胺基)丙-2-醇(2.7公克,8.4毫莫耳)及三乙胺(1.3毫升,9.2毫莫耳)之冷攪拌溶液中,將其以外部冰浴保持在0-5℃。將溶液在0℃下攪拌2小時,接著以二氯甲烷稀釋且以兩次0.25N水性氫氯酸和水和飽和水性氯化鈉連續清洗。將有機物乾燥(無水硫酸鈉),過濾且在真空中濃縮。將粗製殘餘物以矽膠管柱層析術純化(在二氯甲烷中的0-10%之乙酸乙酯),得到成為白色固體的所欲產物(1.5公克,45%)。1H NMR(d6-DMSO,300MHz)δ 8.09-8.06(d,2H,J=8.1Hz),7.42-7.37(m,5H),7.18-7.14(m,2H),6.37-6.35(dd,1H,J=1.8,3Hz),6.31-6.30(d,1H,J=3Hz),4.52-4.39(dd,2H,J=15.9,24.6Hz),4.39-4.30(dd,
1H,J=3.3,14.4Hz),4.22-4.10(m,1H),4.20-4.05(br m,1H),3.40-3.33(m,1H)3.26-3.17(m,1H),2.90(s,3H)。ESI(m/z):398.9(M+H)。HPLC分析:(C18,在水+0.1%之三氟乙酸中的10-90%之乙腈經10分鐘滯留時間,在254奈米之面積%):8.6分鐘,97.9%。
化合物2至12係以那些類似於化合物1所使用之程序或使用吡啶(4當量)代替三乙胺而製備。
化合物13至19係以下列通用方法製備:將對應的磺醯氯(0.9毫莫耳)添加至無水吡啶(1毫升)中的2-((第三丁基二甲基矽烷基)氧基)-3-(9H-咔唑-9-基)-N-(呋喃-2-基甲基)丙-1-胺(0.100公克,0.2毫莫耳)之攪拌
溶液中。將反應混合物在室溫下攪拌隔夜且將混合物在真空中濃縮。將粗製殘餘物以水處理且以乙酸乙酯(20毫升)萃取。將有機層以飽和性氯化鈉和飽和水性碳酸鈉清洗,乾燥(無水硫酸鈉),過濾且濃縮。將殘餘物以矽膠管柱層析術純化(在己烷中的0-80%之乙酸乙酯),以供給經TBS-保護之產物。將產物溶解在無水四氫呋喃(5毫升)中且添加在水中的水性氟化四丁基銨(0.040公克,0.1毫莫耳)。將混合物在室溫下攪拌隔夜且接著濃縮。將粗製殘餘物以矽膠管柱層析術純化(在己烷中的0-50%之乙酸乙酯),以供給純產物。
將氫化鈉(在礦油中的60%,0.053公克,1.3毫莫耳)添加至無水N,N-二甲基甲醯胺(20毫升)中的1,3-丙烷磺內醯胺(0.80公克,6.6毫莫耳)之攪拌溶液中且將混合物在
室溫下攪拌1小時。添加9-(環氧乙烷-2-基甲基)-9H-咔唑(1.622公克,7.3毫莫耳)且將混合物在70℃下攪拌隔夜。在冷卻之後,將反應以水稀釋且以乙酸乙酯萃取三次。將合併的有機層以飽和水性氯化鈉清洗,乾燥(無水硫酸鈉),過濾且濃縮。將殘餘物以矽膠管柱層析術純化(在己烷中的0-70%之乙酸乙酯)及接著自乙酸乙酯/己烷再結晶,得到成為白色固體的純化合物(1.6公克,70%)。1H NMR(300MHz,CDCl3)δ 8.10(d,2H,J=7.5Hz),7.48(d,4H,J=3.9Hz),7.30-7.22(m,2H),4.55-4.35(m,3H),3.42-3.12(m,6H),2.59(d,1H,J=3.0Hz),2.37(m,2H)。ESI(m/z):344.9(M+H)。HPLC分析:(C18,在水+0.1%之三氟乙酸中的10-90%之乙腈經10分鐘滯留時間,在254奈米之面積%):11.8分鐘,>98%。
化合物21至235係以那些類似於化合物20所使用之程序或使用在N,N-二甲基乙醯胺中的碳酸銫(1當量)於100℃下隔夜而製備。
光學活性實例之鏡像異構物過量係以HPLC獲得,該HPLC係使用Chiralpak AD-H管柱,0.46公分×25公分,以己烷中的25%之異丙醇溶析0-30分鐘;流速:1毫升/分鐘,UV 254nM。
將無水N,N-二甲基甲醯胺(1毫升)中的1-氟-9H-咔唑(0.099公克,0.54毫莫耳)、N-(呋喃-2-基甲基)-N-(環氧乙烷-2-基甲基)甲烷磺醯胺(0.142公克,0.62毫莫耳)及碳酸
銫(0.174公克,0.54毫莫耳)之懸浮液在微波反應器中以110℃加熱30分鐘。將反應混合物冷卻且倒入水及乙酸乙酯中。將有機層分離,以水及飽和水性氯化鈉清洗,乾燥(無水硫酸鈉),過濾且在真空中濃縮。將粗製殘餘物以矽膠管柱層析術純化(在己烷中的10-80%之乙酸乙酯),得到白色固體(0.103公克,46%)。1H NMR(CDCl3,300MHz)δ 8.08-8.06(dt,1H,J=0.9Hz,7.5Hz),7.88-7.85(m,1H),7.50-7.48(m,2H),7.29-7.27(m 1H),2.24-2.12(m,3H),6.16-6.14(dd,1H,J=2.1,3.3Hz),5.97-5.96(d,1H,J=3.3Hz),4.54-4.31(m,5H),3.51-3.43(dd,1H,J=8.3,14.8Hz),3.27-3.22(dd,1H,J=3.0,15Hz),2.85(s,3H),2.65-2.64(d,1H,J=3.3Hz)。ESI(m/z):417.1(M+H),349.3(M-呋喃)。HPLC分析:(C18,在水+0.1%之三氟乙酸中的10-90%之乙腈經10分鐘滯留時間,在254奈米之面積%):9.73分鐘,100%。
化合物237至245係以那些類似於化合物236所使用之程序製備。
用於評估式I化合物之特定的檢定法包括評估試驗化合物之效力的Per2檢定法及評估試驗化合物之標靶的Cry1檢定法,如上文所述。
化合物係使用高通量晝夜檢定系統篩選,如在Zhang,E.E.等人之Cell,2009,139,199-210中所述。簡言之,潛伏(harboring)Per2-dLuc之穩定的U2OS報導子細胞係以8,000個細胞/槽孔之密度接種在Corning 96-槽孔中,其為白色實體及底部平坦的經TC-處理之微量盤(Corning®),且在37℃及5% CO2的存在下培育24小時。接著將細胞以介質交換進行血清衝擊之同步化至最小培植體介質(10mM HEPES(pH 7.0)、2%之B27、1xPSG(Invitrogen®)和1.0mM甲蟲螢光素(Promega®)),接著添加溶解在二甲亞碸中的式I化合物(0.5%之最終二甲亞碸濃度)。基因表現係藉由在35℃下測量4-5天的發光性(Tecan® M200)來監控。相關之晝夜節律的週期、幅度和相位係使用MulticycleTM軟體(Actimetrics,Inc)來測定。式I化合物之EC50值係使用GraphpadTM(Prism®)來計算。
下表提供特定實例之Per2 EC50數據。EC50係以微莫耳濃度記錄。
一般熟諳本技藝者可輕易地使此檢定法最優化,以測定本文所述之化合物中任一者之Per2 EC50數據。
將HEK293細胞(2.5×106個細胞)以Lipofectamine 2000逆轉染在具有2微克表現載體之6-槽孔盤上。在28小時之後,將細胞收集在冰冷的PBS中且再懸浮在100微升培育緩衝液中(50mM Tris、50mM NaCl、2mM EDTA、10%之甘油、1mM DTT、完全蛋白酶抑制劑雞尾酒、磷酸酶抑制劑雞尾酒1和3;pH 8.0)。以NP-40(最終1%)補充混合物且在冰上培育15分鐘,接著在4℃下離心(16,000×公克)10分鐘。將上層清液用於檢定。用於C-端
型3XFlag-標記之mCRY1的表現載體係以p3XFLAG-CMV-14(Sigma)為基底。
將Cry1::Luc或Luc報導子HEK293細胞(1.0×104個細胞)以每一槽孔50微升接種在白色實體底部的384-槽孔盤上。在24小時之後,將500毫微升化合物(最終1%之二甲亞碸)施予介質。在24小時之後,以螢光素(最終1mM)及HEPES-NaOH(pH7.2;最終10mM)補充介質,且以微量盤讀取機每7.5分鐘記錄發光為期1小時。發光強度參數係藉由將實驗期間的強度平均來計算。排除分析的第一個數據點,因為瞬時的發光變化。將Cry::Luc強度標準化成Luc強度,以提供最終EC50值。式I化合物之EC50值係使用GraphpadTM(Prism®)來計算。
下表提供特定實例之Cry1 EC50數據。EC50係以微莫耳濃度記錄。
將HEK293細胞在具有含C-端型編碼之MycDDK標記(Origene)或FLAG-標記(Sigma)的cDNA編碼全長度CRY1之哺乳類表現載體(0.5微克/槽孔)的24槽孔盤中使
用Lipofectamine 2000或同等試劑轉染。在24小時之後,將細胞以具有最終濃度至多1%之DMSO的試驗化合物處理。在再24小時之後,將細胞溶解在含有蛋白酶抑制劑雞尾酒之RIPA緩衝液中(150mM NaCl、1.0%之IGEPAL® CA-630(或NP-40)、0.5%之去氧膽酸鈉、0.1%之SDS和50mM Tris,pH 8.0)。將蛋白質凝膠樣品緩衝液添加至等量的各樣品中,且將該等在SDS-聚丙烯醯胺凝膠上分離及經電泳轉移至PVDF薄膜。將經標記之蛋白質以標記引導之初級抗體及與HRP共軛之二級抗體偵測。標記之CRY1蛋白質係以ECL+或其他類似試劑的化學發光來顯露且以數位相機記錄為RAW檔案。使用Photoshop和ImageJ軟體定量個別譜帶。可將經標記之CRY1蛋白質的量與載入之樣品中的總蛋白質比較或與後續偵測之內對照用蛋白質(諸如GAPDH)比較。經標記之CRY1蛋白質的相對量可藉由比較經化合物處理之細胞樣品與經DMSO處理之細胞樣品來測定。與對照樣品比較而增加的經標記之CRY1蛋白質表明化合物增加CRY1穩定性。與對照樣品比較而降低的經標記之CRY1蛋白質表明化合物降低CRY1穩定性。前述之檢定法可由那些熟諳本技藝者輕易地修改且最優化,以測量或測定涉及晝夜節律及/或CRY-調控之路徑的蛋白質中任一者(例如,Cry2、Per1、Per2、CLOCK、BMAL1、TIM蛋白質或VEGF)之內源性蛋白質值。
將表現經標記之CRY1蛋白質之穩定的系胞系在至多1%之DMSO中以試驗化合物處理24小時。在再24小時之後,將細胞溶解在含有蛋白酶抑制劑雞尾酒之RIPA緩衝液中(150mM NaCl、1.0%之IGEPAL® CA-630(或NP-40)、0.5%之去氧膽酸鈉、0.1%之SDS和50mM Tris,pH 8.0)。將含有SDS之蛋白質凝膠樣品緩衝液添加至等量的各樣品中,且將該等在SDS-聚丙烯醯胺凝膠上分離及經電泳轉移至PVDF薄膜。將經標記之蛋白質以標記引導之初級抗體及與HRP共軛之二級抗體偵測。經標記之CRY1蛋白質係以ECL+或其他類似試劑的化學發光來偵測且以數位相機記錄為RAW檔案。使用Photoshop和ImageJ軟體定量個別譜帶。可將經標記之CRY1蛋白質的量與載入之樣品中的總蛋白質比較或與後續偵測之內對照用蛋白質(諸如GAPDH)比較。經標記之CRY1蛋白質的相對量可藉由比較經化合物處理之細胞樣品與對照組或經DMSO處理之細胞樣品來測定。與對照樣品比較而增加的經標記之CRY1蛋白質表明化合物增加CRY1穩定性。與對照樣品比較而降低的經標記之CRY1蛋白質表明化合物降低CRY1穩定性。前述之檢定法可由那些熟諳本技藝者輕易地修改且最優化,以測量或測定涉及晝夜節律及/或CRY-調控之路徑的蛋白質中任一者(例如,Cry2、Per1、Per2、CLOCK、BMAL1、TIM蛋白質或VEGF)之內源性
蛋白質值。
將表現經標記之CRY1蛋白質的瞬時轉染之HEK293細胞或穩定的細胞系暴露於試驗化合物24小時及接著暴露於環己醯亞胺(cycloheximide)(1微克/毫升)。在培育從15分鐘至6小時之後,將細胞溶解在RIPA緩衝液中。將含有SDS之蛋白質凝膠樣品緩衝液添加至等量的各樣品中,且將該等在SDS-聚丙烯醯胺凝膠上分離及經電泳轉移至PVDF薄膜。將經標記之蛋白質以標記引導之初級抗體及與HRP共軛之二級抗體偵測。經標記之CRY1蛋白質係以ECL+或其他類似試劑的化學發光來偵測且以數位相機記錄為RAW檔案。使用Photoshop和ImageJ軟體定量個別譜帶。可將經標記之CRY1蛋白質的量與載入之樣品中的總蛋白質比較或與後續偵測之內對照用蛋白質(諸如GAPDH)比較。經標記之CRY1蛋白質豐度的衰退率可在經試驗化合物處理之樣品與對照組或經DMSO處理之樣品之間進行比較。與對照樣品比較而在經化合物處理之樣品中的經標記之CRY1蛋白質更快的衰退率表明化合物降低CRY1穩定性。與對照樣品比較而在經化合物處理之樣品中的經標記之CRY1蛋白質更慢的衰退率表明化合物增加CRY1穩定性。前述之檢定法可由那些熟諳本技藝者輕易地修改且最優化,以測量或測定涉及晝夜節律及/或CRY-調控之路徑的蛋白質中任一者(例如,Cry2、Per1、
Per2、CLOCK、BMAL1、TIM蛋白質或VEGF)之半生期。
在收穫及在含有蛋白酶抑制劑雞尾酒之RIPA緩衝液中均質化之前,將細胞或組織暴露於試驗化合物或媒劑2小時至4天。將含有SDS之蛋白質凝膠樣品緩衝液添加至等量的各樣品中,且將該等在SDS-聚丙烯醯胺凝膠上分離及經電泳轉移至PVDF薄膜。內源性蛋白質的量係以引導至CRY蛋白質之特異性抗體及與HRP共軛之二級抗體偵測。CRY蛋白質係以ECL+或其他類似試劑的化學發光來顯露且以數位相機記錄為RAW檔案。使用Photoshop和ImageJ軟體定量個別譜帶。可將經標記之CRY1蛋白質的量與載入之樣品中的總蛋白質比較或與後續偵測之內對照用蛋白質(諸如GAPDH)比較。CRY蛋白質的相對量可藉由比較經化合物處理之細胞或組織樣品與對照組或經DMSO處理之細胞或組織樣品來測定。與對照樣品比較而增加的CRY蛋白質表明化合物增加CRY穩定性。與對照樣品比較而降低的CRY蛋白質表明化合物降低CRY穩定性。前述之檢定法可由那些熟諳本技藝者輕易地修改且最優化,以測量或測定涉及晝夜節律及/或CRY-調控之路徑的蛋白質中任一者(例如,Cry2、Per1、Per2、CLOCK、BMAL1、TIM蛋白質或VEGF)之內源性蛋白質值。
將本申請案中所引述之所有文件(包括科學發表案、
專利和專利申請案)特此併入其全文以供參考。
Claims (39)
- 一種式I化合物,
- 根據申請專利範圍第1項之化合物,其中A、B、C、D、E、F、G和H之各者為C;R1和R2之各者係獨立選自H或鹵基;R4為H或(C1-C6)烷基;R3和R5為H;R6為-CF3、-CHF2、-CH2F、(C1-C6)烷基、(C2-C6)烯基、(C2-C6)炔基、-(CR8R9)d(3-10)-員環烷基、-(CR8R9)e(C6-C10)芳基、-(CR8R9)e(4-10)-員雜環基、-(CR8R9)eO(CR8R9)f(C6-C10)芳基、-(CR8R9)eO(CR8R9)f(4-10)-員雜環基、-(CR8R9)fS(O)d(CR8R9)e(C6-C10)芳基和-(CR8R9)fS(O)d(CR8R9)e(4-10)-員雜環基;R7為-CF3、-CHF2、-CH2F、(C1-C6)烷基、(C2-C6)烯基、(C2-C6)炔基、-(CR8R9)d(3-10)-員環烷基、-(CR8R9)e(C6-C10)芳基、-(CR8R9)e(4-10)-員雜環基、-(CR8R9)eO(CR8R9)f(C6-C10)芳基、-(CR8R9)eO(CR8R9)f(4-10)-員雜環基、-(CR8R9)fS(O)d(CR8R9)e(C6-C10)芳基和-(CR8R9)fS(O)d(CR8R9)e(4-10)-員雜環基。
- 根據申請專利範圍第1項之化合物,其中A、B、C、D、E、F、G和H之各者為C;R1和R2之各者係獨立選自H或鹵基;R4為H或(C1-C6)烷基;R3和R5為H;R6與R7互相連結成4-12員單-或雙環狀環。
- 根據申請專利範圍第1項之化合物,其中A、B、C、D、E、F、G和H之各者為C;R1和R2之各者係獨立選自H或鹵基;R4為H或(C1-C6)烷基;R3和一個R5為H;一個R5與R6互相連結成4-12員單-或雙環狀環;R7 為-CF3、-CHF2、-CH2F、(C1-C6)烷基、(C2-C6)烯基、(C2-C6)炔基、-(CR8R9)d(3-10)-員環烷基、-(CR8R9)e(C6-C10)芳基、-(CR8R9)e(4-10)-員雜環基、-(CR8R9)eO(CR8R9)f(C6-C10)芳基、-(CR8R9)eO(CR8R9)f(4-10)-員雜環基、-(CR8R9)fS(O)d(CR8R9)e(C6-C10)芳基和-(CR8R9)fS(O)d(CR8R9)e(4-10)-員雜環基。
- 根據申請專利範圍第1項之化合物,其中該化合物為在C-3上帶有(S)組態之單一鏡像異構物,A、B、C、D、E、F、G和H之各者為C;R1和R2之各者係獨立選自H或鹵基;R4為H或(C1-C6)烷基;R3和R5為H;R6為-CF3、-CHF2、-CH2F、(C1-C6)烷基、(C2-C6)烯基、(C2-C6)炔基、-(CR8R9)d(3-10)-員環烷基、-(CR8R9)e(C6-C10)芳基、-(CR8R9)e(4-10)-員雜環基、-(CR8R9)eO(CR8R9)f(C6-C10)芳基、-(CR8R9)eO(CR8R9)f(4-10)-員雜環基、-(CR8R9)fS(O)d(CR8R9)e(C6-C10)芳基和-(CR8R9)fS(O)d(CR8R9)e(4-10)-員雜環基;R7為-CF3、-CHF2、-CH2F、(C1-C6)烷基、(C2-C6)烯基、(C2-C6)炔基、-(CR8R9)d(3-10)-員環烷基、-(CR8R9)e(C6-C10)芳基、-(CR8R9)e(4-10)-員雜環基、-(CR8R9)eO(CR8R9)f(C6-C10)芳基、-(CR8R9)eO(CR8R9)f(4-10)-員雜環基、-(CR8R9)fS(O)d(CR8R9)e(C6-C10)芳基和-(CR8R9)fS(O)d(CR8R9)e(4-10)-員雜環基。
- 根據申請專利範圍第1項之化合物,其中該化合物為在C-3上帶有(S)組態之單一鏡像異構物,A、B、C、D、E、F、G和H之各者為C;R1和R2之各者為係獨立選自H或鹵基;R4為H或(C1-C6)烷基;R3和R5為H;R6與R7互相連結成4-12員單-或雙環狀環。
- 一種選自由下列者所組成之群組的化合物,(S)-N-(3-(9H-咔唑-9-基)-2-羥丙基)-1,2-噻(thiazinane)-1,1-二氧化物;N-(3-(3,6-二氟-9H-咔唑-9-基)-2-羥丙基)-異噻唑啶-1,1-二氧化物;(S)-N-(3-(9H-咔唑-9-基)-2-羥丙基)異噻唑啶-1,1-二氧化物;2-(3-(9H-咔唑-9-基)-2-羥丙基)-5-氟-異噻唑啶-1,1-二氧化物;2-(3-(3,6-二氟-9H-咔唑-9-基)-2-羥丙基)-1,2,6-噻二-1,1-二氧化物;N-(3-(9H-咔唑-9-基)-2-羥丙基)-N-(1-甲基環戊基)甲烷磺醯胺;N-(3-(9H-咔唑-9-基)-2-羥丙基)異噻唑啶-1,1-二氧化物;N-(3-(9H-咔唑-9-基)-2-羥丙基)-2,3-二氫苯並[d]異噻唑-1,1-二氧化物;N-(3-(2,6-二氟-9H-咔唑-9-基)-2-羥丙基)-1,2-噻-1,1-二氧化物; 2-(3-(9H-咔唑-9-基)-2-羥丙基)-1,2,6-噻二-1,1-二氧化物;或其醫藥上可接受之鹽或水合物。
- 根據申請專利範圍第7項之化合物,其為(S)-N-(3-(9H-咔唑-9-基)-2-羥丙基)-1,2-噻-1,1-二氧化物;或其醫藥上可接受之鹽。
- 根據申請專利範圍第7項之化合物,其為N-(3-(3,6-二氟-9H-咔唑-9-基)-2-羥丙基)-異噻唑啶-1,1-二氧化物;或其醫藥上可接受之鹽或水合物。
- 根據申請專利範圍第7項之化合物,其為(S)-N-(3-(9H-咔唑-9-基)-2-羥丙基)異噻唑啶-1,1-二氧化物;或其醫藥上可接受之鹽或水合物。
- 根據申請專利範圍第7項之化合物,其為2-(3-(9H-咔唑-9-基)-2-羥丙基)-5-氟-異噻唑啶-1,1-二氧化物;或其醫藥上可接受之鹽或水合物。
- 根據申請專利範圍第7項之化合物,其為2-(3-(3,6-二氟-9H-咔唑-9-基)-2-羥丙基)-1,2,6-噻二-1,1-二氧化物;或其醫藥上可接受之鹽或水合物。
- 根據申請專利範圍第7項之化合物,其為N-(3-(9H-咔唑-9-基)-2-羥丙基)-N-(1-甲基環戊基)甲烷磺醯胺;或其醫藥上可接受之鹽或水合物。
- 根據申請專利範圍第7項之化合物,其為N-(3-(9H-咔唑-9-基)-2-羥丙基)異噻唑啶-1,1-二氧化物;或其醫藥上可接受之鹽或水合物。
- 根據申請專利範圍第7項之化合物,其為N-(3- (9H-咔唑-9-基)-2-羥丙基)-2,3-二氫苯並[d]異噻唑-1,1-二氧化物;或其醫藥上可接受之鹽或水合物。
- 根據申請專利範圍第7項之化合物,其為N-(3-(2,6-二氟-9H-咔唑-9-基)-2-羥丙基)-1,2-噻-1,1-二氧化物;或其醫藥上可接受之鹽或水合物。
- 根據申請專利範圍第7項之化合物,其為2-(3-(9H-咔唑-9-基)-2-羥丙基)-1,2,6-噻二-1,1-二氧化物;或其醫藥上可接受之鹽或水合物。
- 根據申請專利範圍第1項之化合物,其中該化合物調節Cry1或Cry2。
- 根據申請專利範圍第18項之化合物,其中該調節包含下列中之任一者:(i)與Cry1或Cry2結合;(ii)抑制Cry1或Cry2之修飾;(iii)改變Cry1或Cry2定位;(iv)增加或降低Cry1或Cry2穩定性;(v)增加或降低Cry1或Cry2與標靶之間的結合;(vi)增加或降低Cry1或Cry2活性;及(vii)增加或降低Cry1或Cry2標靶之活性。
- 根據申請專利範圍第19項之化合物,其中該標靶為Per1、Per2、糖皮質素受體(GR)、CLOCK、BMAL1或CLOCK-BMAL1啟動子序列。
- 一種醫藥組成物,其包含根據申請專利範圍第1項之化合物或其醫藥上可接受之鹽或水合物及醫藥上可接 受之載劑、佐劑或稀釋劑。
- 根據申請專利範圍第21項之組成物,其進一步包含一或多種額外的治療劑。
- 一種治療在受驗者中的Cry-介導之疾病或病症之方法,其包含投予該受驗者治療有效量之根據申請專利範圍第21項之醫藥組成物。
- 一種減輕在受驗者中的Cry-介導之疾病或病症的徵候之方法,其包含投予該受驗者治療有效量之根據申請專利範圍第21項之醫藥組成物。
- 根據申請專利範圍第23或24項之方法,其中該Cry-介導之疾病或病症為糖尿病、肥胖症、代謝症候群、胰島素抗性症候群、庫欣氏(Cushing’s)症候群和青光眼、精神病性抑鬱症、阿茲海默爾氏症、神經性疼痛、藥物濫用、骨質疏鬆症、癌症、黃斑變性和肌病變。
- 根據申請專利範圍第23或24項之方法,其進一步包含投予受驗者一或多種額外的治療劑。
- 一種監控在受驗者中的Cry-介導之疾病或病症的進展或預後之方法,其包含:測量在第一時期在來自該受驗者的第一樣品中的一或多種隱花色素之有效量;測量在第二時期在來自該受驗者的第二樣品中的一或多種隱花色素之有效量;及比較在該第一樣品中所偵測之一或多種隱花色素的量與在該第二樣品中所偵測之一或多種隱花色素的量或參考 值。
- 根據申請專利範圍第27項之方法,其中該監控包含評估在該受驗者中發展Cry-介導之疾病或病症的風險變化。
- 根據申請專利範圍第27項之方法,其中該受驗者包含先前對該Cry-介導之疾病或病症進行治療者、先前對該Cry-介導之疾病或病症未進行治療者或先前未診斷出患有Cry-介導之疾病或病症者。
- 根據申請專利範圍第27項之方法,其中該樣品為全血、血清、血漿、血細胞、內皮細胞、組織生檢、淋巴液、腹水液、間隙液、骨髓、腦脊髓液(CSF)、精液、唾液、黏液、痰、汗或尿。
- 根據申請專利範圍第27項之方法,其中該第一樣品係取自對該Cry-介導之疾病或病症進行治療前之該受驗者。
- 根據申請專利範圍第27項之方法,其中該第二樣品係取自對該Cry-介導之疾病或病症進行治療後之該受驗者。
- 根據申請專利範圍第27項之方法,其中該受驗者係以根據申請專利範圍第21項之醫藥組成物治療。
- 根據申請專利範圍第27項之方法,其中該監控進一步包含選擇用於該受驗者的治療及/或監控對該Cry-介導之疾病或病症治療的有效性。
- 根據申請專利範圍第34項之方法,其中對該 Cry-介導之疾病或病症的治療包含手術介入、投予單獨或與一或多種額外的治療劑組合的根據申請專利範圍第21項之醫藥組成物、在投予單獨或與一或多種額外的治療劑組合的根據申請專利範圍第21項之醫藥組成物之後或之前的手術介入、或不採取進一步的行動。
- 根據申請專利範圍第27項之方法,其中該參考值包含指數值、從一或多種Cry-介導之疾病或病症風險預測演算法所導出之值、從未患有Cry-介導之疾病或病症的受驗者所導出之值、或從診斷出患有Cry-介導之疾病或病症的受驗者所導出之值。
- 根據申請專利範圍第27項之方法,其中該測量包含偵測一或多種隱花色素的存在或不存在、定量一或多種隱花色素的量、定性一或多種隱花色素的類型及評定一或多種隱花色素與標靶結合的能力。
- 根據申請專利範圍第37項之方法,其中該標靶為Per1、Per2、糖皮質素受體(GR)或CLOCK-BMAL1啟動子序列。
- 根據申請專利範圍第27項之方法,其中該Cry-介導之疾病或病症係選自由下列者所組成之群組:糖尿病、肥胖症、代謝症候群、胰島素抗性症候群、庫欣氏症候群和青光眼、精神病性抑鬱症、阿茲海默爾氏症、神經性疼痛、藥物濫用、骨質疏鬆症、癌症、黃斑變性和肌病變。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261645918P | 2012-05-11 | 2012-05-11 | |
US201361778176P | 2013-03-12 | 2013-03-12 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW201408638A true TW201408638A (zh) | 2014-03-01 |
TWI601714B TWI601714B (zh) | 2017-10-11 |
Family
ID=48444649
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW106124610A TWI643845B (zh) | 2012-05-11 | 2013-05-10 | 隱花色素調節劑之含咔唑磺醯胺類 |
TW102116699A TWI601714B (zh) | 2012-05-11 | 2013-05-10 | 隱花色素調節劑之含咔唑磺醯胺類 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW106124610A TWI643845B (zh) | 2012-05-11 | 2013-05-10 | 隱花色素調節劑之含咔唑磺醯胺類 |
Country Status (16)
Country | Link |
---|---|
US (3) | US9265772B2 (zh) |
EP (1) | EP2855458B1 (zh) |
JP (5) | JP6377054B2 (zh) |
KR (1) | KR102136431B1 (zh) |
CN (2) | CN104640856B (zh) |
AR (1) | AR092319A1 (zh) |
AU (1) | AU2013259294B2 (zh) |
CA (1) | CA2873214C (zh) |
HK (1) | HK1250232A1 (zh) |
IL (1) | IL235602A0 (zh) |
MX (1) | MX361457B (zh) |
NZ (2) | NZ728724A (zh) |
RU (1) | RU2654484C1 (zh) |
SG (1) | SG11201407402TA (zh) |
TW (2) | TWI643845B (zh) |
WO (1) | WO2013170186A1 (zh) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6377054B2 (ja) | 2012-05-11 | 2018-08-22 | リセット セラピューティークス, インコーポレイテッド | クリプトクロム調節薬としてのカルバゾール含有スルホンアミド |
GB201309333D0 (en) | 2013-05-23 | 2013-07-10 | Agency Science Tech & Res | Purine diones as WNT pathway modulators |
AR098747A1 (es) * | 2013-12-13 | 2016-06-08 | Allergan Inc | Formas polimórficas de un compuesto similar a esteroides y métodos para su preparación y uso |
TWI690521B (zh) * | 2014-04-07 | 2020-04-11 | 美商同步製藥公司 | 作為隱花色素調節劑之含有咔唑之醯胺類、胺基甲酸酯類及脲類 |
KR101542324B1 (ko) * | 2014-04-09 | 2015-08-05 | 동아대학교 산학협력단 | 손상된 dna의 회복 속도 비교를 위한 정보 제공 방법 |
EP3152185B1 (en) * | 2014-06-04 | 2023-10-04 | Roche Diagnostics GmbH | Method and usage of a salt for separating epimers by ion mobility spectrometry |
EP3478659B1 (en) | 2016-07-04 | 2022-08-17 | Bayer CropScience Aktiengesellschaft | Benzosultams and analogues and their use as fungicides |
CN107941976B (zh) * | 2017-09-28 | 2019-11-19 | 浙江新化化工股份有限公司 | 一种2-甲氧基环己胺的含量测定方法 |
JP7187152B2 (ja) * | 2018-01-12 | 2022-12-12 | 三星電子株式会社 | 化合物、有機エレクトロルミネッセンス素子用材料、有機エレクトロルミネッセンス素子用組成物、有機エレクトロルミネッセンス素子、及び化合物の製造方法 |
MX2021001752A (es) * | 2018-08-14 | 2021-06-23 | Osteoqc Inc | Compuestos de pirrolo-dipiridina. |
WO2020051319A1 (en) * | 2018-09-05 | 2020-03-12 | Assembly Biosciences, Inc. | Cyclic sulfamide compounds for treatment of hbv |
CN109232596B (zh) * | 2018-09-05 | 2020-03-17 | 大连九信精细化工有限公司 | 一种二苯并呋喃咔唑的合成方法 |
CN114854803A (zh) * | 2022-04-21 | 2022-08-05 | 山东农业大学 | 镰刀菌对3,6-二氯咔唑生物降解的方法 |
Family Cites Families (112)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4302386A (en) | 1978-08-25 | 1981-11-24 | The Ohio State University | Antigenic modification of polypeptides |
US4105776A (en) | 1976-06-21 | 1978-08-08 | E. R. Squibb & Sons, Inc. | Proline derivatives and related compounds |
CA1178414A (en) | 1978-02-08 | 1984-11-27 | Toyo Boseki Kabushiki Kaisha (Trading Under The Name Of Toyobo Co., Ltd.) | Packaging material having excellent seal packaging property |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4233402A (en) | 1978-04-05 | 1980-11-11 | Syva Company | Reagents and method employing channeling |
US4325952A (en) | 1978-04-18 | 1982-04-20 | Aziende Chimiche Riunite Angelini Francesco | Method of treating abstinence syndrome with cycloaklyltriazoles |
US4316906A (en) | 1978-08-11 | 1982-02-23 | E. R. Squibb & Sons, Inc. | Mercaptoacyl derivatives of substituted prolines |
IL58849A (en) | 1978-12-11 | 1983-03-31 | Merck & Co Inc | Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them |
US4276890A (en) | 1979-04-11 | 1981-07-07 | Fichera Anthony T | Tobacco smoking inhibitor |
US4231938A (en) | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
US4508729A (en) | 1979-12-07 | 1985-04-02 | Adir | Substituted iminodiacids, their preparation and pharmaceutical compositions containing them |
US4444784A (en) | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
MX7065E (es) | 1980-06-06 | 1987-04-10 | Sankyo Co | Un procedimiento microbiologico para preparar derivados de ml-236b |
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4344949A (en) | 1980-10-03 | 1982-08-17 | Warner-Lambert Company | Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids |
ZA817261B (en) | 1980-10-23 | 1982-09-29 | Schering Corp | Carboxyalkyl dipeptides,processes for their production and pharmaceutical compositions containing them |
US4337201A (en) | 1980-12-04 | 1982-06-29 | E. R. Squibb & Sons, Inc. | Phosphinylalkanoyl substituted prolines |
US4410520A (en) | 1981-11-09 | 1983-10-18 | Ciba-Geigy Corporation | 3-Amino-[1]-benzazepin-2-one-1-alkanoic acids |
GB2128984B (en) | 1982-05-12 | 1985-05-22 | Hoffmann La Roche | Diaza-bicyclic compounds |
US4659678A (en) | 1982-09-29 | 1987-04-21 | Serono Diagnostics Limited | Immunoassay of antigens |
US4739073A (en) | 1983-11-04 | 1988-04-19 | Sandoz Pharmaceuticals Corp. | Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof |
US4727022A (en) | 1984-03-14 | 1988-02-23 | Syntex (U.S.A.) Inc. | Methods for modulating ligand-receptor interactions and their application |
US4780401A (en) | 1984-04-09 | 1988-10-25 | Ciba-Geigy Corporation | Novel monoclonal antibodies to human renin and hybridoma cells, processes for their preparation and their applications |
US4845079A (en) | 1985-01-23 | 1989-07-04 | Luly Jay R | Peptidylaminodiols |
US5066643A (en) | 1985-02-19 | 1991-11-19 | Sandoz Ltd. | Fluorine and chlorine statine or statone containing peptides and method of use |
US4894437A (en) | 1985-11-15 | 1990-01-16 | The Upjohn Company | Novel renin inhibiting polypeptide analogs containing S-aryl-D- or L- or DL-cysteinyl, 3-(arylthio)lactic acid or 3-(arylthio)alkyl moieties |
US4885292A (en) | 1986-02-03 | 1989-12-05 | E. R. Squibb & Sons, Inc. | N-heterocyclic alcohol renin inhibitors |
US4816463A (en) | 1986-04-01 | 1989-03-28 | Warner-Lambert Company | Substituted diimidazo [1,5-a: 4',5'-d]pyridines having antihypertensive activity |
CA1334092C (en) | 1986-07-11 | 1995-01-24 | David John Carini | Angiotensin ii receptor blocking imidazoles |
US4772684A (en) | 1987-01-20 | 1988-09-20 | Triton Biosciences, Inc. | Peptides affecting blood pressure regulation |
US4786653A (en) | 1987-08-24 | 1988-11-22 | Golwyn Daniel H | Treatment of neurotransmitter-linked drug abuse |
US5089471A (en) | 1987-10-01 | 1992-02-18 | G. D. Searle & Co. | Peptidyl beta-aminoacyl aminodiol carbamates as anti-hypertensive agents |
US4980283A (en) | 1987-10-01 | 1990-12-25 | Merck & Co., Inc. | Renin-inhibitory pepstatin phenyl derivatives |
US5034512A (en) | 1987-10-22 | 1991-07-23 | Warner-Lambert Company | Branched backbone renin inhibitors |
US5063207A (en) | 1987-10-26 | 1991-11-05 | Warner-Lambert Company | Renin inhibitors, method for using them, and compositions containing them |
US5055466A (en) | 1987-11-23 | 1991-10-08 | E. R. Squibb & Sons, Inc. | N-morpholino derivatives and their use as anti-hypertensive agents |
US5081127A (en) | 1988-01-07 | 1992-01-14 | E. I. Du Pont De Nemours And Company | Substituted 1,2,3-triazole angiotensin II antagonists |
US5036054A (en) | 1988-02-11 | 1991-07-30 | Warner-Lambert Company | Renin inhibitors containing alpha-heteroatom amino acids |
US4788189A (en) | 1988-02-29 | 1988-11-29 | Glazer Howard I | Method to treat smoking withdrawal symptoms by potentiated central noradrenergic blocking |
US5036053A (en) | 1988-05-27 | 1991-07-30 | Warner-Lambert Company | Diol-containing renin inhibitors |
DE3841520A1 (de) | 1988-12-09 | 1990-06-13 | Hoechst Ag | Enzymhemmende harnstoffderivate von dipeptiden, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung |
US5106835A (en) | 1988-12-27 | 1992-04-21 | American Cyanamid Company | Renin inhibitors |
DE4004820A1 (de) | 1989-08-05 | 1991-04-25 | Bayer Ag | Renininhibitoren, verfahren zur herstellung und ihre verwendung in arzneimitteln |
US5064825A (en) | 1989-06-01 | 1991-11-12 | Merck & Co., Inc. | Angiotensin ii antagonists |
US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
US5063208A (en) | 1989-07-26 | 1991-11-05 | Abbott Laboratories | Peptidyl aminodiol renin inhibitors |
US5098924A (en) | 1989-09-15 | 1992-03-24 | E. R. Squibb & Sons, Inc. | Diol sulfonamide and sulfinyl renin inhibitors |
US5104869A (en) | 1989-10-11 | 1992-04-14 | American Cyanamid Company | Renin inhibitors |
US5114937A (en) | 1989-11-28 | 1992-05-19 | Warner-Lambert Company | Renin inhibiting nonpeptides |
US5073566A (en) | 1989-11-30 | 1991-12-17 | Eli Lilly And Company | Angiotensin ii antagonist 1,3-imidazoles and use thereas |
US5750015A (en) | 1990-02-28 | 1998-05-12 | Soane Biosciences | Method and device for moving molecules by the application of a plurality of electrical fields |
US5064965A (en) | 1990-03-08 | 1991-11-12 | American Home Products Corporation | Renin inhibitors |
US5075451A (en) | 1990-03-08 | 1991-12-24 | American Home Products Corporation | Pyrrolimidazolones useful as renin inhibitors |
US5095119A (en) | 1990-03-08 | 1992-03-10 | American Home Products Corporation | Renin inhibitors |
US5085992A (en) | 1990-07-19 | 1992-02-04 | Merck & Co., Inc. | Microbial transformation process for antihypertensive products |
US5087634A (en) | 1990-10-31 | 1992-02-11 | G. D. Searle & Co. | N-substituted imidazol-2-one compounds for treatment of circulatory disorders |
US5071837A (en) | 1990-11-28 | 1991-12-10 | Warner-Lambert Company | Novel renin inhibiting peptides |
US5604260A (en) | 1992-12-11 | 1997-02-18 | Merck Frosst Canada Inc. | 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2 |
GB9602877D0 (en) | 1996-02-13 | 1996-04-10 | Merck Frosst Canada Inc | 3,4-Diaryl-2-hydroxy-2,5- dihydrofurans as prodrugs to cox-2 inhibitors |
US5474995A (en) | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
US5538848A (en) | 1994-11-16 | 1996-07-23 | Applied Biosystems Division, Perkin-Elmer Corp. | Method for detecting nucleic acid amplification using self-quenching fluorescence probe |
CN1143365A (zh) | 1994-01-10 | 1997-02-19 | 麦克弗罗斯特(加拿大)有限公司 | 作为cox-2抑制剂的苯基杂环类化合物 |
US5521213A (en) | 1994-08-29 | 1996-05-28 | Merck Frosst Canada, Inc. | Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2 |
ES2139959T3 (es) | 1994-10-27 | 2000-02-16 | Merck Frosst Canada Inc | Derivados de estilbeno utiles como inhibidores de la ciclooxigenasa-2. |
US5552422A (en) | 1995-01-11 | 1996-09-03 | Merck Frosst Canada, Inc. | Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents |
US5801155A (en) | 1995-04-03 | 1998-09-01 | Epoch Pharmaceuticals, Inc. | Covalently linked oligonucleotide minor grove binder conjugates |
US5691374A (en) | 1995-05-18 | 1997-11-25 | Merck Frosst Canada Inc. | Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors |
US5604253A (en) | 1995-05-22 | 1997-02-18 | Merck Frosst Canada, Inc. | N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors |
US5639780A (en) | 1995-05-22 | 1997-06-17 | Merck Frosst Canada, Inc. | N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors |
US5643933A (en) | 1995-06-02 | 1997-07-01 | G. D. Searle & Co. | Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors |
US5789413A (en) | 1996-02-01 | 1998-08-04 | Merck Frosst Canada, Inc. | Alkylated styrenes as prodrugs to COX-2 inhibitors |
US5733909A (en) | 1996-02-01 | 1998-03-31 | Merck Frosst Canada, Inc. | Diphenyl stilbenes as prodrugs to COX-2 inhibitors |
GB9607503D0 (en) | 1996-04-11 | 1996-06-12 | Merck Frosst Canada Inc | Bisaryl cyclobutenes derivatives as cyclooxygenase inhibitors |
US5922742A (en) | 1996-04-23 | 1999-07-13 | Merck Frosst Canada | Pyridinyl-2-cyclopenten-1-ones as selective cyclooxygenase-2 inhibitors |
US5677318A (en) | 1996-07-11 | 1997-10-14 | Merck Frosst Canada, Inc. | Diphenyl-1,2-3-thiadiazoles as anti-inflammatory agents |
US5861419A (en) | 1996-07-18 | 1999-01-19 | Merck Frosst Canad, Inc. | Substituted pyridines as selective cyclooxygenase-2 inhibitors |
AR008331A1 (es) | 1997-01-23 | 1999-12-29 | Smithkline Beecham Corp | Compuestos antagonistas de un receptor de il-8, uso de los mismos para la fabricacion de medicamentos, procedimiento para su obtencion, composicionesfarmaceuticas que los contienen |
CA2365503A1 (en) * | 1999-04-01 | 2000-10-12 | Koki Matsubara | Method for the preparation of tricyclic amino alcohol derivatives through azides |
US6475744B1 (en) * | 1999-07-22 | 2002-11-05 | The General Hospital Corporation | Methods for identifying compounds which modulate circadian rhythm |
US6399631B1 (en) * | 1999-07-23 | 2002-06-04 | Pfizer Inc. | Carbazole neuropeptide Y5 antagonists |
EP1236173A2 (en) | 1999-10-27 | 2002-09-04 | Biowulf Technologies, LLC | Methods and devices for identifying patterns in biological systems |
WO2001044187A1 (fr) * | 1999-12-16 | 2001-06-21 | Asahi Kasei Kabushiki Kaisha | Nouveaux composes tricycliques substitues |
KR101054732B1 (ko) | 2000-07-18 | 2011-08-05 | 더 유나이티드 스테이츠 오브 아메리카 애즈 리프리젠티드 바이 더 세크레터리 오브 더 디파트먼트 오브 헬쓰 앤드 휴먼 써비시즈 | 생물학적 데이터의 숨겨진 패턴에 근거한 생물학적 상태의 식별 방법 |
CA2429633A1 (en) | 2000-11-16 | 2002-05-30 | Ciphergen Biosystems, Inc. | Method for analyzing mass spectra |
US7113896B2 (en) | 2001-05-11 | 2006-09-26 | Zhen Zhang | System and methods for processing biological expression data |
US20020193950A1 (en) | 2002-02-25 | 2002-12-19 | Gavin Edward J. | Method for analyzing mass spectra |
AU2003248672A1 (en) | 2002-06-12 | 2003-12-31 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Pharmacologic inhibition of myc function |
US20040121305A1 (en) | 2002-12-18 | 2004-06-24 | Wiegand Roger Charles | Generation of efficacy, toxicity and disease signatures and methods of use thereof |
US20050101023A1 (en) | 2003-03-28 | 2005-05-12 | Rogers James A. | Methods for diagnosing urinary tract and prostatic disorders |
US20090163454A1 (en) | 2003-05-02 | 2009-06-25 | Duramed Pharmaceuticals, Inc. | Methods of Step-Down Hormone Treatment |
US7280776B2 (en) | 2003-08-25 | 2007-10-09 | Lexmark International, Inc. | Method and apparatus to control waste toner collection in an image forming apparatus |
ATE408599T1 (de) * | 2004-03-26 | 2008-10-15 | Hoffmann La Roche | Tetrahydrocarbazole und derivate |
DK1791537T3 (da) * | 2004-08-19 | 2010-03-01 | Aventis Pharma Inc | 3-arylthioindol-2-carboxamidderivater og analoger deraf som inhibitorer af casein-kinase |
PL3091011T3 (pl) | 2006-04-07 | 2018-06-29 | Vertex Pharmaceuticals Incorporated | Modulatory transporterów posiadających kasetę wiążącą ATP |
CL2007003591A1 (es) | 2006-12-12 | 2008-02-29 | Wyeth Corp | Compuestos derivados de sulfonamida ciclicos, inhibidores de retoma de monoamina; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de disfuncion sexual, trastorno gastrointestinal, trastorno genitourinari |
WO2008119017A1 (en) * | 2007-03-28 | 2008-10-02 | High Point Pharmaceuticals, Llc | 11beta-hsd1 active compounds |
CA2709784A1 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
UA107652C2 (en) | 2008-10-06 | 2015-02-10 | Incuron Llc | Carbazole compounds and therapeutic uses of the compounds |
US9162980B2 (en) | 2009-01-09 | 2015-10-20 | Board Of Regents Of The University Of Texas System | Anti-depression compounds |
US9962368B2 (en) * | 2009-01-09 | 2018-05-08 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
AU2010203356B2 (en) | 2009-01-09 | 2015-11-26 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
US8362277B2 (en) * | 2009-01-09 | 2013-01-29 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
DK2590647T3 (en) * | 2010-07-07 | 2018-02-12 | Univ Texas | Pro-neurogenic compounds |
WO2012009372A2 (en) | 2010-07-12 | 2012-01-19 | Colorado State University Research Foundation | Triazolium carbene catalysts and processes for asymmetric carbon-carbon bond formation |
JP6377054B2 (ja) | 2012-05-11 | 2018-08-22 | リセット セラピューティークス, インコーポレイテッド | クリプトクロム調節薬としてのカルバゾール含有スルホンアミド |
MA37931A1 (fr) * | 2012-08-13 | 2016-07-29 | Teni Boulikas | Procédés améliorés permettant de traiter un cancer avec une toxicité rénale réduite |
EP2925129A4 (en) * | 2012-08-24 | 2016-06-08 | Univ Texas | PRO-NEUROGENIC COMPOUNDS |
WO2014039515A2 (en) | 2012-09-04 | 2014-03-13 | University Of Massachusetts | Antifungal agents and uses thereof |
WO2014179785A1 (en) | 2013-05-03 | 2014-11-06 | Inscent, Inc. | Improved honeybee repellents and uses thereof |
US9353078B2 (en) | 2013-10-01 | 2016-05-31 | New York University | Amino, amido and heterocyclic compounds as modulators of rage activity and uses thereof |
TWI690521B (zh) | 2014-04-07 | 2020-04-11 | 美商同步製藥公司 | 作為隱花色素調節劑之含有咔唑之醯胺類、胺基甲酸酯類及脲類 |
-
2013
- 2013-05-10 JP JP2015511772A patent/JP6377054B2/ja active Active
- 2013-05-10 EP EP13722971.2A patent/EP2855458B1/en active Active
- 2013-05-10 SG SG11201407402TA patent/SG11201407402TA/en unknown
- 2013-05-10 TW TW106124610A patent/TWI643845B/zh active
- 2013-05-10 WO PCT/US2013/040604 patent/WO2013170186A1/en active Application Filing
- 2013-05-10 NZ NZ728724A patent/NZ728724A/en unknown
- 2013-05-10 AU AU2013259294A patent/AU2013259294B2/en active Active
- 2013-05-10 CN CN201380036733.4A patent/CN104640856B/zh active Active
- 2013-05-10 RU RU2014150075A patent/RU2654484C1/ru active
- 2013-05-10 MX MX2014013760A patent/MX361457B/es active IP Right Grant
- 2013-05-10 TW TW102116699A patent/TWI601714B/zh active
- 2013-05-10 US US13/891,407 patent/US9265772B2/en active Active
- 2013-05-10 CN CN201710908594.XA patent/CN107674071B/zh active Active
- 2013-05-10 KR KR1020147034255A patent/KR102136431B1/ko active IP Right Grant
- 2013-05-10 CA CA2873214A patent/CA2873214C/en active Active
- 2013-05-10 NZ NZ701702A patent/NZ701702A/en unknown
- 2013-05-13 AR ARP130101653A patent/AR092319A1/es active IP Right Grant
-
2014
- 2014-11-10 IL IL235602A patent/IL235602A0/en active IP Right Grant
-
2016
- 2016-01-12 US US14/994,005 patent/US9775845B2/en active Active
-
2017
- 2017-07-20 JP JP2017140820A patent/JP2017200946A/ja not_active Withdrawn
- 2017-09-22 US US15/712,983 patent/US10383880B2/en active Active
-
2018
- 2018-07-26 HK HK18109672.6A patent/HK1250232A1/zh unknown
-
2019
- 2019-01-31 JP JP2019015689A patent/JP2019077722A/ja not_active Withdrawn
-
2020
- 2020-09-24 JP JP2020159390A patent/JP2020203948A/ja not_active Withdrawn
-
2022
- 2022-10-17 JP JP2022166167A patent/JP2023002659A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI601714B (zh) | 隱花色素調節劑之含咔唑磺醯胺類 | |
US10759777B2 (en) | Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators | |
BR112014028427B1 (pt) | Compostos sulfonamidas contendo carbazola, composição farmacêutica compreendendo ditos compostos e usos terapêuticos da dita composição | |
BR112016023446B1 (pt) | Composto modulador de criptocromo (cry), composição farmacêutica que compreende o mesmo e uso da dita composição para o tratamento ou alívio de um sintoma de uma doença ou transtorno mediado por cry |